<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        3101221655
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2022
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        HADLIMA 40MG/0.8ML INJECTION IN PRE-FILLED SYRING	
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ADALIMUMAB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store in a refrigerator (2°C – 8°C), do not freeze
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1889.10
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Catalent Belgium SA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Catalent Belgium SA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Samsung Bioepis Co Ltd
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L04AB04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Hadlima contains the active substance adalimumab, a medicine that acts on your body&rsquo;s immune (defence) system.</p><p>&nbsp;</p><p>Hadlima is intended for treatment of:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rheumatoid arthritis,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; polyarticular juvenile idiopathic arthritis,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; enthesitis-related arthritis,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ankylosing spondylitis,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; axial spondyloarthritis without radiographic evidence of ankylosing spondylitis,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; psoriatic arthritis,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; psoriasis,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hidradenitis suppurativa,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Crohn&rsquo;s disease,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ulcerative colitis and</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; non-infectious uveitis affecting the back of the eye.</p><p>&nbsp;</p><p>The active ingredient in Hadlima, adalimumab, is a monoclonal antibody. Monoclonal antibodies are proteins that attach to a specific target.</p><p>&nbsp;</p><p>The target of adalimumab is a protein called tumour necrosis factor (TNF&alpha;), which is present at increased levels in the inflammatory diseases listed above. By attaching to TNF&alpha;, Hadlima decreases the process of inflammation in these diseases.</p><p>&nbsp;</p><p><u>Rheumatoid arthritis</u></p><p><u>&nbsp;</u></p><p>Rheumatoid arthritis is an inflammatory disease of the joints.</p><p>&nbsp;</p><p>Hadlima is used to treat rheumatoid arthritis in adults. If you have moderate to severe active rheumatoid arthritis, you may first be given other disease-modifying medicines, such as methotrexate. If these medicines do not work well enough, you will be given Hadlima to treat your rheumatoid arthritis.</p><p>&nbsp;</p><p>Hadlima can also be used to treat severe, active and progressive rheumatoid arthritis without previous methotrexate treatment.</p><p>&nbsp;</p><p>Hadlima can slow down the damage to the cartilage and bone of the joints caused by the disease and improve physical function.</p><p>&nbsp;</p><p>Usually, Hadlima is used with methotrexate. If your doctor considers that methotrexate is inappropriate, Hadlima can be given alone.</p><p>&nbsp;</p><p><u>Polyarticular juvenile idiopathic arthritis and enthesitis-related arthritis</u></p><p>&nbsp;</p><p>Polyarticular juvenile idiopathic arthritis and enthesitis-related arthritis are inflammatory diseases of the joints that usually first appear in childhood.</p><p>&nbsp;</p><p>Hadlima is used to treat polyarticular juvenile idiopathic arthritis in children and adolescents aged 2 to 17&nbsp;years and enthesitis-related arthritis in children and adolescents aged 6 to 17&nbsp;years. Patients may first be given other disease-modifying medicines, such as methotrexate. If these medicines do not work well enough, patients will be given Hadlima to treat their polyarticular juvenile idiopathic arthritis or enthesitis-related arthritis.</p><p>&nbsp;</p><p><u>Ankylosing spondylitis and axial spondyloarthritis without radiographic evidence of ankylosing spondylitis</u></p><p>&nbsp;</p><p>Ankylosing spondylitis and axial spondyloarthritis without radiographic evidence of ankylosing spondylitis, are inflammatory diseases of the spine.</p><p>&nbsp;</p><p>Hadlima is used to treat ankylosing spondylitis and axial spondyloarthritis without radiographic evidence of ankylosing spondylitis in adults. If you have ankylosing spondylitis or axial spondyloarthritis without radiographic evidence of ankylosing spondylitis, you will first be given other medicines. If these medicines do not work well enough, you will be given Hadlima to reduce the signs and symptoms of your disease.</p><p>&nbsp;</p><p><u>Psoriatic arthritis</u></p><p><u>&nbsp;</u></p><p>Psoriatic arthritis is an inflammatory disease of the joints associated with psoriasis.</p><p>&nbsp;</p><p>Hadlima is used to treat psoriatic arthritis in adults. Hadlima can slow down the damage to the cartilage and bone of the joints caused by the disease and to improve physical function.</p><p>&nbsp;</p><p><u>Plaque psoriasis </u><u>in adults and children</u></p><p>&nbsp;</p><p>Plaque psoriasis is an inflammatory skin condition that causes red, flaky, crusty patches of skin covered with silvery scales. Plaque psoriasis can also affect the nails, causing them to crumble, become thickened and lift away from the nail bed which can be painful. Psoriasis is believed to be caused by a problem with the body&rsquo;s immune system that leads to an increased production of skin cells.</p><p>&nbsp;</p><p>Hadlima is used to treat moderate to severe plaque psoriasis in adults. Hadlima is also used to treat severe plaque psoriasis in children and adolescents weighing 30&nbsp;kg or greater for whom topical therapy and phototherapies have either not worked very well or are not suitable.</p><p>&nbsp;</p><p><u>Hidradenitis suppurativa in adults and adolescents</u></p><p><u>&nbsp;</u></p><p>Hidradenitis suppurativa (sometimes called acne inversa) is a chronic and often painful inflammatory skin disease. Symptoms may include tender nodules (lumps) and abscesses (boils) that may leak pus. It most commonly affects specific areas of the skin, such as under the breasts, the armpits, inner thighs, groin and buttocks. Scarring may also occur in affected areas.</p><p>&nbsp;</p><p>Hadlima is used to treat hidradenitis suppurativa in adults and adolescents from 12&nbsp;years of age. Hadlima can reduce the number of nodules and abscesses you have, and the pain that is often associated with the disease. You may first be given other medicines. If these medicines do not work well enough, you will be given Hadlima.</p><p>&nbsp;</p><p><u>Crohn&rsquo;s disease in adults and children</u></p><p>&nbsp;</p><p>Crohn&rsquo;s disease is an inflammatory disease of the digestive tract.</p><p>&nbsp;</p><p>Hadlima is used to treat Crohn&rsquo;s disease in adults and children aged 6 to 17&nbsp;years. If you have Crohn&rsquo;s disease you will first be given other medicines. If these medicines do not work well enough, you will be given Hadlima to reduce the signs and symptoms of your Crohn&rsquo;s disease.</p><p>&nbsp;</p><p><u>Ulcerative colitis</u></p><p><u>&nbsp;</u></p><p>Ulcerative colitis is an inflammatory disease of the bowel.</p><p>&nbsp;</p><p>Hadlima is used to treat ulcerative colitis in adults. If you have ulcerative colitis you will first be given other medicines. If these medicines do not work well enough, you will be given Hadlima to reduce the signs and symptoms of your disease.</p><p>&nbsp;</p><p><u>N</u><u>on-infectious uveitis in adults and children</u></p><p>&nbsp;</p><p>Non-infectious uveitis is an inflammatory disease affecting certain parts of the eye.</p><p>&nbsp;</p><p>Hadlima is used to treat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adults with non-infectious uveitis with inflammation affecting the back of the eye</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Children from 2&nbsp;years of age with chronic non-infectious uveitis with inflammation affecting the front of the eye</p><p>&nbsp;</p><p>This inflammation may lead to a decrease of vision and/or the presence of floaters in the eye (black dots or wispy lines that move across the field of vision). Hadlima works by reducing this inflammation.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Hadlima</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic to adalimumab or any of the other ingredients of this medicine (listed in section 6).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a severe infection, including tuberculosis (see &ldquo;Warnings and precautions&rdquo;). It is important that you tell your doctor if you have symptoms of infections, e.g. fever, wounds, feeling tired, dental problems.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have moderate or severe heart failure. It is important to tell your doctor if you have had or have a serious heart condition (see &ldquo;Warnings and precautions&rdquo;).</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>&nbsp;</p><p>Talk to your doctor or pharmacist before using Hadlima.</p><p>&nbsp;</p><p><u>Allergic reaction</u></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have <strong>allergic reactions</strong> with symptoms such as chest tightness, wheezing, dizziness, swelling or rash do not inject more Hadlima and contact your doctor immediately since, in rare cases, these reactions can be life-threatening.</p><p>&nbsp;</p><p><u>Infection</u></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have an <strong>infection</strong>, including long-term or localised infection (for example, leg ulcer) consult your doctor before starting Hadlima. If you are unsure, contact your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You might get infections more easily while you are receiving Hadlima treatment. This risk may increase if your lung function is impaired. These infections may be serious and include tuberculosis, infections caused by viruses, fungi, parasites or bacteria, other opportunistic infections (unusual infections associated with a weakened immune system) and sepsis (blood poisoning). In rare cases, these infections may be life-threatening. It is important to tell your doctor if you get symptoms such as fever, wounds, feeling tired or dental problems. Your doctor may recommend temporary discontinuation of Hadlima.</p><p>&nbsp;</p><p><u>Tuberculosis</u></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; As cases of <strong>tuberculosis</strong> have been reported in patients treated with Hadlima, your doctor will check you for signs and symptoms of tuberculosis before starting Hadlima. This will include a thorough medical evaluation including your medical history and screening tests (for example chest X-ray and a tuberculin test). The conduct and results of these tests should be recorded on your Patient Alert Card. It is very important that you tell your doctor if you have ever had tuberculosis, or if you have been in close contact with someone who has had tuberculosis. Tuberculosis can develop during therapy even if you have received preventative treatment for tuberculosis. If symptoms of tuberculosis (persistent cough, weight loss, listlessness, mild fever), or any other infection appear during or after therapy tell your doctor immediately.</p><p>&nbsp;</p><p><u>Travel/recurrent infection</u></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tell your doctor if you reside or travel in regions where fungal infections such as histoplasmosis, coccidioidomycosis or blastomycosis are endemic.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tell your doctor if you have a history of recurrent infections or other conditions that increase the risk of infections.</p><p>&nbsp;</p><p><u>Hepatitis B virus</u></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tell your doctor if you are a carrier of the <strong>hepatitis B virus (HBV)</strong>, if you have active HBV infection or if you think you might be at risk of contracting HBV. Your doctor should test you for HBV. Hadlima can reactivate HBV infection in people who carry this virus. In some rare cases, especially if you are taking other medicines that suppress the immune system, reactivation of HBV infection can be life-threatening.</p><p>&nbsp;</p><p><u>Age over 65 years</u></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are over 65&nbsp;years you may be more susceptible to infections while taking Hadlima. You and your doctor should pay special attention to signs of infection while you are being treated with Hadlima. It is important to tell your doctor if you get symptoms of infections, such as fever, wounds, feeling tired or dental problems.</p><p>&nbsp;</p><p><u>Surgery or dental procedure</u></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are about to have <strong>surgery or dental procedures</strong> tell your doctor that you are taking Hadlima. Your doctor may recommend temporary discontinuation of Hadlima.</p><p>&nbsp;</p><p><u>Demyelinating disease</u></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have or develop <strong>demyelinating disease</strong> (a disease that affects the insulating layer around the nerves, such as multiple sclerosis), your doctor will decide if you should receive or continue to receive Hadlima. Tell your doctor immediately if you get symptoms like changes in your vision, weakness in your arms or legs or numbness or tingling in any part of your body.</p><p>&nbsp;</p><p><u>Vaccine</u></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Certain <strong>vaccines</strong> contain weakened but live forms of disease-causing bacteria or viruses, and these vaccines should not be given while receiving Hadlima. Check with your doctor before you receive any vaccines. It is recommended that children, if possible, be given all the scheduled vaccinations for their age before they start treatment with Hadlima. If you receive Hadlima while you are pregnant, your baby may be at higher risk for getting an infection for up to about twelve months after birth. Therefore, at least twelve-month waiting period following birth is recommnded before your baby receives live vaccines. It is important that you tell your baby&#39;s doctors and other health care professionals about your Hadlima use during your pregnancy so they can decide when your baby should receive any vaccine.</p><p>&nbsp;</p><p><u>Heart Failure</u></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have <strong>mild heart failure</strong> and you are being treated with Hadlima, your heart failure status must be closely monitored by your doctor. It is important to tell your doctor if you have had or have a serious heart condition. If you develop new or worsening symptoms of heart failure (e.g. shortness of breath, or swelling of your feet), you must contact your doctor immediately. Your doctor will decide if you should receive Hadlima.</p><p>&nbsp;</p><p><u>Fever, bruising, bleeding or looking pale</u></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In some patients the body may fail to produce enough of the blood cells to fight off infections or help you to stop bleeding. If you develop a <strong>fever</strong> that does not go away, or you <strong>bruise</strong> or <strong>bleed</strong> very easily or look very <strong>pale</strong>, call your doctor right away. Your doctor may decide to stop treatment.</p><p>&nbsp;</p><p><u>Cancer</u></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; There have been very rare cases of certain kinds of <strong>cancer</strong> in children and adults taking Hadlima or other TNF&alpha; blockers. People with more serious rheumatoid arthritis who have had the disease for a long time may have a higher than average risk of getting <strong>lymphoma</strong> (a cancer that affects the lymph system), and leukaemia (a cancer that affects the blood and bone marrow). If you take Hadlima the risk of getting lymphoma, leukaemia, or other cancers may increase. On rare occasions, a specific and severe type of lymphoma has been observed in patients taking Hadlima. Some of those patients were also treated with the medicines azathioprine or mercaptopurine. Tell your doctor if you are taking azathioprine or mercaptopurine with Hadlima.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In addition, cases of <strong>non-melanoma skin cancer</strong> have been observed in patients taking Hadlima. If new areas of damaged skin appear during or after therapy or if existing marks or areas of damage change appearance, tell your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; There have been cases of <strong>cancers, other than lymphoma</strong> in patients with a specific type of lung disease called chronic obstructive pulmonary disease (COPD) treated with another TNF&alpha; blocker. If you have COPD, or you are a heavy smoker, you should discuss with your doctor whether treatment with a TNF&alpha; blocker is appropriate for you.</p><p>&nbsp;</p><p><u>Lupus-like syndrome</u></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; On rare occasions, treatment with Hadlima could result in lupus-like syndrome. Contact your doctor if symptoms such as persistent unexplained rash, fever, joint pain or tiredness occur.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not give Hadlima to children with polyarticular juvenile idiopathic arthritis below the age of 2&nbsp;years.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use the 40&nbsp;mg pre-filled syringe if doses other than 40&nbsp;mg are recommended.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and </strong><strong>Hadlima</strong></p><p>&nbsp;</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>Hadlima can be taken together with methotrexate or certain disease-modifying anti-rheumatic agents (sulfasalazine, hydroxychloroquine, leflunomide and injectable gold preparations), corticosteroids or pain medications including non-steroidal anti-inflammatory drugs (NSAIDs).</p><p>&nbsp;</p><p>You should not take Hadlima with medicines containing the active substances anakinra or abatacept due to increased risk of serious infection. If you have questions, please ask your doctor.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You should consider the use of adequate contraception to prevent pregnancy and continue its use for at least 5&nbsp;months after the last Hadlima injection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice about taking this medicine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hadlima should only be used during a pregnancy if needed.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; According to a pregnancy study, there was no higher risk of birth defects when the mother had received adalimumab during pregnancy compared with mothers with the same disease who did not receive adalimumab.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hadlima can be used during breast-feeding.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you received Hadlima during your pregnancy, your baby may have a higher risk for getting an infection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is important that you tell your baby&rsquo;s doctors and other health care professionals about your Hadlima use during your pregnancy before the baby receives any vaccine (for more information on vaccines see the &ldquo;Warnings and precautions&rdquo; section).</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>&nbsp;</p><p>Hadlima may have a minor influence on your ability to drive, cycle or use machines. Room spinning sensation (vertigo) and vision disturbances may occur after taking Hadlima.</p><p>&nbsp;</p><p><strong>Hadlima contains sodium and sorbitol</strong></p><p>&nbsp;</p><p>This medicinal product contains 20 mg sorbitol in each pre-filled syringe. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p><p>&nbsp;</p><p>Also this medicinal product contains less than 1 mmol of sodium (23&nbsp;mg) per 0.8&nbsp;ml dose, i.e. essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>Hadlima is only available as 40&nbsp;mg pre-filled syringe or pre-filled pen. Thus, it is not possible to use Hadlima for children who require less than a full 40&nbsp;mg dose. If an alternate dose is required, other adalimumab products offering such an option should be used.</p><p>&nbsp;</p><p><u>Adults with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis or axial spondyloarthritis without radiographic evidence of ankylosing spondylitis</u></p><p>&nbsp;</p><p>Hadlima is injected under the skin (subcutaneous use). The usual dose for adults with rheumatoid arthritis, ankylosing spondylitis, axial spondyloarthritis without radiographic evidence of ankylosing spondylitis, and for patients with psoriatic arthritis is 40&nbsp;mg adalimumab given every two weeks as a single dose.</p><p>&nbsp;</p><p>In rheumatoid arthritis, methotrexate is continued while using Hadlima. If your doctor determines that methotrexate is inappropriate, Hadlima can be given alone.</p><p>&nbsp;</p><p>If you have rheumatoid arthritis and you do not receive methotrexate with your Hadlima therapy, your doctor may decide to give 40&nbsp;mg adalimumab every week or 80&nbsp;mg every other week.</p><p>&nbsp;</p><p><u>Children, adolescents and adults with polyarticular juvenile idiopathic arthritis</u></p><p><u>&nbsp;</u></p><p><em>Children, adolescents and adults from 2&nbsp;years of age weighing 30&nbsp;kg or more</em></p><p>&nbsp;</p><p>The recommended dose of Hadlima is 40&nbsp;mg every other week.</p><p>&nbsp;</p><p><u>Children, adolescents and adults with enthesitis-related arthritis</u></p><p><u>&nbsp;</u></p><p><em>Children, adolescents and adults from 6&nbsp;years of age weighing 30&nbsp;kg or more</em></p><p>&nbsp;</p><p>The recommended dose of Hadlima is 40&nbsp;mg every other week.</p><p><u>&nbsp;</u></p><p><u>Adults with psoriasis</u></p><p>&nbsp;</p><p>The usual dose for adults with psoriasis is an initial dose of 80&nbsp;mg (as two 40&nbsp;mg injections in one day), followed by 40&nbsp;mg given every other week starting one week after the initial dose. You should continue to inject Hadlima for as long as your doctor has told you. Depending on your response, your doctor may increase the dosage to 40&nbsp;mg every week or 80&nbsp;mg every other week.</p><p>&nbsp;</p><p><u>Children and adolescents with plaque psoriasis</u></p><p>&nbsp;</p><p><em>Children and adolescents from 4 to 17&nbsp;years of age weighing 30&nbsp;kg or more</em></p><p>&nbsp;</p><p>The recommended dose of Hadlima is an initial dose of 40&nbsp;mg, followed by 40&nbsp;mg one week later. Thereafter, the usual dose is 40&nbsp;mg every other week.</p><p>&nbsp;</p><p><u>Adults with hidradenitis suppurativa</u></p><p><u>&nbsp;</u></p><p>The usual dose regimen for hidradenitis suppurativa is an initial dose of 160&nbsp;mg (as four 40-mg injections in one day or two 40-mg injections per day for two consecutive days), followed by an 80-mg dose (as two 40&nbsp;mg injections in one day) two weeks later. After two further weeks, continue with a dose of 40&nbsp;mg every week or 80&nbsp;mg every other week, as prescribed by your doctor.</p><p>&nbsp;</p><p>It is recommended that you use an antiseptic wash daily on the affected areas.</p><p>&nbsp;</p><p><u>Adolescents with hidradenitis suppurativa from 12</u><u> to 17</u><u>&nbsp;years of age weighing 30&nbsp;kg</u><u> or more</u></p><p><u>&nbsp;</u></p><p>The recommended dose of Hadlima is an initial dose of 80&nbsp;mg (as two 40&nbsp;mg injections in one day), followed by 40&nbsp;mg every other week starting one week later. If this dose does not work well enough to Hadlima 40&nbsp;mg every other week, your doctor may increase the dosage to 40&nbsp;mg every week or 80&nbsp;mg every other week.</p><p>&nbsp;</p><p>It is recommended that you use an antiseptic wash daily on the affected areas.</p><p><u>&nbsp;</u></p><p><u>Adults with Crohn&rsquo;s disease</u></p><p>&nbsp;</p><p>The usual dose regimen for Crohn&rsquo;s disease is 80&nbsp;mg (as two 40&nbsp;mg injections in one day) initially followed by 40&nbsp;mg every other week starting two weeks later. If a faster effect is required your doctor may prescribe an initial dose of 160&nbsp;mg (as four 40&nbsp;mg injections in one day or two 40&nbsp;mg injections per day for two consecutive days), followed by 80&nbsp;mg (as two 40&nbsp;mg injections in one day) two weeks later, and thereafter as 40&nbsp;mg every other week. If this dose does not work well enough, your doctor may increase the dosage to 40&nbsp;mg every week or 80&nbsp;mg every other week.</p><p>&nbsp;</p><p><u>Children </u><u>and</u><u> adolescents with Crohn&#39;s </u><u>d</u><u>isease</u></p><p>&nbsp;</p><p><em>Children and adolescents from 6 to 17 years of age weighing 40&nbsp;kg or more:</em></p><p>&nbsp;</p><p>The usual dose regimen is 80&nbsp;mg (as two 40&nbsp;mg injections in one day) initially followed by 40&nbsp;mg two weeks later. If a faster response is required, your doctor may prescribe an initial dose of 160&nbsp;mg (as four 40&nbsp;mg injections in one day or as two 40&nbsp;mg injections per day for two consecutive days) followed by 80&nbsp;mg (as two 40&nbsp;mg injections in one day) two weeks later.</p><p>&nbsp;</p><p>Thereafter, the usual dose is 40&nbsp;mg every other week. If this dose does not work well enough, your doctor may increase the dosage to 40&nbsp;mg every week or 80&nbsp;mg every other week.</p><p>&nbsp;</p><p><u>Adults with ulcerative colitis</u></p><p><u>&nbsp;</u></p><p>The usual Hadlima dose for adults with ulcerative colitis is 160&nbsp;mg initially (as four 40&nbsp;mg injections in one day or as two 40 mg injections per day for two consecutive days) followed by 80&nbsp;mg (as two 40&nbsp;mg injections in one day) two weeks later and thereafter 40&nbsp;mg every other week. If this dose does not work well enough, your doctor may increase the dose to 40&nbsp;mg every week or 80&nbsp;mg every other week.</p><p>&nbsp;</p><p><u>Adults with non-infectious uveitis</u></p><p>&nbsp;</p><p>The usual dose for adults with non-infectious uveitis is an initial dose of 80&nbsp;mg (as two 40&nbsp;mg injections in one day), followed by 40&nbsp;mg given every other week starting one week after the initial dose. You should continue to inject Hadlima for as long as your doctor has told you.</p><p>&nbsp;</p><p>In non-infectious uveitis, corticosteroids or other medicines that influence the immune system may be continued while using Hadlima. Hadlima can also be given alone.</p><p>&nbsp;</p><p><u>Children and adolescents with chronic non-infectious uveitis from 2</u><u>&nbsp;</u><u>years of age</u></p><p>&nbsp;</p><p><em>Children and adolescents from 2</em><em>&nbsp;</em><em>years of age weighing 30</em><em>&nbsp;</em><em>kg or more</em></p><p>&nbsp;</p><p>The usual dose of Hadlima is 40&nbsp;mg every other week with methotrexate.</p><p>&nbsp;</p><p>Your doctor may also prescribe an initial dose of 80&nbsp;mg which may be administered one week prior to the start of the usual dose.</p><p>&nbsp;</p><p><strong>Method and route of administration</strong></p><p>&nbsp;</p><p>Hadlima is given by injection under the skin (by subcutaneous injection). For instructions for use, refer to section 7.</p><p>&nbsp;</p><p><strong>If you use more Hadlima than you should</strong></p><p>&nbsp;</p><p>If you accidentally inject Hadlima more frequently than you should, call your doctor or pharmacist and explain that you have taken more. Always take the outer carton of the medicine with you, even if it is empty.</p><p>&nbsp;</p><p><strong>If you forget to use</strong><strong> Hadlima</strong></p><p>&nbsp;</p><p>If you forget to give yourself an injection, you should inject the next dose of Hadlima as soon as you remember. Then take your next dose as you would have on your originally scheduled day, had you not forgotten a dose.</p><p>&nbsp;</p><p><strong>If you stop using</strong><strong> Hadlima</strong></p><p>&nbsp;</p><p>The decision to stop using Hadlima should be discussed with your doctor. Your symptoms may return upon stopping treatment.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Most side effects are mild to moderate. However, some may be serious and require treatment. Side effects may occur up to 4 months or more after the last Hadlima injection.</p><p>&nbsp;</p><p><strong>Seek medical attention urgently </strong>if you notice any of the following:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe rash, hives or other signs of allergic reaction;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swollen face, hands, feet;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; trouble breathing, swallowing;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath with exertion or upon lying down or swelling of the feet.</p><p>&nbsp;</p><p><strong>Tell your doctor as soon as possible </strong>if you notice any of the following:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; signs of infection such as fever, feeling sick, wounds, dental problems, burning on urination;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling weak or tired;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; coughing;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tingling;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; numbness;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; double vision;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; arm or leg weakness;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a bump or open sore that doesn&#39;t heal;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; signs and symptoms suggestive of blood disorders such as persistent fever, bruising, bleeding, paleness.</p><p>&nbsp;</p><p>The symptoms described above can be signs of the below listed side effects, which have been observed with adalimumab:</p><p>&nbsp;</p><p><strong>Very common</strong> (may affect more than 1 in 10 people):</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; injection site reactions (including pain, swelling, redness or itching);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; respiratory tract infections (including cold, runny nose, sinus infection, pneumonia);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abdominal (belly) pain;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea and vomiting;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in the muscles.</p><p>&nbsp;</p><p><strong>Common</strong> (may affect up to 1 in 10&nbsp;people):</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serious infections (including blood poisoning and influenza);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; intestinal infections (including gastroenteritis);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin infections (including cellulitis and shingles);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ear infections;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mouth infections (including tooth infections and cold sores);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reproductive tract infections;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; urinary tract infection;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fungal infections;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint infections;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; benign tumours;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin cancer;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reactions (including seasonal allergy);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dehydration;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mood swings (including depression);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anxiety;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty sleeping;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sensation disorders such as tingling, prickling or numbness;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; migraine;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; symptoms of nerve root compression(including low back pain and leg pain);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vision disturbances;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; eye inflammation;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the eyelid and eye swelling;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vertigo (sensation of the room spinning);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sensation of heart beating rapidly;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood pressure;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; flushing;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; haematoma (a solid swelling with clotted blood);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; asthma;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gastrointestinal bleeding;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dyspepsia (indigestion, bloating, heart burn);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acid reflux disease;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sicca syndrome (including dry eyes and dry mouth);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itchy rash;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bruising;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the skin (such as eczema);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breaking of finger nails and toe nails;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased sweating;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hair loss;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; new onset or worsening of psoriasis;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle spasms;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood in urine;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; kidney problems;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; oedema (a build up of fluid in the body which causes the affected tissue to swell);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduction in blood platelets which increases risk of bleeding or bruising;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; impaired healing.</p><p>&nbsp;</p><p><strong>Uncommon</strong> (may affect up to 1 in 100&nbsp;people):</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; opportunistic infections (which include tuberculosis and other infections that occur when resistance to disease is lowered);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; neurological infections (including viral meningitis);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; eye infections;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bacterial infections;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diverticulitis (inflammation and infection of the large intestine);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cancer, including cancer of the lymph system (lymphoma) and melanoma (a type of skin cancer);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; immune disorders that could affect the lungs, skin and lymph nodes (most commonly as a condition called sarcoidosis);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vasculitis (inflammation of blood vessels);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tremor;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; neuropathy (nerve damage);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stroke;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hearing loss, buzzing;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sensation of heart beating irregularly such as skipped beats;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart problems that can cause shortness of breath or ankle swelling;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; myocardial infarction;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a sac in the wall of a major artery, inflammation and clot of a vein; blockage of a blood vessel;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lung diseases causing shortness of breath (including inflammation);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pulmonary embolism (blockage in an artery of the lung);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pleural effusion (abnormal collection of fluid in the pleural space);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the pancreas which causes severe pain in the abdomen and back;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty in swallowing;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; facial oedema;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gallbladder inflammation, gallbladder stones;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fatty liver (build up of fat in liver cells);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; night sweats;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; scar;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal muscle breakdown;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; systemic lupus erythematosus (including inflammation of skin, heart, lung, joints and other organ systems);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sleep interruptions;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; impotence;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammations.</p><p>&nbsp;</p><p><strong>Rare </strong>(may affect up to 1 in 1,000&nbsp;people):</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; leukaemia (cancer affecting the blood and bone marrow);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe allergic reaction with shock;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; multiple sclerosis;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nerve disorders (such as inflammation of the optic nerve to the eye, and Guillain-Barr&eacute; syndrome, a condition that may cause muscle weakness, abnormal sensations, tingling in the arms and upper body);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart stops pumping;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pulmonary fibrosis (scarring of the lung);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; intestinal perforation;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hepatitis;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reactivation of hepatitis B;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; autoimmune hepatitis (inflammation of the liver caused by the body&#39;s own immune system);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cutaneous vasculitis (inflammation of blood vessels in the skin);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stevens-Johnson syndrome (early symptoms include malaise, fever, headache and rash);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; facial oedema associated with allergic reactions;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; erythema multiforme (inflammatory skin rash);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lupus-like syndrome;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; angioedema (localized swelling of the skin);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lichenoid skin reaction (itchy reddish-purple skin rash).</p><p>&nbsp;</p><p><strong>Not known</strong> (frequency cannot be estimated from available data):</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hepatosplenic T-cell lymphoma (a rare blood cancer that is often fatal);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Merkel cell carcinoma (a type of skin cancer);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver failure;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; worsening of a condition called dermatomyositis (seen as a skin rash accompanying muscle weakness).</p><p>&nbsp;</p><p>Some side effects observed with adalimumab may not have symptoms and may only be discovered through blood tests. These include:</p><p>&nbsp;</p><p><strong>Very common</strong> (may affect more than 1 in 10&nbsp;people):</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood measurements for white blood cells;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood measurements for red blood cells;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased lipids in the blood;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; raised liver enzymes.</p><p>&nbsp;</p><p><strong>Common </strong>(may affect up to 1 in 10&nbsp;people):</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood measurements for white blood cells;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood measurements for platelets;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased uric acid in the blood;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal blood measurements for sodium;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood measurements for calcium;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood measurements for phosphate;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood sugar;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood measurements for lactate dehydrogenase;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; autoantibodies present in the blood;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood potassium.</p><p>&nbsp;</p><p><strong>Uncommon</strong> (may affect up to 1 in 100 people)</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; elevated bilirubin measurement (liver blood test).</p><p>&nbsp;</p><p><strong>Rare</strong> (may affect up to 1 in 1,000&nbsp;people):</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood measurements for white blood cells, red blood cells and platelet count.</p><p><strong>&nbsp;</strong></p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p><p>To reports any side effect(s):</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><u>Please report adverse drug events to: </u></p><p>The National Pharmacovigilance Centre (NPC):</p><p>Fax: +966-11-205-7662</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>This is a Medicament</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicament is a product which affects your health and its consumption contrary to instructions is dangerous for you.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Follow strictly the doctor‟s prescription, the method of use and the instructions of the pharmacist who sold the medicament.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The doctor and the pharmacist are the experts in medicines, their benefits and risks.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not by yourself interrupt the period of treatment prescribed for you.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not repeat the same prescription without consulting your doctor.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep all medicaments out of reach of children.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the label of the carton after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store in a refrigerator (2&deg;C &ndash; 8&deg;C). Do not freeze.</p><p>&nbsp;</p><p>Keep the pre-filled syringe in the outer carton in order to protect from light.</p><p>&nbsp;</p><p>Alternative Storage:</p><p>&nbsp;</p><p>When needed (for example when you are travelling), a single Hadlima pre-filled syringe may be stored at room temperature (up to 25&deg;C) for a maximum period of 28&nbsp;days &ndash; be sure to protect it from light. Once removed from the refrigerator for room temperature storage, the syringe must be used within 28&nbsp;days or discarded, even if it is returned to the refrigerator.</p><p>You should record the date when the syringe is first removed from refrigerator, and the date after which it should be discarded.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>&nbsp;</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is adalimumab.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are sodium citrate, citric acid monohydrate, histidine, histidine hydrochloride monohydrate, sorbitol, polysorbate 20 and water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	Hadlima 40 mg solution for injection in pre-filled syringe is supplied as a 0.8 ml clear and colourless solution.
	
	Hadlima is available in packs containing 2 pre-filled syringe(s) (type I glass) with a stainless steel needle, a rigid needle shield, a rubber plunger, a plunger rod, a safe-shield body and a finger flange .

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Samsung Bioepis</p><p>76, Songdogyoyuk-ro,</p><p>Yeonsu-gu, Incheon,</p><p>21987,</p><p>Republic of Korea</p><p><strong>&nbsp;</strong></p><p><strong>Manufacturer</strong></p><p>Catalent Belgium SA</p><p>Font Saint Landry 10</p><p>Brussels, 1120</p><p>Belgium</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 08/2023; version number 2.2
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي هادليما على مادة أداليموماب الفعالة، وهو دواء يقوي الجهاز المناعي في جسدك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُعد هادليما مخصص لعلاج ما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الْتِهابُ المَفاصِلِ الرُّوماتويديّ،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الْتِهابٌ مَفْصِلِيٌّ الروماتويدي اليَفَعِيّ،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المفاصل ذات الصلة بالتهاب الارتكاز</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;الْتِهابُ الفَقارِ المُقَسِّط،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الْتِهابُ المَفاصِلِ الفَقارِيَّة المحورية بدون الدليل الإشعاعي على الْتِهابُ الفَقارِ المُقَسِّط</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المفاصل الصدافي،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصدفية،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الْتِهابُ الغُدَدِ العَرَقِيَّةِ القَيحِيّ،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; داء كرون،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب القولون التقرحي و</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;التهاب العنبية غير المعدي الذي يؤثر على الجزء الخلفي من العين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">العنصر الفعال في هادليما، أداليموماب هو الأجسام المضادة أحادية النسيلة. تُعتبر الأجسام المضادة أحادية النسيلة، بروتينات ترتبط بهدف معين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الهدف المتمثل في أداليموماب هو بروتين يُدعي عامل نخر الورم والذي يوجد بمستويات متزايدة في الأمراض الالتهابية المذكورة أعلاه. من خلال الارتباط بعامل نخر الورم، يُقلل هادليما عملية الالتهاب في هذه الأمراض.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الْتِهابُ المفاصِلِ الرُّوماتويديّ</u></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL">التهاب المفاصل الروماتويدي هو مرض التهابي يصيب المفاصل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يستخدم هادليما لعلاج التهاب المفاصل الروماتويدي لدي البالغين إذا كنت تعاني من التهاب المفاصل الروماتويدي النشط والمتوسط إلى الشديد، فقد يتم إعطاؤك أولاً أدوية أخرى معدلة للمرض، مثل ميثوتركسيت. إذا لم تعمل هذه الأدوية على نحو جيد، سيتم إعطاؤك هادليما لعلاج التهاب المفاصل الروماتويدي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أيضًا استخدام هادليما لعلاج التهاب المفاصل الروماتويدي الحاد والنشط والمتزايد دون تعاطي دواء ميثوتركسيت مسبقًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يساعد هادليما على الحد من الضرر الذي يلحق بالغضروف وعظام المفاصل الناجم عن المرض كما يحسن القدرة البدنية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">عادة، يُستخدم هادليما مع دواء ميثوتركسيت. إذا رأى طبيبك أن علاج ميثوتركسيت. غير مناسب، عندئذٍ يمكن إعطاء هادليما بمفرده.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الْتِهابٌ مَفْصِلِيٌّ الروماتويدي اليَفَعِيّ والتهاب المفاصل ذات الصلة بالتهاب الارتكاز</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">يُعد الْتِهابٌ مَفْصِلِيٌّ الروماتويدي اليَفَعِيّ والتهاب المفاصل ذات الصلة بالتهاب الارتكاز من الأمراض الالتهابية التي تصيب المفاصل والتي تظهر لأول مرة عادةً في مرحلة الطفولة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستخدم هادليما لعلاج الْتِهابٌ مَفْصِلِيٌّ الروماتويدي اليَفَعِيّ لدى الأطفال والمراهقين الذين تتراوح أعمارهم من 2 إلى 17 عامًا والتهاب المفاصل ذات الصلة بالتهاب الارتكاز لدي الأطفال والمراهقين الذين تتراوح أعمارهم من 6 إلى 17 سنوات. يمكن إعطاء المرضى أولاً أدوية أخرى معدلة للمرض، مثل الميثوتركسيت. إذا لم تعمل هذه الأدوية على نحو جيد، يُعطي للمريض حقنة هادليما لعلاج التهاب المفاصل الروماتويدي. أو التهاب المفاصل ذات الصلة بالتهاب الارتكاز.</p><p dir="RTL"><u>الْتِهابُ الفَقارِ المُقَسِّط والْتِهابُ المَفاصِلِ الفَقارِيَّة المحورية بدون الدليل الإشعاعي على الْتِهابُ الفَقارِ المُقَسِّط</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">يُعد الْتِهابُ الفَقارِ المُقَسِّط والْتِهابُ المَفاصِلِ الفَقارِيَّة المحورية بدون الدليل الإشعاعي على الْتِهابُ الفَقارِ المُقَسِّط من الأمراض الالتهابية التي تُصيب العمود الفقري.</p><p dir="RTL">يُستخدم هادليما لعلاج الْتِهابُ الفَقارِ المُقَسِّط والْتِهابُ المَفاصِلِ الفَقارِيَّة المحورية بدون الدليل الإشعاعي على الْتِهابُ الفَقارِ المُقَسِّط لدي البالغين إذا كنت تعاني من الْتِهابُ المَفاصِلِ الفَقارِيَّة المحورية بدون الدليل الإشعاعي ذات الصلة بالْتِهابُ الفَقارِ المُقَسِّط، عندئذ تُعطي أولاً الأدوية أخرى. إذا لم تعمل هذه الأدوية على نحو جيد، فيتعاطى دواء هادليما للحد من علامات وأعراض المرض.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>التهاب المفاصل الصدافي</u></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL">يُعد التهاب المفاصل الروماتويدي من الأمراض الالتهابية التي تُصيب المفاصل الصدفية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يستخدم هادليما لعلاج التهاب المفاصل الصدافي لدي البالغين يساعد هادليما على الحد من الضرر الذي يلحق بالغضروف وعظام المفاصل الناجم عن المرض كما يحسن القدرة البدنية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الصدفية اللويحية لدي البالغين والأطفال</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">تُعد الصدفية اللويحية من حالات أمراض الجلد الالتهابية التي تسبب احمرار الجلد وظهور رقع وتقشرات على الجلد مغطاة بقشور فضية اللون. قد تؤثر الصدفية اللويحية أيضًا على الأظافر، مما يؤدي إلى تدهورها، وتصبح سميكة، وتبتعد عن بطانة الظفر مما يسبب الألم. يُعتقد أن الصدفية ناتجة عن مشكلة في الجهاز المناعي للجسم تؤدي إلى زيادة إنتاج خلايا الجلد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتم يُتعاطى دواء هادليما لعلاج الصدفية اللويحية المتوسطة والحادة لدي البالغين. يُتناول دواء هادليما أيضًا في علاج الصدفية اللويحية الشديدة لدي الأطفال والمراهقين الذين يبلغ وزنهم 30 كجم أو أكثر بسبب عدم نجاح العلاج الموضعي والعلاجات الضوئية أو عندما تكون غير مناسبة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>التهاب الغدد العرقية القيحي لدي البالغين والمراهقين</u></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL">التهاب الغدد العرقية القيحي (يسمى أحيانًا بحبّ الشباب العكسي) هو مرض جلدي التهابي مزمن وغالبًا ما يكون مؤلمًا. قد تشمل الأعراض عقيدات رقيقة (كتل) وخراجات (دمامل) قد تؤدي إلى تسرب القيح. يؤثر بشكل شائع على مناطق معينة من الجلد، مثل تحت الثديين والإبطين والفخذين الداخليين والفخذين والأرداف. قد تحدث ندبات أيضًا في المناطق المصابة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُعطي دواء هادليما لعلاج التهاب الغدد العرقية القيحي لدي البالغين والمراهقين بدءًا من سن 12 سنة يُساعد دواء هادليما في الحد من عدد العقيدات والخراجات التي لديك، والألم المصاحب للمرض. تتعاطي أولاً أدوية آخري إذا لم تعمل هذه الأدوية على نحو جيد، فيتعاطي دواء هادليما</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>داء كرون لدي البالغين والأطفال</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">داء كرون هو مرض التهابي يصيب الجهاز الهضمي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُعطي دواء هادليما لعلاج مرض كرون لدي البالغين والأطفال الذين تتراوح أعمارهم من 6 إلى 17 سنة. إذا كنت تُعاني من مرض كرون عليك أولاً تناول أدوية أخري. إذا لم تعمل هذه الأدوية على نحو جيد، فيتعاطي دواء هادليما للحد من علامات وأعراض مرض كرون.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>التهاب القولون التقرحي</u></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL">التهاب القولون التقرحي هو مرض التهابي يصيب الأمعاء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يستخدم هادليما لعلاج التهاب القولون التقرحي لدي البالغين إذا كنت تُعاني من التهاب القولون التقرحي، عليك أولاً تناول أدوية أخري. إذا لم تعمل هذه الأدوية على نحو جيد، فتناول دواء هادليما للحد من علامات وأعراض المرض.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>التهاب العنبية غير المعدي لدي البالغين والأطفال</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">التهاب العنبية غير المعدي هو مرض التهابي يصيب أجزاء معينة من العين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;يُعطي دواء هادليما لعلاج</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;التهاب العنبية غير المعدي لدي البالغين وكذلك الالتهابات التي تؤثر على الجزء الخلفي من العين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب العنبية المزمن غير المعدي لدي الأطفال من عمر سنتين وكذلك الالتهابات التي تؤثر على الجزء الخلفي من العين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يؤدي هذا الالتهاب إلى انخفاض الرؤية و/ أو وجود عوائم في العين (نقاط سوداء أو خطوط ضعيفة تتحرك عبر مجال الرؤية). يُساعد هادليما على الحد من هذه الالتهابا</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">حالات عدم استخدام هادليما</p><p dir="RTL">-إذا كنت تُعاني من حساسية ضد أداليموماب أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم 6).</p><p dir="RTL">- إذا كنت تعاني من عدوى شديدة، بما في ذلك مرض السل (انظر &quot;التحذيرات والاحتياطات&quot;). - يُرجي إخبار طبيبك إذا كانت لديك أعراض العدوى، على سبيل المثال. الحمى والجروح والشعور بالتعب ومشاكل بالأسنان.</p><p dir="RTL">إذا كنت تُعاني من فشل القلب الحاد أو المتوسط. - يُرجي إخبار طبيبك إذا كنت تعاني من حالة قلبية خطيرة (انظر &quot;التحذيرات والاحتياطات&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL">التحذيرات والتدابير الوقائية</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي. قبل تعاطي دواء هادليما.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>تفاعلات أرجية</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعاني من <strong>تفاعلات أرجية</strong> مصحوبة بأعراض مثل ضيق في الصدر أو صفير عند التنفس أو دوار أو أورام أو طفح جلدي، فلا تُحقن المزيد من هادليما، واتصل بطبيبك على الفور، لأنه في حالات نادرة، يمكن أن تسبب هذه التفاعلات لحدوث وفاة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>العدوى</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تُعاني من <strong>عدوى</strong>، بما في ذلك العدوى طويلة الأمد أو العدوي المحلية (على سبيل المثال، القرحة الساق) استشر طبيبك قبل بدء تعاطي دواء هادليما. إذا كنت غير متأكدًا، اتصل بطبيبك على الفور.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تصاب بالعدوى بسهولة أكبر أثناء تعاطيك دواء هادليما. قد يزداد هذا الخطر إذا كنت تُعاني من قصور في وظيفة الرئة. قد تكون هذه العدوى خطيرة وتشمل السل والعدوى التي تسببها الفيروسات أو الفطريات أو الطفيليات أو البكتيريا، والعدوى الانتهازية الأخرى (عدوى غير عادية مرتبطة بضعف جهاز المناعة) والتسمم (تسمم الدم). في حالات نادرة، قد تسبب هذه العدوى لحدوث وفاة. - يُرجي إخبار طبيبك إذا ظهرت لديك أعراض العدوى، على سبيل المثال. الحمى والجروح والشعور بالتعب ومشاكل بالأسنان. قد يوصي طبيبك بإيقاف مؤقت لـدواء هادليما.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>السل</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نظرًا للإصابة بمرض <strong>السل</strong> في الحالات التي عولجت بدواء هادليما كما أبلغ بذلك، لذا سيفحص الطبيب المريض أولاً بحثًا عن علامات وأعراض السل قبل بدء تعاطي هادليما. يشمل ذلك تقييمًا طبيًا شاملاً بما في ذلك تاريخك الطبي واختبارات الفحص (على سبيل المثال، تصوير الصدر بالأشعة السينية واختبار السل). يجب تسجيل إجراء ونتائج هذه الاختبارات على بطاقة تنبيه المريض. من المهم جداً أن تخبر طبيبك إذا كنت تعرضت للسل سابقًا، أو إذا كنت على اتصال وثيق مع شخص مصاب بالسل. يمكن أن يتطور مرض السل أثناء تناول العلاج حتى في حال تناولك علاجًا وقائيًا لمرض السل. أخبر طبيبك على الفور، ذا ظهرت لديك أعراض السل (سعال مستمر أو فقدان الوزن أو الخمول أو الحمى الخفيفة)، أو أي عدوى أخرى أثناء العلاج أو بعده.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>العدوي المتنقلة/المزمنة</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبر طبيبك إذا كنت تقيم في منطقة أو تسافر إلى المناطق التي تنتشر فيها العدوى الفطرية مثل داء النوسجات أو فُطارٌ كُرَوانِيّ أو فُطَارٌ بُرْعُمِيّ.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبر طبيبك إذا كان لديك تاريخ من العدوى المزمنة أو غيرها من الحالات التي تزيد من خطر الإصابة بالعدوى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>فيروس التهاب الكبد (ب)</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبر طبيبك إذا كنت مصابًا بفيروس التهاب الكبد (ب)، أو إذا كنت مُصابًا بعدوي فيروس التهاب الكبد (ب) النشط أو تعتقد أنك معرض لخطر الإصابة بفيروس التهاب الكبد (ب). يجب أن يقوم طبيبك باختبار فيروس التهاب الكبد (ب). يُساعد هادليما على إعادة تنشيط عدوي فيروس التهاب الكبد (ب) لدي الأشخاص المصابين بهذا الفيروس. في بعض الحالات النادرة، خاصة إذا كنت تتناول أدوية أخرى تثبط جهاز المناعة، فيُصبح إعادة تنشيط عدوى التهاب الكبد (ب) مهددًا للحياة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الأشخاص الذين تبلغ أعمارهم أكثر من 65 عام</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان عمرك أكثر من 65 عامًا، فستكون أكثر عرضة للإصابة بالعدوى أثناء تعاطي هادليما. يجب أن تولي أنت وطبيبك اهتمامًا خاصًا بأعراض العدوى أثناء علاجك بدواء هادليما. - يُرجي إخبار طبيبك إذا ظهرت لديك أعراض العدوى، على سبيل المثال. الحمى والجروح والشعور بالتعب ومشاكل بالأسنان.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>العمليات الجراحية أو علاج الأسنان</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت على وشك <strong>إجراء عملية جراحية أو إجراءات علاج الأسنان</strong>، أخبر طبيبك أنك تتعاطي هادليما. قد يوصي طبيبك بإيقاف مؤقت لـدواء هادليما.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>مرض إزالة الميالين</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض إزالة الميالين (مرض يؤثر على الطبقة العازلة حول الأعصاب، مثل التصلب المتعدد)، فسيقرر طبيبك ما إذا كان يجب أن تتناول أو تستمر في تعاطيك دواء هادليما. أخبر طبيبك على الفور إذا ظهرت عليك أعراض مثل تغيرات في الرؤية أو ضعف في ذراعيك أو ساقيك أو تنميل أو وخز في أي جزء من جسمك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>اللقاح</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحتوي بعض <strong>اللقاحات</strong> على أشكال ضعيفة من البكتيريا أو الفيروسات المسببة للمرض ولكنها حية، ويجب عدم إعطاء هذه اللقاحات أثناء تعاطي دواء هادليما. استشر طبيبك قبل تلقيك أي لقاحات. يوصى بإعطاء الأطفال، إن أمكن، جميع التطعيمات المقررة لأعمارهم قبل أن يبدأوا تعاطي حقن هادليما. إذا تعاطيت حقن هادليما أثناء الحمل، فسيكون طفلك أكثر عرضة للإصابة بالعدوى لمدة تصل إلى اثني عشر شهرًا بعد الولادة. لذلك، يوصى بفترة انتظار لا تقل عن اثني عشر شهرًا بعد الولادة قبل أن يتلقى طفلك اللقاحات الحية. من المهم أن تخبر أطباء طفلك وغيرهم من أخصائيين الرعاية الصحية عن تعاطيِ حقن هادليما أثناء الحمل حتى يتمكنوا من تحديد موعد تلقي طفلك لأي لقاح.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>فشل القلب</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من فشل بسيط في القلب وكنت تُعالج بـدواء هادليما، فيجب أن يراقب طبيبك حالة فشل القلب عن كثب. - يُرجي إخبار طبيبك إذا كنت تعاني من حالة قلبية خطيرة إذا ظهرت عليك أعراض جديدة أو متفاقمة لفشل القلب (مثل ضيق التنفس أو تورم قدميك)، يجب عليك الاتصال بطبيبك على الفور. يُقرر طبيبك ما إذا كانت حالتك تحتاج إلى تعاطي حقن هادليما أم لا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>حمى أو كدمات أو نزيف أو مظهر شاحب</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في بعض المرضى، قد يفشل الجسم في إنتاج خلايا الدم الكافية لمواجهة الالتهابات أو مساعدتك على وقف النزيف. إذا أصبت بحمى مستمرة، أو أصبت <strong>بكدمات</strong> أو <strong>تنزف</strong> بسهولة شديدة أو تبدو <strong>شاحبًا</strong> جدًا، فاتصل بطبيبك على الفور. قد يُقرر طبيبك إيقاف الدواء</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>السرطان</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>كان هناك حالات نادرة لأنواع بعينها من السرطان لدى الأطفال والبالغين الذين يتناولون هادليما أو عوامل نخر الورم وحاصرات. </strong>&nbsp;الأشخاص المصابين بالْتِهابُ المَفاصِلِ الرُّوماتويديّ الأكثر خطورة والذين كان يعانون من المرض لفترة طويلة قد يتعرضون لخطر أكبر من المتوسط في الإصابة بسرطان الغدد الليمفاوية (سرطان يؤثر على الجهاز الليمقي) واللوكيميا (سرطان يؤثر على الدم ونخاع العظم) إذا تناولت هادليما، فإن خطر الإصابة بالغدد اللمفاوية واللوكيميا أو أي سرطانات أخرى قد يرتفع. وفي حالات نادرة، تمت ملاحظة وجود نوع محدد وحاد من سرطان الغدد الليمفاوية في المرضى الذين يتنالون هادليما. بعض هؤلاء الأشخاص تلقوا علاجا بأدوية بها مادة أزاثيوبرين أو الميركابتوبيورين. أخبر طبيبك إذا كنت تتناول مادة أزاثيويرين أو لميركابتوبيورين مع هادليما.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بالإضافة إلى ذلك، تمت ملاحظة سرطان جلدي غير قتامي لدى المرضى الذين يتعاطون هادليما. إذا ظهرت أماكن جديدة للجلد المتضرر أثناء أو بعد العلاج أو ظهور تغييرات في علامات أو أماكن موجودة بالفعل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هناك حالات سرطان بخلاف الغدد الليمفاوية لدى مرضى نوع محدد من أمراض الرئة يسمى مرض انسداد الشعب الهوائية المزمن، وتم علاجه بطرق أخرى لنخر الورم والحاصرات. إذا كنت مصابا بمرض انسداد الشعب الهوائية المزمن أو مدخن شره، يجب عليك استشارة طبيبك بشأن ما إذا كان العلاج بنخر الورم والحاصرات مناسبا لك أم لا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>متلازمة مثيلة الذئبة؛</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالات نادرة، قد يؤدي العلاج بهادليما إلى متلازمة مثيلة الذئبة. اتصل بطبيبك إذا ظهرت عليك أعراض مثل طفح غير مبرر مستمر أو حمى أو ألم مفاصل أو إرهاق.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يُتعاطى هادليما للأطفال المصابين بالالتهاب المَفْصِلِيٌّ الروماتويدي اليَفَعِيّ دون عمر سنتين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يوصى بعدم استخدام الحقنة مسبقة التعبئة سعة 40 مليغرام إذا كانت الجرعات بخلاف 40 مليغرام.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&nbsp;علاجات أخرى وعلاج هادليما</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك أو الصيدلي في حال كنت تتناول أو تناولت مؤخراً أو قد تتناول أي أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكنك تناول هادليما مع ميتوتريكسات أو بعض العوامل المضادة للروماتيزم المعدلة للمرض (سلفاسالازين وهيدروكسي كلوروكوين ولفلونوميد والسائل القابل للحقن) أو كورتيكوستيرويد أو الأدوية المسكنة بما في ذلك الأدوية المضادة للالتهابات اللاستيرويدية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">عدم تناول علاج هادليما مع الأدوية التي تحتوي على مادة فعالة مثل أناكينرا أو أباتاسيبت بسبب تزايد خطر الإصابة بأي عدوى خطيرة. يُرجى مراجعة الطبيب إذا كانت لديك أي أسئلة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الحمل والرضاعة</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عليك النظر في استخدام وسائل منع الحمل ومواصلة استخدامها لمدة 5 أشهر على الأقل بعد آخر حقن لهادليما.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;عليكِ استشارة الطبيب حول تناول هذا الدواء إذا كنتِ حاملاً أو تعتقدي أنكِ حامل أو تخططين للحمل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استخدام هادليما أثناء فترة الحمل إذا لزم الأمر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وفقاً لدراسة أجريت بشأن الحمل، لا يوجد نسبة خطورة عالية للإصابة بعيوب خلقية عند تناول الأم لأداليموماب خلال فترة الحمل مقارنةً مع الأمهات اللاتي لم يتناولن لأداليموماب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُستخدم علاج هادليما أثناء الرضاعة الطبيعية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عند تناول علاج هادليما أثناء فترة الحمل، قد يُشكل ذلك نسبة خطورة عالية للإصابة بالعدوى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;من المهم إخبار طبيب الأطفال وأخصائي الرعاية الصحية حول استخدام علاج هادليما خلال فترة الحمل قبل تناول الطفل لأي لقاح (لمزيد من المعلومات حول اللقاحات راجع قسم &quot;التحذيرات والتدابير الوقائية&quot;)</p><p dir="RTL">&nbsp;</p><p dir="RTL">القيادة واستخدام الآلات</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يكون لعلاج هادليما تأثير بسيط على قدرتك على القيادة أو ركوب الدراجات أو استخدام الآلات. قد تشعر بالدوران في الغرفة (الدوخة) والاضرابات البصرية بعد تناول علاج هادليما.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الصوديوم والسوربيتول في علاج هادليما</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي هذا المنتج الطبي على 20 ملغ من السوربيتول. راجع طبيبك قبل تناول هذا المنتج الطبي إذا أخبرك بعدم تحملك للسكريات.</p><p dir="RTL">&nbsp;</p><p>يحتوي هذا المنتج على أقل من 1 مللي مول من الصوديوم (23 ملغ) لكل جرعة 0.8 مل، أي &quot;خالية من الصوديوم&quot; تماماً.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">عليك دومًا استخدام هادليما وفقًا لتوجيهات الطبيب أو الصيدلي الخاص بك. ارجع لطبيبك أو الصيدلي الخاص بك إذا لم تكن متأكّدًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُعد هادليما 40 مجم متاح فقط في شكل حقنة أو قلم جاهز للاستعمال. وبالتالي، لا يُمكن استخدام هادليما للأطفال الذين يحتاجون جرعة أقل من 40 مجم الكاملة. إذا كانت هناك حاجة إلى استخدام جرعة بديلة، فيجب استخدام منتجات أداليموماب الأخرى التي تُتيح مثل هذا الخيار.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>للبالغين المصابين بالْتِهابُ المفاصِلِ الرُّوماتويديّ والْتِهابُ المَفاصِلِ الصدافي والْتِهابُ الفَقارِ المُقَسِّط أو الْتِهابُ المَفاصِلِ الفَقارِيَّة المحورية بدون الدليل الإشعاعي على الْتِهابُ الفَقارِ المُقَسِّط</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">يتم تناول حقن هادليما تحت الجلد (تُستخدم تحت الجلد). يوصى بتناول الجرعة المعتادة المتمثلة في 40 مجم من دواء أداليموماب للبالغين المُصابين بالتهاب المفاصل الروماتويدي والْتِهابُ الفَقارِ المُقَسِّط والْتِهابُ المَفاصِلِ الفَقارِيَّة المحورية بدون الدليل الإشعاعي على الْتِهابُ الفَقارِ المُقَسِّط وللمرضى المُصابين بالْتِهابُ المَفاصِلِ الصدافي كل أسبوعين كجرعة واحدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يستمر استخدام دواء ميثوتركسيت أثناء استخدام هادليما، وذلك للمرضى المصابين بالْتِهابُ المَفاصِلِ الرُّوماتويديّ. إذا حدد طبيبك أن دواء ميثوتركسيت. غير مناسب، عندئذٍ يمكن إعطاء هادليما بمفرده.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تعاني من الْتِهابُ المَفاصِلِ الرُّوماتويديّ ولا تتناول دواء ميثوتركسيت. مع هادليما الخاص بك، فقد يُقرر طبيبك إعطائك 40 مجم من أداليموماب كل أسبوع أو 80 مجم كل أسبوعين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>للأطفال والمراهقين والبالغين المصابين بالْتِهابٌ مَفْصِلِيٌّ الروماتويدي اليَفَعِيّ</u></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL">للأطفال والمراهقين والبالغين من عمر سنتين ويزنون 30 كجم أو أكثر</p><p dir="RTL">&nbsp;</p><p dir="RTL">تبلغ الجرعة الموصي بها من هادليما 40 مجم كل أسبوعين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>للأطفال والمراهقين والبالغين المصابين بالتهاب المفاصل ذات الصلة بالتهاب الارتكاز</u></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL">للأطفال والمراهقين والبالغين من عمر ست سنوات ويزنون 30 كجم أو أكثر</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL">تبلغ الجرعة الموصي بها من هادليما 40 مجم كل أسبوعين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>البالغين المصابين بالصدفية</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة المعتادة للبالغين المصابين بالصدفية هي جرعة أولية تبلغ 80 مجم (على شكل حقنتين بمقدار 40 مجم في يوم واحد)، تليها 40 مجم كل أسبوعين بدءًا من أسبوع واحد بعد الجرعة الأولية. يجب أن تستمر في تناول حقن هادليما وفقًا لتوجيهات طبيبك. استناداً إلى استجابتك، قد يزيد طبيبك الجرعة إلى 40 مجم كل أسبوع أو 80 مجم كل أسبوعين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الأطفال والمراهقين المصابين بالصدفية اللويحية</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">للأطفال والمراهقين والبالغين الذين تتراوح أعمارهم من 4 إلى 17 سنة ويزنون 30 كجم أو أكثر</p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة الموصي بها من هادليما هي جرعة أولية تبلغ 40 مجم، تليها جرعة تبلغ 40 مجم بعد أسبوع واحد. بعد ذلك، تبلغ الجرعة المعتادة 40 مجم كل أسبوعين.</p><p dir="RTL"><u>البالغين المصابين بالْتِهابُ الغُدَدِ العَرَقِيَّةِ القَيحِيّ</u></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL">يتمثل نظام الجرعات المعتادة للمصابين بالْتِهابُ الغُدَدِ العَرَقِيَّةِ القَيحِيّ في جرعة أولية تبلغ 160 مجم (على شكل أربع حقن بمقدار 40 مجم في اليوم الواحد أو حقنتين بمقدار 40 مجم في اليوم لمدة يومين متتاليين)، تليها جرعة تبلغ 80 مجم (على شكل حقنتين بمقدار 40 مجم في اليوم) بعد أسبوعين. بعد أسبوعين آخرين، استمر في تناول الجرعة التي تبلغ 40 مجم كل أسبوع أو 80 مجم كل أسبوعين، كما وصفها طبيبك، يوصي باستخدام غسول مطهر على المناطق المصابة بشكل يومي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>للمراهقين المصابين بالْتِهابُ الغُدَدِ العَرَقِيَّةِ القَيحِيّ الذين تتراوح أعمارهم من 12 إلى 17 سنة ويزنون 30 كجم أو أكثر</u></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL">تتمثل الجرعة المعتادة من هادليما في الجرعة الأولية التي تبلغ 80 مجم (على شكل حقنتين بمقدار 40 مجم في يوم واحد)، تليها 40 مجم كل أسبوعين بدءًا من أسبوع واحد بعد ذلك. إذا لم تكن الجرعة فعالة بشكل جيد وكافي من هادليما 40 مجم كل أسبوعين، قد يُزيد طبيبك الجرعة إلى 40 مجم كل أسبوع أو 80 مجم كل أسبوعين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يوصي باستخدام غسول مطهر على المناطق المصابة بشكل يومي.</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><u>البالغين المصابين بداء كرون</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;يبلغ نظام الجرعة المعتادة لداء كرون 80 مجم (على شكل حقنتين بمقدار 40 مجم في يوم واحد)، تليها تناول جرعة بمقدار 40 مجم بشكل مبدئي كل أسبوعين بدءًا من أسبوع واحد بعد ذلك. إذا تطلب الأمر الحصول على التأثير الدوائي بشكل سريع، ربما يصف طبيبك جرعة أولية تبلغ 160 مجم (على شكل أربع حقن بمقدار 40 مجم في اليوم الواحد أو حقنتين بمقدار 40 مجم في اليوم لمدة يومين متتاليين)، تليها جرعة تبلغ 80 مجم (على شكل حقنتين بمقدار 40 مجم في اليوم) بعد أسبوعين وبعد ذلك 40 مجم كل أسبوعين. إذا لم تكن الجرعة فعالة بشكل جيد وكافي، قد يزيد طبيبك الجرعة إلى 40 مجم كل أسبوع أو 80 مجم كل أسبوعين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الأطفال والمراهقين المصابين بداء كرون</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;للأطفال والمراهقين الذين تتراوح أعمارهم من 6 إلى 17 سنة ويزنون 40 كجم أو أكثر:</p><p dir="RTL">&nbsp;</p><p dir="RTL">يبلغ نظام الجرعة المعتادة 80 مجم (على شكل حقنتين بمقدار 40 مجم في يوم واحد)، تليها تناول جرعة بمقدار 40 مجم بشكل مبدئي بعد أسبوعين. إذا تطلب الأمر تحقيق استجابة سريعة، ربما يصف طبيبك جرعة أولية تبلغ 160 مجم (على شكل أربع حقن بمقدار 40 مجم في اليوم الواحد أو حقنتين بمقدار 40 مجم في اليوم لمدة يومين متتاليين)، تليها جرعة تبلغ 80 مجم (على شكل حقنتين بمقدار 40 مجم في اليوم) بعد أسبوعين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بعد ذلك، تبلغ الجرعة المعتادة 40 مجم كل أسبوعين. إذا لم تكن الجرعة فعالة بشكل جيد وكافية، قد يزيد طبيبك الجرعة إلى 40 مجم كل أسبوع أو 80 مجم كل أسبوعين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>البالغين المصابين بالتهاب القولون التقرحي</u></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL">إذا تطلب الأمر الحصول على التأثير الدوائي بشكل سريع، ربما يصف طبيبك جرعة أولية تبلغ 160 مجم (على شكل أربع حقن بمقدار 40 مجم في اليوم الواحد أو حقنتين بمقدار 40 مجم في اليوم لمدة يومين متتاليين)، تليها جرعة تبلغ 80 مجم (على شكل حقنتين بمقدار 40 مجم في اليوم) بعد أسبوعين وبعد ذلك 40 مجم كل أسبوعين. إذا لم تكن الجرعة فعالة بشكل جيد وكافية، قد يزيد طبيبك الجرعة إلى 40 مجم كل أسبوع أو 80 مجم كل أسبوعين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>البالغين المصابين بالتهاب العنبية </u></p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة المعتادة للبالغين المصابين بالتهاب العنبية غير المعدية هي جرعة أولية تبلغ 80 مجم (على شكل حقنتين بمقدار 40 مجم في يوم واحد)، تليها 40 مجم كل أسبوعين بدءًا من أسبوع واحد بعد الجرعة الأولية. يجب أن تستمر في تناول حقن هادليما وفقًا لتوجيهات طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يؤثر دواء الكورتيكوستيرويدات أو الأدوية الأخرى على جهاز المناعة أثناء استخدام هادليما، وذلك في حالة الإصابة بالتهاب العنبية غير المعدي. يُمكن أيضًا إعطاء هادليما بمفرده.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الأطفال والمراهقين المصابين بالتهاب العنبية من عمر سنتين</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">للأطفال والمراهقين من عمر سنتين ويزنون 30 كجم أو أكثر</p><p dir="RTL">&nbsp;</p><p dir="RTL">تبلغ الجرعة الموصي بها من هادليما 40 مجم كل أسبوعين مع تناول دواء ميثوتركسيت.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يصف طبيبك الجرعة الأولية التي تبلغ 80 مجم والتي يمكن إعطاؤها قبل أسبوع واحد من بدء الجرعة المعتادة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>طريقة إعطاء هذا الدواء:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يتم تناول حقنة هادليما تحت الجلد (حقنة تحت الجلد). للحصول على مزيد من تعليمات الاستخدام، راجع القسم 7.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تستخدم هادليما أكثر من اللازم</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا قُمت بتناول هادليما عن طريق الخطأ بشكل متكرر أكثر مما ينبغي، اتصل بطبيبك أو الصيدلي واشرح له أنك قد تناولت المزيد. احرص دائمًا على أخذ العلبة الخارجية من الدواء معك، حتى لو كانت فارغة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا نسيت استخدام هادليما</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا نسيت أن تتناول حقن هادليما، فيجب عليك تناول الجرعة التالية من حقن هادليما بمجرد تذكرك. ثم تناول الجرعة التالية في موعدها كما لو لم تنسى موعد الجرعة الأولى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا توقفت عن استخدام هادليما</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب أن تُناقش قرار التوقف عن استخدام هادليما مع طبيبك. ستظهر الأعراض عليك بعد التوقف عن تناول العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أي استفسارات بشأن استخدام هذا الدواء، أسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كل الأدوية يسبب هذا الدواء آثار جانبية، على الرغم من أنها لا تصيب الجميع. تتراوح معظم الآثار الجانبية من خفيفة إلى متوسطة. ومع ذلك، تكون معظم الحالات خطيرة وتطلب العلاج الطبي. تظهر الآثار الجانبية لمدة تصل إلى 4 أشهر أو أكثر بعد تناول حقنة هادليما الأخيرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">استدع الرعاية الطبية على الفور إذا لاحظت ظهور أي من الأعراض التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي شديد أو شَرَي أو علامات أخرى من الحساسية؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه واليدين والقدمين؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التنفس والبلع؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في التنفس مع الإجهاد أو الاستلقاء أو تورم القدمين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك في أقرب وقت ممكن إذا لاحظت ظهور أي من الأعراض التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علامات العدوى مثل الحمى والشعور بالغثيان والجروح ومشاكل الأسنان والحرقان أثناء التبول؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالضعف والإرهاق؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السعال؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الوخز؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التَخَدُّر؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ازدواج في الرؤية؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف الذراع أو الساق؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النتوء أو الجرح المفتوح الذي لا يلتئم؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علامات وأعراض اضطرابات الدم مثل الحمى المستمرة والكدمات والنزيف والشحوب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن تُشير الأعراض الواردة أعلاه إلى الآثار الجانبية الواردة أدناه، والتي تمت ملاحظتها أثناء استخدام أداليموماب:</p><p dir="RTL">&nbsp;</p><p dir="RTL">أعراض شائعة جدًا (تؤثر على أكثر من 1 في كل 10 أشخاص):</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات موضع الحقن (بما في ذلك ظهور آلام أو تورم أو احمرار أو حكة)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهابات الجهاز التنفسي (بما في ذلك البرد وسيلان الأنف والتهاب الجيوب الأنفية والالتهاب الرئوي)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في البطن؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان والقيء؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في العضلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أعراض شائعة (تؤثر على شخص 1 في كل 10 أشخاص):</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهابات خطيرة (بما في ذلك تسمم الدم والأنفلونزا)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الالتهابات المعوية (بما في ذلك التهاب المعدة والأمعاء)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهابات جلدية (بما في ذلك التهاب النسيج الخلوي الهربس النطاقي)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهابات الأذن؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهابات الفم (بما في ذلك التهابات الأسنان وقروح البرد)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهابات الجهاز التناسلي؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهابات المسالك البولية؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب فطري؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهابات المفاصل؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أورام حميدة؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الجلد؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ردود فعل الحساسية (بما في ذلك الحساسية الموسمية)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجفاف؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقلبات المزاج (بما في ذلك الاكتئاب)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القلق؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في النوم؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الإحساس مثل الوخز أو التنميل أو التَخَدُّر؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع نصفي؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض انْضِغاطُ جَذْرِ العَصَب (بما في ذلك آلام أسفل الظهر وآلام الساق)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الرؤية؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب العين؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الجفن وتورم العين؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوار (الإحساس بدوران الغرفة)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإحساس بسرعة ضربات القلب؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاحمرار؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ورم دموي (تورم مع تجلط الدم)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الربو؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق التنفس؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف معوي؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عسر الهضم (الانتفاخ وحرقة المعدة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض ارتجاع المريء؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مُتَلاَزِمَةٌ جُفافِيَّة (بما في ذلك جفاف العين والفم)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي والحكة؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكدمة؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الجلد (مثل الأكزيما)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كسر أظافر أصابع اليدين والقدمين؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة التعرق؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظهور الصدفية مرة أخرى أو من جديد؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تَشَنُّجٌات عَضَلِيّة؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دم في البول؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل الكلى؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الصدر؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الوذمة (تراكم السوائل في الجسم مما يؤدي إلى تضخم الأنسجة المصابة)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد الصفائح الدموية مما يُزيد من خطر حدوث نزيف أو كدمات؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تأخر الشفاء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أعراض غير شائعة (تؤثر على شخص 1 في كل 100 أشخاص):</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى الانتهازية (التي تشمل السل والالتهابات الأخرى التي تحدث عند انخفاض مقاومة المرض)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الالتهابات العصبية (بما في ذلك التهاب السحايا الفيروسي)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهابات العينين؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الالتهابات البكتيرية؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الرتج (التهاب وعدوى الأمعاء الغليظة)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السرطان، بما في ذلك سرطان جهاز لمفي (الغدد الليمفاوية) والورم الميلاني (نوع من سرطان الجلد)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاضطرابات المناعية التي تؤثر على الرئتين والجلد والعقد الليمفاوية (الأكثر شيوعًا كحالة تسمى الساركويد)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب وعائي (التهاب الأوعية الدموية)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرعاش؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اعتلال الأعصاب (تلف الأعصاب)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السكتة الدماغية؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان السمع والطنين؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإحساس بعدم انتظام ضربات القلب مثل الضربات المتفاوتة؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل القلب التي يُمكن أن تسبب ضيق التنفس أو تورم الكاحل؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احتشاء عَضَلة القلب؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كيس في جدار الشريان الرئيسي والتهاب وجلطة في الوريد؛ انسداد الأوعية الدموية؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمراض الرئة التي تسبب ضيق التنفس (بما في ذلك الالتهاب)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الانسداد الرئوي (انسداد في أحد شرايين الرئة)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الانصباب الجنبي (تجمع غير طبيعي للسوائل في حَيِّزٌ جَنْبِيّ)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس الذي يسبب آلامًا شديدة في البطن والظهر؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في البلع؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وذمة الوجه؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المرارة وحصى المرارة؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكبد الدهني (تراكم دهون في خلايا الكبد)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعرق الليلي؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الندبات؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انهيار العضلات الغير طبيعي؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الذئبة الحمامية الجهازية (بما في ذلك التهاب الجلد والقلب والرئة والمفاصل وأجهزة الجسم الأخرى)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انقطاع النوم؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الضعف الجنسي؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الالتهابات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أعراض نادرة (تؤثر على شخص 1 في كل 1,000 أشخاص):</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الدم (سرطان يصيب الدم ونخاع العظم)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل تحسسي شديد مع صَدْمَةٌ أَرَجِيَّة؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التصلُّب المضاعَف؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الأعصاب (مثل التهاب العصب البصري في العين ومتلازمة غيلان باريه وهي حالة قد تتسبب في ضعف العضلات والحساسية غير العادية والتنميل في الأذرع والجزء العلوي من الجسم)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; توقف القلب عن النبض؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التليف الرئوي (تندب الرئة)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ثقب معوي؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب كبدي؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تنشيط التهاب الكبدي بي،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكبد المناعي الذاتي (التهاب في الكبد بسبب جهاز المناعة في الجسم)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأوعية الدموية الجلدية (التهاب في الأوعية الدموية في الجلد)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة ستيفنز جونسون (أعراض مبكرة تشمل التوعك والحمى والصداع والطفح الجلدي)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وذمة الوجه المرتبطة بردود فعل الحساسية؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمامي عديدة الأشكال (طفح جلدي التهابي)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة تشبه الذئبة؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وذمة وعائية (تورم موضعي في الجلد)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل الجلد الحزازي (طفح جلدي أرجواني محمر وحكة)؛</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير معروفة</strong> (لا يمكن تقدير تكرارها من البيانات المتاحة):</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لمفومة الخلايا التائية الكبدية الطحالية (نوع نادر من السرطان، ومميت في أغلب الأحيان)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان خلايا ميركل (نوع من سرطان الجلد)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل كبدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالة متفاقمة معروفة بالتهاب الجلد والعضلات (تتسم بالطفح الجلدي مصحوبًا بضعف العضلات)</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد لا تظهر الأعراض الجانبية التي تمت ملاحظتها من أداليموماب، والتي يمكن اكتشافاها عن طريق فحوصات تحليل الدم. تشتمل هذه الأعراض على ما يلي:</p><p dir="RTL">&nbsp;</p><p dir="RTL">أعراض شائعة جدًا (تؤثر على أكثر من 1 في كل 10 أشخاص):</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص خلايا الدم البيضاء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص خلايا الدم الحمراء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة نسبة الدهون في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة إنزيمات الكبد</p><p dir="RTL">&nbsp;</p><p dir="RTL">أعراض شائعة (تؤثر على شخص 1 في كل 10 أشخاص):</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة خلايا الدم البيضاء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص عدد الصفائح الدموية في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع نسبة حمض اليوريك في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قياسات غير طبيعية في مستوى الصوديوم في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص الكالسيوم في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص الفوسفات في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة السكر في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة نازعة هيدروجين اللاكتات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود الأجساد المضادة في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص البوتاسيوم في الدم</p><p dir="RTL">&nbsp;</p><p dir="RTL">أعراض غير شائعة (تؤثر على شخص 1 في كل 100 أشخاص)</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;ارتفاع نسبة البيليروبين في الدم (فحص الدم للكبد)</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">أعراض نادرة (تؤثر على شخص 1 في كل 1,000 أشخاص):</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص عدد خلايا الدم البيضاء وخلايا الدم الحمراء، ونقص عدد الصفائح الدموية.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">إذا تفاقمت الأعراض الجانبية للدواء، أو في حال لاحظت أعراض جانبية أخرى غير مدرجة في هذه النشرة، يرجى إخبار طبيبك الخاص أو الصيدلي.</p><p>&nbsp;</p><p dir="RTL">للإبلاغ حول الأعراض الجانبية التي قد تحدث يرجى التواصل عبر العناوين التالية:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المملكة العربية السعودية</p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المركز الوطني للتيقظ الدوائي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفاكس: 7662-205-11-966+</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مركز الاتصال الموحد: 19999</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://ade.sfda.gov.sa &nbsp;</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">هذا المنتج هو دواء طبي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; منتج يؤثر على صحتك واستخدامه بما يتناقض مع التعليمات يعد أمرا خطيرا بالنسبة لك</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اتبع بدقة وصفة الطبيب، وطريقة الاستعمال وتعليمات الصيدلي الذي باعك هذا المستحضر الدوائي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن الطبيب والصيدلي هما أصحاب الخبرة فيما يتعلق بهذا الدواء، وفوائده وأضراره.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تقطع بنفسك فترة العلاج التي حددها لك الطبيب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تكرر هذه الوصفة الطبية دون استشارة طبيبك الخاص.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تُحفظ كافة الأدوية بعيدًا عن متناول الأطفال.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ بعيدًا عن متناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على الشريط والعلبة بعد عبارة (EXP) تاريخ انتهاء الصلاحية. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من هذا الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُحفَظ في الثلاجة عند درجة حرارة (2-8 درجة مئوية) يُحظَر تجميد هذا الدواء.</p><p dir="RTL">&nbsp;</p><p>تُحفَظ الحقنة مسبقة التعبئة في العلبة الخارجية لحمايتها من الضوء.</p><p dir="RTL">&nbsp;طرق التخزين البديلة:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;إذا لزم الأمر (إذا كنت مسافرًا على سبيل المثال)، يمكن تخزين الحقنة المعبأة بدواء هادليما في درجة حرارة الغرفة (25 درجة مئوية) لمدة لا تزيد عن 28 يومًا -تأكد من حفظها بعيدًا عن الضوء. بمجرد إخراج الحقنة المعبأة من الثلاجة إلى التخزين في درجة حرارة الغرفة، يجب استخدام الحقنة في مدة أقصاها 28 يومًا أو يتم التخلص منها، حتى ولو حُفِظت مرة أخرى في الثلاجة.</p><p dir="RTL">يجب عليك تسجيل تاريخ إخراج الحقنة من الثلاجة، والتاريخ الذي يجب التخلص فيه منها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من الأدوية بإلقائها في مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. هذه الإجراءات ستساعدكم على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;- المادة الفعالة هي أداليموماب</p><p dir="RTL">- يحتوي الدواء على مكونات أخرى مثل سترات الصوديوم، ومونوهيدرات حامض الستريك، ومونوهيدرات هيدروكلوريد الهستيدين، والسربيتول، وبوليسوربات 20، ومياه للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">محلول هادليما 40 مجم (Hadlima) للحقن في شكل حقنة جاهزة للاستعمال مزود على 0.8 مل على شكل محلول صافي وعديم اللون.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">يتوفر هادليما في عبوات تحتوي على حقنتين (حُقن) مسبقة التعبئة مكونة من (زجاج من الفئة الأولي) مزودة بإبرة من الفولاذ المقاوم للصدأ وغطاء واقي صلب للإبرة ومكبس مطاطي وذراع مكبس وجسم حماية وشفة إصبع.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مالك حق التفويض بالتسويق:</p><p dir="RTL">مالك حق التسويق: &nbsp;Samsung Bioepis</p><p dir="RTL">سامسونج بايوبيس،</p><p dir="RTL">76 سونقدوقيوياك-رو،يونسو-غو،</p><p dir="RTL">انشيون، 21987</p><p dir="RTL">جمهورية كوريا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">شركة التصنيع</p><p dir="RTL">شركة كاتالنت بلجيكا</p><p dir="RTL">فونت سانت لاندري، 10</p><p dir="RTL">بروكسل، 1120</p><p dir="RTL">بلجيكا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            هذه النشرة تعتبر اخر نسخة منقحة بتاريخ 08/2023، ورقم النسخة  2.2.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hadlima 40 mg solution for injection in pre-filled syringe
Hadlima 40 mg solution for injection in pre-filled pen

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hadlima 40 mg solution for injection in pre-filled syringe
Each 0.8 ml single dose pre-filled syringe contains 40 mg of adalimumab.

Hadlima 40 mg solution for injection in pre-filled pen
Each 0.8 ml single dose pre-filled pen contains 40 mg of adalimumab.

Adalimumab is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary cells.

Excipient(s) with known effect

This medicinal product contains 20.0 mg sorbitol.
For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection.
Clear, colourless solution.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Rheumatoid arthritis</u></p><p>&nbsp;</p><p>Hadlima in combination with methotrexate, is indicated for:</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.</p><p>&nbsp;</p><p>Hadlima can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.</p><p>&nbsp;</p><p>Adalimumab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.</p><p>&nbsp;</p><p><u>Juvenile idiopathic arthritis</u></p><p>&nbsp;</p><p><em>Polyarticular juvenile idiopathic arthritis</em></p><p>&nbsp;</p><p>Hadlima in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2&nbsp;years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Hadlima can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5.1). Adalimumab has not been studied in patients aged less than 2&nbsp;years.</p><p><em>&nbsp;</em></p><p><em>Enthesitis-related arthritis</em></p><p>&nbsp;</p><p>Hadlima is indicated for the treatment of active enthesitis-related arthritis in patients, 6&nbsp;years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5.1).</p><p>&nbsp;</p><p><u>Axial spondyloarthritis</u></p><p><u>&nbsp;</u></p><p><em>Ankylosing spondylitis (AS)</em></p><p><em>&nbsp;</em></p><p>Hadlima is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.</p><p>&nbsp;</p><p><em>Axial spondyloarthritis without radiographic evidence of AS</em></p><p><em>&nbsp;</em></p><p>Hadlima is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and / or MRI, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs.</p><p>&nbsp;</p><p><u>Psoriatic arthritis</u></p><p><u>&nbsp;</u></p><p>Hadlima is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate.</p><p>&nbsp;</p><p>Adalimumab has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease (see Section 5.1) and to improve physical function.</p><p>&nbsp;</p><p><u>Psoriasis</u></p><p><u>&nbsp;</u></p><p>Hadlima is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy.</p><p>&nbsp;</p><p><u>Paediatric plaque psoriasis</u></p><p>&nbsp;</p><p>Hadlima is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4&nbsp;years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies.</p><p>&nbsp;</p><p><u>Hidradenitis suppurativa (HS)</u></p><p>&nbsp;</p><p>Hadlima is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12&nbsp;years of age with an inadequate response to conventional systemic HS therapy (see sections 5.1 and 5.2).</p><p>&nbsp;</p><p><u>Crohn&rsquo;s disease</u></p><p><u>&nbsp;</u></p><p>Hadlima is indicated for treatment of moderately to severely active Crohn&rsquo;s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.</p><p>&nbsp;</p><p><u>Paediatric Crohn&#39;s disease</u></p><p>&nbsp;</p><p>Hadlima is indicated for the treatment of moderately to severely active Crohn&#39;s disease in paediatric patients (from 6&nbsp;years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies.</p><p>&nbsp;</p><p><u>Ulcerative colitis </u></p><p><u>&nbsp;</u></p><p>Hadlima is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.</p><p>&nbsp;</p><p><u>Uveitis</u></p><p>&nbsp;</p><p>Hadlima is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid- sparing, or in whom corticosteroid treatment is inappropriate.</p><p>&nbsp;</p><p><u>Paediatric Uveitis</u></p><p>&nbsp;</p><p>Hadlima is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2&nbsp;years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hadlima treatment should be initiated and supervised by specialist physicians experienced in the diagnosis and treatment of conditions for which Hadlima is indicated. Ophthalmologists are advised to consult with an appropriate specialist before initiation of treatment with Hadlima (see section 4.4). Patients treated with Hadlima should be given the Patient Reminder Card.</p><p>&nbsp;</p><p>After proper training in injection technique, patients may self-inject with Hadlima if their physician determines that it is appropriate and with medical follow-up as necessary.</p><p>&nbsp;</p><p>During treatment with Hadlima, other concomitant therapies (e.g., corticosteroids and/or immunomodulatory agents) should be optimised.</p><p>&nbsp;</p><p><u>Posology</u></p><p><u>&nbsp;</u></p><p><em>Rheumatoid arthritis</em></p><p><em>&nbsp;</em></p><p>The recommended dose of Hadlima for adult patients with rheumatoid arthritis is 40&nbsp;mg adalimumab administered every other week as a single dose via subcutaneous injection. Methotrexate should be continued during treatment with Hadlima.</p><p>&nbsp;</p><p>Glucocorticoids, salicylates, nonsteroidal anti-inflammatory drugs, or analgesics can be continued during treatment with Hadlima. Regarding combination with disease modifying anti-rheumatic drugs other than methotrexate see sections 4.4 and 5.1.</p><p>&nbsp;</p><p>In monotherapy, some patients who experience a decrease in their response to Hadlima 40&nbsp;mg every other week dosing may benefit from an increase in dosage to 40&nbsp;mg adalimumab every week or 80&nbsp;mg every other week.</p><p>&nbsp;</p><p>Available data suggest that the clinical response is usually achieved within 12&nbsp;weeks of treatment. Continued therapy should be reconsidered in a patient not responding within this time period.</p><p>&nbsp;</p><p><em><u>Dose </u></em><em><u>i</u></em><em><u>nterruption </u></em></p><p><em><u>&nbsp;</u></em></p><p>There may be a need for dose interruption, for instance before surgery or if a serious infection occurs.</p><p>&nbsp;</p><p>Available data suggest that re-introduction of adalimumab after discontinuation for 70&nbsp;days or longer resulted in the same magnitudes of clinical response and similar safety profile as before dose interruption.</p><p>&nbsp;</p><p><em>Ankylosing spondylitis, axial spondyloarthritis without radiographic evidence of AS and psoriatic arthritis</em></p><p><em>&nbsp;</em></p><p>The recommended dose of Hadlima for patients with ankylosing spondylitis, axial spondyloarthritis without radiographic evidence of AS and for patients with psoriatic arthritis is 40&nbsp;mg adalimumab administered every other week as a single dose via subcutaneous injection.</p><p>&nbsp;</p><p>Available data suggest that the clinical response is usually achieved within 12&nbsp;weeks of treatment. Continued therapy should be reconsidered in a patient not responding within this time period.</p><p>&nbsp;</p><p><em>Psoriasis </em></p><p><em>&nbsp;</em></p><p>The recommended dose of Hadlima for adult patients is an initial dose of 80&nbsp;mg administered subcutaneously, followed by 40&nbsp;mg subcutaneously given every other week starting one week after the initial dose.</p><p>&nbsp;</p><p>Continued therapy beyond 16&nbsp;weeks should be carefully reconsidered in a patient not responding within this time period.</p><p>&nbsp;</p><p>Beyond 16&nbsp;weeks, patients with inadequate response to Hadlima 40&nbsp;mg every other week may benefit from an increase in dosage to 40&nbsp;mg every week or 80 mg every other week. The benefits and risks of continued 40&nbsp;mg weekly or 80&nbsp;mg every other week therapy should be carefully reconsidered in a patient with an inadequate response after the increase in dosage (see section 5.1). If adequate response is achieved with 40&nbsp;mg every week or 80&nbsp;mg every other week, the dosage may subsequently be reduced to 40&nbsp;mg every other week.</p><p>&nbsp;</p><p><em>Hidradenitis suppurativa</em></p><p><em>&nbsp;</em></p><p>The recommended Hadlima dose regimen for adult patients with hidradenitis suppurativa (HS) is 160&nbsp;mg initially at Day 1 (given as four 40&nbsp;mg injections in one day or as two 40&nbsp;mg injections per day for two consecutive days), followed by 80&nbsp;mg two weeks later at Day 15 (given as two 40&nbsp;mg injections in one day). Two weeks later (Day 29) continue with a dose of 40&nbsp;mg every week or 80&nbsp;mg every other week (given as two 40&nbsp;mg injections in one day). Antibiotics may be continued during treatment with Hadlima if necessary. It is recommended that the patient should use a topical antiseptic wash on their HS lesions on a daily basis during treatment with Hadlima.</p><p>&nbsp;</p><p>Continued therapy beyond 12&nbsp;weeks should be carefully reconsidered in a patient with no improvement within this time period.</p><p>&nbsp;</p><p>Should treatment be interrupted, Hadlima 40&nbsp;mg every week or 80&nbsp;mg every other week may be re-introduced (see section 5.1).</p><p>&nbsp;</p><p>The benefit and risk of continued long-term treatment should be periodically evaluated (see section 5.1).</p><p>&nbsp;</p><p><em>Crohn&rsquo;s disease</em></p><p><em>&nbsp;</em></p><p>The recommended Hadlima induction dose regimen for adult patients with moderately to severely active Crohn&rsquo;s disease is 80&nbsp;mg at week 0 followed by 40&nbsp;mg at week 2. In case there is a need for a more rapid response to therapy, the regimen 160&nbsp;mg at week 0 (given as four 40&nbsp;mg injections in one day or as two 40&nbsp;mg injections per day for two consecutive days), 80&nbsp;mg at week 2 (given as two 40&nbsp;mg injections in one day), can be used with the awareness that the risk for adverse events is higher during induction.</p><p>&nbsp;</p><p>After induction treatment, the recommended dose is 40&nbsp;mg every other week via subcutaneous injection. Alternatively, if a patient has stopped Hadlima and signs and symptoms of disease recur, Hadlima may be re-administered. There is little experience from re-administration after more than 8 weeks since the previous dose.</p><p>&nbsp;</p><p>During maintenance treatment, corticosteroids may be tapered in accordance with clinical practice guidelines.</p><p>&nbsp;</p><p>Some patients who experience decrease in their response to Hadlima 40&nbsp;mg every other week may benefit from an increase in dosage to 40&nbsp;mg Hadlima every week or 80&nbsp;mg every other week.</p><p>&nbsp;</p><p>Some patients who have not responded by week 4 may benefit from continued maintenance therapy through week 12. Continued therapy should be carefully reconsidered in a patient not responding within this time period.</p><p>&nbsp;</p><p><em>Ulcerative colitis</em></p><p><em>&nbsp;</em></p><p>The recommended Hadlima induction dose regimen for adult patients with moderate to severe ulcerative colitis is 160&nbsp;mg at week 0 (given as four 40&nbsp;mg injections in one day or as two 40&nbsp;mg injections per day for two consecutive days) and 80&nbsp;mg at week 2 (given as two 40&nbsp;mg injections in one day). After induction treatment, the recommended dose is 40&nbsp;mg every other week via subcutaneous injection.</p><p>&nbsp;</p><p>During maintenance treatment, corticosteroids may be tapered in accordance with clinical practice guidelines.</p><p>&nbsp;</p><p>Some patients who experience decrease in their response to Hadlima 40&nbsp;mg every other week may benefit from an increase in dosage to 40&nbsp;mg Hadlima every week or 80&nbsp;mg every other week.</p><p>&nbsp;</p><p>Available data suggest that the clinical response is usually achieved within 2-8&nbsp;weeks of treatment. Hadlima therapy should not be continued in patients failing to respond within this time period.</p><p><u>&nbsp;</u></p><p><em>Uveitis</em></p><p>&nbsp;</p><p>The recommended dose of Hadlima for adult patients with uveitis is an initial dose of 80&nbsp;mg, followed by 40&nbsp;mg given every other week starting one week after the initial dose. There is limited experience in the initiation of treatment with Hadlima alone. Treatment with Hadlima can be initiated in combination with corticosteroids and/or with other non-biologic immunomodulatory agents. Concomitant corticosteroids may be tapered in accordance with clinical practice starting two weeks after initiating treatment with Hadlima.</p><p>&nbsp;</p><p>It is recommended that the benefit and risk of continued long-term treatment should be evaluated on a yearly basis (see section 5.1).</p><p><u>&nbsp;</u></p><p><u>Special populations</u></p><p><u>&nbsp;</u></p><p><em>Elderly </em></p><p><u>&nbsp;</u></p><p>No dose adjustment is required.</p><p>&nbsp;</p><p><em>R</em><em>enal and/or hepatic </em><em>impairment</em></p><p><u>&nbsp;</u></p><p>Adalimumab has not been studied in these patient populations. No dose recommendations can be made.</p><p>&nbsp;</p><p><em>Paediatric </em><em>p</em><em>opulation</em></p><p><u>&nbsp;</u></p><p>Hadlima is only available as 40&nbsp;mg pre-filled syringe and pre-filled pen. Thus, it is not possible to administer Hadlima to<u> </u>paediatric patients that require less than a full 40&nbsp;mg dose. If an alternate dose is required, other adalimumab products offering such an option should be used.</p><p>&nbsp;</p><p><em><u>Juvenile idiopathic arthritis</u></em></p><p>&nbsp;</p><p>Polyarticular juvenile idiopathic arthritis from 2&nbsp;years of age</p><p><em>&nbsp;</em></p><p>The recommended dose of Hadlima for patients with polyarticular juvenile idiopathic arthritis from 2&nbsp;years of age is based on body weight (Table 1). Hadlima is administered every other week via subcutaneous injection.</p><p>&nbsp;</p><p><strong>Table 1. Hadlima</strong><strong> Dose for Patients with Polyarticular Juvenile Idiopathic Arthr</strong><strong>i</strong><strong>tis </strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Patient Weight</strong></p></td><td><p><strong>Dosing Regimen</strong></p></td></tr><tr><td><p>10&nbsp;kg to &lt;&nbsp;30&nbsp;kg</p></td><td><p>-</p></td></tr><tr><td><p>&ge;&nbsp;30&nbsp;kg</p></td><td><p>40&nbsp;mg every other week</p></td></tr></tbody></table><p>- Not applicable, Hadlima is only available as 40&nbsp;mg pre-filled syringe and pre-filled pen</p><p>&nbsp;</p><p>Available data suggest that clinical response is usually achieved within 12 weeks of treatment. Continued therapy should be carefully reconsidered in a patient not responding within this time period.</p><p>&nbsp;</p><p>There is no relevant use of adalimumab in patients aged less than 2&nbsp;years for this indication.</p><p>&nbsp;</p><p><em><u>Enthesitis-related arthritis</u></em></p><p>&nbsp;</p><p>The recommended dose of Hadlima for patients with enthesitis-related arthritis from 6&nbsp;years of age is based on body weight (Table 2). Hadlima is administered every other week via subcutaneous injection.</p><p>&nbsp;</p><p><strong>Table 2. Hadlima</strong><strong> Dose for Patients with Enthesitis-Related Arthritis</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Patient Weight</strong></p></td><td><p><strong>Dosing Regimen</strong></p></td></tr><tr><td><p>15&nbsp;kg to &lt;&nbsp;30&nbsp;kg</p></td><td><p>-</p></td></tr><tr><td><p>&ge;&nbsp;30&nbsp;kg</p></td><td><p>40&nbsp;mg every other week</p></td></tr></tbody></table><p>- Not applicable, Hadlima is only available as 40&nbsp;mg pre-filled syringe and pre-filled pen</p><p>&nbsp;</p><p>Adalimumab has not been studied in patients with enthesitis-related arthritis aged less than 6&nbsp;years.</p><p>&nbsp;</p><p><em><u>Paediatric plaque psoriasis</u></em></p><p>&nbsp;</p><p>The recommended Hadlima dose for patients with plaque psoriasis from 4 to 17 years of age is based on body weight (Table 3). Hadlima is administered via subcutaneous injection.</p><p>&nbsp;</p><p><strong>Table 3. Hadlima</strong><strong> Dose for Paediatric Patients with Plaque Psoriasis</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Patient Weight</strong></p></td><td><p><strong>Dosing Regimen</strong></p></td></tr><tr><td><p>15&nbsp;kg to &lt;&nbsp;30&nbsp;kg</p></td><td><p>-</p></td></tr><tr><td><p>&ge;&nbsp;30&nbsp;kg</p></td><td><p>Initial dose of 40&nbsp;mg, followed by 40&nbsp;mg given every other week starting one week after the initial dose</p></td></tr></tbody></table><p>- Not applicable, Hadlima is only available as 40&nbsp;mg pre-filled syringe and pre-filled pen</p><p>&nbsp;</p><p>Continued therapy beyond 16&nbsp;weeks should be carefully considered in a patient not responding within this time period.</p><p>&nbsp;</p><p>If retreatment with Hadlima is indicated, the above guidance on dose and treatment duration should be followed.</p><p>&nbsp;</p><p>The safety of adalimumab in paediatric patients with plaque psoriasis has been assessed for a mean of 13&nbsp;months.</p><p>&nbsp;</p><p>Patients above 4&nbsp;years of age but with a weight less than 30&nbsp;kg are not possible to dose with this product. There is no relevant use of adalimumab in children aged less than 4&nbsp;years for this indication.</p><p><em>&nbsp;</em></p><p><em>Adolescent hidradenitis suppurativa (from 12&nbsp;years of age, weighing at least 30&nbsp;kg)</em></p><p>&nbsp;</p><p>There are no clinical trials with adalimumab in adolescent patients with HS. The posology of adalimumab in these patients has been determined from pharmacokinetic modelling and simulation (see section 5.2).</p><p>&nbsp;</p><p>The recommended Hadlima dose is 80&nbsp;mg at week 0 followed by 40&nbsp;mg every other week starting at week 1 via subcutaneous injection.</p><p>&nbsp;</p><p>In adolescent patients with inadequate response to Hadlima 40&nbsp;mg every other week, an increase in dosage to 40&nbsp;mg every week or 80&nbsp;mg every other week may be considered.</p><p>&nbsp;</p><p>Antibiotics may be continued during treatment with Hadlima if necessary. It is recommended that the patient should use a topical antiseptic wash on their HS lesions on a daily basis during treatment with Hadlima.</p><p>&nbsp;</p><p>Continued therapy beyond 12&nbsp;weeks should be carefully reconsidered in a patient with no improvement within this time period.</p><p>&nbsp;</p><p>Should treatment be interrupted, Hadlima may be re-introduced as appropriate.</p><p>&nbsp;</p><p>The benefit and risk of continued long-term treatment should be periodically evaluated (see adult data in section 5.1).</p><p>&nbsp;</p><p>There is no relevant use of adalimumab in children aged less than 12&nbsp;years in this indication.</p><p>&nbsp;</p><p><em><u>Paediatric Crohn&#39;s disease</u></em></p><p>&nbsp;</p><p>The recommended dose of Hadlima for patients with Crohn&rsquo;s disease from 6 to 17&nbsp;years of age is based on body weight (Table 4). Hadlima is administered via subcutaneous injection.</p><p>&nbsp;</p><p><strong>Table 4. Hadlima</strong><strong> Dose for Paediatric Patients with Crohn&rsquo;s disease</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Patient Weight</strong></p></td><td style="vertical-align:top"><p><strong>Induction Dose</strong></p></td><td style="vertical-align:top"><p><strong>Maintenance</strong></p><p><strong>Dose</strong></p><p><strong>Starting at</strong></p><p><strong>Week 4</strong></p></td></tr><tr><td><p>&lt;&nbsp;40&nbsp;kg</p></td><td style="vertical-align:top"><p>-</p></td><td><p>-</p></td></tr><tr><td><p>&ge;&nbsp;40&nbsp;kg</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp; 80&nbsp;mg at week 0 and 40&nbsp;mg at week 2</p><p>&nbsp;</p><p>In case there is a need for a more rapid response to therapy with the awareness that the risk for adverse events may be higher with use of the higher induction dose, the following dose may be used:</p><p>&middot;&nbsp;&nbsp;&nbsp; 160&nbsp;mg at week 0 and 80&nbsp;mg at week 2</p></td><td><p>40&nbsp;mg every</p><p>other week</p></td></tr></tbody></table><p>- Not applicable, Hadlima is only available as 40 mg pre-filled syringe and pre-filled pen</p><p>&nbsp;</p><p>Patients who experience insufficient response may benefit from an increase in dosage:</p><p>&nbsp;&nbsp; &lt;&nbsp;40&nbsp;kg: Not applicable, Hadlima is only available as 40&nbsp;mg pre-filled syringe and pre-filled pen</p><p>&nbsp;&nbsp; &ge;&nbsp;40&nbsp;kg: 40&nbsp;mg every week or 80&nbsp;mg every other week</p><p>&nbsp;</p><p>Continued therapy should be carefully considered in a subject not responding by week 12.</p><p>&nbsp;</p><p>There is no relevant use of adalimumab in children aged below 6&nbsp;years for this indication.</p><p>&nbsp;</p><p><em>Paediatric ulcerative colitis</em></p><p>&nbsp;</p><p>The safety and efficacy of adalimumab in children aged 4-17&nbsp;years have not yet been established. No data are available. There is no relevant use of Hadlima in children aged less than 4&nbsp;years for this indication.</p><p>&nbsp;</p><p><em>Psoriatic arthritis and axial spondyloarthritis including ankylosing spondyliti</em>s</p><p>&nbsp;</p><p>There is no relevant use of adalimumab in the paediatric population for the indications of ankylosing spondylitis and psoriatric arthritis.</p><p>&nbsp;</p><p><em>Paediatric uveitis</em></p><p>&nbsp;</p><p>The recommended dose of Hadlima for paediatric patients with uveitis from 2&nbsp;years of age is based on body weight (Table 5). Hadlima is administered via subcutaneous injection.</p><p>&nbsp;</p><p>In paediatric uveitis, there is no experience in the treatment with adalimumab without concomitant treatment with methotrexate.</p><p>&nbsp;</p><p><strong>Table 5 Hadlima</strong><strong> Dose for Paediatric Patients with </strong><strong>Uveitis</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Patient Weight</strong></p></td><td><p><strong>Dosing Regimen</strong></p></td></tr><tr><td><p>&lt; 30&nbsp;kg</p></td><td><p>-</p></td></tr><tr><td><p>&ge; 30&nbsp;kg</p></td><td><p>40&nbsp;mg every other week in combination with methotrexate</p></td></tr></tbody></table><p>- Not applicable, Hadlima is only available as 40 mg pre-filled syringe and pre-filled pen</p><p>&nbsp;</p><p>When Hadlima therapy is initiated, a loading dose of 40&nbsp;mg for patients &lt;&nbsp;30&nbsp;kg or 80&nbsp;mg for patients &ge;&nbsp;30&nbsp;kg may be administered one week prior to the start of maintenance therapy. No clinical data are available on the use of an adalimumab loading dose in children &lt;&nbsp;6&nbsp;years of age (see section 5.2).</p><p>&nbsp;</p><p>There is no relevant use of adalimumab in children aged less than 2 years in this indication.</p><p>&nbsp;</p><p>It is recommended that the benefit and risk of continued long-term treatment should be evaluated on a yearly basis (see section 5.1).</p><p>&nbsp;</p><p><u>Method of administration </u></p><p><u>&nbsp;</u></p><p>Hadlima is administered by subcutaneous injection. Full instructions for use are provided in the package leaflet.</p><p>&nbsp;</p><p>A 40&nbsp;mg pre-filled syringe and pre-filled pen are available for patients to administer a full 40&nbsp;mg dose.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Active tuberculosis or other severe infections such as sepsis, and opportunistic infections (see section 4.4).

Moderate to severe heart failure (NYHA class III/IV) (see section 4.4).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability</u></p><p>&nbsp;</p><p>In order to improve traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p>&nbsp;</p><p><u>Infections</u></p><p><u>&nbsp;</u></p><p>Patients taking TNF-antagonists are more susceptible to serious infections. Impaired lung function may increase the risk for developing infections. Patients must therefore be monitored closely for infections, including tuberculosis, before, during and after treatment with Hadlima. Because the elimination of adalimumab may take up to four months, monitoring should be continued throughout this period.</p><p>&nbsp;</p><p>Treatment with Hadlima should not be initiated in patients with active infections including chronic or localised infections until infections are controlled. In patients who have been exposed to tuberculosis and patients who have travelled in areas of high risk of tuberculosis or endemic mycoses, such as histoplasmosis, coccidioidomycosis, or blastomycosis, the risk and benefits of treatment with Hadlima should be considered prior to initiating therapy (see <em>Other opportunistic infections</em>).</p><p>&nbsp;</p><p>Patients who develop a new infection while undergoing treatment with Hadlima, should be monitored closely and undergo a complete diagnostic evaluation. Administration of Hadlima should be discontinued if a patient develops a new serious infection or sepsis, and appropriate antimicrobial or antifungal therapy should be initiated until the infection is controlled. Physicians should exercise caution when considering the use of Hadlima in patients with a history of recurring infection or with underlying conditions which may predispose patients to infections, including the use of concomitant immunosuppressive medications.</p><p>&nbsp;</p><p><em>Serious infections</em></p><p><em>&nbsp;</em></p><p>Serious infections, including sepsis, due to bacterial, mycobacterial, invasive fungal, parasitic, viral, or other opportunistic infections such as listeriosis, legionellosis and pneumocystis have been reported in patients receiving adalimumab.</p><p>&nbsp;</p><p>Other serious infections seen in clinical trials include pneumonia, pyelonephritis, septic arthritis and septicaemia. Hospitalisation or fatal outcomes associated with infections have been reported.</p><p><em>&nbsp;</em></p><p><em>Tuberculosis</em></p><p><em>&nbsp;</em></p><p>Tuberculosis, including reactivation and new onset of tuberculosis, has been reported in patients receiving adalimumab. Reports included cases of pulmonary and extra-pulmonary (i.e. disseminated) tuberculosis.</p><p>&nbsp;</p><p>Before initiation of therapy with Hadlima, all patients must be evaluated for both active or inactive (&ldquo;latent&rdquo;) tuberculosis infection. This evaluation should include a detailed medical assessment of patient history of tuberculosis or possible previous exposure to people with active tuberculosis and previous and/or current immunosuppressive therapy. Appropriate screening tests (i.e. tuberculin skin test and chest X-ray) should be performed in all patients (local recommendations may apply). It is recommended that the conduct and results of these tests are recorded in the Patient Reminder Card. Prescribers are reminded of the risk of false negative tuberculin skin test results, especially in patients who are severely ill or immunocompromised.</p><p>&nbsp;</p><p>If active tuberculosis is diagnosed, Hadlima therapy must not be initiated (see section 4.3).</p><p>&nbsp;</p><p>In all situations described below, the benefit/risk balance of therapy should be very carefully considered.</p><p>&nbsp;</p><p>If latent tuberculosis is suspected, a physician with expertise in the treatment of tuberculosis should be consulted.</p><p>&nbsp;</p><p>If latent tuberculosis is diagnosed, appropriate treatment must be started with anti-tuberculosis prophylaxis treatment before the initiation of Hadlima, and in accordance with local recommendations.</p><p>&nbsp;</p><p>Use of anti-tuberculosis prophylaxis treatment should also be considered before the initiation of Hadlima in patients with several or significant risk factors for tuberculosis despite a negative test for tuberculosis and in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed.</p><p>&nbsp;</p><p>Despite prophylactic treatment for tuberculosis, cases of reactivated tuberculosis have occurred in patients treated with adalimumab. Some patients who have been successfully treated for active tuberculosis have redeveloped tuberculosis while being treated with adalimumab.</p><p>&nbsp;</p><p>Patients should be instructed to seek medical advice if signs/symptoms suggestive of a tuberculosis infection (e.g., persistent cough, wasting/weight loss, low grade fever, listlessness) occur during or after therapy with Hadlima.</p><p>&nbsp;</p><p><em>Other opportunistic infections</em></p><p><em>&nbsp;</em></p><p>Opportunistic infections, including invasive fungal infections have been observed in patients receiving adalimumab. These infections have not consistently been recognised in patients taking TNF-antagonists and this has resulted in delays in appropriate treatment, sometimes resulting in fatal outcomes.</p><p>&nbsp;</p><p>For patients who develop the signs and symptoms such as fever, malaise, weight loss, sweats, cough, dyspnoea, and/or pulmonary infiltrates or other serious systemic illness with or without concomitant shock an invasive fungal infection should be suspected and administration of Hadlima should be promptly discontinued. Diagnosis and administration of empiric antifungal therapy in these patients should be made in consultation with a physician with expertise in the care of patients with invasive fungal infections.</p><p>&nbsp;</p><p><u>Hepatitis B reactivation </u></p><p><u>&nbsp;</u></p><p>Reactivation of hepatitis B has occurred in patients receiving a TNF-antagonist including adalimumab, who are chronic carriers of this virus (i.e. surface antigen positive). Some cases have had a fatal outcome. Patients should be tested for HBV infection before initiating treatment with Hadlima. For patients who test positive for hepatitis B infection, consultation with a physician with expertise in the treatment of hepatitis B is recommended.</p><p>&nbsp;</p><p>Carriers of HBV who require treatment with Hadlima should be closely monitored for signs and symptoms of active HBV infection throughout therapy and for several months following termination of therapy. Adequate data from treating patients who are carriers of HBV with anti-viral therapy in conjunction with TNF-antagonist therapy to prevent HBV reactivation are not available. In patients who develop HBV reactivation, Hadlima should be stopped and effective anti-viral therapy with appropriate supportive treatment should be initiated.</p><p>&nbsp;</p><p><u>Neurological events </u></p><p><u>&nbsp;</u></p><p>TNF-antagonists including adalimumab have been associated in rare instances with new onset or exacerbation of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disease including multiple sclerosis and optic neuritis, and peripheral demyelinating disease, including Guillain-Barr&eacute; syndrome. Prescribers should exercise caution in considering the use of Hadlima in patients with pre-existing or recent-onset central or peripheral nervous system demyelinating disorders; discontinuation of Hadlima should be considered if any of these disorders develop. There is a known association between intermediate uveitis and central demyelinating disorders. Neurologic evaluation should be performed in patients with non-infectious intermediate uveitis prior to the initiation of Hadlima therapy and regularly during treatment to assess for pre-existing or developing central demyelinating disorders.</p><p>&nbsp;</p><p><u>Allergic reactions</u></p><p><u>&nbsp;</u></p><p>Serious allergic reactions associated with adalimumab were rare during clinical trials. Non-serious allergic reactions associated with adalimumab were uncommon during clinical trials. Reports of serious allergic reactions including anaphylaxis have been received following adalimumab administration. If an anaphylactic reaction or other serious allergic reaction occurs, administration of Hadlima should be discontinued immediately and appropriate therapy initiated.</p><p>&nbsp;</p><p><u>Immunosuppression</u></p><p><u>&nbsp;</u></p><p>In a study of 64 patients with rheumatoid arthritis that were treated with adalimumab, there was no evidence of depression of delayed-type hypersensitivity, depression of immunoglobulin levels, or change in enumeration of effector T-, B, - NK-cells, monocyte/macrophages, and neutrophils.</p><p>&nbsp;</p><p><u>Malignancies and lymphoproliferative disorders</u></p><p><u>&nbsp;</u></p><p>In the controlled portions of clinical trials of TNF-antagonists, more cases of malignancies including lymphoma have been observed among patients receiving a TNF-antagonist compared with control patients. However, the occurrence was rare. In the post marketing setting, cases of leukaemia have been reported in patients treated with a TNF-antagonist. There is an increased background risk for lymphoma and leukaemia in rheumatoid arthritis patients with long-standing, highly active, inflammatory disease, which complicates the risk estimation. With the current knowledge, a possible risk for the development of lymphomas, leukaemia, and other malignancies in patients treated with a TNF-antagonist cannot be excluded.</p><p>&nbsp;</p><p>Malignancies, some fatal, have been reported among children, adolescents and young adults (up to 22&nbsp;years of age) treated with TNF-antagonists (initiation of therapy &le;18&nbsp;years of age), including adalimumab in the post marketing setting. Approximately half the cases were lymphomas. The other cases represented a variety of different malignancies and included rare malignancies usually associated with immunosuppression. A risk for the development of malignancies in children and adolescents treated with TNF-antagonists cannot be excluded.</p><p>&nbsp;</p><p>Rare postmarketing cases of hepatosplenic T-cell lymphoma have been identified in patients treated with adalimumab. This rare type of T-cell lymphoma has a very aggressive disease course and is usually fatal. Some of these hepatosplenic T-cell lymphomas with adalimumab have occurred in young adult patients on concomitant treatment with azathioprine or 6-mercaptopurine used for inflammatory bowel disease. The potential risk with the combination of azathioprine or 6-mercaptopurine and adalimumab should be carefully considered. A risk for the development of hepatosplenic T-cell lymphoma in patients treated with Hadlima cannot be excluded (see section 4.8).</p><p>&nbsp;</p><p>No studies have been conducted that include patients with a history of malignancy or in whom treatment with adalimumab is continued following development of malignancy. Thus additional caution should be exercised in considering adalimumab treatment of these patients (see section 4.8).</p><p>&nbsp;</p><p>All patients, and in particular patients with a medical history of extensive immunosuppressant therapy or psoriasis patients with a history of PUVA treatment should be examined for the presence of non-melanoma skin cancer prior to and during treatment with Hadlima. Melanoma and Merkel cell carcinoma have also been reported in patients treated with TNF-antagonists including adalimumab (see section 4.8).</p><p>&nbsp;</p><p>In an exploratory clinical trial evaluating the use of another TNF-antagonist, infliximab, in patients with moderate to severe chronic obstructive pulmonary disease (COPD), more malignancies, mostly in the lung or head and neck, were reported in infliximab-treated patients compared with control patients. All patients had a history of heavy smoking. Therefore, caution should be exercised when using any TNF-antagonist in COPD patients, as well as in patients with increased risk for malignancy due to heavy smoking.</p><p>&nbsp;</p><p>With current data it is not known if adalimumab treatment influences the risk for developing dysplasia or colon cancer. All patients with ulcerative colitis who are at increased risk for dysplasia or colon carcinoma (for example, patients with long-standing ulcerative colitis or primary sclerosing cholangitis), or who had a prior history of dysplasia or colon carcinoma should be screened for dysplasia at regular intervals before therapy and throughout their disease course. This evaluation should include colonoscopy and biopsies per local recommendations.</p><p>&nbsp;</p><p><u>Haematologic reactions</u></p><p><u>&nbsp;</u></p><p>Rare reports of pancytopenia including aplastic anaemia have been reported with TNF-antagonists. Adverse events of the haematologic system, including medically significant cytopenia (e.g. thrombocytopenia, leukopenia) have been reported with adalimumab. All patients should be advised to seek immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias (e.g. persistent fever, bruising, bleeding, pallor) while on Hadlima. Discontinuation of Hadlima therapy should be considered in patients with confirmed significant haematologic abnormalities.</p><p>&nbsp;</p><p><u>Vaccinations</u></p><p><u>&nbsp;</u></p><p>Similar antibody responses to the standard 23-valent pneumococcal vaccine and the influenza trivalent virus vaccination were observed in a study in 226&nbsp;adult subjects with rheumatoid arthritis who were treated with adalimumab or placebo. No data are available on the secondary transmission of infection by live vaccines in patients receiving adalimumab.</p><p>&nbsp;</p><p>It is recommended that paediatric patients, if possible, be brought up to date with all immunisations in agreement with current immunisation guidelines prior to initiating adalimumab therapy.</p><p>&nbsp;</p><p>Patients on adalimumab may receive concurrent vaccinations, except for live vaccines.</p><p>At least twelve-month waiting period following birth is recommended before the administration of live vaccines to infants exposed in utero to Hadlima during the latter parts of pregnancy (see section 4.6).</p><p>&nbsp;</p><p><u>Congestive heart failure </u></p><p><u>&nbsp;</u></p><p>In a clinical trial with another TNF-antagonist worsening congestive heart failure and increased mortality due to congestive heart failure have been observed. Cases of worsening congestive heart failure have also been reported in patients receiving adalimumab. Hadlima should be used with caution in patients with mild heart failure (NYHA class I/II). Hadlima is contraindicated in moderate to severe heart failure (see section 4.3). Treatment with Hadlima must be discontinued in patients who develop new or worsening symptoms of congestive heart failure.</p><p>&nbsp;</p><p><u>Autoimmune processes </u></p><p><u>&nbsp;</u></p><p>Treatment with Hadlima may result in the formation of autoimmune antibodies. The impact of long-term treatment with adalimumab on the development of autoimmune diseases is unknown. If a patient develops symptoms suggestive of a lupus-like syndrome following treatment with Hadlima and is positive for antibodies against double-stranded DNA, further treatment with Hadlima should not be given (see section&nbsp;4.8).</p><p>&nbsp;</p><p><u>Concurrent administration of biologic DMARDS or TNF-antagonists </u></p><p><u>&nbsp;</u></p><p>Serious infections were seen in clinical studies with concurrent use of anakinra and another TNF-antagonist, etanercept, with no added clinical benefit compared to etanercept alone. Because of the nature of the adverse events seen with the combination of etanercept and anakinra therapy, similar toxicities may also result from the combination of anakinra and other TNF-antagonists. Therefore, the combination of adalimumab and anakinra is not recommended. (See section 4.5).</p><p>&nbsp;</p><p>Concomitant administration of adalimumab with other biologic DMARDS (e.g, anakinra and abatacept) or other TNF-antagonists is not recommended based upon the possible increased risk for infections, including serious infections and other potential pharmacological interactions. (See section 4.5).</p><p>&nbsp;</p><p><u>Surgery</u></p><p><u>&nbsp;</u></p><p>There is limited safety experience of surgical procedures in patients treated with adalimumab. The long half-life of adalimumab should be taken into consideration if a surgical procedure is planned. A patient who requires surgery while on Hadlima should be closely monitored for infections, and appropriate actions should be taken. There is limited safety experience in patients undergoing arthroplasty while receiving adalimumab.</p><p>&nbsp;</p><p><u>Small bowel obstruction</u></p><p><u>&nbsp;</u></p><p>Failure to respond to treatment for Crohn&rsquo;s disease may indicate the presence of fixed fibrotic stricture that may require surgical treatment. Available data suggest that adalimumab does not worsen or cause strictures.</p><p>&nbsp;</p><p><u>Elderly</u></p><p><u>&nbsp;</u></p><p>The frequency of serious infections among adalimumab treated subjects over 65&nbsp;years of age (3.7%) was higher than for those under 65&nbsp;years of age (1.5%). Some of those had a fatal outcome. Particular attention regarding the risk for infection should be paid when treating the elderly.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p><u>&nbsp;</u></p><p>See Vaccinations above.</p><p>&nbsp;</p><p><u>Excipients with known effects</u></p><p>&nbsp;</p><p>This medicinal product contains 20 mg sorbitol in each pre-filled syringe/pre-filled pen. Patients with rare hereditary problems of fructose intolerance should not take this medicinal product.</p><p>&nbsp;</p><p>Also, this medicinal product contains less than 1&nbsp;mmol of sodium (23&nbsp;mg) per 0.8&nbsp;ml dose, i.e. essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adalimumab has been studied in rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and psoriatic arthritis patients taking adalimumab as monotherapy and those taking concomitant methotrexate. Antibody formation was lower when adalimumab was given together with methotrexate in comparison with use as monotherapy. Administration of adalimumab without methotrexate resulted in increased formation of antibodies, increased clearance and reduced efficacy of adalimumab (see section 5.1).</p><p>&nbsp;</p><p>The combination of Hadlima and anakinra is not recommended (see section 4.4 &ldquo;Concurrent administration of biologic DMARDS or TNF-antagonists&rdquo;).</p><p>&nbsp;</p><p>The combination of Hadlima and abatacept is not recommended (see section 4.4 &ldquo;Concurrent administration of biologic DMARDS or TNF-antagonists&rdquo;).</p><p>&nbsp;</p><p>It is recommended that live vaccines not be given to infants after in utero exposure to Hadlima during the latter parts of pregnancy for at least 12 months following birth (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of child bearing potential</u></p><p><u>&nbsp;</u></p><p>Women of childbearing potential should consider the use of adequate contraception to prevent pregnancy and continue its use for at least five months after the last Hadlima treatment.</p><p><u>&nbsp;</u></p><p><u>Pregnancy </u></p><p><u>&nbsp;</u></p><p>A large number (approximately 2,100) of prospectively collected pregnancies exposed to adalimumab resulting in live birth with known outcomes, including more than 1,500 exposed during the first trimester, does not indicate an increase in the rate of malformation in the newborn.</p><p>&nbsp;</p><p>In a prospective cohort registry, 257&nbsp;women with rheumatoid arthritis (RA) or Crohn&rsquo;s disease (CD) treated with adalimumab at least during the first trimester and 120&nbsp;women with RA or CD not treated with adalimumab were enrolled. The primary endpoint was the birth prevalence of major birth defects. The rate of pregnancies ending with at least one live born infant with a major birth defect was 6/69 (8.7&nbsp;%) in the adalimumab-treated women with RA and 5/74 (6.8&nbsp;%) in the untreated women with RA (unadjusted OR 1.31, 95&nbsp;% CI 0.38-4.52) and 16/152 (10.5&nbsp;%) in the adalimumab-treated women with CD and 3/32 (9.4&nbsp;%) in the untreated women with CD (unadjusted OR 1.14, 95&nbsp;% CI 0.31-4.16). The adjusted OR (accounting for baseline differences) was 1.10 (95&nbsp;% CI 0.45-2.73) with RA and CD combined. There were no distinct differences between adalimumab-treated and untreated women for the secondary endpoints spontaneous abortions, minor birth defects, preterm delivery, birth size and serious or opportunistic infections and no stillbirths or malignancies were reported. The interpretation of data may be impacted due to methodological limitations of the study, including small sample size and non-randomized design.</p><p>&nbsp;</p><p>In a developmental toxicity study conducted in monkeys, there was no indication of maternal toxicity, embryotoxicity or teratogenicity. Preclinical data on postnatal toxicity of adalimumab are not available (see section 5.3).</p><p>&nbsp;</p><p>Due to its inhibition of TNF&alpha;, adalimumab administered during pregnancy could affect normal immune responses in the newborn. Adalimumab should only be used during pregnancy if clearly needed.</p><p>&nbsp;</p><p>Adalimumab may cross the placenta into the serum of infants born to women treated with adalimumab during pregnancy. Consequently, these infants may be at increased risk for infection.</p><p>&nbsp;</p><p>Administration of live vaccines (e.g. BCG vaccine) to infants exposed to Hadlima in utero during the latter parts of pregnancy is not recommended for at least 12 months after birth (see sections 4.4 and 4.5).</p><p>&nbsp;</p><p><u>Breast feeding</u></p><p><u>&nbsp;</u></p><p>Limited information from the published literature indicates that adalimumab is excreted in breast milk at very low concentrations with the presence of adalimumab in human milk at concentrations of 0.1&nbsp;% to 1&nbsp;% of the maternal serum level. Given orally, immunoglobulin G proteins undergo intestinal proteolysis and have poor bioavailability. No effects on the breastfed newborns/infants are anticipated. Consequently, adalimumab can be used during breastfeeding.</p><p>&nbsp;</p><p><u>Fertility</u></p><p><u>&nbsp;</u></p><p>Preclinical data on fertility effects of adalimumab are not available.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hadlima may have a minor influence on the ability to drive and use machines. Vertigo and visual impairment may occur following administration of Hadlima (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p><u>&nbsp;</u></p><p>Adalimumab was studied in 9,506&nbsp;patients in pivotal controlled and open label trials for up to 60&nbsp;months or more. These trials included rheumatoid arthritis patients with short term and long standing disease, juvenile idiopathic arthritis (polyarticular juvenile idiopathic arthritis and enthesitis-related arthritis) as well as axial spondyloarthritis (ankylosing spondylitis and axial spondyloarthritis without radiographic evidence of AS), psoriatic arthritis, Crohn&rsquo;s disease, ulcerative colitis, psoriasis, hidradenitis suppurativa, and uveitis patients. The pivotal controlled studies involved 6,089&nbsp;patients receiving adalimumab and 3,801 patients receiving placebo or active comparator during the controlled period.</p><p>&nbsp;</p><p>The proportion of patients who discontinued treatment due to adverse events during the double-blind, controlled portion of pivotal studies was 5.9&nbsp;% for patients taking adalimumab and 5.4&nbsp;% for control treated patients.</p><p>&nbsp;</p><p>The most commonly reported adverse reactions are infections (such as nasopharyngitis, upper respiratory tract infection and sinusitis), injection site reactions (erythema, itching, haemorrhage, pain or swelling), headache and musculoskeletal pain.</p><p>&nbsp;</p><p>Serious adverse reactions have been reported for adalimumab. TNF-antagonists, such as adalimumab affect the immune system and their use may affect the body&rsquo;s defense against infection and cancer.</p><p>&nbsp;</p><p>Fatal and life-threatening infections (including sepsis, opportunistic infections and TB), HBV reactivation and various malignancies (including leukaemia, lymphoma and HSTCL) have also been reported with use of adalimumab.</p><p>&nbsp;</p><p>Serious haematological, neurological and autoimmune reactions have also been reported. These include rare reports of pancytopenia, aplastic anaemia, central and peripheral demyelinating events and reports of lupus, lupus-related conditions and Stevens-Johnson syndrome.</p><p>&nbsp;</p><p><em>Paediatric population </em></p><p><u>&nbsp;</u></p><p>In general, the adverse events in paediatric patients were similar in frequency and type to those seen in adult patients.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p><u>&nbsp;</u></p><p>The following list of adverse reactions is based on experience from clinical trials and on postmarketing experience and are displayed by system organ class and frequency in Table 6 below:</p><p>very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;&nbsp;1/10,000 to &lt;1/1,000); and not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. The highest frequency seen among the various indications has been included. An asterisk (*) appears in the System Organ Class (SOC) column if further information is found elsewhere in sections 4.3, 4.4 and 4.8.</p><p><u>&nbsp;</u></p><p><strong>Table 6</strong></p><p><strong>Undesirable Effects</strong></p><p><u>&nbsp;</u></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td><p><strong>System Organ Class</strong></p></td><td><p><strong>Frequency</strong></p></td><td><p><strong>Adverse Reaction</strong></p></td></tr></thead><tbody><tr><td rowspan="3" style="vertical-align:top"><p>Infections and infestations*</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Respiratory tract infections (including lower and upper respiratory tract infection, pneumonia, sinusitis, pharyngitis, nasopharyngitis and pneumonia herpes viral)</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Systemic infections (including sepsis, candidiasis and influenza),</p><p>intestinal infections (including gastroenteritis viral),</p><p>skin and soft tissue infections (including paronychia, cellulitis, impetigo, necrotising fasciitis and herpes zoster),</p><p>ear infections,</p><p>oral infections (including herpes simplex, oral herpes and tooth infections),</p><p>reproductive tract infections (including vulvovaginal mycotic infection),</p><p>urinary tract infections (including pyelonephritis),</p><p>fungal infections,</p><p>joint infections</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Neurological infections (including viral meningitis),</p><p>opportunistic infections and tuberculosis (including coccidioidomycosis, histoplasmosis and mycobacterium avium complex infection),</p><p>bacterial infections,</p><p>eye infections,</p><p>diverticulitis<sup>1)</sup></p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Neoplasms benign, malignant and unspecified (including cysts and polyps)*</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Skin cancer excluding melanoma (including basal cell carcinoma and squamous cell carcinoma),</p><p>benign neoplasm</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Lymphoma**,</p><p>solid organ neoplasm (including breast cancer, lung neoplasm and thyroid neoplasm),</p><p>melanoma**</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Leukaemia<sup>1)</sup></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Hepatosplenic T-cell lymphoma<sup>1)</sup></p><p>Merkel cell carcinoma (neuroendocrine carcinoma of the skin)<sup>1)</sup></p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Blood and the lymphatic system disorders*</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Leukopenia (including neutropenia and agranulocytosis),</p><p>anaemia</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Leukocytosis,</p><p>thrombocytopenia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Idiopathic thrombocytopenic purpura</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Pancytopenia</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Immune system disorders*</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hypersensitivity,</p><p>allergies (including seasonal allergy)</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Sarcoidosis<sup>1)</sup>,</p><p>vasculitis</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Anaphylaxis<sup>1)</sup></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Lipids increased</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hypokalaemia,</p><p>uric acid increased,</p><p>blood sodium abnormal,</p><p>hypocalcaemia,</p><p>hyperglycaemia,</p><p>hypophosphatemia,</p><p>dehydration</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Mood alterations (including depression),</p><p>anxiety,</p><p>Insomnia</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Nervous system disorders*</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Headache</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Paraesthesias (including hypoesthesia),</p><p>migraine,</p><p>nerve root compression</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Cerebrovascular accident<sup>1)</sup>,</p><p>tremor,</p><p>neuropathy</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Multiple sclerosis,</p><p>demyelinating disorders (e.g. optic neuritis, Guillain-Barr&eacute; syndrome)<sup>1)</sup></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Visual impairment,</p><p>conjunctivitis,</p><p>blepharitis,</p><p>eye swelling</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Diplopia</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Vertigo</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Deafness,</p><p>tinnitus</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Cardiac disorders*</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Tachycardia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Myocardial infarction<sup>1)</sup>,</p><p>arrhythmia,</p><p>congestive heart failure</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Cardiac arrest</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hypertension,</p><p>flushing,</p><p>haematoma</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Aortic aneurysm,</p><p>vascular arterial occlusion,</p><p>thrombophlebitis</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders*</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Asthma,</p><p>dyspnoea,</p><p>cough</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Pulmonary embolism<sup>1)</sup>,</p><p>interstitial lung disease,</p><p>chronic obstructive pulmonary disease,</p><p>pneumonitis,</p><p>pleural effusion<sup>1)</sup></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Pulmonary fibrosis<sup>1)</sup></p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Abdominal pain,</p><p>nausea and vomiting</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>GI haemorrhage,</p><p>dyspepsia,</p><p>gastroesophageal reflux disease,</p><p>sicca syndrome</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Pancreatitis,</p><p>dysphagia,</p><p>face oedema</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Intestinal perforation<sup>1)</sup></p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Hepatobiliary disorders*</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Elevated liver enzymes</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Cholecystitis and cholelithiasis,</p><p>hepatic steatosis,</p><p>bilirubin increased</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Hepatitis</p><p>reactivation of hepatitis B<sup>1)</sup></p><p>autoimmune hepatitis<sup>1</sup>)</p></td></tr><tr><td style="vertical-align:top"><p>Not Known</p></td><td style="vertical-align:top"><p>Liver failure<sup>1)</sup></p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Rash (including exfoliative rash)</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Worsening or new onset of psoriasis (including palmoplantar pustular psoriasis)<sup>1)</sup>,</p><p>urticaria,</p><p>bruising (including purpura),</p><p>dermatitis (including eczema),</p><p>onychoclasis,</p><p>hyperhidrosis,</p><p>alopecia<sup>1)</sup>,</p><p>pruritus</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Night sweats,</p><p>scar</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Erythema multiforme<sup>1)</sup>,</p><p>Stevens-Johnson syndrome<sup>1)</sup>,</p><p>angioedema<sup>1)</sup>,</p><p>cutaneous vasculitis<sup>1)</sup></p><p>lichenoid skin reaction<sup>1)</sup></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Worsening of symptoms of dermatomyositis<sup>1)</sup></p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Musculoskeletal pain</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Muscle spasms (including blood creatine phosphokinase increased)</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rhabdomyolysis,</p><p>systemic lupus erythematosus</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Lupus-like syndrome<sup>1)</sup></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Renal impairment,</p><p>haematuria</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Nocturia</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Erectile dysfunction</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>General disorders and administration site conditions*</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Injection site reaction (including injection site erythema)</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Chest pain,</p><p>oedema,</p><p>pyrexia<sup>1)</sup></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Inflammation</p></td></tr><tr><td style="vertical-align:top"><p>Investigations*</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Coagulation and bleeding disorders (including activated partial thromboplastin time prolonged),</p><p>autoantibody test positive (including double stranded DNA antibody),</p><p>blood lactate dehydrogenase increased</p></td></tr><tr><td style="vertical-align:top"><p>Injury, poisoning and procedural complications</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Impaired healing</p></td></tr></tbody></table><p>* further information is found elsewhere in sections 4.3, 4.4 and 4.8</p><p>** including open label extension studies</p><p><sup>1)</sup> including spontaneous reporting data</p><p>&nbsp;</p><p><u>Hidradenitis suppurativa</u></p><p><u>&nbsp;</u></p><p>The safety profile for patients with HS treated with adalimumab weekly was consistent with the known safety profile of adalimumab.</p><p>&nbsp;</p><p><u>Uveitis</u></p><p>&nbsp;</p><p>The safety profile for patients with uveitis treated with adalimumab every other week was consistent with the known safety profile of adalimumab.</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p><em>Injection site reactions</em></p><p><em>&nbsp;</em></p><p>In the pivotal controlled trials in adults and children, 12.9&nbsp;% of patients treated with adalimumab developed injection site reactions (erythema and/or itching, haemorrhage, pain or swelling), compared to 7.2&nbsp;% of patients receiving placebo or active control. Injection site reactions generally did not necessitate discontinuation of the medicinal product.</p><p>&nbsp;</p><p><em>Infections</em></p><p><em>&nbsp;</em></p><p>In the pivotal controlled trials in adults and children, the rate of infection was 1.51 per patient year in the adalimumab treated patients and 1.46 per patient year in the placebo and active control-treated patients. The infections consisted primarily of nasopharyngitis, upper respiratory tract infection, and sinusitis. Most patients continued on adalimumab after the infection resolved.</p><p>&nbsp;</p><p>The incidence of serious infections was 0.04 per patient year in adalimumab treated patients and 0.03 per patient year in placebo and active control-treated patients.</p><p>&nbsp;</p><p>In controlled and open label adult and paediatric studies with adalimumab, serious infections (including fatal infections, which occurred rarely) have been reported, which include reports of tuberculosis (including miliary and extra-pulmonary locations) and invasive opportunistic infections (e.g. disseminated or extrapulmonary histoplasmosis, blastomycosis, coccidioidomycosis, pneumocystis, candidiasis, aspergillosis and listeriosis). Most of the cases of tuberculosis occurred within the first eight months after initiation of therapy and may reflect recrudescence of latent disease.</p><p><u>&nbsp;</u></p><p><em>Malignancies and lymphoproliferative disorders </em></p><p><em>&nbsp;</em></p><p>No malignancies were observed in 249&nbsp;paediatric patients with an exposure of 655.6&nbsp;patient years during adalimumab trials in patients with juvenile idiopathic arthritis (polyarticular juvenile idiopathic arthritis and enthesitis-related arthritis). In addition, no malignancies were observed in 192&nbsp;paediatric patients with an exposure of 498.1&nbsp;patient years during adalimumab trials in paediatric patients with Crohn&rsquo;s disease. No malignancies were observed in 77&nbsp;paediatric patients with an exposure of 80.0&nbsp;patient years during an adalimumab trial in paediatric patients with chronic plaque psoriasis. No malignancies were observed in 60&nbsp;paediatric patients with an exposure of 58.4&nbsp;patient years during an adalimumab trial in paediatric patients with uveitis.</p><p>&nbsp;</p><p>During the controlled portions of pivotal adalimumab trials in adults of at least 12&nbsp;weeks in duration in patients with moderately to severely active rheumatoid arthritis, ankylosing spondylitis, axial spondyloarthritis without radiographic evidence of AS, psoriatic arthritis, psoriasis, hidradenitis suppurativa, Crohn&rsquo;s disease, ulcerative colitis, and uveitis, malignancies, other than lymphoma and non-melanoma skin cancer, were observed at a rate (95%&nbsp;confidence interval) of 6.8 (4.4, 10.5) per 1,000&nbsp;patient-years among 5,291&nbsp;adalimumab treated patients <em>versus </em>a rate of 6.3 (3.4, 11.8) per 1,000 patient-years among 3,444&nbsp;control patients (median duration of treatment was 4.0 months for adalimumab and 3.8&nbsp;months for control-treated patients). The rate (95%&nbsp;confidence interval) of non-melanoma skin cancers was 8.8 (6.0, 13.0) per 1,000&nbsp;patient-years among adalimumab-treated patients and 3.2 (1.3, 7.6) per 1,000&nbsp;patient-years among control patients. Of these skin cancers, squamous cell carcinomas occurred at rates (95% confidence interval) of 2.7 (1.4, 5.4) per 1,000&nbsp;patient-years among adalimumab-treated patients and 0.6 (0.1, 4.5) per 1,000&nbsp;patient-years among control patients. The rate (95&nbsp;% confidence interval) of lymphomas was 0.7 (0.2, 2.7) per 1,000&nbsp;patient-years among adalimumab-treated patients and 0.6 (0.1, 4.5) per 1,000&nbsp;patient-years among control patients.</p><p><u>&nbsp;</u></p><p>When combining controlled portions of these trials and ongoing and completed open label extension studies with a median duration of approximately 3.3&nbsp;years including 6,427&nbsp;patients and over 26,439&nbsp;patient-years of therapy, the observed rate of malignancies, other than lymphoma and non-melanoma skin cancers is approximately 8.5 per 1,000&nbsp;patient years. The observed rate of non-melanoma skin cancers is approximately 9.6 per 1,000&nbsp;patient years, and the observed rate of lymphomas is approximately 1.3 per 1,000&nbsp;patient-years.</p><p>&nbsp;</p><p>In post-marketing experience from January 2003 to December 2010, predominantly in patients with rheumatoid arthritis, the reported rate of malignancies is approximately 2.7 per 1,000&nbsp;patient treatment years. The reported rates for non-melanoma skin cancers and lymphomas are approximately 0.2 and 0.3 per 1,000&nbsp;patient treatment years, respectively (see section 4.4).</p><p>&nbsp;</p><p>Rare post-marketing cases of hepatosplenic T-cell lymphoma have been reported in patients treated with adalimumab (see section 4.4).</p><p><u>&nbsp;</u></p><p><em>Autoantibodies</em></p><p><em>&nbsp;</em></p><p>Patients had serum samples tested for autoantibodies at multiple time points in rheumatoid arthritis studies I &minus; V. In these trials, 11.9&nbsp;% of patients treated with adalimumab and 8.1% of placebo and active control &minus; treated patients that had negative baseline anti-nuclear antibody titres reported positive titres at week 24. Two patients out of 3,441 treated with adalimumab in all rheumatoid arthritis and psoriatic arthritis studies developed clinical signs suggestive of new-onset lupus-like syndrome. The patients improved following discontinuation of therapy. No patients developed lupus nephritis or central nervous system symptoms.</p><p>&nbsp;</p><p><em>Hepato-biliary events</em></p><p><em>&nbsp;</em></p><p>In controlled Phase 3 trials of adalimumab in patients with rheumatoid arthritis and psoriatic arthritis with a control period duration ranging from 4 to 104&nbsp;weeks, ALT elevations &ge;3 &times;ULN occurred in 3.7&nbsp;% of adalimumab-treated patients and 1.6&nbsp;% of control-treated patients.</p><p><u>&nbsp;</u></p><p>In controlled Phase 3 trials of adalimumab in patients with polyarticular juvenile idiopathic arthritis who were 4 to 17 years and enthesitis-related arthritis who were 6 to 17&nbsp;years, ALT elevations &ge;3 &times; ULN occurred in 6.1&nbsp;% of adalimumab-treated patients and 1.3&nbsp;% of control-treated patients. Most ALT elevations occurred with concomitant methotrexate use. No ALT elevations &ge;3 &times; ULN occurred in the Phase 3 trial of adalimumab in patients with polyarticular juvenile idiopathic arthritis who were 2 to &lt;4&nbsp;years.</p><p>&nbsp;</p><p>In controlled Phase 3 trials of adalimumab in patients with Crohn&rsquo;s disease and ulcerative colitis with a control period ranging from 4 to 52&nbsp;weeks. ALT elevations &ge;3 &times; ULN occurred in 0.9% of adalimumab-treated patients and 0.9&nbsp;% of controlled-treated patients.</p><p>&nbsp;</p><p>In the Phase 3 trial of adalimumab in patients with paediatric Crohn&rsquo;s disease which evaluated efficacy and safety of two body weight adjusted maintenance dose regimens following body weight adjusted induction therapy up to 52&nbsp;weeks of treatment, ALT elevations &ge;3 &times; ULN occurred in 2.6&nbsp;% (5/192) of patients of whom 4 were receiving concomitant immunosuppressants at baseline.</p><p>&nbsp;</p><p>In controlled Phase 3 trials of adalimumab in patients with plaque psoriasis with a control period duration ranging from 12 to 24 weeks, ALT elevations &ge;3 &times; ULN occurred in 1.8% of adalimumab-treated patients and 1.8&nbsp;% of control-treated patients.</p><p>&nbsp;</p><p>No ALT elevations &ge;3 &times; ULN occurred in the Phase 3 trial of adalimumab in paediatric patients with plaque psoriasis.</p><p>&nbsp;</p><p>In controlled trials of adalimumab (initial doses of 160&nbsp;mg at week 0 and 80&nbsp;mg at week 2, followed by 40&nbsp;mg every week starting at week 4), in patients with hidradenitis suppurativa with a control period duration ranging from 12 to 16&nbsp;weeks, ALT elevations &ge;3 &times; ULN occurred in 0.3&nbsp;% of adalimumab-treated patients and 0.6&nbsp;% of control-treated patients.</p><p>&nbsp;</p><p>In controlled trials of adalimumab (initial doses of 80&nbsp;mg at week 0 followed by 40&nbsp;mg every other week starting at week 1) in adult patients with uveitis up to 80 weeks with a median exposure of 166.5&nbsp;days and 105.0&nbsp;days in adalimumab-treated and control-treated patients, respectively, ALT elevations &ge;3 &times; ULN occurred in 2.4&nbsp;% of adalimumab-treated patients and 2.4&nbsp;% of control-treated patients.</p><p>&nbsp;</p><p>Across all indications in clinical trials patients with raised ALT were asymptomatic and in most cases elevations were transient and resolved on continued treatment. However, there have also been post-marketing reports of liver failure as well as less severe liver disorders that may precede liver failure, such as hepatitis including autoimmune hepatitis in patients receiving adalimumab.</p><p><u>&nbsp;</u></p><p><u>Concurrent treatment with azathioprine/6-mercaptopurine</u></p><p><u>&nbsp;</u></p><p>In adult Crohn&rsquo;s disease studies, higher incidences of malignant and serious infection-related adverse events were seen with the combination of adalimumab and azathioprine/6-mercaptopurine compared with adalimumab alone.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p><u>&nbsp;</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.</p><p>&nbsp;</p><p>To reports any side effect(s)</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Please report adverse drug events to:</p><p>The National Pharmacovigilance Centre (NPC):</p><p>Fax: +966-11-205-7662</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No dose-limiting toxicity was observed during clinical trials. The highest dose level evaluated has been multiple intravenous doses of 10&nbsp;mg/kg, which is approximately 15&nbsp;times the recommended dose.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Immunosuppressants, Tumour Necrosis Factor alpha (TNF-&alpha;) inhibitors. ATC code: L04AB04</p><p>&nbsp;</p><p>Hadlima is a biosimilar medicinal product.</p><p><strong>&nbsp;</strong></p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Adalimumab binds specifically to TNF and neutralises the biological function of TNF by blocking its interaction with the p55 and p75 cell surface TNF receptors.</p><p>&nbsp;</p><p>Adalimumab also modulates biological responses that are induced or regulated by TNF, including changes in the levels of adhesion molecules responsible for leukocyte migration (ELAM-1, VCAM-1, and ICAM-1 with an IC50 of 0.1-0.2&nbsp;nM).</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p><u>&nbsp;</u></p><p>After treatment with adalimumab, a rapid decrease in levels of acute phase reactants of inflammation (C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)) and serum cytokines (IL-6) was observed, compared to baseline in patients with rheumatoid arthritis. Serum levels of matrix metalloproteinases (MMP-1 and MMP-3) that produce tissue remodelling responsible for cartilage destruction were also decreased after adalimumab administration. Patients treated with adalimumab usually experienced improvement in haematological signs of chronic inflammation.</p><p>&nbsp;</p><p>A rapid decrease in CRP levels was also observed in patients with polyarticular juvenile idiopathic arthritis, Crohn&rsquo;s disease, ulcerative colitis, and hidradenitis suppurativa after treatment with adalimumab. In patients with Crohn&rsquo;s disease, a reduction of the number of cells expressing inflammatory markers in the colon including a significant reduction of expression of TNF&alpha; was seen. Endoscopic studies in intestinal mucosa have shown evidence of mucosal healing in adalimumab treated patients.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p><u>&nbsp;</u></p><p><em>Rheumatoid arthritis</em></p><p><em>&nbsp;</em></p><p>Adalimumab was evaluated in over 3,000&nbsp;patients in all rheumatoid arthritis clinical trials. The efficacy and safety of adalimumab were assessed in five randomised, double-blind and well-controlled studies. Some patients were treated for up to 120&nbsp;months duration.</p><p>&nbsp;</p><p>RA study I evaluated 271 patients with moderately to severely active rheumatoid arthritis who were &ge;18 years old, had failed therapy with at least one disease-modifying, anti-rheumatic drug and had insufficient efficacy with methotrexate at doses of 12.5 to 25&nbsp;mg (10&nbsp;mg if methotrexate-intolerant) every week and whose methotrexate dose remained constant at 10 to 25&nbsp;mg every week. Doses of 20, 40 or 80&nbsp;mg of adalimumab or placebo were given every other week for 24&nbsp;weeks.</p><p>&nbsp;</p><p>RA study II evaluated 544&nbsp;patients with moderately to severely active rheumatoid arthritis who were &ge;18 &nbsp;years old and had failed therapy with at least one disease-modifying, anti-rheumatic drugs. Doses of 20 or 40&nbsp;mg of adalimumab were given by subcutaneous injection every other week with placebo on alternative weeks or every week for 26&nbsp;weeks; placebo was given every week for the same duration. No other disease-modifying anti-rheumatic drugs were allowed.</p><p>&nbsp;</p><p>RA study III evaluated 619&nbsp;patients with moderately to severely active rheumatoid arthritis who were &ge;18&nbsp;years old, and who had an ineffective response to methotrexate at doses of 12.5 to 25&nbsp;mg or have been intolerant to 10&nbsp;mg of methotrexate every week. There were three groups in this study. The first received placebo injections every week for 52&nbsp;weeks. The second received 20&nbsp;mg of adalimumab every week for 52&nbsp;weeks. The third group received 40&nbsp;mg of adalimumab every other week with placebo injections on alternate weeks. Upon completion of the first 52&nbsp;weeks, 457&nbsp;patients enrolled in an open-label extension phase in which 40&nbsp;mg of adalimumab/MTX was administered every other week up to 10&nbsp;years.</p><p>&nbsp;</p><p>RA study IV primarily assessed safety in 636&nbsp;patients with moderately to severely active rheumatoid arthritis who were &ge; 18&nbsp;years old. Patients were permitted to be either disease-modifying, anti-rheumatic drug-na&iuml;ve or to remain on their pre-existing rheumatologic therapy provided that therapy was stable for a minimum of 28&nbsp;days. These therapies include methotrexate, leflunomide, hydroxychloroquine, sulfasalazine and/or gold salts. Patients were randomised to 40&nbsp;mg of adalimumab or placebo every other week for 24&nbsp;weeks.</p><p>&nbsp;</p><p>RA study V evaluated 799&nbsp;methotrexate-na&iuml;ve, adult patients with moderate to severely active early rheumatoid arthritis (mean disease duration less than 9&nbsp;months). This study evaluated the efficacy of adalimumab 40&nbsp;mg every other week/methotrexate combination therapy, adalimumab 40&nbsp;mg every other week monotherapy and methotrexate monotherapy in reducing the signs and symptoms and rate of progression of joint damage in rheumatoid arthritis for 104&nbsp;weeks. Upon completion of the first 104&nbsp;weeks, 497&nbsp;patients enrolled in an open-label extension phase in which 40&nbsp;mg of adalimumab was administered every other week up to 10&nbsp;years.</p><p>&nbsp;</p><p>The primary end point in RA studies I, II and III and the secondary endpoint in RA study IV was the percent of patients who achieved an ACR 20 response at week 24 or 26. The primary endpoint in RA study V was the percent of patients who achieved an ACR 50 response at week 52. RA studies III and V had an additional primary endpoint at 52&nbsp;weeks of retardation of disease progression (as detected by X-ray results). RA study III also had a primary endpoint of changes in quality of life.</p><p>&nbsp;</p><p><em><u>ACR response</u></em></p><p><em><u>&nbsp;</u></em></p><p>The percent of adalimumab-treated patients achieving ACR 20, 50 and 70 responses was consistent across RA studies I, II and III. The results for the 40&nbsp;mg every other week dose are summarised in Table 7.</p><p>&nbsp;</p><p><strong>Table 7</strong></p><p><strong>ACR Responses in Placebo Controlled Trials</strong></p><p><strong>(Percent of Patients)</strong></p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="2"><p><strong>Response</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>RA study I<sup>a</sup>**</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>RA study II<sup>a</sup>**</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>RA study III<sup>a</sup>**</strong></p></td></tr><tr><td style="vertical-align:top"><p>Placebo/ MTX<sup>c</sup></p><p>N=60</p></td><td style="vertical-align:top"><p>Adalimumab<sup>b</sup>/ MTX<sup>c</sup></p><p>N=63</p></td><td style="vertical-align:top"><p>Placebo</p><p>&nbsp;</p><p>N=110</p></td><td style="vertical-align:top"><p>Adalimumab<sup>b</sup></p><p>&nbsp;</p><p>N=113</p></td><td style="vertical-align:top"><p>Placebo/ MTX<sup>c</sup></p><p>N=200</p></td><td style="vertical-align:top"><p>Adalimumab<sup>b</sup>/ MTX<sup>c</sup></p><p>N=207</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>ACR 20</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>6</strong><strong>&nbsp;</strong><strong>months</strong></p></td><td><p>13.3%</p></td><td><p>65.1%</p></td><td><p>19.1%</p></td><td><p>46.0%</p></td><td><p>29.5%</p></td><td><p>63.3%</p></td></tr><tr><td style="vertical-align:top"><p><strong>12</strong><strong>&nbsp;</strong><strong>months</strong></p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>24.0%</p></td><td><p>58.9%</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>ACR 50</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>6</strong><strong>&nbsp;</strong><strong>months</strong></p></td><td><p>6.7%</p></td><td><p>52.4%</p></td><td><p>8.2%</p></td><td><p>22.1%</p></td><td><p>9.5%</p></td><td><p>39.1%</p></td></tr><tr><td style="vertical-align:top"><p><strong>12</strong><strong>&nbsp;</strong><strong>months</strong></p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>9.5%</p></td><td><p>41.5%</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>ACR 70</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>6</strong><strong>&nbsp;</strong><strong>months</strong></p></td><td><p>3.3%</p></td><td><p>23.8%</p></td><td><p>1.8%</p></td><td><p>12.4%</p></td><td><p>2.5%</p></td><td><p>20.8%</p></td></tr><tr><td style="vertical-align:top"><p><strong>12</strong><strong>&nbsp;</strong><strong>months</strong></p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>4.5%</p></td><td><p>23.2%</p></td></tr></tbody></table><p><sup>a</sup>&nbsp; RA study I at 24&nbsp;weeks, RA study II at 26&nbsp;weeks, and RA study III at 24 and 52&nbsp;weeks</p><p><sup>b</sup>&nbsp; 40 mg adalimumab administered every other week</p><p><sup>c</sup> &nbsp;MTX = methotrexate</p><p>**p &lt;0.01, adalimumab <em>versus</em> placebo</p><p>- Not applicable</p><p>&nbsp;</p><p>In RA studies I-IV, all individual components of the ACR response criteria (number of tender and swollen joints, physician and patient assessment of disease activity and pain, disability index (HAQ) scores and CRP (mg/dl) values) improved at 24 or 26&nbsp;weeks compared to placebo. In RA study III, these improvements were maintained throughout 52&nbsp;weeks.</p><p>&nbsp;</p><p>In the open-label extension for RA study III, most patients who were ACR responders maintained response when followed for up to 10&nbsp;years. Of 207&nbsp;patients who were randomised to adalimumab 40&nbsp;mg every other week, 114&nbsp;patients continued on adalimumab 40&nbsp;mg every other week for 5&nbsp;years. Among those, 86&nbsp;patients (75.4&nbsp;%) had ACR 20 responses; 72&nbsp;patients (63.2&nbsp;%) had ACR 50 responses; and 41&nbsp;patients (36&nbsp;%) had ACR 70 responses. Of 207&nbsp;patients, 81&nbsp;patients continued on adalimumab 40&nbsp;mg every other week for 10&nbsp;years. Among those, 64&nbsp;patients (79.0&nbsp;%) had ACR 20 responses; 56&nbsp;patients (69.1&nbsp;%) had ACR 50 responses; and 43&nbsp;patients (53.1&nbsp;%) had ACR 70 responses.</p><p>&nbsp;</p><p>In RA study IV, the ACR 20 response of patients treated with adalimumab plus standard of care was statistically significantly better than patients treated with placebo plus standard of care (p &lt;0.001).</p><p>&nbsp;</p><p>In RA studies I-IV, adalimumab -treated patients achieved statistically significant ACR 20 and 50 responses compared to placebo as early as one to two weeks after initiation of treatment.</p><p>&nbsp;</p><p>In RA study V with early rheumatoid arthritis patients who were methotrexate na&iuml;ve, combination therapy with adalimumab and methotrexate led to faster and significantly greater ACR responses than methotrexate monotherapy and adalimumab monotherapy at week 52 and responses were sustained at week 104 (see Table 8).</p><p>&nbsp;</p><p><strong>Table 8</strong></p><p><strong>ACR Responses in RA Study V</strong></p><p><strong>(Percent of Patients)</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><p><strong>Response</strong></p></td><td><p><strong>MTX</strong></p><p><strong>&nbsp;</strong></p><p><strong>N=257</strong></p></td><td><p><strong>Adalimumab</strong></p><p><strong>&nbsp;</strong></p><p><strong>N=274</strong></p></td><td><p><strong>Adalimumab/</strong></p><p><strong>MTX</strong></p><p><strong>N=268</strong></p></td><td><p><strong>p-value<sup>a</sup></strong></p></td><td><p><strong>p-value<sup>b</sup></strong></p></td><td><p><strong>p-value<sup>c</sup></strong></p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>ACR 20</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>52</strong><strong>&nbsp;</strong><strong>Week</strong></p></td><td style="vertical-align:top"><p>62.6%</p></td><td style="vertical-align:top"><p>54.4%</p></td><td style="vertical-align:top"><p>72.8%</p></td><td style="vertical-align:top"><p>0.013</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td><td style="vertical-align:top"><p>0.043</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>104</strong><strong>&nbsp;</strong><strong>Week</strong></p></td><td style="vertical-align:top"><p>56.0%</p></td><td style="vertical-align:top"><p>49.3%</p></td><td style="vertical-align:top"><p>69.4%</p></td><td style="vertical-align:top"><p>0.002</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td><td style="vertical-align:top"><p>0.140</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>ACR 50</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>52</strong><strong>&nbsp;</strong><strong>Week</strong></p></td><td style="vertical-align:top"><p>45.9%</p></td><td style="vertical-align:top"><p>41.2%</p></td><td style="vertical-align:top"><p>61.6%</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td><td style="vertical-align:top"><p>0.317</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>104</strong><strong>&nbsp;</strong><strong>Week</strong></p></td><td style="vertical-align:top"><p>42.8%</p></td><td style="vertical-align:top"><p>36.9%</p></td><td style="vertical-align:top"><p>59.0%</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td><td style="vertical-align:top"><p>0.162</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>ACR 70</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>52</strong><strong>&nbsp;</strong><strong>Week</strong></p></td><td style="vertical-align:top"><p>27.2%</p></td><td style="vertical-align:top"><p>25.9%</p></td><td style="vertical-align:top"><p>45.5%</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td><td style="vertical-align:top"><p>0.656</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>104</strong><strong>&nbsp;</strong><strong>Week</strong></p></td><td style="vertical-align:top"><p>28.4%</p></td><td style="vertical-align:top"><p>28.1%</p></td><td style="vertical-align:top"><p>46.6%</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td><td style="vertical-align:top"><p>0.864</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="8" style="vertical-align:top"><p><sup>a</sup> p-value is from the pairwise comparison of methotrexate monotherapy and adalimumab/methotrexate combination therapy using the Mann-Whitney U test.</p><p><sup>b</sup> p-value is from the pairwise comparison of adalimumab monotherapy and adalimumab/methotrexate combination therapy using the Mann-Whitney U test</p><p><sup>c</sup> p-value is from the pairwise comparison of adalimumab monotherapy and methotrexate monotherapy using the Mann-Whitney U test</p></td></tr></tbody></table><p>&nbsp;</p><p>In the open-label extension for RA study V, ACR response rates were maintained when followed for up to 10&nbsp;years. Of 542&nbsp;patients who were randomised to adalimumab 40&nbsp;mg every other week, 170&nbsp;patients continued on adalimumab 40&nbsp;mg every other week for 10&nbsp;years. Among those, 154 patients (90.6&nbsp;%) had ACR 20 responses; 127&nbsp;patients (74.7&nbsp;%) had ACR 50 responses; and 102 patients (60.0&nbsp;%) had ACR 70 responses.</p><p>&nbsp;</p><p>At week 52, 42.9&nbsp;% of patients who received adalimumab/methotrexate combination therapy achieved clinical remission (DAS28 &lt;2.6) compared to 20.6&nbsp;% of patients receiving methotrexate monotherapy and 23.4&nbsp;% of patients receiving adalimumab monotherapy. Adalimumab/methotrexate combination therapy was clinically and statistically superior to methotrexate (p &lt;0.001) and adalimumab monotherapy (p &lt;0.001) in achieving a low disease state in patients with recently diagnosed moderate to severe rheumatoid arthritis. The response for the two monotherapy arms was similar (p = 0.447). Of 342&nbsp;subjects originally randomized to adalimumab monotherapy or adalimumab/methotrexate combination therapy who entered the open-label extension study, 171&nbsp;subjects completed 10&nbsp;years of adalimumab treatment. Among those, 109&nbsp;subjects (63.7&nbsp;%) were reported to be in remission at 10&nbsp;years.</p><p>&nbsp;</p><p><em><u>Radiographic response </u></em></p><p><em><u>&nbsp;</u></em></p><p>In RA study III, where adalimumab treated patients had a mean duration of rheumatoid arthritis of approximately 11&nbsp;years, structural joint damage was assessed radiographically and expressed as change in modified Total Sharp Score (TSS) and its components, the erosion score and joint space narrowing score. Adalimumab /methotrexate patients demonstrated significantly less radiographic progression than patients receiving methotrexate alone at 6 and 12&nbsp;months (see Table 9).</p><p>&nbsp;</p><p>In the open-label extension of RA study III, the reduction in rate of progression of structural damage is maintained for 8 and 10&nbsp;years in a subset of patients. At 8&nbsp;years, 81 of 207&nbsp;patients originally treated with 40&nbsp;mg adalimumab every other week were evaluated radiographically. Among those, 48&nbsp;patients showed no progression of structural damage defined by a change from baseline in the mTSS of 0.5 or less. At 10&nbsp;years, 79 of 207&nbsp;patients originally treated with 40&nbsp;mg adalimumab every other week were evaluated radiographically. Among those, 40&nbsp;patients showed no progression of structural damage defined by a change from baseline in the mTSS of 0.5 or less.</p><p>&nbsp;</p><p><strong>Table </strong><strong>9</strong></p><p><strong>Radiographic Mean Changes Over 12 Months in RA Study III</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td><p><strong>Placebo/MTX</strong><strong><sup>a</sup></strong></p></td><td><p><strong>A</strong><strong>dalimumab/MTX</strong></p><p><strong>40</strong><strong>&nbsp;</strong><strong>mg every other week</strong></p></td><td><p><strong>Placebo/MTX-</strong><strong> A</strong><strong>dalimumab</strong><strong>/MTX (95% Confidence Interval<sup>b</sup>)</strong></p></td><td><p><strong>p-value</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Total Sharp Score</strong></p></td><td style="vertical-align:top"><p>2.7</p></td><td style="vertical-align:top"><p>0.1</p></td><td style="vertical-align:top"><p>2.6 (1.4, 3.8)</p></td><td style="vertical-align:top"><p>&lt;0.001<sup>c</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Erosion Score</strong></p></td><td style="vertical-align:top"><p>1.6</p></td><td style="vertical-align:top"><p>0.0</p></td><td style="vertical-align:top"><p>1.6 (0.9, 2.2)</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td></tr><tr><td style="vertical-align:top"><p><strong>JSN<sup>d</sup> Score</strong></p></td><td style="vertical-align:top"><p>1.0</p></td><td style="vertical-align:top"><p>0.1</p></td><td style="vertical-align:top"><p>0.9 (0.3, 1.4)</p></td><td style="vertical-align:top"><p>0.002</p></td></tr></tbody></table><p><sup>a</sup> methotrexate</p><p><sup>b</sup> 95&nbsp;% confidence intervals for the differences in change scores between methotrexate and adalimumab.</p><p><sup>c</sup> Based on rank analysis</p><p><sup>d</sup> Joint Space Narrowing</p><p>&nbsp;</p><p>In RA study V, structural joint damage was assessed radiographically and expressed as change in modified Total Sharp Score (see Table 10).</p><p>&nbsp;</p><p><strong>Table 10</strong></p><p><strong>Radiographic Mean Changes at Week 52 in RA Study V</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td><p><strong>MTX</strong></p><p><strong>N=257</strong></p><p><strong>(95% confidence interval)</strong></p></td><td><p><strong>A</strong><strong>dalimumab</strong><strong> </strong></p><p><strong>N=274</strong></p><p><strong>(95% confidence interval)</strong></p></td><td><p><strong>A</strong><strong>dalimumab</strong><strong> /MTX</strong></p><p><strong>N=268</strong></p><p><strong>(95% confidence interval)</strong></p></td><td><p><strong>p-value<sup>a</sup></strong></p></td><td><p><strong>p-value<sup>b</sup></strong></p></td><td><p><strong>p-value<sup>c</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Total Sharp Score</strong></p></td><td><p>5.7 (4.2-7.3)</p></td><td><p>3.0 (1.7-4.3)</p></td><td><p>1.3 (0.5-2.1)</p></td><td><p>&lt;0.001</p></td><td><p>0.0020</p></td><td><p>&lt;0.001</p></td></tr><tr><td style="vertical-align:top"><p><strong>Erosion Score</strong></p></td><td><p>3.7 (2.7-4.7)</p></td><td><p>1.7 (1.0-2.4)</p></td><td><p>0.8 (0.4-1.2)</p></td><td><p>&lt;0.001</p></td><td><p>0.0082</p></td><td><p>&lt;0.001</p></td></tr><tr><td style="vertical-align:top"><p><strong>JSN Score</strong></p></td><td><p>2.0 (1.2-2.8)</p></td><td><p>1.3 (0.5-2.1)</p></td><td><p>0.5 (0-1.0)</p></td><td><p>&lt;0.001</p></td><td><p>0.0037</p></td><td><p>0.151</p></td></tr></tbody></table><p><sup>a</sup> p-value is from the pairwise comparison of methotrexate monotherapy and adalimumab/methotrexate combination therapy using the Mann-Whitney U test</p><p><sup>b</sup> p-value is from the pairwise comparison of adalimumab monotherapy and adalimumab/methotrexate combination therapy using the Mann-Whitney U test</p><p><sup>c</sup> p-value is from the pairwise comparison of adalimumab monotherapy and methotrexate monotherapy using the Mann-Whitney U test</p><p>&nbsp;</p><p>Following 52&nbsp;weeks and 104&nbsp;weeks of treatment, the percentage of patients without progression (change from baseline in modified Total Sharp Score &le;0.5) was significantly higher with adalimumab/methotrexate combination therapy (63.8&nbsp;% and 61.2&nbsp;% respectively) compared to methotrexate monotherapy (37.4&nbsp;% and 33.5&nbsp;% respectively, p &lt;0.001) and adalimumab monotherapy (50.7&nbsp;%, p &lt;0.002 and 44.5&nbsp;%, p &lt;0.001 respectively).</p><p>&nbsp;</p><p>In the open-label extension of RA study V, the mean change from baseline at Year 10 in the modified Total Sharp Score was 10.8, 9.2 and 3.9 in patients originally randomized to methotrexate monotherapy, adalimumab monotherapy and adalimumab/methotrexate combination therapy, respectively. The corresponding proportions of patients with no radiographic progression were 31.3&nbsp;%, 23.7&nbsp;% and 36.7&nbsp;% respectively.</p><p>&nbsp;</p><p><em><u>Quality of life and physical function</u></em></p><p><em><u>&nbsp;</u></em></p><p>Health-related quality of life and physical function were assessed using the disability index of the Health Assessment Questionnaire (HAQ) in the four original adequate and well-controlled trials, which was a pre-specified primary endpoint at week 52 in RA study III. All doses/schedules of adalimumab in all four studies showed statistically significantly greater improvement in the disability index of the HAQ from baseline to Month 6 compared to placebo and in RA study III the same was seen at week 52. Results from the Short Form Health Survey (SF 36) for all doses/schedules of adalimumab in all four studies support these findings, with statistically significant physical component summary (PCS) scores, as well as statistically significant pain and vitality domain scores for the 40&nbsp;mg every other week dose. A statistically significant decrease in fatigue as measured by functional assessment of chronic illness therapy (FACIT) scores was seen in all three studies in which it was assessed (RA studies I, III, IV).</p><p>&nbsp;</p><p>In RA study III, most subjects who achieved improvement in physical function and continued treatment maintained improvement through week 520 (120&nbsp;months) of open-label treatment. Improvement in quality of life was measured up to week 156 (36&nbsp;months) and improvement was maintained through that time.</p><p>&nbsp;</p><p>In RA study V, the improvement in the HAQ disability index and the physical component of the SF 36 showed greater improvement (p &lt;0.001) for adalimumab/methotrexate combination therapy <em>versus </em>methotrexate monotherapy and adalimumab monotherapy at week 52, which was maintained through week 104. Among the 250&nbsp;subjects who completed the open-label extension study, improvements in physical function were maintained through 10&nbsp;years of treatment.</p><p>&nbsp;</p><p><em>Juvenile idiopathic arthritis (JIA)</em></p><p>&nbsp;</p><p><em><u>Polyarticular juvenile idiopathic arthritis (pJIA)</u></em></p><p>&nbsp;</p><p>The safety and efficacy of adalimumab was assessed in two studies (pJIA I and II) in children with active polyarticular or polyarticular course juvenile idiopathic arthritis, who had a variety of JIA onset types (most frequently rheumatoid-factor negative or positive polyarthritis and extended oligoarthritis).</p><p>&nbsp;</p><p>pJIA I</p><p>&nbsp;</p><p>The safety and efficacy of adalimumab were assessed in a multicentre, randomised, double-blind, parallel-group study in 171&nbsp;children (4-17&nbsp;years old) with polyarticular JIA. In the open-label lead in phase (OL LI) patients were stratified into two groups, MTX (methotrexate)-treated or non-MTX- treated. Patients who were in the non-MTX stratum were either na&iuml;ve to or had been withdrawn from MTX at least two weeks prior to study drug administration. Patients remained on stable doses of NSAIDs and or prednisone (&le; 0.2&nbsp;mg /kg/day or 10&nbsp;mg/day maximum). In the OL LI phase all patients received 24&nbsp;mg/m<sup>2</sup> up to a maximum of 40&nbsp;mg adalimumab every other week for 16&nbsp;weeks. The distribution of patients by age and minimum, median and maximum dose received during the OL LI phase is presented in Table 11.</p><p>&nbsp;</p><p><strong>Table 11</strong></p><p><strong>Distribution of patients by age and adalimumab dose received during the OL LI phase</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Age Group</strong></p></td><td style="vertical-align:top"><p><strong>Number of patients at Baseline N (%)</strong></p></td><td style="vertical-align:top"><p><strong>Minimum, median and maximum dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>4 to 7&nbsp;years</p></td><td style="vertical-align:top"><p>31 (18.1)</p></td><td style="vertical-align:top"><p>10, 20 and 25&nbsp;mg</p></td></tr><tr><td style="vertical-align:top"><p>8 to 12&nbsp;years</p></td><td style="vertical-align:top"><p>71 (41.5)</p></td><td style="vertical-align:top"><p>20, 25 and 40&nbsp;mg</p></td></tr><tr><td style="vertical-align:top"><p>13 to 17&nbsp;years</p></td><td style="vertical-align:top"><p>69 (40.4)</p></td><td style="vertical-align:top"><p>25, 40 and 40&nbsp;mg</p></td></tr></tbody></table><p>&nbsp;</p><p>Patients demonstrating a Paediatric ACR 30 response at week 16 were eligible to be randomised into the double blind (DB) phase and received either adalimumab 24&nbsp;mg/m<sup>2</sup> up to a maximum of 40&nbsp;mg, or placebo every other week for an additional 32&nbsp;weeks or until disease flare. Disease flare criteria were defined as a worsening of &ge;30% from baseline in &ge;3 of 6 Paediatric ACR core criteria, &ge;2 active joints, and improvement of &gt;30% in no more than 1 of the 6 criteria. After 32&nbsp;weeks or at disease flare, patients were eligible to enrol into the open label extension phase.</p><p>&nbsp;</p><p><strong>Table 12</strong></p><p><strong>Paed ACR 30 Responses in the JIA study</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><p><strong>Stratum</strong></p></td><td colspan="2" rowspan="2"><p><strong>MTX</strong></p></td><td colspan="2" rowspan="2"><p><strong>Without MTX</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Phase</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>OL-LI 16 weeks</p></td></tr><tr><td><p>Ped ACR 30 response (n/N)</p></td><td colspan="2"><p>94.1&nbsp;% (80/85)</p></td><td colspan="2"><p>74.4&nbsp;% (64/86)</p></td></tr><tr><td colspan="5"><p>Efficacy Outcomes</p></td></tr><tr><td><p>Double Blind 32&nbsp;weeks</p></td><td><p>Adalimumab /MTX</p><p>(N=38)</p></td><td><p>Placebo / MTX (N=37)</p></td><td><p>Adalimumab</p><p>(N=30)</p></td><td><p>Placebo</p><p>(N=28)</p></td></tr><tr><td><p>Disease flares at the end of 32&nbsp;weeks<sup>a</sup> (n/N)</p></td><td><p>36.8&nbsp;% (14/38)</p></td><td><p>64.9&nbsp;% (24/37)<sup>b</sup></p></td><td><p>43.3 % (13/30)</p></td><td><p>71.4 % (20/28)<sup>c</sup></p></td></tr><tr><td><p>Median time to disease flare</p></td><td><p>&gt;32 weeks</p></td><td><p>20 weeks</p></td><td><p>&gt;32 weeks</p></td><td><p>14 weeks</p></td></tr></tbody></table><p><sup>a</sup> Ped ACR 30/50/70 responses week 48 significantly greater than those of placebo treated patients</p><p><sup>b</sup> p = 0.015</p><p><sup>c</sup> p = 0.031</p><p>&nbsp;</p><p>Amongst those who responded at week 16 (n=144), the Paediatric ACR 30/50/70/90 responses were maintained for up to six years in the OLE phase in patients who received adalimumab throughout&nbsp; the study. Over all 19 subjects, of which 11 of the baseline age group 4 to 12 and 8 of the baseline age group 13 to 17&nbsp;years were treated 6 years or longer.</p><p>&nbsp;</p><p>Overall responses were generally better and, fewer patients developed antibodies when treated with the combination of adalimumab and MTX compared to adalimumab alone. Taking these results into consideration, adalimumab is recommended for use in combination with MTX and for use as monotherapy in patients for whom MTX use is not appropriate (see section 4.2).</p><p>&nbsp;</p><p>pJIA II</p><p>&nbsp;</p><p>The safety and efficacy of adalimumab was assessed in an open-label, multicentre study in 32 children (2 - &lt;4&nbsp;years old or aged 4 and above weighing &lt;15&nbsp;kg) with moderately to severely active polyarticular JIA. The patients received 24&nbsp;mg/m<sup>2</sup> body surface area (BSA) of adalimumab up to a maximum of 20 mg every other week as a single dose via SC injection for at least 24&nbsp;weeks. During the study, most subjects used concomitant MTX, with fewer reporting use of corticosteroids or NSAIDs.</p><p>&nbsp;</p><p>At week 12 and week 24, PaedACR30 response was 93.5% and 90.0%, respectively, using the observed data approach. The proportions of subjects with PaedACR50/70/90 at week 12 and week 24 were 90.3%/61.3%/38.7% and 83.3%/73.3%/36.7%, respectively. Amongst those who responded (Paediatric ACR 30) at week 24 (n=27 out of 30 patients), the Paediatric ACR 30 responses were maintained for up to 60&nbsp;weeks in the OLE phase in patients who received adalimumab throughout this time period. Overall, 20 subjects were treated for 60&nbsp;weeks or longer.</p><p>&nbsp;</p><p><em><u>Enthesitis-related arthritis</u></em></p><p>&nbsp;</p><p>The safety and efficacy of adalimumab were assessed in a multicentre, randomised, double-blind study in 46 paediatric patients (6 to 17&nbsp;years old) with moderate enthesitis-related arthritis. Patients were randomised to receive either 24&nbsp;mg/m<sup>2</sup> body surface area (BSA) of adalimumab up to a maximum of 40&nbsp;mg, or placebo every other week for 12&nbsp;weeks. The double-blind period is followed by an open-label (OL) period during which patients received 24&nbsp;mg/m<sup>2</sup> BSA of adalimumab up to a maximum of 40&nbsp;mg every other week subcutaneously for up to an additional 192&nbsp;weeks. The primary endpoint was the percent change from Baseline to week 12 in the number of active joints with arthritis (swelling not due to deformity or joints with loss of motion plus pain and/or tenderness), which was achieved with mean percent decrease of -62.6% (median percent change -88.9&nbsp;%) in patients in the adalimumab group compared to -11.6% (median percent change -50.0&nbsp;%) in patients in the placebo group. Improvement in number of active joints with arthritis was maintained during the OL period through week&nbsp;156 for the 26 of 31 (84 %) patients in the adalimumab group who remained in the study. Although not statistically significant, the majority of patients demonstrated clinical improvement in secondary endpoints such as number of sites of enthesitis, tender joint count (TJC), swollen joint count (SJC), Paediatric ACR 50 response, and Paediatric ACR 70 response.</p><p>&nbsp;</p><p><em>Axial spondyloarthritis</em></p><p><u>&nbsp;</u></p><p><em><u>Ankylosing spondylitis (AS)</u></em></p><p><em><u>&nbsp;</u></em></p><p>Adalimumab 40&nbsp;mg every other week was assessed in 393 patients in two randomised, 24&nbsp;week double &minus; blind, placebo &minus; controlled studies in patients with active ankylosing spondylitis (mean baseline score of disease activity [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)] was 6.3 in all groups) who have had an inadequate response to conventional therapy. Seventy-nine (20.1%) patients were treated concomitantly with disease modifying anti &minus; rheumatic drugs, and 37 (9.4%) patients with glucocorticoids. The blinded period was followed by an open &minus; label period during which patients received adalimumab 40&nbsp;mg every other week subcutaneously for up to an additional 28 weeks. Subjects (n=215, 54.7%) who failed to achieve ASAS 20 at weeks 12, or 16 or 20 received early escape open-label adalimumab 40&nbsp;mg every other week subcutaneously and were subsequently treated as non-responders in the double-blind statistical analyses.</p><p>&nbsp;</p><p>In the larger AS study I with 315 patients, results showed statistically significant improvement of the signs and symptoms of ankylosing spondylitis in patients treated with adalimumab compared to placebo. Significant response was first observed at week 2 and maintained through 24&nbsp;weeks (Table&nbsp;13).</p><p>&nbsp;</p><p><strong>Table </strong><strong>13</strong></p><p><strong>Efficacy Responses in Placebo-Controlled AS Study &ndash; Study I</strong></p><p><strong>Reduction of Signs and Symptoms</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><p><strong>Response</strong></p></td><td><p><strong>Placebo</strong></p><p><strong>N=107</strong></p></td><td><p><strong>A</strong><strong>dalimumab</strong></p><p><strong>N=208</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>ASAS<sup>a</sup> 20</p></td></tr><tr><td style="vertical-align:top"><p>Week 2</p></td><td style="vertical-align:top"><p>16%</p></td><td style="vertical-align:top"><p>42%***</p></td></tr><tr><td style="vertical-align:top"><p>Week 12</p></td><td style="vertical-align:top"><p>21%</p></td><td style="vertical-align:top"><p>58%***</p></td></tr><tr><td style="vertical-align:top"><p>Week 24</p></td><td style="vertical-align:top"><p>19%</p></td><td style="vertical-align:top"><p>51%***</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>ASAS 50</p></td></tr><tr><td style="vertical-align:top"><p>Week 2</p></td><td style="vertical-align:top"><p>3%</p></td><td style="vertical-align:top"><p>16%***</p></td></tr><tr><td style="vertical-align:top"><p>Week 12</p></td><td style="vertical-align:top"><p>10%</p></td><td style="vertical-align:top"><p>38%***</p></td></tr><tr><td style="vertical-align:top"><p>Week 24</p></td><td style="vertical-align:top"><p>11%</p></td><td style="vertical-align:top"><p>35%***</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>ASAS 70</p></td></tr><tr><td style="vertical-align:top"><p>Week 2</p></td><td style="vertical-align:top"><p>0%</p></td><td style="vertical-align:top"><p>7%**</p></td></tr><tr><td style="vertical-align:top"><p>Week 12</p></td><td style="vertical-align:top"><p>5%</p></td><td style="vertical-align:top"><p>23%***</p></td></tr><tr><td style="vertical-align:top"><p>Week 24</p></td><td style="vertical-align:top"><p>8%</p></td><td style="vertical-align:top"><p>24%***</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>BASDAI<sup>b</sup> 50</p></td></tr><tr><td style="vertical-align:top"><p>Week 2</p></td><td style="vertical-align:top"><p>4%</p></td><td style="vertical-align:top"><p>20%***</p></td></tr><tr><td style="vertical-align:top"><p>Week 12</p></td><td style="vertical-align:top"><p>16%</p></td><td style="vertical-align:top"><p>45%***</p></td></tr><tr><td style="vertical-align:top"><p>Week 24</p></td><td style="vertical-align:top"><p>15%</p></td><td style="vertical-align:top"><p>42%***</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>***,** Statistically significant at p &lt; 0.001, &lt; 0.01 for all comparisons between adalimumab and placebo at weeks 2, 12 and 24</p><p><sup>a</sup> Assessments in Ankylosing Spondylitis</p><p><sup>b</sup> Bath Ankylosing Spondylitis Disease Activity Index</p></td></tr></tbody></table><p>&nbsp;</p><p>Adalimumab treated patients had significantly greater improvement at week 12 which was maintained through week 24 in both the SF36 and Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL).</p><p>&nbsp;</p><p>Similar trends (not all statistically significant) were seen in the smaller randomised, double &minus; blind, placebo controlled AS study II of 82 adult patients with active ankylosing spondylitis.</p><p>&nbsp;</p><p><em><u>Axial spondyloarthritis without radiographic evidence of AS</u></em></p><p><em><u>&nbsp;</u></em></p><p>The safety and efficacy of adalimumab were assessed in two randomized, double-blind placebo-controlled studies in patients with non-radiographic axial spondyloarthritis (nr-axSpA). Study nr-axSpA I evaluated patients with active nr-axSpA. Study nr-axSpA II was a treatment withdrawal study in active nr-axSpA patients who achieved remission during open-label treatment with adalimumab.</p><p>&nbsp;</p><p><u>Study nr-axSpA I</u></p><p>&nbsp;</p><p>In study nr-axSpA I, adalimumab 40&nbsp;mg every other week was assessed in 185&nbsp;patients in a randomised, 12&nbsp;week double - blind, placebo - controlled study in patients with active nr-axSpA (mean baseline score of disease activity [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)] was 6.4 for patients treated with adalimumab and 6.5 for those on placebo) who have had an inadequate response to or intolerance to &ge;1&nbsp;NSAIDs, or a contraindication for NSAIDs.</p><p>&nbsp;</p><p>Thirty-three (18&nbsp;%) patients were treated concomitantly with disease modifying anti-rheumatic drugs, and 146 (79&nbsp;%) patients with NSAIDs at baseline. The double-blind period was followed by an open-label period during which patients receive adalimumab 40&nbsp;mg every other week subcutaneously for up to an additional 144&nbsp;weeks. week 12 results showed statistically significant improvement of the signs and symptoms of active nr-axSpA in patients treated with adalimumab compared to placebo (Table 14).</p><p>&nbsp;</p><p><strong>Table </strong><strong>14</strong></p><p><strong>Efficacy Response in Placebo-Controlled Study</strong> <strong>nr-axSpA</strong><strong> I</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><p><strong>Double-Blind</strong></p><p><strong>Response at Week 12</strong></p></td><td><p><strong>Placebo</strong></p><p><strong>N</strong><strong>=94</strong></p></td><td><p><strong>A</strong><strong>dalimumab</strong></p><p><strong>N</strong><strong>=91</strong></p></td></tr><tr><td><p>ASAS<sup>a</sup> 40</p></td><td><p>15%</p></td><td><p>36%***</p></td></tr><tr><td><p>ASAS 20</p></td><td><p>31%</p></td><td><p>52%**</p></td></tr><tr><td><p>ASAS 5/6</p></td><td><p>6%</p></td><td><p>31%***</p></td></tr><tr><td><p>ASAS partial remission</p></td><td><p>5%</p></td><td><p>16%*</p></td></tr><tr><td><p>BASDAI<sup>b</sup> 50</p></td><td><p>15%</p></td><td><p>35%**</p></td></tr><tr><td><p>ASDAS<sup>c,d,e</sup></p></td><td><p>-0.3</p></td><td><p>-1.0***</p></td></tr><tr><td><p>ASDAS Inactive Disease</p></td><td><p>4%</p></td><td><p>24%***</p></td></tr><tr><td><p>hs-CRP<sup>d,f,g</sup></p></td><td><p>-0.3</p></td><td><p>-4.7***</p></td></tr><tr><td><p>SPARCC<sup>h</sup> MRI Sacroiliac Joints<sup>d,i</sup></p></td><td><p>-0.6</p></td><td><p>-3.2**</p></td></tr><tr><td><p>SPARCC MRI Spine<sup>d,j</sup></p></td><td><p>-0.2</p></td><td><p>-1.8**</p></td></tr><tr><td colspan="3"><p><sup>a</sup> Assessments in SpondyloArthritis International Society</p><p><sup>b</sup> Bath Ankylosing Spondylitis Disease Activity Index</p><p><sup>c</sup> Ankylosing Spondylitis Disease Activity Score</p><p><sup>d</sup> mean change from baseline</p><p><sup>e</sup> n=91 placebo and n=87 adalimumab</p><p><sup>f</sup> high sensitivity C-Reactive Protein (mg/L)</p><p><sup>g</sup> n=73 placebo and n=70 adalimumab</p><p><sup>h</sup> Spondyloarthritis Research Consortium of Canada</p><p><sup>i</sup> n=84 placebo and adalimumab</p><p><sup>j</sup> n=82 placebo and n=85 adalimumab</p><p>***, **, * Statistically significant at p &lt;0.001, &lt;0.01, and &lt;0.05, respectively, for all comparisons between adalimumab and placebo.</p></td></tr></tbody></table><p>&nbsp;</p><p>In the open-label extension, improvement in the signs and symptoms was maintained with adalimumab therapy through week 156.</p><p>&nbsp;</p><p>Inhibition of inflammation</p><p>&nbsp;</p><p>Significant improvement of signs of inflammation as measured by hs-CRP and MRI of both Sacroiliac Joints and the Spine was maintained in adalimumab-treated patients through week 156 and week 104, respectively.</p><p>&nbsp;</p><p>Quality of life and physical function</p><p>&nbsp;</p><p>Health-related quality of life and physical function were assessed using the HAQ-S and the SF-36 questionnaires. Adalimumab showed statistically significantly greater improvement in the HAQ-S total score and the SF-36 Physical Component Score (PCS) from baseline to week 12 compared to placebo. Improvement in health-related quality of life and physical function was maintained during the openlabel extension through week 156.</p><p>&nbsp;</p><p><u>Study nr-axSpA II</u></p><p>&nbsp;</p><p>673&nbsp;patients with active nr-axSpA (mean baseline disease activity [BASDAI] was 7.0) who had an inadequate response to &sup3;&nbsp;2 NSAIDs, or an intolerance to or a contraindication for NSAIDs enrolled into the open-label period of study nr-axSpA II during which they received adalimumab 40&nbsp;mg eow for 28 weeks. These patients also had objective evidence of inflammation in the sacroiliac joints or spine on MRI or elevated hs-CRP. Patients who achieved sustained remission for at least 12 weeks (N=305) (ASDAS &lt;&nbsp;1.3 at Weeks 16, 20, 24, and 28) during the open-label period were then randomized to receive either continued treatment with adalimumab 40&nbsp;mg eow (N=152) or placebo (N=153) for an additional 40 weeks in a double-blind, placebo-controlled period (total study duration 68 weeks). Subjects who flared during the double-blind period were allowed adalimumab 40&nbsp;mg eow rescue therapy for at least 12 weeks.</p><p>&nbsp;</p><p>The primary efficacy endpoint was the proportion of patients with no flare by Week 68 of the study. Flare was defined as ASDAS &ge;&nbsp;2.1 at two consecutive visits four weeks apart. A greater proportion of patients on adalimumab had no disease flare during the double-blind period, when compared with those on placebo (70.4% vs. 47.1%, p&lt;0.001) (Figure 1).</p><p><strong>&nbsp;</strong></p><p><strong>Figure 1: Kaplan-Meier Curves Summarizing Time to Flare in </strong></p><p><strong>Study nr-axSpA II</strong></p><p><strong><img src="data:image/jpeg;base64,/9j/4AAQSkZJRgABAQEAyADIAAD/2wBDAAMCAgMCAgMDAwMEAwMEBQgFBQQEBQoHBwYIDAoMDAsKCwsNDhIQDQ4RDgsLEBYQERMUFRUVDA8XGBYUGBIUFRT/2wBDAQMEBAUEBQkFBQkUDQsNFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBQUFBT/wAARCAO7BvgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD9U6KKKACiiigAooooAKKKKACioJLjG/Ebvj0FeYal+098ItE1KfTtS+KPg3TNQt3eCe2uvENpHLDJGcSRyIZBscHPX0oA9WoryWP9rD4JHr8Y/AEf/c02H/x2n/8ADV/wS/6LJ4A/8Kix/wDjtAHq9FeUf8NX/BL/AKLJ4A/8Kix/+O0f8NX/AAS/6LJ4A/8ACosf/jtAHq9FeUf8NX/BL/osngD/AMKix/8AjtH/AA1f8Ev+iyeAP/Cosf8A47QB6vRXlH/DV/wS/wCiyeAP/Cosf/jtH/DV/wAEv+iyeAP/AAqLH/47QB6vRXlH/DV/wS/6LJ4A/wDCosf/AI7R/wANX/BL/osngD/wqLH/AOO0Aer0V5R/w1f8Ev8AosngD/wqLH/47R/w1f8ABL/osngD/wAKix/+O0Aer0V5R/w1f8Ev+iyeAP8AwqLH/wCO0f8ADV/wS/6LJ4A/8Kix/wDjtAHq9FeUf8NX/BL/AKLJ4A/8Kix/+O0f8NX/AAS/6LJ4A/8ACosf/jtAHq9FeUf8NX/BL/osngD/AMKix/8AjtH/AA1f8Ev+iyeAP/Cosf8A47QB6vRXlH/DV/wS/wCiyeAP/Cosf/jtH/DV/wAEv+iyeAP/AAqLH/47QB6vRXlH/DV/wS/6LJ4A/wDCosf/AI7R/wANX/BL/osngD/wqLH/AOO0Aer0V5R/w1f8Ev8AosngD/wqLH/47R/w1f8ABL/osngD/wAKix/+O0Aer0V5R/w1f8Ev+iyeAP8AwqLH/wCO0f8ADV/wS/6LJ4A/8Kix/wDjtAHq9FeUf8NX/BL/AKLJ4A/8Kix/+O0f8NX/AAS/6LJ4A/8ACosf/jtAHq9FeUf8NX/BL/osngD/AMKix/8AjtH/AA1f8Ev+iyeAP/Cosf8A47QB6vRXlH/DV/wS/wCiyeAP/Cosf/jtH/DV/wAEv+iyeAP/AAqLH/47QB6vRXlH/DV/wS/6LJ4A/wDCosf/AI7R/wANX/BL/osngD/wqLH/AOO0Aer0V5R/w1f8Ev8AosngD/wqLH/47R/w1f8ABL/osngD/wAKix/+O0Aer0V5R/w1f8Ev+iyeAP8AwqLH/wCO0f8ADV/wS/6LJ4A/8Kix/wDjtAHq9FeUf8NX/BL/AKLJ4A/8Kix/+O0f8NX/AAS/6LJ4A/8ACosf/jtAHq9FeUf8NX/BL/osngD/AMKix/8AjtH/AA1f8Ev+iyeAP/Cosf8A47QB6vRXlH/DV/wS/wCiyeAP/Cosf/jtH/DV/wAEv+iyeAP/AAqLH/47QB6vRXlH/DV/wS/6LJ4A/wDCosf/AI7R/wANX/BL/osngD/wqLH/AOO0Aer0V5R/w1f8Ev8AosngD/wqLH/47R/w1f8ABL/osngD/wAKix/+O0Aer0V5R/w1f8Ev+iyeAP8AwqLH/wCO0f8ADV/wS/6LJ4A/8Kix/wDjtAHq9FeUf8NX/BL/AKLJ4A/8Kix/+O0f8NX/AAS/6LJ4A/8ACosf/jtAHq9FeUf8NX/BL/osngD/AMKix/8AjtH/AA1f8Ev+iyeAP/Cosf8A47QB6vRXlH/DV/wS/wCiyeAP/Cosf/jtH/DV/wAEv+iyeAP/AAqLH/47QB6vRXlH/DV/wS/6LJ4A/wDCosf/AI7R/wANX/BL/osngD/wqLH/AOO0Aer0V5R/w1f8Ev8AosngD/wqLH/47R/w1f8ABL/osngD/wAKix/+O0Aer0V5R/w1f8Ev+iyeAP8AwqLH/wCO0f8ADV/wS/6LJ4A/8Kix/wDjtAHq9FeUf8NX/BL/AKLJ4A/8Kix/+O0f8NX/AAS/6LJ4A/8ACosf/jtAHq9FeUf8NX/BL/osngD/AMKix/8AjtH/AA1f8Ev+iyeAP/Cosf8A47QB6vRXlH/DV/wS/wCiyeAP/Cosf/jtH/DV/wAEv+iyeAP/AAqLH/47QB6vRXlH/DV/wS/6LJ4A/wDCosf/AI7R/wANX/BL/osngD/wqLH/AOO0Aer0V5R/w1f8Ev8AosngD/wqLH/47R/w1f8ABL/osngD/wAKix/+O0Aer0V5R/w1f8Ev+iyeAP8AwqLH/wCO0f8ADV/wS/6LJ4A/8Kix/wDjtAHq9FeUf8NX/BL/AKLJ4A/8Kix/+O0f8NX/AAS/6LJ4A/8ACosf/jtAHq9FeUf8NX/BL/osngD/AMKix/8AjtH/AA1f8Ev+iyeAP/Cosf8A47QB6vRXlH/DV/wS/wCiyeAP/Cosf/jtH/DV/wAEv+iyeAP/AAqLH/47QB6vRXlH/DV/wS/6LJ4A/wDCosf/AI7R/wANX/BL/osngD/wqLH/AOO0Aer0V5R/w1f8Ev8AosngD/wqLH/47R/w1f8ABL/osngD/wAKix/+O0Aer0V5R/w1f8Ev+iyeAP8AwqLH/wCO0f8ADV/wS/6LJ4A/8Kix/wDjtAHq9FeUf8NX/BL/AKLJ4A/8Kix/+O0f8NX/AAS/6LJ4A/8ACosf/jtAHq9FeUf8NX/BL/osngD/AMKix/8AjtH/AA1f8Ev+iyeAP/Cosf8A47QB6vRXlH/DV/wS/wCiyeAP/Cosf/jtH/DV/wAEv+iyeAP/AAqLH/47QB6vRXlH/DV/wS/6LJ4A/wDCosf/AI7R/wANX/BL/osngD/wqLH/AOO0Aer0V5R/w1f8Ev8AosngD/wqLH/47R/w1f8ABL/osngD/wAKix/+O0Aer0V5R/w1f8Ev+iyeAP8AwqLH/wCO0f8ADV/wS/6LJ4A/8Kix/wDjtAHq9FeUf8NX/BL/AKLJ4A/8Kix/+O0f8NX/AAS/6LJ4A/8ACosf/jtAHq9FeUf8NX/BL/osngD/AMKix/8AjtH/AA1f8Ev+iyeAP/Cosf8A47QB6vRXlH/DV/wS/wCiyeAP/Cosf/jtH/DV/wAEv+iyeAP/AAqLH/47QB6vRXlH/DV/wS/6LJ4A/wDCosf/AI7R/wANX/BL/osngD/wqLH/AOO0Aer0V5R/w1f8Ev8AosngD/wqLH/47R/w1f8ABL/osngD/wAKix/+O0Aer0V5R/w1f8Ev+iyeAP8AwqLH/wCO0f8ADV/wS/6LJ4A/8Kix/wDjtAHq9FeUf8NX/BL/AKLJ4A/8Kix/+O0f8NX/AAS/6LJ4A/8ACosf/jtAHq9FeUf8NX/BL/osngD/AMKix/8AjtH/AA1f8Ev+iyeAP/Cosf8A47QB6vRXlH/DV/wS/wCiyeAP/Cosf/jtH/DV/wAEv+iyeAP/AAqLH/47QB6vRXlH/DV/wS/6LJ4A/wDCosf/AI7R/wANX/BL/osngD/wqLH/AOO0Aer0V5R/w1f8Ev8AosngD/wqLH/47R/w1f8ABL/osngD/wAKix/+O0Aer0V5R/w1f8Ev+iyeAP8AwqLH/wCO0f8ADV/wS/6LJ4A/8Kix/wDjtAHq9FeUf8NX/BL/AKLJ4A/8Kix/+O0f8NX/AAS/6LJ4A/8ACosf/jtAHq9FeUf8NX/BL/osngD/AMKix/8AjtH/AA1f8Ev+iyeAP/Cosf8A47QB6vRXlH/DV/wS/wCiyeAP/Cosf/jtH/DV/wAEv+iyeAP/AAqLH/47QB6vRXlH/DV/wS/6LJ4A/wDCosf/AI7R/wANX/BL/osngD/wqLH/AOO0Aer0V5R/w1f8Ev8AosngD/wqLH/47R/w1f8ABL/osngD/wAKix/+O0Aer0V5R/w1f8Ev+iyeAP8AwqLH/wCO0f8ADV/wS/6LJ4A/8Kix/wDjtAHq9FeUf8NX/BL/AKLJ4A/8Kix/+O0f8NX/AAS/6LJ4A/8ACosf/jtAHq9FeUf8NX/BL/osngD/AMKix/8AjtH/AA1f8Ev+iyeAP/Cosf8A47QB6vRXlH/DV/wS/wCiyeAP/Cosf/jtH/DV/wAEv+iyeAP/AAqLH/47QB6vRXlH/DV/wS/6LJ4A/wDCosf/AI7R/wANX/BL/osngD/wqLH/AOO0Aer0V5R/w1f8Ev8AosngD/wqLH/47R/w1f8ABL/osngD/wAKix/+O0Aer0V5R/w1f8Ev+iyeAP8AwqLH/wCO0f8ADV/wS/6LJ4A/8Kix/wDjtAHq9FeUf8NX/BL/AKLJ4A/8Kix/+O0f8NX/AAS/6LJ4A/8ACosf/jtAHq9FeUf8NX/BL/osngD/AMKix/8AjtH/AA1f8Ev+iyeAP/Cosf8A47QB6vRXlH/DV/wS/wCiyeAP/Cosf/jtH/DV/wAEv+iyeAP/AAqLH/47QB6vRXlH/DV/wS/6LJ4A/wDCosf/AI7R/wANX/BL/osngD/wqLH/AOO0Aer0V5R/w1f8Ev8AosngD/wqLH/47R/w1f8ABL/osngD/wAKix/+O0Aer0V5R/w1f8Ev+iyeAP8AwqLH/wCO0f8ADV/wS/6LJ4A/8Kix/wDjtAHq9FeUf8NX/BL/AKLJ4A/8Kix/+O0f8NX/AAS/6LJ4A/8ACosf/jtAHq9FeUf8NX/BL/osngD/AMKix/8AjtH/AA1f8Ev+iyeAP/Cosf8A47QB6vRXlH/DV/wS/wCiyeAP/Cosf/jtH/DV/wAEv+iyeAP/AAqLH/47QB6vRXlH/DV/wS/6LJ4A/wDCosf/AI7R/wANX/BL/osngD/wqLH/AOO0Aer0V5R/w1f8Ev8AosngD/wqLH/47R/w1f8ABL/osngD/wAKix/+O0Aer0V5R/w1f8Ev+iyeAP8AwqLH/wCO0f8ADV/wS/6LJ4A/8Kix/wDjtAHq9FeUf8NX/BL/AKLJ4A/8Kix/+O0f8NX/AAS/6LJ4A/8ACosf/jtAHq9FeUf8NX/BL/osngD/AMKix/8AjtH/AA1f8Ev+iyeAP/Cosf8A47QB6vRXlH/DV/wS/wCiyeAP/Cosf/jtH/DV/wAEv+iyeAP/AAqLH/47QB6vRXlH/DV/wS/6LJ4A/wDCosf/AI7R/wANX/BL/osngD/wqLH/AOO0Aer0V5R/w1f8Ev8AosngD/wqLH/47R/w1f8ABL/osngD/wAKix/+O0Aer0V5R/w1f8Ev+iyeAP8AwqLH/wCO0f8ADV/wS/6LJ4A/8Kix/wDjtAHq9FeUf8NX/BL/AKLJ4A/8Kix/+O0f8NX/AAS/6LJ4A/8ACosf/jtAHq9FeUf8NX/BL/osngD/AMKix/8AjtH/AA1f8Ev+iyeAP/Cosf8A47QB6vRXlH/DV/wS/wCiyeAP/Cosf/jtH/DV/wAEv+iyeAP/AAqLH/47QB6vRXlH/DV/wS/6LJ4A/wDCosf/AI7R/wANX/BL/osngD/wqLH/AOO0Aer0V5R/w1f8Ev8AosngD/wqLH/47R/w1f8ABL/osngD/wAKix/+O0Aer0V5R/w1f8Ev+iyeAP8AwqLH/wCO0f8ADV/wS/6LJ4A/8Kix/wDjtAHq9FeUf8NX/BL/AKLJ4A/8Kix/+O0f8NX/AAS/6LJ4A/8ACosf/jtAHq9FeUf8NX/BL/osngD/AMKix/8AjtH/AA1f8Ev+iyeAP/Cosf8A47QB6vRXlH/DV/wS/wCiyeAP/Cosf/jtH/DV/wAEv+iyeAP/AAqLH/47QB6vRXlH/DV/wS/6LJ4A/wDCosf/AI7R/wANX/BL/osngD/wqLH/AOO0Aer0V5R/w1f8Ev8AosngD/wqLH/47R/w1f8ABL/osngD/wAKix/+O0Aer0V5R/w1f8Ev+iyeAP8AwqLH/wCO0f8ADV/wS/6LJ4A/8Kix/wDjtAHq9FeUf8NX/BL/AKLJ4A/8Kix/+O0f8NX/AAS/6LJ4A/8ACosf/jtAHq9FeUf8NX/BL/osngD/AMKix/8AjtW/DP7Qnwv8Za9a6P4d+IfhPxHrF1uFvp+ka7aXNzJhC7/u45CeiGgD0yimRyCSMN2p9ABRRRQAVWF1w+EZ9r7OKs18e/tYft8eE/gV/wAJR4S8NQXPi/4r6dCWTw7DZXBjtE+y/aXuLiTy9n2eO3/eSeVJvxx+7G+RAD6/jk8wU+vDf2O/jFrPx8/Zz8JeOvEdrY2us6mbxp4dOjkjt4/KvJ4B5e+Rz9yP++ete5UAQSXPl/8ALNz+FD3Cb9n3zXyb+15+1lrPwl8YeHPhp8NfDB8bfF/xN5U+n6TdRSfY4IMyD7RNzHvz5Un/AC0CR+XJJIUEY8zhPhn+2T8WfBXxk8OeAP2kPAVp4Jl8XpHbeHdY0LzJrd7jzfK8qfbcTo5d/L5Q5j8yPeNk/mIAfeKSCTlafUNvF5MeypqAKsm/7R7V+Lvwo/Zp8MftYf8ABQD4+eDfF17qun6fZ6nr2qRz6NLHHL5kerpGB+8jkGCJ5O1ftN/y2r8sv2B/+Upn7Rf08R/+ny3oA9U/4cs/BH/oaPH/AP4MLD/5Do/4cs/BH/oaPH//AIMLD/5Dr78j/wBWtPoA+AP+HLPwR/6Gjx//AODCw/8AkOj/AIcs/BH/AKGjx/8A+DCw/wDkOvv+igD4A/4cs/BH/oaPH/8A4MLD/wCQ6P8Ahyz8Ef8AoaPH/wD4MLD/AOQ6+/6KAPgD/hyz8Ef+ho8f/wDgwsP/AJDo/wCHLPwR/wCho8f/APgwsP8A5Dr7/ooA+AP+HLPwR/6Gjx//AODCw/8AkOj/AIcs/BH/AKGjx/8A+DCw/wDkOvv+igD4A/4cs/BH/oaPH/8A4MLD/wCQ6P8Ahyz8Ef8AoaPH/wD4MLD/AOQ6+/6KAPgD/hyz8Ef+ho8f/wDgwsP/AJDo/wCHLPwR/wCho8f/APgwsP8A5Dr7/ooA+AP+HLPwR/6Gjx//AODCw/8AkOj/AIcs/BH/AKGjx/8A+DCw/wDkOvv+igD4A/4cs/BH/oaPH/8A4MLD/wCQ6P8Ahyz8Ef8AoaPH/wD4MLD/AOQ6+/6KAPgD/hyz8Ef+ho8f/wDgwsP/AJDo/wCHLPwR/wCho8f/APgwsP8A5Dr7/ooA+AP+HLPwR/6Gjx//AODCw/8AkOj/AIcs/BH/AKGjx/8A+DCw/wDkOvv+igD4A/4cs/BH/oaPH/8A4MLD/wCQ6P8Ahyz8Ef8AoaPH/wD4MLD/AOQ6+/6KAPgD/hyz8Ef+ho8f/wDgwsP/AJDo/wCHLPwR/wCho8f/APgwsP8A5Dr7/ooA+AP+HLPwR/6Gjx//AODCw/8AkOj/AIcs/BH/AKGjx/8A+DCw/wDkOvv+igD4A/4cs/BH/oaPH/8A4MLD/wCQ6P8Ahyz8Ef8AoaPH/wD4MLD/AOQ6+/6KAPgD/hyz8Ef+ho8f/wDgwsP/AJDo/wCHLPwR/wCho8f/APgwsP8A5Dr7/ooA+AP+HLPwR/6Gjx//AODCw/8AkOj/AIcs/BH/AKGjx/8A+DCw/wDkOvv+igD4A/4cs/BH/oaPH/8A4MLD/wCQ6P8Ahyz8Ef8AoaPH/wD4MLD/AOQ6+/6Z5g8zb3oA+A/+HLPwR/6Gjx//AODCw/8AkOj/AIcs/BH/AKGjx/8A+DCw/wDkOvqH4G/tKeCP2gh4sHhK+Nz/AMI3q8mj3Bmmgfz8D5LmExyPvgk/eeXJ/H5cnHFetxv5i5oA+A/+HLPwR/6Gjx//AODCw/8AkOj/AIcs/BH/AKGjx/8A+DCw/wDkOvvmS6SOQIeteR/An9pDwl+0Pp+v3HhRNQtn0m7SBrbVoPslxNDJFHcW95HBv8wW9xHIHjkkCeYM8cUAfMX/AA5Z+CP/AENHj/8A8GFh/wDIdH/Dln4I/wDQ0eP/APwYWH/yHX35G/mLmue8XeKtK8C+GdZ8RaxdfZtN0e0mv764WN5PJgjjMkjlE5OEQmgD4k/4cs/BH/oaPH//AIMLD/5Do/4cs/BH/oaPH/8A4MLD/wCQ69hm/b4+Gek+CfCPiTWpNR0AeIPEr+GDpOrNZ2+oaRdxyyR3D38T3H7iOIeU8hzmNLiDj56+k/tyeX5nz+X/ALlAHwX/AMOWfgj/ANDR4/8A/BhYf/IdH/Dln4I/9DR4/wD/AAYWH/yHX3x5yR7938FO86gD4F/4cs/BH/oaPH//AIMLD/5Do/4cs/BH/oaPH/8A4MLD/wCQ6+/d4qP7SnmeX/H6UAfA3/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHR/w5Z+CP/Q0eP/8AwYWH/wAh19/0UAfAH/Dln4I/9DR4/wD/AAYWH/yHXj/gn9mTwx+yp/wVG+EHhDwjfavqOn3+g3uqO+tTRySeY9pqcez93HGCgFunbvX6v1+fnxo/5TFfA/8A7Ey5/wDRGs0AfflvnyfmfzPep6anSnUAFFFFABXz/wDtPeAPDVj8Efjb4stfDmk2fie/8Eaxb3mtW2nxJe3Mf2CT93JcbN8ifu4+M/8ALOP0r6AryL9q6T/jGH4y/wDYl6x/6RXFAHmP/BL3/kxn4bf9xP8A9Ol5X1XXyp/wS5/5MV+Gf/cT/wDTpd12vxQ/a08A/Cn42eCPhZ4guL6DxJ4s8trRoLVngt/Mk8qD7RIP+ekiPGNm/GMyeWnz0AfOfw7z4i/4K+/Fc6mP7SGg+D7caSb0+YbDfFpm/wCz5/1f/Hzcf6vH+vk/vnMP/BX+3Xw/8C/AniHTlNj4k0zxfbnTdTgHl3Np/o1zITbyJ88fzxW/TvHH/crN+Pmuf8Mjf8FANM+Mmrabfn4a/EDSI9A13WjD9rjsLvYieXHGmDGQlpZyYcOXT7R5fmY2Jzn7Tnxw8O/8FBPiN8LPgr8LxeeMPDQ1lNe8UaxZ2Mlo1hZo/kb43n+4Y4J7jeZI8F3twmXJjoA/TiL/AFdfMP7TP/BQDwD+yr49s/Cvi7Q/FGoX93psepxzaLaW8sHlvLJGEJkuIzvzBJ2/wr6hTpVaSN97vHs3/wDTSgD4J/4fPfBTfg+F/H5/652Fn/8AJleIf8EzfGFn4+/4KEfGXxVZQz21jrmma1qUEV0gSZI7jV7SREfn7+H9TX60yGQtsUY/26/LP9gf/lKZ+0X9PEn/AKfLegD9UI/9WtPpkf8Aq1p9ABRRRQAUUUUAFFFFABXJ/EDxnafD3wH4h8UXdtcXtjoWn3GpzQWqh55I4I3kcRhiAX+Q966yq8sAMm8fin96gD4I/wCH03wQ/wChV8ff+AFh/wDJlH/D6b4I/wDQr+P/APwX2H/yZX3z+82fwU7bJ/fH/fP/ANegD4E/4fTfBH/oV/H/AP4L7D/5Mo/4fTfBH/oV/H//AIL7D/5Mr772yf3x/wB8/wD16Nsn98f98/8A16APgT/h9N8Ef+hX8f8A/gvsP/kyj/h9N8Ef+hX8f/8AgvsP/kyvvvbJ/fH/AHz/APXo2yf3x/3z/wDXoA+BP+H03wR/6Ffx/wD+C+w/+TKP+H03wR/6Ffx//wCC+w/+TK++9sn98f8AfP8A9ejbJ/fH/fP/ANegD4E/4fTfBH/oV/H/AP4L7D/5Mo/4fTfBH/oV/H//AIL7D/5Mr772yf3x/wB8/wD16Nsn98f98/8A16APgT/h9N8Ef+hX8f8A/gvsP/kyj/h9N8Ef+hX8f/8AgvsP/kyvvvbJ/fH/AHz/APXo2yf3x/3z/wDXoA+BP+H03wR/6Ffx/wD+C+w/+TKP+H03wR/6Ffx//wCC+w/+TK++9sn98f8AfP8A9ejbJ/fH/fP/ANegD4E/4fTfBH/oV/H/AP4L7D/5Mo/4fTfBH/oV/H//AIL7D/5Mr772yf3x/wB8/wD16Nsn98f98/8A16APgT/h9N8Ef+hX8f8A/gvsP/kyj/h9N8Ef+hX8f/8AgvsP/kyvvvbJ/fH/AHz/APXo2yf3x/3z/wDXoA+BP+H03wR/6Ffx/wD+C+w/+TKP+H03wR/6Ffx//wCC+w/+TK++9sn98f8AfP8A9ejbJ/fH/fP/ANegD4E/4fTfBH/oV/H/AP4L7D/5Mo/4fTfBH/oV/H//AIL7D/5Mr772yf3x/wB8/wD16Nsn98f98/8A16APgT/h9N8Ef+hX8f8A/gvsP/kyj/h9N8Ef+hX8f/8AgvsP/kyvvvbJ/fH/AHz/APXo2yf3x/3z/wDXoA+BP+H03wR/6Ffx/wD+C+w/+TK4r4vf8Fb/AAD4v+HOvaN4Ns/Gnh7WtWg/s+HV7jT7fFikjok88XlXiSeekTyPH86DzPLzxX6WPI0blP8Avj5a+P8A4e/tFfDHxl8aPGnxG1/4qeENLt7Df4T8Kabe+JLWHNnBIJLy88v7Y6f6XdImyTy0fyLK3PSTkA+bLP8A4KPfBrwJ8R/A2v8AgbRPGWi6BpugnwpqulzQxzC402KMyaf5WdQ2faLefzEDyI+Y7u4+fKCvWh/wWg+CVv8AI/hj4gMU9dPsP/kyvonxV+0B8A/GnhvVdA1f4reA73StWs5bK8t/+EstEDwSJ5cicT/3Hesv9jv4vQ/EL4c3nhy78UWXi/xN4Juv+EfvtYsbyC7OpxIAbPUN8dxcc3Fv5ZcvJ/r47hP4DQB8r/GH/grd8P8Axr8ONe0XwZa+NPDGuavF9ii1m602D/Q43ZY57iDyr5H8+OGR3j5A8xI+QM1y9j/wUe+DPgT4h+Bdc8DaP4z0nw7pOgnwlq2lXEUMhn02CMPp5iH2/Z59vPlBJJG++O7uf3nyCvpT4e/tFfDHxl8afGvxG8QfFLwhpltYb/CfhTTbzxNawE2cMgkvLzy/tjp/pd0ibJPLR/Isrc9H59Q8VftAfAPxp4b1XQNX+K3gO90rVrOWyvLf/hLLRA8EieXInE/9x3oA+do/+Cz3wSt18l/DHxBcr/z0sLD/AOTK8r+Ov/BUb4XfGb/hE/Dlx4Y8Vf8ACCjWI9R8TW93p9g8l9b2o8+3sxBJLIkiSXSW7yfvIz5cZT5/Mr6w/Zo/aC0LUPgv4jXxH4zsfEd58MRPY614isbqO/S+s7ePzLfVMQXFxI/n2+yR+S/npcJ1TFeGWX7QHhb/AIUrrmtWXxI8H6Z8XPjTrMZvtStdbsBL4UsJ08uLz5BJZyf6Bp8eE3/P9rfGP3lAHiFx+358INa/aB+Ini7XfDPiS+8E+MtCm0STSYk2XAjkt7OK5kb/AImAjSS4Fv5cmxEcJYWRR8vJXov/AATK/bCOs3HiDwV8Q/HmqahqC2b+IIda8VXhxC0Rf7ZafaJ7g74/s8cVwn7tNn+mk8R739H+Lnj/AOFvxEm8J/B/wp8ZPDPgj4feGNCOo/23Z+KIP3d3HE1po1pBKl/HJI9vIhvH37/ntrPLjzK/Njx54R0n4V/Cnw7feF/ixPqeteJpbqDWfC2kC3EenvbpLaSebPb3kvmJJ588cEnl4kt7iQ/IkhRwD9EvEfxU+MPhfT9D+KWkazcvbfG7Uf8AhG/D/hvVb5IrPw2bpY08P6hHH5d2hfyI57i4jjKB3uEHl/u69/8A2c9U1bwB4q8WfBzxN4hvPEOteHUj1vQ9Y16dJNQ1jRLuSTbJO5leSSS3uBcQOfLjHyW5xiSvkz9i/wDZvk/aS8E+KfFvxV8aeIPih4d1HSP7E8N3GvtPPLYT3EEEmp3NoLyOTZJBcbLeO5jPzvbz/J9yu7+Odv4y+Ln7L7+KZfEWu+Dfi78Kb260rxXqfhuSeC4ubSPyf7TkiR3s45I57dLPUEj4BCRRp9/IAPufVtV0/wAO6VqGpahd22m6dp8Ul3dXs0gijgjj/eSSO/THHz18k/C3xz460nxZ4U+L+u6jqzeAPitqI0+PwzIx+z+HreTYnh+4jijFx5f2gRiO4Iljj8zVLfj93RNoF7qHw/8Ahd+z03xEu/iZca/BJr/inxY13me78Mpcee/zJeedi7kuLawR0eQPGbg9I67b9sj9lLW/2sNI0PQ7b4jan4E0OzNx/aVhbWb3NtqfmPA9v58f2iNH8p4i/IfrxsNAH05a/wCpFSbxXjP7OPxD1jxl8O4rLxblPHfhu9k8PeIzskije8g2YuIw8UGY7iOW3uE2R4EdyiVzkn7OfjS4/aqf4qn4y6//AMIceP8AhXW2f+zs/Y/sv/Pz5f3/AN//AKr7/vzQB9C/aU8zZ3pv2iPbI/8AcOw0vlv9/C+ZXzz+y7+zf40+AJ8Tf8Jd8X9c+LI1YWhtP7aScf2d5Blz5fmXE/3/ADI+mP8AV0AfQ/mfu6mrzH49/DfW/ix8K9X8K6B4xvvh/qt8bf7P4j0rf9otCk8ch8vZJGfnEZT/AFnSSnfAf4e638I/hTofhXxF4y1D4g6xYG4Nx4i1Tf8AaLvfPJIN++SQ/IjhP9Yf9X+FAHpTMEp1fO/7Uv7O/jj4/Dwy3g74y6/8JBpQuvtn9hef/p/mGLZ5nl3EH+r8uTrn/WV1Xxu/ag+Gf7OL6OvxF8RHw82tCc2J+w3V15vl+X5gzBHJsx5kfX1oA9b81N23dzUf2lf4FaT6Cvm79pn9pTWvhHqmg6b4W0GDxHqEFvJ4q8T2bSwNcaf4ZtCBeXCRtcR/6QXkQQffRzHL/czTPhj+1ZbfE/436z4WjtreLwbqEUsXg/xUtwnleI7ix8saoLcuQZEje4gSPy43R/s944kONiAH03RVO3mQ26MD+7/g5+/WfpOv2HiDSbTVNMvINS0+8jjuILuyl82OaN8bHR04dOfyoA3KKYkgk5Wn0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABX5+fGj/lMV8D/wDsTLn/ANEazX6B1+fnxo/5TFfA/wD7Ey5/9EazQB+gKdKdTU6U6gAooooAKxdY0ez8QaVfabqEEOoabfI9tcWk6b45Y3GySN/Uda2qKAOc8K+E9F8C+H7bQ/Duj2fh/R7YyGDT9Ptkt4Id7lz5caAIPncnjuTTNW8G6LrHiLR9bu9JsbnWdHL/ANnahcWqPPZeYhSXy5D86eYmUOP1rpqKAOW8UeD9I8baDc6L4g0qx17SLohrmw1SBLm3l8t98ZMT/IfnCPz6VneDPhR4O+GzX58IeEPD/hZ7vZ540fToLMXAT/V+YI0Gdm44ruqKAI40MaYd9/uakoooAh/5bV+WP7A//KUz9o3/ALmP/wBPlvX6nf8ALavyx/YF/wCUpn7Rn/cyf+ny3oA/VGP/AFa0+mR/6tafQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAQSW/mSb8LUcccnlfvvLz/AB+XVuigCDyX7vv+tL5f/bOpqKAIPK4+b/gfH36Z9m/2/wB5VqigCnJA0ndI+M/8DqXY25P/AIup6KAPnPwT8Hfin4BOvPafEjwndXGva1ca3qF5qPhK/uJJp5SiBBnWP3cccaQQRxjhEgSvzp/bQ/Z2+KXxt8VeNfihBcX/AMRXsPEcHgyys/Dfhy/UPHb2sn2yaG3eSd4reK7jeDekjpJObg5T+P8AT79pTx14i8B/CvXLzwfp9/f+Kb8R6dpL6fpd3qH2S5mJj+2SR29vcHy7dCZzmM7/ACvL6yJnlfhf8Qfh38I/h94f8GeHdC8d22jaLaR2dsv/AArnXlkfy/8AlrJ5enxgvId8jnHzvJJQB+cPwd/ad/aZ/Zf0bRfhxonwguI/7TnmudH0fXPD2ryXEzx28f2kWsfn5KfIbiRI+I5LiU/Ih2DqNF/aY/a/8PfFLXvHdl8A7ix1HXtNtbDUrK38C6mba+kt5HMFxKfM8zz40kki/wBZjZsQp+7Qp9mftFfE6y8beAzfeD9M8dDx34bvIvEPhxW8A+I0SXULcH/R5NkEeY7iJ57SQO4TZcH+5X0p4Q8RHxH4T0XWTZX2l/2jZw3f2HVrfybu38xA/lTx5/dyJnDj1FAH4+/BT4yftWfAZtXPh/4A6/qLX32eOD+3fDWvX/2G0g8wW1hb75/3dtB9on2D7/7w73evTv8Ahuz9tr/o3Y/+ENrX/wAdr9WKKAPx+0j9pf8Aa70P4pa/49074AT2ereINOs9P1Szt/AuqC2uzbySGC5k+fzTOiSyR5Mmwx7AR8iEdVH+3l+21Gmz/hnVv/CJ1z/5Ir9V6KAPyp/4bz/bb/6N1b/witc/+SKP+G8/22/+jdW/8IrXP/kiv1WooA/Kn/hvP9tv/o3Vv/CK1z/5IrB8Yf8ABSf9qvwHp8OpeMfg5ofhWwln8iO+17wtq1pC0h+fyw8lwMn5M4H9yv10rxb9pj9mLwx+1V4IsvCfi7UtX03T7PUo9USTRZoopmlSOSMcyRyfJieTjHpQBznwn/bD+GPib4W+C9b8T/FHwHpHiTUNGs7zU9Ol8QWkBt7mSCN5IzHJJvj2PkbDXLfG++/ZI/aO/sUfETx54C8SLopn+yf8VrHaeT53l+Z/qLhN+fLj6/3K81/4cs/BH/oaPH//AIMLD/5DryD42f8ABMn4XfDTxJ4C0zSn+Kmp6dq+pyjXdWsdJ/tqHT7CGAuU22lp5iTzyPbpG+yRBiUkfJigDsvE37Sniy1+E/iT4qfCm50/xj8VPiJ4kh0iPQbBjq174e0VLS9k06P7JBcXCR3Gy3nvHyNnmXFwHjfy+OX0/wAdN+zP+yPpvg7xpfnw18RPAX9j+PPBdtJH9juL77fJ5ktvJafa0kk8ueTVLK4j+TED+Z5ea+YP2Cf2hPhj+zH4/wBY8ZePtD17WNYW1W00X+xbS0nSDfk3ErmeRCkmwRxo8Z+5LcA/fr1j9o79u74e/tB/Ebwnq1vZ+KNO8OaBpl3pn2WTRrX7Zd2+pxyWesOJBeeXGY7PZJb/ALuQGff5gEYoA+4fiD8YNI/aW+GHg/wV4A1n7SnxQAtNUlsZEa40PSEiiuNV+0NHHcRx3Xl3EVn5chT9/exntVvwD4t8L/so+NvEvwz8X6zo/hPwZNJL4l8GXuozx2VnHBcSE3+nRyGCONHt7uSSRIxJI/kXsf8Azzr8+P2N/wBrf4M/su+OviRqSeHfFdzpGrrb2fh65uYLO91SC0j80yefKJLcASP5Ehjj/uImX8tJKZ+31+2B8L/2vNH8LSeG4PF+iav4aN46Wuo6VbGG+E5t8mSaO8d4/LSB+fLfOcfJQB+2NtIJIEKSeaP+en96rFeX678fPBXg34NxfFHWdae08Cz21vfpq62k8n7i6kjEEnlhPM58+PjZ356V2ui+ILDxFplpqekXUOoadeQRzwXtnKksE8b/AHJEk6P/APXoA26KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvz8+NH/KYr4H/wDYmXP/AKI1mv0Dr8/PjR/ymK+B/wD2Jlz/AOiNZoA/QFOlOpqdKdQAUUUUAFFFFABRRRQAUUUUAFFFFAEP/Lavyy/YH/5SmftF/TxH/wCny3r9Tf8AltX5Y/sC/wDKUz9oz/uZP/T5b0AfqjH/AKtafTI/9WtPoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCHyX87fv49KSOMRx/wDj9T0UAQmN/wCF6emdnzU+igAooooAKKKKACiiigAooooAKgeN/M3g1PRQB4x+0t8Zrb4D/CfWPFE81m2sMsenaLbX13DbxXV/PmO3R3kkjGzfmSQ+Z8kcckn8FeX+G/F/wH0z9nuT4T6h8dfB+o2l9pNxpup603im0N5fXF0JPtl7+/uJMSSTySz8l8GTv3+q9j732BIvnz/v1NFv8vDv89AH56fGrWfhx4W8D2Hi3wd+0po+ueLfhxB9s8N6b/aXheApb+V5dzZ2f2fTch5LPzI44/LdPM8g7DsGPjr/AIKCfEHWfipN4O8SWvjHV/HPw2NxqFn4Y1bXrGK1ub6SKOze/uEjisLTEG+WOAZ3/PaTnvX64ftIfEDXPBPgA2Hg8oPG3iO7i8N+HcxPJHFqE4P+kSFIpNkdvBHcXMnmJs2W/wCFeTfH79mH4NeEf2dNEt/E/gKfxlpnw90xrHw3pkFxdW89/eXDxwRxf6BgvPd3H2fe/l/6yUvj79AHyv8ABH9rD4P6bafCvQvGXi3TbLwv8P8A+0Nekit9OlnttT8RT3l35EtvBHpaeRBFFJPcRgeX5ZvLdMM9vJj1L4Bf8FAfgZ8K7HxL4GvPHMi+FtB1IxeFNSl0nUpfN0uSMSx20hfzJybR3ktxvSMGOKDZn59nOr/wTg+F/wAHdQ+EkvjnQJfF2latB/wjniiWPU7wRWmt3BR7O8j8hI38h5w9nh3jQfaLQkb97v2v7Rf7A/wP+Hnw7k8aeHfh409p4Yu49a8Q6T/ad/I9/pCCQXkcfmXkflyRxO88bg/ftwn8b0Aepx/8FQv2Y9n/ACUny/n/AOgDqf8A8jVJ/wAPRP2Y/wDopv8A5QdU/wDkaqGi/wDBN39lzxNpdlqmm+AYdR069gS4gvLfxDqckc8bgOjo4ucOpBBzV/8A4dd/sx/9Ey/8r2qf/JNAB/w9E/Zj/wCim/8AlB1T/wCRqP8Ah6J+zH/0U3/yg6p/8jUf8Ou/2Y/+iZf+V7VP/kmj/h13+zH/ANEy/wDK9qn/AMk0AH/D0T9mP/opv/lB1T/5Go/4eifsx/8ARTf/ACg6p/8AI1H/AA67/Zj/AOiZf+V7VP8A5Jo/4dd/sx/9Ey/8r2qf/JNAB/w9E/Zj/wCim/8AlB1T/wCRqP8Ah6J+zH/0U3/yg6p/8jUf8Ou/2Y/+iZf+V7VP/kmj/h13+zH/ANEy/wDK9qn/AMk0AH/D0T9mP/opv/lB1T/5GqN/+Co37M38HxGeT6aDqf8A8j1J/wAOu/2Y/wDomX/le1T/AOSa+Yf2/v8Agn/4L8B/CPSb/wCCPwu1e48Uya5BDcrozahq0ptPs9wX3xyPIAnmCD58en4gH6UeEfFemeOPDGjeIdIuDeaTq1pFf2NyY3j3wSoHjfD+qOD+Nb+8V+R3gb9rz9sb4c+B/D/hDSP2fLq50rQ9Nt9Ls5rzwXrXnvBBGI4/M2T434TsBW7/AMN5/tt/9G6t/wCEVrn/AMkUAfqpvFRfak3bP+Wn/POvyz/4bw/bbm6fs6HH/Yla3H/7cVwPxk/bW/av8W/DbxP4R8Q/Cb/hE7DWtIu31C8j8J6hBcpp8YjjvJMzu8flhJEjkk2fu/OH3DsNAH68aRr9hr+lWWpaVeQ6jp15FHPbXltIJI5o5MFHRwcOhzWskgk5Wvzf/wCCfH7XXhDT/BupeGfH/ibwP4RS4nuvFOhWVveRWFvpkFxeXCTaeBIkccDxzo8iRvK8jwXkf8EZr7Ih/au+CSphvjJ4AB/7Gmw/+O0Aet0V5R/w1f8ABL/osngD/wAKix/+O0f8NX/BL/osngD/AMKix/8AjtAHq9FeUf8ADV/wS/6LJ4A/8Kix/wDjtH/DV/wS/wCiyeAP/Cosf/jtAHq9FeUf8NX/AAS/6LJ4A/8ACosf/jtH/DV/wS/6LJ4A/wDCosf/AI7QB6vRXlH/AA1f8Ev+iyeAP/Cosf8A47R/w1f8Ev8AosngD/wqLH/47QB6vRXlH/DV/wAEv+iyeAP/AAqLH/47R/w1f8Ev+iyeAP8AwqLH/wCO0Aer0V5R/wANX/BL/osngD/wqLH/AOO0f8NX/BL/AKLJ4A/8Kix/+O0Aer1i61rVloGn3eqajeQ2GnWML3F3eXLrHFbRoN8jyO5wiBRk+grz7/hrD4J/vP8Ai8HgP5P+pmsP/jtfPv7R/wAdfg78cvFHhb4R33xK8IN4Evsa/wCLr7/hIIII5rO3kj+yWMc+CnmXE7xyP5ckciQW0nTzENAH20jb0FPr5e/ZP/aQ8O+KfCtn4C1bx/oniPx34dvJtAjuIdUgln8QwW8fmw38SJcTvIZLQpJIc8TpOhxsr6ejkEkYbtQA+iiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvz8+NH/ACmK+B//AGJlz/6I1mv0Dr8/PjR/ymK+B/8A2Jlz/wCiNZoA/QFOlOpqdKdQAUUUUAFFRSSeVSfaP+mcn/fFAE1FQfaU8zZ82fpT4ZPMTcV2fWgCSioHmMTbFjeQ1HJfJGmf+mfmUAW6KKKAKv8Ay8/5/wBuvy1/YF/5SmftGf8Acyf+ny3r9Tv+W1flj+wL/wApTP2jP+5k/wDT5b0AfqjH/q1p9Mj/ANWtPoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPNfiX8DfCfxW1zw5rev2d/JrPh43B0rUNP1i8024tBOESfZJaSxvl0THX19a5PXv2Pvhv4ql06XWofFmrtpt2moWP27xzrtwbW6TPlzxb7s+XIOcSDkV7tRQB8dfD/8A4Ji/BvwDo3iPRPO8W+JdK1v7GL/TdQ12e2tpfILvH+7tPs6SHe+/955mwjKeWeuN8KfH3wh+L3x08X/CrRR8XLXX/Ci3bXl5qHjrWRZv9nuI7cmPGpu75kcFPkHrX2s9vxJsCjf6iuO8deM7P4c+CfEvibVomm0vQtPuNZultUBkZIE811jR8Jv+Tj5/v0AYmieLPh38MdY8JfCew1ax07U/7IU6F4be58y4ksLdRGCnmMS+Ez33uI5T8/lyEeoRSpLGHQ5WvhzwHpOs/tIfBTxH8dfCd5cj4iazrn9veDYrmS4gjtoNMuLi1s9MkT7Z5ey4j+2CfDiPfqkvB8tK9w0v9rr4XyaF8LdSuvEP2OP4ktHF4ZtzBJcNPcGSKM28rweZHHJHJOkcnmPxIH/uGgD3eioJLlYlyUfH0ryTwT+1J8NviR8TvEXw98Na/JqfjHw+Lk6lphsbiA25t50gk/eSRpG/7yRBw560AexUVzPi7xdpfgnwzrniLWJnstI0mzmv764EZk8u3jjMkkm1Pn4RD2zXMfBz4++CPj54au9f8Aau2vaRb3cmnyXItJ7fFwkcchj2Tojk7JEOcYoA9NorzH4zfHzwJ+z94YtvEXj/AFz+w9FuLpLBLoWc9xuneN5Ej2RRueUjc56cV1nhDxdpXjbwpoviPRbs3ukataR39lcNE8fmwSJvjfY4D8oR1HfpQBtySeWPuMQleeaV8aPB2vfEzxN4B07XYbzxpoEME+o6Ssckc8McqJJFJyn7yPEkWTHvCeYN+M4rh/2gP2vfAPwL1eTwrfXt1qXxFutO+36F4Vs9Pu5ZNXkcyR29vHJHBIgMskZj9Qa828QfCa//AGefhD4V+I8Uy6v468E3t54i8b3NmiD+3Y78+Zr8exHto5D9yeDzE4/s+2SgD7IRt6Cn14d8Kv2sfhP8aPHOqeDvBPi238QeItNjnuLmDT7W4MXlRypHJIk/l+XIm+SPDo/z5yM17THcebwqPt/v4oAjkkEgeND+8T+5/BXy/wDDP4fWf7Sml/Ez4keIxdQ6d8RdOuPCfh6WKIR3Nt4XQSRRyR+ZbxyRveSST3nz+YmyS27JivffiH4LtviR4D8S+FtSeSGw13TbjS53gx5scM0ckTumQfn2SelcLo/wD1/QdNtNO034zeNrGztII4ILa103w9FHDGgwiIg0rCoMcD2FAHxv8Yv+CSPw98J/DfXte8JXfjHxN4j0uL7bHolxqEGL2NJEkuLePy7N5PPeDzEi4f8AeGPOa3PCv/BI34B+PPCuj+IdJ8Y+Pr3StZtodQtLg31pH50EiCSN8PZ7h8jjivraT4J+KJleOT42+PJY5E2PG9h4d/8AlVW18GfhXpfwX8B2HhDRJ7i50+0uLudHuo4In3z3Mlw+I4Ioo0TfI4SOKNECDGKAPkX/AIcs/BH/AKGjx/8A+DCw/wDkOj/hyz8Ef+ho8f8A/gwsP/kOvv8AooA+AP8Ahyz8Ef8AoaPH/wD4MLD/AOQ6P+HLPwR/6Gjx/wD+DCw/+Q6+/wCigD4A/wCHLPwR/wCho8f/APgwsP8A5Do/4cs/BH/oaPH/AP4MLD/5Dr7/AKKAPgD/AIcs/BH/AKGjx/8A+DCw/wDkOj/hyz8Ef+ho8f8A/gwsP/kOvv8AooA+AP8Ahyz8Ef8AoaPH/wD4MLD/AOQ6P+HLPwR/6Gjx/wD+DCw/+Q6+/wCigD4A/wCHLPwR/wCho8f/APgwsP8A5Do/4cs/BH/oaPH/AP4MLD/5Dr7/AKKAPzo8Wf8ABI/4B+AfC+r+INW8W+PINF0mxn1C6uvt1tIYI40MkkmEs+yIawfhP/wSU+Hvi/4b6BrvjK78YeGdf1OL7XLo1rfwf6HG58y3t5PPskfz44DGknyf6zzOK+4/jV8ILD44eD28K61quoafps17Bezx2MFrOLgW8nmpFIl1bzxvH5gR9hT5/LA+4XQ4Ot/DjXPDem3mo6l8ffG+nadYwvd3d5cWvh1I4I4x88kj/wBl8YT19KAPzq1D4W/D7/gn9/wUQ+EdtZ6nrMnhibS/tN5qGtXEEn2W4u/tliJJHAgRIIzsd3P8G/r0r9gkXYlfgj+0/c+JNW+LGjeLfGXxC161Txd4MvNc0i+1K2j+1Q6XIL+PT9PkSxPlp9rgji8zyxGif2hLvQ4k3/st+zn8QPD/AMSPgf4L1rwzqusa9o0+nR29te68T/aMvkZgkN2c/PPvjkDuPkdwcHkGgD1uimRyeYKfQAUUUUAFFFFABRRRQAUUUUAFFFFABRUElx5XRHf6Cka5SMfMj/8AfFAFiiq7XSRqXYgIn3/9ipY38xc0APooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK/Pz40f8AKYr4H/8AYmXP/ojWa/QOvz8+NH/KYr4H/wDYmXP/AKI1mgD9AU6U6mp0p1ABRRRQBSk2/aCi/wCs4c7f8/7Fflz4I+Ds3/BTn4mfEDxx428V6wPhV4X1GTw/4Qi8OpFZpKgk8ySXZPveM+R5Dyb498hnTBxB5dfqNI8f2xB5nlyc/J/f/wA7K+Bv+CMpx+y74nyvzt40uPv/APXnp9AEH7Kv/CRfsnftY61+zdq3iGbVPAWqadJrfgb+0oA9zvz5jRo8XyRgpHfeZvEYeS38xBH553/oPbf8e8f0r4A+MUh/4fC/A5z+7H/CF3G/5/8ApnrFffZuY7WP94UioA/Or9o7TfEf7an7bFz+zyuuS+Dvh74P06PVtdFncyfaNZjkjs5T+7x5ZdDPbxx+YD5f7yT95/q6wvHHwv1D/gmT8QPhp4k8EeNvEE3wc13Wf7K8Uabr0qXVtaySbfMuFjj8v96YIpCjxx70+yYd3STy6639pL4b/Fv4E/tZT/tCfCbwtdePtL1nTILLxPoFtKkt06o1vAUjgRDP5bxx27o8fmPHJHI7jy/kfwD9uT4pfHD9oz4Y+Fr7xB8LL74beCk8SwaZbeG7pJLjVtV1aeC58uSOMxRybI4gUCYTe9x/y0/5ZAH7EwqEjVF24XjC1HLc+XvVEaSQfwVOnSviX9s5P2uG+KWn/wDCgXP/AAh/9kxC82vpGf7Q8yfP/H58/wDq/s/TigD7Rkm8thIyZ/vnP3K/Lf8AYH/5SmftF/TxJ/6fLekz/wAFL5Nnz+XH/v8AhiuX/wCCXH/CSP8At7fFj/hNMf8ACX/2Lq/9tbfL/wCP3+1LP7R/q/k/1m/7nFAH68x/6tafTI/9WtPoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAr50/aKuo/iP4u8LfBCwn/e+KM6z4t+z3Hlvb+HbWSMTo/l3Ecn+ly+VZgjfmOS44/d19F15l4u+Bvhnxx4mn8R30uu2Osy2cFjJPoniXUtMMlvA8rxxyC0uIw+x7icjP/PSgDovCPhbT/CHg7RdA0OyW20vR7KOx06NpHkNvBGgjjGX+fIQAd+lfMF98EvA9l+1fY6D410839rd3lx8QPh7d3WpTRDTtU8+CTWbRP9MzJ+8jt79IxF5Y8+74whr3D/hmnwt/0GvH3/hxPEX/AMn07Sf2e/Cuh+JtK1+N/EWqalpMklxYHWfFmranHBcPBJA8gjuLmSPPlyyJ9z+OgD002/7soP3f/TSvJvBP7MHw7+GvxQ8RfEXwz4bOm+MfEZuxquqfbrpzOLiUXEn7t5NiZkRD8idq9eji8uPZU1AHK+LPB9h448M6v4e1qE3OkarZT2F9AJHQzxTRlJEymz+DIz15rnvgx8BfBP7P/hm68P8Aw+0f+wNFuLuTUJrUXc9wHuHjjjMm+Z3cHZGnGccV6XRQB5l8YfgP4L/aE8N23h/4g6KuvaLb3aX8NqLue38u4SORA/mRSI/SST866jwh4Y0zwR4V0Xw5pNl9i0vSrSOwsLcSvJ5FvGmyNA7/AD8IgGevFdLVWW2En8FAHyT4u+DfhH9oD9t7TvE9/o1xPH8LdNtI7zURcXEf2rVpJvtVjabPLEbpbITcuY5Ml7y3R8ojpX1lHH/H/l68lt/2Wfh/Z3uu3unR+JNGm1zUp9Z1FdG8Yavp8VxeTn95OY7e7RMvj09Kur+zZ4U2/wDIV8ff+HI8Rf8AybQB4R+yp8Bvh1+z38fPiX4Z0/w9baT43t4ft+i6kLyUG/8ADl3LvRPIe7lybe7t5Ld5PLjysdu//LXNegeD/i38T9X/AGvfG/gbVPBxsfhRpujx3mmeJ20i4jN/dlLPMf2t38h8ebcDCD/ll7GvQvCfwL8MeC/F48R2D69darFZz2ENzrXiXUtXKQSPBJIEF3cSJGS9vHnA/wCWaV6NHG8X/PPy6APHv2lv2oPDH7KvgXT/ABZ4vsNX1LTr7Uo9LSPRYYpJVleOSQcSSR/JiCTv6V3/AMPfHVl8RfBPhvxXp0VxHp+vadb6paxzqiyJBPGkiBxn0ft71F44+Hnhn4kadDpnivw3pHiiwhl+0RW2s2EV5CkoGzfskBTf88n51lfEDSdV8O/B3xFpvw60+Gz16z0K4g8PWNvHGlvBOlv5dtHHE/7sRgiMbMbOKAPQ0begp9eQ/st/8LK/4UX4Z/4W/n/hY2bz+1sfZ+v2uXy/+Pf93/qvL+5xXr1ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXzp+0RcS/EzxV4W+CNjeFn8TZ1fxQYLjy5Lfw7aPH9oj/d3EU8f2yd4rQY35jkuTj93X0XXmXi74G+GfHHiafxHfS67Y6zLZwWMk+ieJdS0wyW8DyvHHILS4jD7HuJyM/8APSgDyH9s39lP4f8Axr8C+L/GWqeEp/EfxC07wveW2iyWtzdrJ5kcU8lvHFBHJskfzJD1R8n8K/PT4E/tHftN/su+G9J+GWmfCzUJ11S7u73R9P8AFHh7VHvXxGhuIrSMSR+ZGn+vdI4+Hkkc8Gv1b/4Zs8Kf9BXx9u/7KR4i/wDk2naX+zz4S0TXtJ1xZPEt7qek3D3Ni2seMNW1OOCV4pIDKkdzcyR7/LnkH3P+WlAHwD/w3p+23v4/Z13/APcla3/8kU3/AIbw/ba/6N0k/wDCK17/AOSK/VdOlOoA/Kb/AIbw/ba/6N0k/wDCK17/AOSKP+G8P22v+jdJP/CK17/5Ir9WaKAPym/4bw/ba/6N0k/8IrXv/kij/hvD9tr/AKN0k/8ACK17/wCSK/VmigD8pv8AhvD9tr/o3ST/AMIrXv8A5Io/4bw/ba/6N0k/8IrXv/kiv1ZooA/Kb/hvD9tr/o3ST/wite/+SKP+G8P22v8Ao3ST/wAIrXv/AJIr9WaKAPym/wCG8P22v+jdJP8Awite/wDkij/hvD9tr/o3ST/wite/+SK/VmigD82f2c/27Pj549/ab8HfDH4neAtK8Exa9HdzmGfRr+w1Dy47O4lR0FxOf3Zkgx09cV9ufGX4hRfCn4Y694rk0y61abT4RHZ6ZDG73Go3kkiR21mmyOR/9IneKL7h/wBYDjFeBftTfsOax8fPjhoPxJ0H4q6l8O9b0nR/7HgbS9PeW4TBuHMiXEdxG6ZFxsIx/wCh185v+w18Vvih8YNW8GXP7SPjDWtH8ENYX58Q6jb37raa04MsUFvFJclPMit3jm+0RyZj+0Rp/HlAD3/wr8VLn9jPWb7Tfj98SLrVdO8QaZB4ktvEN+xuAmp5it9U0+3jj/eeQJJLW4t447ePZHLP/wA8nr630PXNP1rSbLUtMuoNR067gjuLW8t50kjnjcZjdJOjbxjmvxR/bG+HHxW+C17ctefG3xZ8QtI8K6tpcM+oapcX9p9k1ue3uLuJIPMlkjkkgt445PMjk3x/bI/evpL9ij9vv4ZfCn4Q2/gj4h+O7oXXh2C2h07VZdGvJHmt5bZJXtH2eY+bOeS4t/4I/Ljt/L70AfpzRXyhH/wVC/ZjjjCD4mf+UDU//kapP+Hon7Mf/RTf/KDqn/yNQB9V0V8qf8PRP2Y/+im/+UHVP/kaj/h6J+zH/wBFN/8AKDqn/wAjUAfVdFfKn/D0T9mP/opv/lB1T/5Go/4eifsx/wDRTf8Ayg6p/wDI1AH1XRXyp/w9E/Zj/wCim/8AlB1T/wCRqP8Ah6J+zH/0U3/yg6p/8jUAfVdFfKn/AA9E/Zj/AOim/wDlB1T/AORqP+Hon7Mf/RTf/KDqn/yNQB9V0V8qf8PRP2Y/+im/+UHVP/kaj/h6J+zH/wBFN/8AKDqn/wAjUAfVdFfKn/D0T9mP/opv/lB1T/5Go/4eifsx/wDRTf8Ayg6p/wDI1AH1XVeS4jR5E/jQbyK+XP8Ah6J+zH/0U3/yg6p/8jVha9+2NoX7Rzab4B/Z68cNL441W8jN5rTaLd7NB0+P97cXciT23lycIluE3p+8uI/3iUAfYscnmCn15F+z58Wj8Uvhnpuo6tBBpXizT5pdG8R6TFKjiw1a3kMFzHiOSQbPMQmP5zmOSM/x161u9moAfRUfmf73/fNHmf73/fNAElFR+Z/vf980eZ/vf980ASUVH5n+9/3zR5n+9/3zQBJRUfmf73/fNHmf73/fNAElFR+Z/vf980eZ/vf980ASUVH5n+9/3zR5n+9/3zQBJRUfmf73/fNc94i8aaH4Zaxj1nVrLSv7Qu49PtBeXEcH2q7k/wBXbxbyN8j9kHNAHS0VHHMJkR05RqbJL5Y+egCaisLSdd0/xDpdnqWnXcOpadeRx3Ntd2b+bFPG43pJG6ffQg/jVbXfGWieF/7OTWNYsdGOpXkWn2S39xHbm7upP9Xbx7z88kmDiMfP1oA6aiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAr8/PjR/wApivgf/wBiZc/+iNZr9A6/Pz40f8pivgf/ANiZc/8AojWaAP0BTpTqanSnUAFFFFAEEiPxs2/fzX58eLvgT+0F+zF8fvHPjj9nuy0jx/onj+WTUNa0vxJJDGbK882SfhzLBlP9Ik8vZJ0kkEifIkh/Q6oJI3aTr+7oA+Mv2Pf2bfiXoPxU8Z/Hf4w3Vtp/xK8WQHTBoGnCNrbT7PfEQZDGZN7gW0CIA5/dpl5HkkOz0f4tRftAL+0X8Mk+H39jf8Kj+f8A4Sj7btefqfM8zf8AP/q9nkfZ/wDlpv8AN/d4r6LTpVeSN9/mIfn/AOedAHzH+0tqH7SnhrxNpGpfBTQ/CXivw4lo9ve6RrTGO9+1u5/0jeZYMRxogRNkmf38nyOPLMfjvw1/Z7+Pv7QXx+8HfEn9olfD+gaH4LvJb7RPCWlbGdbny7cxypJA8n7vzI0k/ezyfvLfZ5flyV9+/Zn3J9zEf3KeLcb5PkTY/WgB9v8A6umT2/mOrpt8xfWlt4zHGEc+Y9T0AVPL/fbH/eV+W37Av/KUz9oz/uZP/T5b1+p3/Lavyx/YF/5SmftGf9zJ/wCny3oA/VGP/VrT6ZH/AKtafQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVUkmEbO+9MJ6vVuuE+LGh6P4j+G/i7R/EuqyaX4f1DSLyz1PUI547f7LaSROJJPMf93EEj3/vHGBjNAHa2v8AqRU1eGfso6H4A8C/ADwnpPw012fxN4CjhmuNO1a5mSWSRJJ5J5PM2JHh0keRCmwOmzDgHNe4Rv5i5oAfRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAU7i2e5+QyYT/cr5CvPCnxL/ZN+C/i7WLDx34T8TanFfXep3Gfh/c/2hr+r30/7qNxa6gB5ks9xb26ER/Inl/wCvsmvPfit8HfC3xo0nTtM8W2Et5b6XqUWr6dLBf3FnJBeRo4jnSSCSNwU81+j+/pQB8zW37DPijxV8I7TwZ4+13wN4je81ifxVq0svhO+SS41icymaeSe01S08zH2iSNMxx/uxH+7TZx5J8Sv+Ccfgj4MeCNd8a6po2jeMbPRNRt9d1LRdJtNRsz/AGLHH5eoW8Zn1d/nCb7yOQyb/Mt3j/eRyeXH9tL+zT4VjRd2sePj7J8RPEX/AMn06T9mvwtj5NZ8eD+5/wAXE1//AOTaAPHdF/4Ju/sueJ9LstU03wDDqOn30CXEN5b+I9TkinjcB0dHFzh1IPB/GtH/AIdd/sx/9Ey/8r2qf/JNfRPhDwjpXgnwjovhzSLQ2WkaTaR2FjbtK8nlQRpsjj3vl+EA688da6KgD5U/4dd/sx/9Ey/8r2qf/JNH/Drv9mP/AKJl/wCV7VP/AJJr6rooA+VP+HXf7Mf/AETL/wAr2qf/ACTR/wAOu/2Y/wDomX/le1T/AOSa+q6KAPlT/h13+zH/ANEy/wDK9qn/AMk0f8Ou/wBmP/omX/le1T/5Jr6rooA+VP8Ah13+zH/0TL/yvap/8k0f8Ou/2Y/+iZf+V7VP/kmvquigD5U/4dd/sx/9Ey/8r2qf/JNH/Drv9mP/AKJl/wCV7VP/AJJr6rooA+VP+HXf7Mf/AETL/wAr2qf/ACTR/wAOu/2Y/wDomX/le1T/AOSa+q6KAPkyT/gmH+zFbt8/wz2R/wDPR9f1P/5Jr86v2XfgT+114F0OPx38HvCy6NZeI7RNmozppAuJrcEmMIl8fMjjkxG/GBIBHJ8/yV+p37XGleMfEnwnvPC/g/w9f+IU8SXcOl65/ZN3ZwXdrpMr/wCmyR/a/wB3I8kAkgQfwGXfn93VzR/iJ4g8P6TaabpPwG8cWNhaQR29rbWdx4dit4Y0QIkccf8AavyIABhO1AH5t6hD+3b8I/FU+qajeHQNR+IGrWumD7Te6D5N9qCWhSBI4/M8uCR4LYR5jCGTy40y7+WD3flf8FNv7v8A6jFfXfxo1bxX8XvhzrXhNvg98Q9Hub2BTYapBqehxz2N3HIk9pcoU1hH3xzwRyYDjPlehNe1/Du+8Rap4B8NXfii3t9O8TXGnW8mrWFtgpb3ZRPPjT95JxHJvH336dTQB+bPl/8ABTf0/wDUYo8r/gpt/d/9Riv1R8uT/npR5cn/AD0oA/K7yv8Agpt/d/8AUYo8v/gpv6f+oxX6o+XJ/wA9KPLk/wCelAH5XeV/wU2/u/8AqMUeV/wU2/u/+oxX6o+XJ/z0o8uT/npQB+V3l/8ABTf0/wDUYo8r/gpt/d/9Riv1R8uT/npR5cn/AD0oA/K7yv8Agpt/d/8AUYo8v/gpv6f+oxX6o+XJ/wA9KPLk/wCelAH5XeV/wU2/u/8AqMUeV/wU2/u/+oxX6o+XJ/z0o8uT/npQB+V//GzbeN//ALrFfLH7SXxi/aQ1D+x4fij4quN3hzXriC0k0u9sIo7TVbWO3klI+wH/AF0AubceZ/yzd3QYfzBX7Q/tBfFGT4Q/Dy71TTYrXU/Fl3JBo/hvSriaNDf6pdv5FpBiSWPKeZseT5wfLjlcfcrx3x9/wTt8C/Fr4c/Dvwl4r8S+Jp7jwlDdyPrOmXYSXUry7eOS8vJzcR3B3yTxtJjfwZZOoxgA6P4M/trfDTxV8MvD+reLPiB4K8K+KnjMGq6XNrtlH5F5HIYrgx4uJMwSSRvJHJvffG6PmuJ/aa/aa+F/jLw3pfw40L4r+FI4fHt02l6tq1tr9uY9K0gRmTUHMxjnjjllgQ28aSbMvcRlP9W9fP8A48/4JifCn4a/GDwRp+reJfF0fgfxT5+ijUGu7BLm11rZ51sjyyRgPHcRR3CII7cv50UY35kAq18Cf+CXPwr+MPgu78Y3ep+M9M0HUtQuP+EbWC7gWe50lTsgvJxPYRuHuHSSdMDHlS2/oaAPcvgV+0F8IvhF478ZfDFPiP4JXwTBOfEvhO+i1uzFnawXckhu9OEkccccclvd+bJGnmO5gu4/+eZxzHxk+IHwu/aY+I2taVq/xd8O+GfC/g3TPL8NapH4ogtmk8RXEQlGrxGHUI/PjsYxFHH8gBknu0z8hrxH9r3/AIJo/DH4F/BHVdf8La34w1XxbJeWOn6LpN7cWk/9oXc9zHH9nijjtkkkk8syOI0P/LOvSvAf/BJH4JeMvAvh/X7Xxn421K11jTre8F/ZSW9nHciSON/Mjge0Lxxv1CSHKd6APor4N/to/DTxh8MtB1bxf4+8F+FPFZjNtq2lz6/YJ5V3HIY7jy/9IkzBJJGzxvvO+Mxv3rvP+Gsfgn/0WPwD/wCFTYf/AB2vgrx1/wAEwfhT8NfjH8P9M1LxH4qj8C+K1n0eO9kvNPjntNb2ebaRvI8YzHPGlxGiJEXE0afP+8AHqH/Dl/4I3H7z/hK/H7+Z8+f7QsOf/JOgD6o/4av+CX/RZPAH/hUWP/x2j/hq/wCCX/RZPAH/AIVFj/8AHa+V/wDhyz8Ef+ho8f8A/gwsP/kOj/hyz8Ef+ho8f/8AgwsP/kOgD6o/4av+CX/RZPAH/hUWP/x2j/hq/wCCX/RZPAH/AIVFj/8AHa+V/wDhyz8Ef+ho8f8A/gwsP/kOj/hyz8Ef+ho8f/8AgwsP/kOgD6o/4av+CX/RZPAH/hUWP/x2o5P2svgpHG7j4weA5fb/AISiw/8AjtfLf/Dln4I/9DR4/wD/AAYWH/yHXIfGL/gkz8Ifhl8JfG3i3TPEHjm91PQdDv8AVbW2ur+0eKWaC3kkQOBaDglMdqAP0L8K+LNF8deH7bXPDusWfiDR7kyCDUNPuUuIJtjlD5ciEofnQjjuDXR1+TX7HP8AwU0+GP7PX7OXhL4feINB8W3us6Kbs3E2lWdo9uwlvJ7gFPMuI3+5IAfkGK9oX/gtJ8En+74V8fZ/68LD/wCTKAPv2ivlf9mf/goB8P8A9qbx7qHhDwroXinTdRsdNk1SeTWrS3jjEUckcf8AyzuJHL5kTtX0aNbsE1K1017uCPULqCW4gtt6CSeOMxo7omeUBki/7+J60AbdFMjkWVN6cin0AFFFFABRRRQAUUUUAFFFFABRXNeJvGOh+FP7OGt6tZaT/aV3Hp9kt5cJAbq7kJ8u3iDkb5H7J14q5q2vWPhvTby/1K7j0/TLOF57i8uH2R28SJveSR37D1oA2aK55fEdhNrMulJdQPqEMUc09qs6+akchl8qTZ/ckMEgB6Hy5P7j4mm1myttattHNxHDqFzDLcQ2e9BJJFGUSSQJnlE82LP/AF0SgDbormvDvjTQvFR1AaLrNjqy6beyaddixuUnNvdR/wCst5Qmdkid0PPSk1PxhomjtqZvtasrEaXaDUL7z7mOP7JbnzQLi4/55x/uJ/3j4T91J/coA6aisWXWLG11W30qSeGHUbqGS5t7NnQSyJE0aSOi9wnmRZ/66J61rxyLKm9ORQA+iiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAr8/PjR/ymK+B/8A2Jlz/wCiNZr9A6/Pz40f8pivgf8A9iZc/wDojWaAP0BTpTqanSnUAFFFFABRRRQAUUUUAFFFFABRRRQBD/y2r8sf2Bf+Upn7Rn/cyf8Ap8t6/U7/AJbV+WP7Av8AylM/aM/7mT/0+W9AH6ox/wCrWn0yP/VrT6ACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAIpJPKr5g/a08Zadqk1j8NLjUhY6JqFnP4o8byQl/OtPDFj893vEc8c/8Apb+Vafu0k/dtc8Hy6+g9Y1iw8P6ZqGqajc22n2FjFJdXd5cP5SQxxxkySSOcYRE/jrwj4E+CI/jB4F8ZeOfGFlNLB8WbfaukyySRtb+HPLePT7TEdxIkbvbyyXEnlmP95eyf886AOc/Z5+LnhhfihfWPhjWTqfw6+JhvvFvgy7k8y3/0+GQx63ZolxKZP9aEvETykj/f3P8Azzr1f41/tR/C/wDZxt9CHxD8SSeH49YW4+wMbG6uzP5HliT/AFUcmCPNj+/jrXJ+Pf2d4PCfwL0zwx8IdMGiax4Jux4l8I2RuZ3R7+OSSSS3kkNxGXjuEnuLeTzJNmy8P9ypPEHwr+Df7dPw48CeNPEWgf8ACUaQbSS90dTqM9u9qZ/L8+OT7JPjzEeNY3BL7HjcetAH0THJ5gryRv2ovhnH8cX+EB8Sf8XEX/mC/YbnGPs/2rPn+X5X+o+f79euLnb81eSN+y/8OP8AheX/AAuBfDa/8LH/AOg19vuP+ff7L/qvM8v/AFPyf6ugD1eS5SL79eTfBX9qD4aftFf2yfh74j/4SF9G8gX+LC4txB5gk8v/AF8ab+YpPueleqmNxyn+sryr4M/sw/Dj9nX+2z8OPDI8ODWRGb5BqF1ceb5e/wAvHmyPsx5kn3MdaAOm+KXxV8NfB3wPfeMvGOpNo3hzT/L+13v2WSXyvMkSND5caO/35EHTvT/hP8UvDnxk8BaX4x8I6j/a3h7U/N+y3v2eSDzPLkeN/kkAf/WRv1HaoviZ8K/D3xo8E6j4R8Z6X/a3hzU/LN3ZfapIA/lyJJH+8jKSD50Tv/BUvwt+F/hz4M+B7DwZ4N0waV4c03zDZ2X2iSUR+ZI8kg8yR3c5d3PJ70Acv8cP2pPhr+ze+i/8LF8Rv4d/tkT/AGEmxuLkTmHy/M/1EcmP9dH1r1uOTzBXkvxw/Zd+GX7RzaKPiJ4dPiU6KJ/sAN/cWvkeZ5fmf6iSPOfLj6+letrnb81AHkbftRfDOP44v8ID4k/4uIv/ADBfsNzjH2f7Vnz/AC/K/wBR8/369XkuVi6q/wCVeUt+y/8ADj/heX/C4F8Nr/wsf/oNfb7j/n3+y/6rzPL/ANT8n+rr1KS3fy/kz/32aAPOfg/8fPA37QHha68Q+AdWm8RaNbXclnJci1uLf9+kcchjAnSPnEif7HPWvSvtQ8vfsbZ9K83+EHwJ8D/AHw7caB4B0I6DpNxfvqUlv9qnuM3EiRxu++V5H+5GnGdnFcF4M/4XhH+2J42TXUB+Bj6Sn9gkvZgpeeXZ+Z9z/SP9Z9p/1nHpQB9ExyCSMN2p9cMvxb8FJ4y/4QpvGGif8Jnnd/wjn9qwf2j/AKvz/wDj38zzMeX+86fc56V2X2n/AFnyN8lAE9FcR4G+Lngz4nzXn/CHeLtC8WtYiP7W2g6nBei3358sSeW77A+x8Z/uH0rtI5BJGG7UAPooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCvJC8k0b/L8tL5f1/77qeigCpNbvINhCSR/9NOat0UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeT/ABV+DKfFLxJ4O1qLxh4m8Kan4XlvLmy/sGe38t5J4DbySSRXEE8cjxxySpGcfJ58mKb/AMKY8Wf9Fx8f/wDgB4d/+VVetUUAfO3xK/ZQufjF4L1Lwd4x+L/jrV/DWqCL7XZGDRIN/lyJIP3kWnI/340rd0f4A65oek2mn6d8ZvG2n2FrBHbwWdrpnh6KKGNABGiRjS/kQAcJ+Fe2UUAfP2ufs16t4m8ReHdev/jP8Qp9S8OyTT6aM6MsUMskEkEknkx6d5cj+W8keZEfYJZNmM0fD/8AZivfhn4dj8P+Gfiv420HRYZ57iGwsrPQVigM88k0nlx/2XiNN8khCD5EBwmAAB9A0UAeA+OP2ZdS+Inh+fQNc+NXxEn06Wa3uCLX+xbOWOWC4S4ikjlg06ORHSSNHyDXvidKdRQAUUUUAFFFFABVdoSZN4+5zvTH3qsUUAQx+Z/sVDcTtHj5RhR88n9yrlQyR/vN9AH4l/Hvw3+0D+xt8cPiB8Y9IhfwdpHiXxJqVjp2syzafffaILq5kuI0+z5k2b0g35Mf/LPFev8AhD42aR42+G9t+0N4l+IfhIfGnQzY3Ok+HrrWtPhu5tPsIJLe/snj+x+bHJqH2nVJQiAjfNZ7P9XX1H+258L9O+Pdr8L/AITXi363+u+I01RpbEvGlnYWkcn2yeST7PJH/q7gRRo+z9/cwfwB0rzof8EZ/gr86f8ACUePk8z/AKfLD/5DoA+kNB/a++CWsaXZXkHxa8GpHcwxzqLnXbe2kG8Zw8cj7435+4/P9NOP9rD4Iyf81j8A/j4nsP8A47XwloP/AASz+F//AAvjxF8PNe1LxhDZNpkeu+G763voMXlp+7t7uOU/YPL8+3ndH4k/1d5b/J/rM+ix/wDBFr4JN8x8UeP0/wC4lYf/ACHQB9V/8NX/AAS/6LJ4A/8ACosf/jtH/DV/wS/6LJ4A/wDCosf/AI7Xyv8A8OWfgj/0NHj/AP8ABhYf/IdH/Dln4I/9DR4//wDBhYf/ACHQB9Uf8NX/AAS/6LJ4A/8ACosf/jtH/DV/wS/6LJ4A/wDCosf/AI7Xyv8A8OWfgj/0NHj/AP8ABhYf/IdH/Dln4I/9DR4//wDBhYf/ACHQB9Uf8NX/AAS/6LJ4A/8ACosf/jtH/DV/wS/6LJ4A/wDCosf/AI7Xyv8A8OWfgj/0NHj/AP8ABhYf/IdH/Dln4I/9DR4//wDBhYf/ACHQB9Uf8NX/AAS/6LJ4A/8ACosf/jtNk/a0+CUf/NYvAP8A4U1n/wDHK+Wf+HLPwR/6Gjx//wCDCw/+Q683+P8A/wAExvgz8F/hre3uleIvGWp+LNRuINK8NaPdajpn+natcP5VnEfMt4xs8zl/nH7tJD2oA9M+M3xB+Ff7TXxK17S9Y+MXhnw14T8HacE8M6snieK33+JriNJE1WDyL9DKlgnkJHvQDzLi7G/92awfHn7WHw1/aQ8B+AvBfxA8W6HoOkTWlzr/AMSLKLVIij/YJfL/ALPtHj+0eaLi8Tz4xBP55tbcFP8AXx1X1j/gkn8FfAPgK513xP438aiLQtJkvNU1G3mt0t9kEZe4kji+zySIn+sIjy55/j7/ADZon7DHhbSvi38EvDXivVNd8O2fje0nvdd0yYbZNCkuEu30e3ku5beOM3Eoj+z+WYxJ59vcbP8AWIEAPVv2UfjpoXgOPwj8TfEnxDtbzxnr2pR+G/H9nrPiCyeW6sZLa2TSNQRBdpkWYFvHO8kck4+06gZP9Wav/GD9oDwdqnhfxZ+0bonjrw3cfE3SfEFongjQZL22ku10S0uJLCSC4t5II7vZdi91C5kjyH8s237weTXE/tTf8E+/hb8A9c+GI07xd4ik07WtfjtPEDa20Mv2TS/Nt7e4v/taRRxW6QSXEEf73q86f3MUv7OX/BODwP8AFD4lfEHw3r/jDVfsXgeb+xr8aVe2DSX1+by5eOSNEkneCAWcdvlJB5nnyXCb827pQB7j8HPjB8I/2Y/EGg3Oj/FvTPE3gTxn4fN34lvf7XkuL2LXoIjcPqs9vJeSTwG9jMySRJHv8+C2j6vivDfEfjbwB8RviB4F1XxX47t72x+KEn9q/FHSNK1+3+z2mm/a7T+wtPkfZbxh7Py4xOY8Xccf2yTPlnNZPj7/AIJ/+BPCfx/8R/D651rWNJ8PaV4ZufHMniu8vhd/ZdLjtzbuklnHZoZ50vh5n7uTDwfJgSHcM/4K/sN+B/ib8PfhbYzXniGP4n+JNf1Cz1/SROsVv4es7Cf/AImEk6CzkeKcQm0jSK4dP3l/EemQQD0H4efGbwzrHgvxD8YNX+KOha18U/h3rNvp/hdtXu4LG51/QdNt5EkTy7iOe6EmoQX9+X6nz/I+55Vfpj8PPiNoHxQ8H6V4n8M6jDrOh6pGJrS7tGAR0Oev9x0IKOh+dChBAIr8bvil+xZ4Z+F/ww8YarPquv6j4i+H+sXmkeLNNtnsMvHcW8j6HqcUfmGSO3keSy82OQySfvLjZs8h6+w/+CVPjrVLf4QaL4G8RoptbqzuvEHhS5iikEcliL6S3vbfzDAieZBc/vT+9d9mox9NmKAP0ESQScrT6qR3Efl/89ON9NjvkdhhH2Y/1mPkWgC7RUCXUcjIq87uakSQScrQA+iiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK/Pz40f8pivgf/2Jlz/6I1mv0Dr8/PjR/wApivgf/wBiZc/+iNZoA/QFOlOpqdKdQAUUUUAFFFFABRRRQAUUUUAFFFFAEP8Ay2r8sf2Bf+Upn7Rn/cyf+ny3r9Tv+W1flj+wL/ylM/aM/wC5k/8AT5b0AfqjH/q1p9Mj/wBWtPoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5nxd4T0zxr4c17w7rMBvdJ1ixmsL63D+X5kEiFJE3p84yjn864tf2afCn/QY8fD/ALqJ4i/+T69aooA8lb9mvwp/Dq3jz/w43iAf+3tdd4D8C6V8N/DsGg6FBNback1xcILq8nu5Wlnnee4kknnd5JHeSWSTLknJrrKKACiiigAooooAKKKKACiiigAooooAKrvC8jON/wC7YVYooA+dv+GMfBX/AA1Z/wANBf2nr/8Awmedv2Lzof7O/wCQf9j/ANX9n8z/AFfP+s+//wB8V9BbHBdvk5qeigD51/Zc/Y18FfseN4nPg/Ude1OPxALd7o61cW8mzyPM8vZ5cUf/AD3kr6Ejj8qP/npXz143/wCF4/8ADXvgf+wt3/CiP7Ik/t3d9g/4/wDZebP9Z/pH3/sf+r+T9a+hbff5fz9aAJqKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPG/FnwF/4SP4nP4+0nxjr3hLxHLo0ehyTaTaaZLugjlklA8y7s53TLy/Psf5/Ljz/AKsVaX4MeLNmz/hePj/Z6fYPDuP/AE1V61RQB4Zafs5rN8QvCvi7X/HnibxbqnhiW4k0+LVLTSY9n2i3kt5B5lrp8U2zZITsD7C6R5/1Yr3OiigAooooAKKKKACiiigAryf4q/BlPil4k8Ha1F4w8TeFNT8Ly3lzZf2DPb+W8k8Bt5JJIriCeOR445JUjOPk8+TFesUUAfPfjj9mG4+JfhifQPFHxY8Za1o088M09leWWgiKR47iOePeBpnzjzETKH5HxyDmsTW/2KbPXZPE8lx8VfH0V14murS+1K+s10i0uLie0EAtH8+DT45I/K+zxFPLdMHf3kkL/T9FAHzV4i/Y6h8Xah4k1DVfih40vNR1/Qz4Yv7uSDRRJLphklaSAONM/dgm4lzsxn5Of3ceyp4D/YuHw11n+0vD3xe+JFlfSWP2Caaa50288+N7ue8cy+fp7+ZJ9ou55PNk+f8AfyDIT5K+oKKAPkPxr/wTj8EfEjxLLrXiPxf4l1fVZdSt9VmvLmw0JpZJ4II4I0cnTMvBsjTNuf3B6mPPXptJ/Y7i0L4jeJviHpfxP8ZQ+O/EMcFvqWsy2uhSSskaJGkY3aZ+7XbHHmOPYJNib+cEfS1QyXSR9aAPhX9tL4cWPwf+DvxD+IniD4w+PrrW9W8Ov4Tjs5pNFjg1XzDIbe3e3FnEj+W888hkjxOkf2jY/GK+SP2afHXiDUfhF4B1nwLqmpajr3wYGr+K/EFnr1rbw6baafl5JLSzuU0+SbzL+C4n/wBZPw9nK/l/JBIn2V+0VeD43RfG7VVnE/hD4V+ENc0m18mfMd34jn0yT7ZIfLuDvFpaSJbgSQf6y9uf+edfmfY/CD49/Buw1qwOgzeH9I1TTNE1fV7DW2szp5tpNSjXT/t6XDmCI/a4/uT4kCfaN4Efn0Afoj4Y+Nvx38faPZ+EFu4dF8V/Et7Txh4W8UW1oby28P8Ah2cGeeKX/Qo4JZ7RILeD94+ZH1S3PmJiuZ8C/ttfFnUvA9p8R7yDSfEun+O5pPCXh7wppMVvJ/YXieOKKO0ju5JJbeRILyQXlw8cnmGCNLfEn7yvhzS/B37RHiIeHRYeCb6b+2vDep3uiiw8OWcfmaPJ9v8Atgt9kX7uOT+07rESbN/2mz8sc2lVbvTfjz8TLXw74nt9TuH03UfFOl6NpMnh7VLW1sodc/s+AWaRW9vIkdvcR2gt4/M2J5fl7HdHRxQB+jXhP9qT4g+HfGEsXivXdD1Pwb8PNbg8HeOtSgWxje6uLu4uILfV5P8ATD9njj8vTPMTZjfc34x/o/yfdVvII48HfKE/5aHvX4WweHv2ptD8A+NtZXUWtvDe668A+Jbi817TJokefU7hLiC8Msp/eG8v5z9ok+dEui4kEcm+vsz/AIJS/tEfEL43aX8QLLx34sufE0fh6DSYdNW8hj82FJPtaPvlRBI8h8uP55HdzjPUmgD9EaKrWspkgVy7P/vpsqzQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFfn58aP+UxXwP/AOxMuf8A0RrNfoHX5+fGj/lMV8D/APsTLn/0RrNAH6Ap0p1NTpTqACiiigCCS48vfuRsCvFvjP8AtafCf9nzV9O0z4g+K18OX+owPdQwraz3UuwHbveOCOQoDg7PM67H/uGvZpbbzHyvFfm5/wAE+fhH4R/ae1b4tfHTx34b0zxPd694kfT7HRfEUH9pxaTbJHHPsjMnySHy57eBP3aeWlv8mEkMdAH3L8Jfjd4N+NXhO18TeCtZi17R5LiS086PfHIksfDpJFIA8b8h9j4Owh+lekV+c3gXwnp37Lv/AAVD/wCEO8K2jWvhL4leHHv/AOxrF2tbPTriMXEwbyvnEnz2Fzs+4I0vHRPkTD/onHF5ceygDzz4tfGjwb8B/DM/iPx1r0Ph3RkmjgkuZklkd5JDgJDHGDJIcAnEaHADv0RyOa+DX7Xfwl+P2r6hpngPxZFrmpWECXM1pLaXFrL5Z4DxpPHGZB0zsBxvTON4r5Q/bastAX9vb4C3nxYnh/4VDPp1xbsurXHmact/G8rt5kX8CeZJpvmSSARumwSZjSTHHfF7T/hRqX7bH7OFv+zw/htPEaalLNrreArmCC3NhG8cn7x4CkG7yE1DfGn7x48I/Dx0AfqXG/mLmn1HF/q1+7/wDpXB+Mfjb8Pvh1rUek+LfG/hnwxqbwfaEtdZ1a3tJXjOQJAkjg7Pkf8A74oA7r/ltX5Y/sC/8pTP2jP+5k/9PlvX3x/w1p8Efv8A/C4vAP8A4U1n/wDHK/P3/gnvqVpr3/BSz496npt9b6hp99b69dWl3ayiSOaKTWLZ0kRx99SMc9OaAP1bj/1a0+mR/wCrWn0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVBJc+XJs2MaAI7zeY32dfuVZj+6K/NT9qDxWdG/aql+PnhmSwurX4ebfh9EL6/sY7S+1yew1CQ/vJLyPEdvJd2Ec4+RwHuD0gevr39nf4i6trWj+IvCPjG9ivvHvgnUpNJ1q5higg+1wH95YX4t45ZPLS4tJI37fvI50wPLxQB7hRTI5PMFPoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAri/iVdeItO8GeIb7wpZW2peJbfTZjpNtdMPLuLvY/lxPl4+C+wffTqeRiu0qHy38zfQB8N6h4C8czfDr4ZfDJ/g9401zwbp+qRar4yvNW1XQZbjXpIne6cGG41C4D/AGi/xPODKh2eZGMiTjN1Dwb8X9d+HPxAtL34L+KLfxn8Ttf/AOKs1a11nw9mz0DeLf7FaObgefJHp8fkJ5safvLieTfn7/3lDG5j2O6f9s6k8uT/AJ6UAfmf4b+CHx58L6Da+IIPhtq198W/B0+l6X4H1JpPD0enJodhBJafZ7xPtsk6PcR3d5JOI5H/AHnkbJEEYxW8K/sp/Ey18Op4G8QeCfH154H8K2c8vgSey1DSbfULHW7iO3d9SnEGsRp/o91HcPbx/vDi7k8yXiv058uT/npR5cn/AD0oA+MND0/4jah4k8QXXi74M+KL3QvH/hSO08caDYatpqxyaxHClvJPZ51j5IJbdzBJjZJ/olsf+elfHf8AwSFi8ax/GXWL3QVuLzwtGsdp4mTKfZ4YpI7iS3uP+PiN3mEtukceI5x5dxcf6vjf+x/lf6v/AGHr8sv+CIR3j40FUQun9ibP4N//ACEKAP1Rtv8Aj3j+lTVHGAqIE+5UlABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV+fnxo/5TFfA/wD7Ey5/9EazX6B1+fnxo/5TFfA//sTLn/0RrNAH6Ap0p1NTpTqACiiigCpJKnmc/wAH/LSvgf8A4JFxt4P+FvxM+G+rKLPxl4b8Y3B1XT/9YLbfbx24/eITG58yzuU/duf9XnuM/fFxbvN5gz5Z/gkr44+N3/BOyHxr8UpPiD8NfiJrHwa8R6pA6a7LoKyn+0HLo5kHlzxlHcoDJy4d445CN4d5ADjPGAbx9/wV48CPoOL4+CPBkieIRjy/sJkivPL+/s8z/kIWf+rz/rf9h9n339qSP/rn/wA9K+cP2U/2OdG/Znt9a1W41a48a/ELXZ5H1bxfqURFzcRvIz7Ey8hjQviR/wB4XkkG93/1aJe+L37KJ+Kn7RHw1+KB8da74dHgwyEaLYy4iu8nflH/AOWHmHMc/D+bAkcf7vrQB8y/F69v/wBqb/goPqfwR8Y+L7jR/hp4b0yC+j8M2NwbM+IpPKs7o20/7xDI++TzOPuR2h8sI5eSuX/bE+H+j/8ABPe68H/Eb4Ga9N4Ev9Q1SOwv/A739xcWGtwxxyP58sUknmSCMSeW/wDc+0RlPKk+eT6j/ap/Yd0P9prxFo3iu28Ral4K+IWhqsWm+ItLO8RIlx5sfmRfIcx5kMbxyI6PJkl9griPhb/wTXh8O/FbR/H/AMTPir4i+K+veHpba50Y6h5kKQvA8joJN8s8kiRyOkiIjoN4ffvDkUAfbVvs8v8AdrhK+Yf2mP8Agn58Pv2qvH1n4r8W614l0/ULPTY9Ljh0W6gjiMccskgciSCQl8zv/nmvqKNPLXFPoA/P3/hyz8Ef+hn8f/8AgfZ//IdeIf8ABMvwbp/w5/4KEfGXwnpzzT6foWmaxpdtJcEb3jg1W0jTd/tYSv1r/wCW1flj+wL/AMpTP2jP+5k/9PlvQB+qMf8Aq1p9Mj/1a0+gAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvIv2hvihL8H/AIe3er6bawal4p1GSDRvD2nXEyRi/wBUuJPLtIMPJHn944d/nQiOOV/4K9dr5e+O1j8RJvi1ZeJvDXgq/wDGFr4c8OXVx4Zt7W8t4LT/AISO6EsHm34l1C33xxQCONNkbnZeXHzg7KAPJf8AhTt38SPDPj3wT4av5vFWnfDPwtrHhuxumvn/AOKg8a6lZynU7yR3vH+eP7X5eJxiOTULkb8R1x/7Pfjv4kfCjUP+Es+Mmveb4i8L6tb+AvG9ne38E0lnol3BaSaNqFxIlykf7q7uJ83EnmSPHeXfP7s7PpD4P6p4p+FHwv0Twknwi+IWsS2cO+81W41DQpJNQu5XMtxcv5msO+Z55J5D85x5hAz1rnfiNpfi/wAafE6x15Pgl4yfQtY0K88J+NNMutS0nGp6ZJHI9uYvL1cKk8cjyR78Z8u8uPnBRKAPoHwP8XvBXxKa+Xwd4s0Txb9h8s3P9iahBeC3Em/y/M8t/k/1b8HrsNd0rbxXzF+w/wDs2ad8AfhaiS+Fj4b8Yamottb/ANJZ5LuO3uLhLOeSMXNxHDJJDJ5jpBIU3yOOgADv2Y/26vBH7U3ijV9F8I+HfFlr/ZNqLy71DVrCFbOPMgRIvMjuJMSP+8dB0KRSf3KAPpWS6SP7yP8A98Ukl4kX3uMff/2PrXnnxm+JUXwv+Guu+LHsJ9Ye2gH2PSraN5JdRupJEgt7OPZHI+Z53gj4jOPMzXjvwJk8W/BX4nRfDn4neMLjxdqPjPTB4n0vW765Qg6nHHGmsafb5kjPkR/uLi3jjgj2RyS/886APquN/MXNPqpHcx+QcI4RPkqX7R/0zb8qAJqKKryXAjzuRuOnH3qALFFFFABRRUUknlUAS0VweofFzwlo/wAR9I8CXviCzt/F+rWkl/Y6G7D7RPDGfnlQD28zH9/y5NmfLkx3EcglUOv3aAJKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCGT/WV+V/8AwQ1+78a/+4J/7kK/VCT/AFlflf8A8ENfu/Gv/uCf+5CgD9U1/wBX130+mx/dFOoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvz8+NH/KYr4H/9iZc/+iNZr9A6/Pz40f8AKYr4H/8AYmXP/ojWaAP0BTpTqanSnUAFFFFABRRRQAUUUUAFFFFABRRRQBD/AMtq/LH9gX/lKZ+0Z/3Mn/p8t6/U7/ltX5Y/sC/8pTP2jP8AuZP/AE+W9AH6ox/6tafTI/8AVrT6ACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKqXELyfOmzzE+5VuigCHyv8Abo8r/bqaigCHY/v/AN9mqz71njDDzHf/AMh1fqpc2r3Pyb8R0AfF3/CnfEPxK/4KDav4hvfF1/r3w68F/wBn6i3hjUIZ/wCz7bWnsJI4kt45D5Bkij8u8M8fzxvcRpjO+RPdv2hfAOueMPh+t34TkYePPC11F4i8OCSaSOKa/g34t5MTx/u7iN57eTe+BHcn0rkPhb8A/it8K/Dt5pGnfEfwVfzXuo3er6hq154AlS5v7y6keSW4n8jU443f5wn3OEjjHau3/wCET+NLRhG8feARGPueX4Hv02/+VmgDyP8AYN+HusaL4Bm8cX/xs1z4w6N4usbG804a8ZC+l7PM8yM5vLhPMDv5cgB/dyQHrivbPjx8OdY+Lfwo1jwv4e8ZX3w/1W/+z/ZfEelK/n2hSeOQ+XsliPziMp/rOj/hWN8E/hN4i+FzeLP7W8T6fr9vrmtya3Ba2OnXFnHps84P2sRCe8uf3ckm+fyxjZJLP18wbPZEXYlAHm3wG+G+t/Cf4UaH4X8Q+M774gazYtcef4i1Lf8AaLvzLiSQb/MkkceWjhP9YfufhXPfGv4J+KPil4++HOtaL8StY8G6R4Y1H7Zqui2Qk8jXYfMgfyJ9k8Y2YgkT94kn+vfjFe20UAeRfGz9qL4afs3/ANir8RfER8O/2uJ/sLGwuLjzjB5fmf6iOTGPMj6+tetRyeYK8l+OH7Lvwy/aObRR8RPDp8SnRRP9gBv7i18jzPL8z/USR5z5cfX0r1tc7fmoA8jb9qL4Zx/HF/hAfEn/ABcRf+YL9hucY+z/AGrPn+X5X+o+f79d7rWsWnh+xvNS1C4g0/TrOGS7u7y5fyY4I0/5aSO3QBFfJ9vxrhG/Zd+G/wDwvD/hb6+Gj/wsT/oM/brjH/Hr9l/1XmeX/qfk/wBX7+9ch+0Ncf8ACzfE3hn4IWFxuHidDq/ioW8/l3EWgWsifaI/3dxFLH9sneG0BGR5b3f9ygD56+EPiyz/AGtvBvxP+Ifw/wBbmn+Mmm65a69oelyx3lrHpdvZm4j0vTJP9LEDpeW6X/n+XJ5YfUZ94+RK+zvhR8UtB+Lfw30bxv4fufN0TWLP7XFJI6b4VIy8cmx3CSRkGOQZ4kQ1z/wP/Zh+Gv7OY1l/hv4aPh860IBeKb+7uBOYPMMf+vkk2Y8yQcetfL/xm/ZD8G/FD9o+HwB441zXtJ0DXf7S8XeDP7Kv4Ix9umMH9uWWLozuSXSC8jSOONB9pu/+edAH6AK28U6vHb79qH4caH4D8Y+L73xA8fhzwfq0mh67eLp9wRZ38ckUUkXl+Xvf95cR/PHvTvv616LpfiCw17SbTUNNuor/AE+7t0uLe9tZEeOeN8eWY3+4+/jv39xQBu0UyOTzBT6ACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAIHPzbMb6/Ir/AIJB/Ezw18Mv+FiDxLqj6X/wkGseHdC0tlgkkNxfXH9oeVEdiHH3JPnfCDHJr9FP2ivHGv8AgXwI1p4QWOT4heKb6Dw34edo3cQXk6OBcybIJf3duiT3b+YmzZA46nFfht+zb4p8A+DdS8aS+PNMs9c0nUfDd/o9raPF/pkdw9vJPHdW7m0njjkEkEdv5hwY/tiP+8SOSgD96tF+M3g/XPiJ4g+HNjrsFz428OxW8+paKsLxyQRyIkkciA8PHiSPJjL7PMQPjNeiRyeYK/Jbwn+158JPh38N/AXi208XJd/F3Q/E1/qHiW1sNOu3Pie3v7t01R8pBZwHzEFveQeeP3f2O3iP3DX17H/wVD/ZljTY/wASX/8ABDqf/wAjUAe7+P8A4qeHvhq3hz/hIr/+yx4g1i20DTf3Ekv2m+n8zy4PkB2Z8tvnfCe9dxX5lfEH9qr9mv8AaI+J/jKX4keMYG8GWuhyeG/C0P8AYV1cXCyXcaSXmqRB9PcwT/Lbww/OcfZ5X2fvRXqXwW/4KefB1vhpocfxA+IFvF40toJLXUbi30jULiK7ljcxm7j2WaYSfYJ9mxNnmbMDZQB9uyyeX/B5lcVqPxY8I6T8QtM8C3et2Nv401W0kv7HRJJT9ouLePl5ET/vsj+/5cmM+XJs8Gf/AIKefs0bsf8ACxNnz7/+QBqf/ff/AB7V4l8K/if4e/aqtfHniPwL4kmk+Pg1JfFvhzQ2t760j0+w0yQ29np8n+kiApcR3FwJ9kgQvqs/D+XQB+jsUqSxh0OVqSuB+FfxN0b4reAtB8ZeH5fM0TV7MXkRkkQyQkjJgkEbuBJFl45EBOx42Fd3G/mLmgB9FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABX5+fGj/AJTFfA//ALEy5/8ARGs1+gdfn58aP+UxXwP/AOxMuf8A0RrNAH6Ap0p1NTpTqACiiigAooooAKKKKACiiigAooooAh/5bV+WP7Av/KUz9oz/ALmT/wBPlvX6nf8ALavyx/YF/wCUpn7Rn/cyf+ny3oA/VGP/AFa0+mR/6tafQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV5n4w+Bvhnxp4mm8SXs2vWGrSWcFlPcaL4l1LSzJBDJK8aOLS4jD7DcXGM95K9MooA8lX9mnwtt+bWvH27/soniL/5PrzD44/DzS/hZo+kaj4Ok8T6n8TL7Uv7F8Hvr3ijWtWt7DVLqCaA3hguJLiPZBaSXk7u8ZXZBIO9fUTTeW4TY5+lfJPirx8lx46+IHxqvdGm1nRvh3a3HhHwPpf2KR5NV1qeSOO9khH2PzAZbn7JpkckbyJ+6uO0lAHyn+zn8D/FfwO/aG0nTfiNHoeveEfDOsaJpF3P4Z0Yx2lvrclpejS5Z5P7PTz5I/tab5/M3pJqFhI8hMexPrj9mXx3pvg74nePf2co7yafU/A7/wBoaALm3nO/RJ0gnt4HmeSTebN7sW4yU/dpBsH+s2db4P8A2Z9Ob9nPVfht41MGs6h4rhurzxVqdtbQf6Zq92/mXN4n+jp86Tv+4cx/u0t4P7grwK10NPDug3n7QB0q4g+NfgDUBpXxKFtJcxjXbCzt44b0xwSS2kGJLH7PqcGyPZmKNMOaAPvmOQYcr+8+f+Cl+0R7tlfI/wC2H8Fvi5+0hovw/wBU+B3xKtfCWnwR3dxdXlj4gu7ODUIpxB9neN7SN/MTYkhHb95x3r60kj/ef7//AC0oAPt0fO7qn+s/2KkkufL/AOWbn8K+T/2K/jt8a/jXH41Pxe+HR8ELpv2P+yf+JLeaf9r8z7R5v/H3JJvx5cA/d/8APTvXp/7T3j7xp8M/gf4l8R/D3RG8U+MrX7N9h0b7BPeGfzLuNJP3EZ8w/u3kPH9ygD2WOTzBUbXGJNnlvXk/7Lfj3xl8T/gb4c8R/ELQT4Z8Y3rXn2/SfsM1n9nKXUkcY8qbMifu0jPJPXNeW/tufHv42fBRvBw+D/w9/wCE/OpNeDVf+JJeal9i8vyDB/x6yJsD+ZJ9/r5fHSgD6ujkEkYbtUclx5XRHf6Cnxf6sfPv/wBqvk9/j98a/wDhuL/hWn/CB7Pg/n/kcf7FvP8AoF+fj7Xv+z5+0fu/ufrQB9WfaMY+Rg7dsU77R/0zb8qrY/efcST/AKaSV89fsa/Fb4ofGL4Z6xrnxV8HL4I8TW+rPaW+nf2Tc2Bmt0t43jfFw7u/zvJyP7lAH0bJc+X/AMs3P4VJHJ5grx/9p7x54z+GPwT8QeJPh54f/wCEp8Y2Utv9h0YabPe+eXuI45P3cBD/AOreSSun+EviDWvE/wALvBuueJNPfS/EGpaNZ3mp2JgeAwXLwI8sflyfOmx942HmgDvKKh+0D0ridQ+LnhLR/iPpHgS98QWdv4v1a0kv7HQ3YfaJ4Yz88qAe3mY/v+XJsz5cmADvKKjjkEqh1+7UlABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVA03luE2OfpU9VZbfzJPM/5aD7lAHxf8UvF2t+LfiV4h8a+H7ORtZ0y8/wCFZfDJrq0d0Ot3R/4nGr/PZSGOO3jgKeYDJGU068H/AC1rzex/4Jx/BXxf8ZtT8F6ToGr2PhXwboaWeu62mo3f2nUdau4x9n/1kfkeZb25+0P5R2b7y3Bj8vzEP0vpP7C/wf0BtBbSdG8QabJoJuP7IFn4v1qD+zftB/0g2+Lz915gb955eN/etPRf2QPh34VGpNocPirRTfXUmpXX2LxxrsZuLt/9ZPJsvfnkfvIfn6UAfDPgT9jn4VadqHw/vfFngC7eGHUp/hv43sYtR1ZYoNe/dnT9Uj/cI/kXf7sdUgT+0LTA+R6Tx1+yP8H/AANrPj/4WjwJa6h8VNV1K3T4fy/2rqESXFhqMjiO5kjhuJ3MenmG88+SSNEMdnATh5yT9rat+wr8H9eGutqWi+INS/4SA2/9s/bPGGtSnUvIOYPtAN5+98vA2eZnZjitPUv2Q/h/q2t6Zrl8vi2+1zS/P+w6jc+ONaa5sfMTy5Ps8hvMx7wOcHmgDzjSf+CXn7OFnpdrBdeALnWZ4II1a8utavoricgfffy5403/APAE+leZ/FL9gH4HfDf4o/D/AFSfwHcXXw+1mc+GdR05dW1Nl0/ULiWP7BfAx75MSSIbNzJOkYM9ufWvq5f2afCqr/yGPH34fETxF/8AJ9Y3in9kf4e+MtFudF16LxZ4h0a62C5sdX8da7c28mzDoXikvCj4dEP1waAPmT4kfsKfAX/hbHgT4b+DPBMFrrWpSv4g1+4/tq7uZLDRbR8SExvfj95cXEkVoj7H2ZuH6x8fS/wc/Y7+EPwA8TXHiP4eeE20DVrqwksJLj+0ry4LwGSOQpsnkfHzxx9AOldV4w+Bnhvxt4om8RX0niCy1iS0gsp7jRvEmpaWZII5JXijf7JcRh9huLgjP/PSqa/s0+Ftvza14+3f9lE8Rf8AyfQBxvgm6HwV/aK1/wABX10IfD3jn7R4v8Mia4+5fZH9sWaeZcSOcvJHeIkcaJ/pFz18uvoaP7n/ANnXlukfs7+EdB8UaPryP4i1XUtJkknsP7Z8W6tqUcErwSQPII7m5kjz5csifc/jr1KOLy49lAE1FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABX5+fGj/AJTFfA//ALEy5/8ARGs1+gdfn58aP+UxXwP/AOxMuf8A0RrNAH6Ap0p1NTpTqACiiigAqF5vLcJszSSXSRybM/PXwn8Uv2zvit42+Nnif4efs4/D3TvGp8HiSDxJq+voYbeK4Enlm3jZ7iBBsdJB875k2SeWnlxeZIAfdn2n95s8t/yqSOQSRhu1fIv7JP7WmvfGLxP4n+GXxL8PjwV8W/DAknvtKt4nSyuLMMmJ43LybMGSIffdHSSN496OfL+uIv8AV/c8ugB+8VD9p/1gVGcpXyD8dPiJ+2HofxT12x+Fvwq8J+JPAkTwHTtT1S6jjuZ/3EZlDg6hF0k8xB8g4ArwH4rftsftkfBpdGi8XfCzwJpt7rmof2bpVlbsb68u7ggfu4reDUJJJOsfITGZIx1dKAP1CVt4p1VrYIsKIm0hPk+ReBUnmfvNlAEX/Lz/AJ/26/LX9gX/AJSmftGf9zJ/6fLev1JMnzJIw/d/+gV+W37Av/KUz9oz/uZP/T5b0AfqjH/q1p9Mj/1a0+gAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAqy2/mSeZ/y0H3K+f7f9h/4TWGl6Bo1houu2+h6JdjUNM02PxdrH2awu0d5I7i3g+17I5N8kj7/r3c19FUUAeQ/8Mz+E9n/IW8edd/8AyUfxB/8AJlYum/sjfD3Tde1XXLL/AIS/Tta1gQDUtQt/HWux3F95a7I/PkF4Hfy0yib+nTvXvFFAHO+D/CemeCfCWi+G9HtTaaRpNpHYWNsZXk8iCOMJGm9yX4QAc88VsyQCSTfz/wB9feqzRQBU8t5M7/3e70el8p/uJ+7jq1RQA1c7fmqOTfv+SpqKAGJnZ81Mk8z+CpqKAKv2X5s/6v8A650eW/mb/wD2erVFAFTy3j+4P4/79fPn7VHjT4/+E38MD4G+CvD/AI0a5Nz/AGsNcuI4vs+PKFv5fmXNvkvvuP7/APqx0r6OqER/O/ydaAOb8YeJtP8AA/hrVfEOr3JstH0e0n1G+vChkEMcEe+R9ifO/wAiP0yeOhr5A8CaDrH7RfwY8Q/HPwpcXEfxD1fXv7c8HW9w09vHa2+kz3FrZ6VLF9t8vZcJ9sE+HSPfqcp+fYlesftGTt8TfFnhb4I2M6iXxMJNV8UfZrgiSDw5byR+fG+y4gkj+2TtFaceYCklyf4K9W+Ffwv8OfCLwFpfhHwdpUelaBpvm/YrXz5J/I8yR5JPnkJk+/JJ1NAHCar+198K/CvwX8IfFTXfEP8AZHgzxIY47K5MUl28c0kcknkSR24l2SJ5csbjojxlM17fHcbusbJ9RXx94u+CngTWvjBrPwe+JOmrrHgTxlcT+O/CVrcalPb+TqkY2araRyC88x+bgXiRoiR/6Zef88+O4/bG+K/xP+Dfwx07WvhR4Qbxt4lm1mOxutPOlXOobLcwXEjyeXblJPvxx8/c/ee9AH0ZHMJkR05RqZLceXJsCF65D4Wa5rXiz4Y+EdY8T6Y2leINQ0q0vNS01oHj+y3jxo8kflud6eW+Rg+leT+Ofi58UNJ/a88E+AtM8Gi8+Fmq6NJd6v4m/sq5lNhcYuyIjcI/kR5MFuP3gz+89xQB9Fx9PubKfVLz/Jjy3znDv+7/AI8VNJdJHJsz89AE9FQx3KSNgUfaP+mbflQBNRVWO+jkp/2lMfJ+8/3KAJ6KZH0+5sp9ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABX5+fGj/lMV8D/+xMuf/RGs1+gdfn58aP8AlMV8D/8AsTLn/wBEazQB+gKdKdTU6U6gAooooAoXA8yTZ1j/AOedfAv/AASDK6v8D/Hfia9Av/EWpeMbhtR1m4BkvLvFpbyfvJ/vyfvJZ5OSeZJP79ff9xIA+/8A551+Yf7Mvxr8M/sCfEj4o/Bz4pNfeEPDv9rvrnhbW7/TpLuW/s3PkfvJLcYk8yKCB0KR7N6XAchwI6AO/wDiMF8O/wDBXj4Wwad/xLItd8HT/wBsLa/J/aeyLU/+Pj/nt/x72/8ArM/8e8f9xK/QSP7v39/vX50/AvxNF+2B/wAFA9R+MOj2F2vw48C6NJofh3XIo/skd7cFGRxKj5d/kvLuT5AhjT7J5mwvh/qH4j/taeAPhL8ZvBPww1651AeJfFnlm0kgtC8EHmyvHB58nbzJEeNNm/oTJsTDkA9saVI3kBbGzZmvgX4WMf2zP25PEPxKdjqXws+E+dI8NKSJLPUdVJ/eXEefMt5TvzIJI3R8DT37V7V+3f8AHkfAX9mvxprSXk9trmqx/wBiaMLeZ4p47yeMjzEkjz5ZjTzJe3+qHz5dK2P2M/gTP+z7+zX4S8K3sVta+JDbi/1fy4I4yLyd/MeOQxufMeMeXb+Zv+cW6HpxQB79bw+XAEr4q/bJ/aM+P/wc+Kml6P8ACr4V/wDCd+HJ9Jiu59Qfw7f6kYLkzypJGXt5Bj92kZwefmr7YjjEcYXtTJI/3m+gD8rm/bs/bW4L/s4qzj5E/wCKH1v/AOSK57/gl5rur+KP28vivq3iXT/7L8Rajo2qXup2XlPH9nupNTs5JYzG/KlJC/XpX62vD+8T53+RP79flt+wL/ylM/aM/wC5k/8AT5b0AfqjH/q1p9Mj/wBWtPoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8z8YfA3wz408TTeJL2bXrDVpLOCynuNF8S6lpZkghkleNHFpcRh9huLjGe8lUV/Zp8Lbfm1rx9u/7KJ4i/8Ak+vWqKAPJtJ/Z78K6F4o0rXkfxDqmq6TJJcacda8W6tqUcErwSQPII7i5kjz5csiZ2fx16fHa/6zf/y0q1RQAyPf5Y3/AHqZJG8hx/BU1FAHiHxo+Cfin4pePfhvq+h/EfVvBOl+F9Ue81bRtP8AMNv4hg8y3k+zz+XPGNmIZU+dJB+/k4/v+ytDlGT5SnTt/wB8VaooA+dvhP8As4+Nfh/8ePGPjvXPjDr3jHw7rS3i2HhG/wDP+x6V59yksYj33EiHy40MY/dpw/4V6z448MX/AIp8F+INEsNZn0K+1HTrizg1W3z5tlNJFsjnT5wQ8Z+fqPrXYUUAeJ/s1/BPxP8ABDwNeaJ4r+I+q/FbVJtRlvYtZ1xJPtEMbxxJ5CeZcSnYPLd/vj/WdK5zxx8Wvifo37Xngb4e6Z4PjvfhXq2jSXWreKP7IuZzYXGLvERuEfyI8mC3x5iH/We9fR9V5I2kOP4P96gDjfiZ8VvDPwY8Cah4u8Z6p/ZXh7TXj+13v2eS4EfmSJHGfLjDv9+SPoO9SfCf4peHPjJ4C0vxj4R1H+1vD2p+b9lvfs8kHmeXI8b/ACSAP/rI36jtTPid8LfDvxn8D6h4R8ZaUureHNUMX2yx+0SW4fy5BJH+8jKOP3iRnr2p/wALfhf4c+DPgew8GeDdMGleHNN8w2dl9oklEfmSPJIPMkd3OXdzye9AGP8AEP4+eCPhH4m8H+HvFWsSadrvi66FhodqLOeT7dceZHHs8yNCifPPH/rCn369Ha4xJs8t684+I3wE8FfFbxL4R8R+J9HbVNZ8I3n9oaFdNdzwfZJ98UhOyN0D/PbxHEm/p7mvHf22/jz8a/gm3g0fB/4djx8NUN2uqqdEvdT+xmPyPIz9nkTZv8yT7/8Ac9qAPq2OQSRhu1PqGOVNn+s8ymyXSxj51ZPwoAWS5EbfMjUvmH/nm9fnp+1p8aPiJpsfiv4n+B/FGraLpngzUJPC3hvRI7G4ntfEF4ltP/bF7cW/kImLTaTHLI8kEb6VcfJ+8r3T9mXxY3h3VfEXwu1Pxc/jSfSbeHxD4Y8T6lfLcXOu6Bdl5ILh5xO7zeRP59u8gRE2fZzjEmKAPpqOTzBT6anSnUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV+fnxo/wCUxXwP/wCxMuf/AERrNfoHX5+fGj/lMV8D/wDsTLn/ANEazQB+gKdKdTU6U6gAooooAh+zjzd9cV44+EvhD4l/2YfF3hLw94rNjvFsmt6VBdi33/f8vzEfZkpH06+WBXd0UAc14Z8G6P4K0m10rw/o2n6DpUA/dWGnWsdvbx/PvPlxoMD7z9O9R33g/SdY1jRtavNJsb3WdG806ZqFzbpJcWgkTZJ5cjjfH5kfyPjrXU0UAcb4i+G/hjxdq2lahr3hrSNYvtIm+06be6hZxzy2EmYyZLd3G+ByY4/uf3EPUV18aeWuKfRQAUUUUAQ/8tq/LH9gX/lKZ+0Z/wBzJ/6fLev1O/5bV+WP7Av/AClM/aM/7mT/ANPlvQB+qMf+rWn0yP8A1a0+gAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKhk37/kqaigD5x/am/Zt8Z/H6Tw0PCfxe1v4SNpJuftX9iieT+0hJ5HlmTy7iDmPyD13/AOs7Ve+JmseJ/gv8A/DnhTR9XuPEfxL1KCz8J6NrV4kjfaNTeDy31G4Hlz/JHHHPeSeZvGyBxnvX0BXz78XvgT408cfFLSvGvhrx1pHhybSNCvNJ0231Twsmqf2bc3cg+0ahbyfaIylx5cccf7wPHgSDGJHoA8Z+D/7PMOsftBeF/FfhfUbnRvhn8FYZ/BWiaTLbyN/bl4Le4i1S9xsijjf7RP5ckkaSefJaSHj5K8i+MHx40/8AYj+JXhDwbrEOvTX3g3WHuvC11bI89tdeDr47LnT5/M1De7wPG8cBkT/mGWh4SQmvrb4Z/BP4n/B34e6F4L8OeOfA1vpGh2cdnbgeBbsSOqA5lk2amE82Q73kkCfO8j187/tAfBP4m/tLfGSezfWvCviRvhFZNqMVmvhi6tLPXdXufKuxo0iT3jxyRmK3s3kkE/7sXiDYcnYAff2hapYeINItdT0y+t9S0y9j+0W17aSJJFcRv86PG6cMMenXr9dmvBP2PH0iy/Zl8DSaR4h/t7RZrFri1uD5g+ywPLJJHZ7JLi4dPsiH7P5fnyFPIxmvdftH/TNvyoAmooqF5vLcJszQBNRUH2hP9r8qi+3RnzMbv3b+W1AFyioftH/TNvyqagAoqGSTyw/yVNQAUVC83luE2ZpPtCf7X5UAT1BJdCOTYUb60z7V5n3Eevk/48XfxI+L3xL1rRvhhrF9o5+G1jBrMkMDyQW3iHX3MdxbaROcRiS3+yf6/ZcBP+Jhbl/9XQB9bROZEztKVJXBfC34o6N8Xfh3oXjXQbn7ToesWyXsMnmJuhBGTFJskcCWM5jdM8SRyV232pf7r/lQBPRTI5PMFPoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK/Pz40f8pivgf/2Jlz/6I1mv0Dr8/PjR/wApivgf/wBiZc/+iNZoA/QFOlOpqdKdQAUUUUAFFFFABRRRQAUUUUAFFFFAEP8Ay2r8sf2Bf+Upn7Rn/cyf+ny3r9Tv+W1flj+wL/ylM/aM/wC5k/8AT5b0AfqjH/q1p9Mj/wBWtPoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA82+NfxEh+FPw18Q+KZ7O41WawhjFnpVrE7yX93JIIba0HlxyOTPO8cYIjOPMz615ha/sx6+P2Ybv4f2fjmbwf8RNdmGsa5430aLbcSatPdpPeXCGD7OSjkSQJ9w+T5aHhMV13xx+C3iD4reJ/h/q2keJ9N0qDwlqE2sLpOteHhqlneXnkmK3nbE8EiPB5k7ph/vuj/8ALMVcTwn8ao148ffD4f8Ach3/AP8ALmgDxz9mfwdr37Lvj7/hTvjPxpP41h8VQXfiXw/4i1LFvczXgkH9qWnz3csm/wDeQXI2D5/Nu3JyhruP2oP2efGvx8h8KnwZ8Ztf+E0eki4Nz/YJnk/tLzPK8veY7iL/AFZjk67/APWGk8dfBT4qfEB9BOpfEjwjaXWg61Brlhdaf4Qv7d454wUKOV1j95HJHLPBJG/3455PYj6IXO35qABOlfPcn7NvjST9qo/FL/hcmv8A/CG/9E52T/2d/wAefkf8/Hl/f/f/AOq+/wDnX0NRQBV8uT7/AMnmV8+fst/s2+NfgC3iceLPjDrfxZGrJafZP7aSdP7O8jzMhPMuJ/v+YnQD/V96+jaKAPMfj38N9b+LHwr1fwroHjG++H+q3xt/s/iPSt/2i0KTxyHy9kkZ+cRlP9Z0kp3wG+G+t/Cf4UaH4X8Q+M774gazYtcef4i1Lf8AaLvzLiSQb/MkkceWjhP9YfufhXplFAHz1+1J+zr44+P3/CMHwh8ZNf8AhINJF0bs6J5/+n+YYvL3+VcQf6vy5Ouf9ZX0GnSnUUAfPMn7NvjST9qo/FL/AIXJr/8Awhv/AETnZP8A2d/x5+R/z8eX9/8Af/6r7/51755cn3/k8yrVFAHy34H8NeIP2Mf2d/F954u8da78Z9Vhu/tdjJqCXH2m4uJBb29np8aeZcSfvLgonHeT7nXNvT/2YteT9l26+H+n+OJvCPxB125Gsa3410aLbO+qzXCXF5PH5H2c7HKyQJ9w+R5aHpXX/HH4LeIPit4n+H+raR4n03SoPCWoTawuk614eGqWd5eeSYredsTwSI8HmTumH++6P/yzFaCeF/jYn/NQvh//AOEFe/8Ay5oA8u+A2h3f7OHxOT4S614guNf0/wAUad/wkWg61qMpa4u9TjSOPXLf/SLmSTfJIY9Q2ImP9Ju+T5db3xS/Z68Z/ET46+DfiDofxi17wl4a0EWn2zwdp4uJLPVRBdSSyb9lwifvI3WI/u34T+PpSePvgv8AFjx82gyal8SfCdjNoOr2+s2NxYeEL+2kinjyhT5NX+eOSKSWB4z99LiQf3MeofFzXNc8L/DHxfrnhm0fUvEem6ReXWm6atu8/wBouUt3eKPZHy5eTYMe9AHb24kSAb+XqevIf2XfHXjT4k/A/wAN+I/iJ4cPhPxbdCf7do32GezEHl3EkcZEE5MiAxpG/X+OuU+K37aHg34M/HbwZ8Jtd0fXrjxL4rFmbG4sIIJLOM3V09vH5jvKjj95Gc4Q8YoA+iaKg+0fvNgjb8q+e/hD+2T4O+Mfxw8XfCvRNG8QweIPC/20313f29vHZv8AZ7hLeQxPHO7nLSAp8gylAH0XRUH2n93v8t/ypfN/2KAJqKqfbk/uP9/y6JL5Io95R/yoAt0VzOieNND8TLqA0TVrLVmsLuTTr37FOkhtLiPiSCTH+rkTP3Hwea3xcALuf92PegCeisPRdesfEGl2Oo6VMmoaffRxz297bv5kU0bp5iSRuPvoQf1rJh+JnhO40nXL+LxLpdzp+hy3EGrXSXaPHpzw4M6XBB/d+WDl9/3Or0AdlRWC2vWc2p3GliZH1GCOOeezWVWkjikeSOOSROyP5UnJH/LOTulV7HxnoWrtpf2HVbS9OrWj6jYLa3COL60QRk3EGDiSP/SIPnTI/ex880AdNRXM+H/GGi+LBqLaPqtrqx0y+fTb4WNwlwbW8jx5kEvln5JU3jeh5GfrRqfjDRNHbUzfa1ZWI0u0GoX3n3Mcf2S3PmgXFx/zzj/cT/vHwn7qT+5QB01FMj6fc2U+gAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK/Pz40f8AKYr4H/8AYmXP/ojWa/QOvz8+NH/KYr4H/wDYmXP/AKI1mgD9AU6U6mp0p1ABRRRQAUVFJJ5VJ9o/6Zyf98UATUVB9pTzNnzZ+lPhk8xNxXZ9aAJKKrPdeXJsZGz/AAf7dNkvljk2bHc7PM4HagC3RTI5PMFPoAh/5bV+WP7Av/KUz9oz/uZP/T5b1+p3/Lavyx/YF/5SmftGf9zJ/wCny3oA/VGP/VrT6ZH/AKtafQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABUE2/B2eX5n8HmVPRQAxF2JUTxzbnKPgdqsUUAUpIX2PGvl4/ubP4PSl+zvtkVAkW//AJaR1cooA+cfBf8Awu9f2xPHn9txKfgX/ZqHQT/oP/H/AOXaeZ/q/wDSP9Z9p/1nHp2r37LLtPzv5nVPv7KsiN/Mk/uNR5bSbN/brQB87fsXv8c/+Faal/wv1Zf+E0bVpPse77Hn+z/s9vj/AI9P3f8ArPN6/PXlH/BST48/GH4J6P8ADW2+FcUttd+ItTntZ7630kX8/wBp2xi2tI/MSSPfJvn+TZ5j+X8nSQV9sGNI1zLHHHHj56+ftFvh8a/2ldS1WO7Fz4T+FfmaXaeVNmK78RXEY+2Sfu7g5+yWksdviSP5JL24/wCedAHB+F/Cen/sP+O/Do1HxAT4F8bWhs/Euu69fSJF/wAJPBE9w+oyPd3b+X9vgS4EgRH/AHlpbpv+fNdb8cPGtn8aPB/hn4eeBtZh1i2+J0s1lca/o1x58Vt4egx/alwk4jnj37P9DHmbP393HzlDXoP7QnwXsf2iPgr4j8A6jq9xY2msxxhdQsokfypI5I7iKTZn503xoCmeU7jh6+Yf+CVPgzS5/gzD8QEuYL/VbhD4es41nt7m40mzgnkuZ7eSRLeN43nu7i4uPLJc+Q9mMny99AG74i+LEP7ENr8Q/BYbTba1mMmufDW1vJI7Ozd76cxz6e77LeAR2l/P5zp55dLS5D9IuPG/jN8PPCPwD8deGfhP4p8Z6hJ8KvFlnba38ULq+W8/0u/s4ryeO7NxLJJ5cmqXFm++C3/fv/Z6COT566b9tP4dL+1Snj/xGk4l8J/BGyljWG1uII/7U1DMd3q9v9oAn2eRYxW8ab4P+PiXD/6t0qW2+HOp/tReGf8AhFWul0PV/i5Zj4ieMNatYVn/ALM0vy/K8N6Wkn2ONJdjxwOYzIj/AOgXp3/v6APn7T/F0vhHw/oeleO/G+reE/ip8QNSg8GfE7T9elQTroM1vYG3vyPM8i3MFgyQeZcx+cZL28/jgJHT6rrtn8MRqvj3wbpM2l+KX1K31z4N2Fxp/wAmqaRJq9/aXGl21v8AYoHHm/2pcXf2eOQyeReWWzH2ffXB+Knsvjxq3gb4/wCs+Jrfwzq3j7Xj4b8S6dorJPBpGgfZLPSNQu555Iili+bnpOZMR6haYf5CX+gvDth428QX1rJol7p+reI/2X7Y6Jp2n6PJAJPEcnnmO4jKRyXkkfmaTZxRonlh/tdxcID+4eNQDrvhD48+Hv7Mi6N4x0b4gweJ/hJ4x03yPEnib7fLPt8UQW/2w3cscl3JPHPeW/2gSW4jMnmW9vH/AMtBXlPxG8JrqHjrw1r3xGXX7DTfiGsXiD4uactz9nstK0m41Czg8N2lxJLFbxp5Elv5UjpsusR3r79lUk+Fmg6R4R8Ufs9eHfE0+mfBPXtB/wCFwz+NrmT7RqLaL9jijjjktPsiFyL+3guMR+W5gj8vId8V738Bfhdpn7YH7Mfj6b4gzTWPjf4g64//AAmcelRQWl5plxYXUcdpp/MbvAkcNpB+7n8x/wB/I+cyZoA9X/ZR+MEGveF5fAmu+KLPxB458Jn7HPcRX8c82s2AjikstYjQXE8kkdxbz2chkP8Ay0kk+leuXHxE8K2ej6Jqtz4g02HTdee3t9IuJb2NIr+Scb4I7d/M2SvIOU2E57V+JXxW8Z2FnofhzxLqPjSXUtf0GZ/h/pmg2enJpsuoeCf7MjSO/iE8cj2z3MF5cYecSb/tYeLi3Ne56/4k8F+MNU8aeF/DmuTar4M0m5e8+CmmaIZNM8/xFq5s5wYJ45LeAf2Zd3aEQSDzII7yXfnytlAH6h2vxG8NT6T4h1S38QaZNpvh2ee31a8S9jkisZIE33Edw+/ETxjBffjZnmuvjk8wV+SfhE+Ctc+IHwy+CepeJJrPT/HzlPip4Y1bUnuLweItOln8zN3JcSxo+oX8EYdIPLkdILcgp5qZ++f2YvG2pX3hvVvAfie/+2eN/Ad//YepzSzoZb632CWw1DH2ieT/AEi3MbnzH/1n2hP+WdAHu1FMjkEkYbtT6ACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK/Pz40f8pivgf8A9iZc/wDojWa/QOvz8+NH/KYr4H/9iZc/+iNZoA/QFOlOpqdKdQAUUUUAUpNv2gov+s4c7f8AP+xX5c+CPg7N/wAFOfiZ8QPHHjbxXrA+FXhfUZPD/hCLw6kVmkqCTzJJdk+94z5HkPJvj3yGdMHEHl1+o0jx/bEHmeXJz8n9/wDzsr4G/wCCMpx+y74nyvzt40uPv/8AXnp9AEH7Kv8AwkX7J37WOtfs3at4hm1TwFqmnSa34G/tKAPc78+Y0aPF8kYKR33mbxGHkt/MQR+ed/6D23/HvH9K+APjFIf+HwvwOc/ux/whdxv+f/pnrFffZuY7WP8AeFIqAPgb9tjWPEfx3+PenfAXwx49Pw/8Kab4cu/EfjrXoL+MpBa+W8fl3cXmR4jCGMuhkw6X8bumyINVH4E/sG/AjTviRoPjn4QfF7Vtev8AwjqceoX8Gka7Y35MRjlH2Zzbx70jkKbP4/MjE8f/AC03p554m+BGmftH/wDBU74q+GPEGp6hZ+HIdIsNQ1XTbEvEdYt44NMxaSyB/kjMnkSdCf3Yx5b4kSp+3F+zJ4R/Yjl+G/xp+Dsc/he/03X47F9Gmu7m4tbomOefLyPJ5oR44pIJI9+ySOT+D5/MAP1YhlSaPKOkif8ATOlkukjkCHrT438xc18s/tNfsofET48+O7PXPDHx78TfC3SYdOjtH0XRo7gRTyCSR/Pfy7yL5zvRPuZ/digD6ikkELb36V+WX7Av/KUz9oz/ALmT/wBPlvXqUf8AwTh+M8b5/wCGxPHn/fu//wDljXiP/BNPw/f+EP8AgoN8YtD1HVrjxBqOkaVq1jd6vclxJqEkeqWkclzJvdzvkI3n5zz3NAH62x/6tafTI/8AVrT6ACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAK8lv50nzHMZHzR+teC+Df2YtV+Hfhe28P6D8aviHFY281xOVvBot3LLJPO9xPJJLPp0kkjvJJI+Xc9favoKigDwnxT+zlqnjTRNU0LWfjP49v8AS9VsZ7G8t/s+gxie3kQxyRny9LBwUc9Dmsvwf+yfceA7zVbnw58X/HmjtqxtDd2VtFo32NBBbx20Qit/7MEdviCKNP3aJkRx5+4K+iqKAPl5P2KbKb4dzeAbn4peO9W8J/bPtsum6tDo179on+2fbTJPJPp7yS77gmR/MJ3k4PycVn+F/wDgn/4Z8B+GvGvh7w3458WaLo3jLzxrttZWehRfa0kR43j3f2ZmOPZJJsjjKJH5j7Ama+saKAPk2H9gHw5DqHi29tvHXiy1ufFeip4b1WW2tNBj8zT0t/I+yR7NLxbxiNEj/deX/q4+8aVq+AP2LYvhhrEmq+HvjD8TrXUJLV7KWa5u9MuzPG13Pdky+bYSeZIZ7y4fzJMv+/fnHFfTtFAHxP8A8OpfhV/0HNex/bX9u/8AIN0H/j4/uf8AIL/49/8Apz/49/8ApnUXxd+Beq6P4ui8G6N8UfH2t638YL3y/E1vfiw+xR6Pb2qW+oXmyPTPLgkNv9ntEI8vfJcW5O/y6+3a8I+Ln7L+lfFrxVq+uS+J9f8ADlxrnhs+EdU/sqOwcz6eZJXeIPcWc7x7zcOH8t0z5cf/ADzBoA+F/it+zX4Z+MXwXm+KPiPX/Et9qlxNF4T+E+jW8um6Z/aFk8nkaQJIPsVoipJO89wAgQpaOOf3dVfC3hbVvg/4613SPD/jNtfs/wBnOzutZ8Nj7EkEWtJIlhP4ntHu0jkijEXmyxpBh545NQizJiKvt29/ZKmuNR8KXkfxa8c2w8J7zo1hZQaLb2dpug8ji3j0wRvsgd403o+wOQmzJritc/4J5+GPE/h3w5oGu+PPGviLT/DmoT61pv8Aa6aReSrdT3Dz3DyTyae8kyyyPvkjkLpJgb0OEwAfO3hH9nbT5PFGnfEfX9dn8NJ+0DpuopBcW11uTwxrt5ex63o/ly+ZbySSbLeMbETm4twm8idMdP4b/bg07UP2gvD+pajpWs+FfFOh6WPC3xRW6kt00eAfbI7eO8hk/tApstNTuDH5hjkP2e8uDnCV9Cn9i60h+GreBbX4qePNK8KpdjUE0zSV0e0+z3AvRfB4HhsEeDE4Dp5ZQJjgAcVkw/sE+G11zx5rUPjnxfb6h48spbDxBeRWegxveW8gKXCcaZmDzM75PL2GR/nf5wDQB9W2sflQInzH/rp1qeub8I6C/hPwtouji+1DVhptpFZnUNWn+0Xl35aCMSzyY+eR/vu+Bk9q6SgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvz8+NH/KYr4H/APYmXP8A6I1mv0Dr8/PjR/ymK+B//YmXP/ojWaAP0BTpTqanSnUAFFFFAEEiPxs2/fzX58eLvgT+0F+zF8fvHPjj9nuy0jx/onj+WTUNa0vxJJDGbK882SfhzLBlP9Ik8vZJ0kkEifIkh/Q6oJI3aTr+7oA+Mf2PP2b/AIjaH8WPGfx5+MV1DYfEbxjGdOHh/TfLaCwtA8RHmGMuC+LeBEAc7Ix88jyOdno/xdh/aAX9o74YJ8Pjo/8AwqLa6+Kftuxp/vnzPM3/ALz/AFezyPI/5ab/ADP3eK+jE6VFJGw3un+s7UAfHH7U37NHxA8QfFjwh8cfhHrGnx/ETwnaPZDSNdSM2l/bgznZHiMYnk8yWOQEpkSjZJGY/n8oX9n39oj9sb4jeGZf2jND0nwl8MfD8nm3HhjQNT2DU5MS/OBBLcO8m/ZG5kkj8uN38rDvIa/RxYWTG0Dg7P8AgFMjgfy5N4XzJP8AaNAE0f3P/s6mpsf3RTqAIf8AltX5Y/sC/wDKUz9oz/uZP/T5b1+p3/Lavyx/YF/5SmftGf8Acyf+ny3oA/VGP/VrT6ZH/q1p9ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAFWT/WfJsr5S+A/xu+NfjT9p74geCvGnw7Xw38ONH+3x6R4ih0O8s/t/l3kcduftEkhjfzI3kk/d19N+INXsND0m91LU7yGy06zjNzPc3TiOOBEy/mO5PCfJXyN8M/HfjjT/Fnhn4v69q2qz/D34ranJp48M3LmWDw3b3HlpoV2kcf2gI9x5fl3H7yNPP1CPKfu6APs+GQSR7w/mCpqit/9XUtABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFfn58aP8AlMV8D/8AsTLn/wBEazX6B1+fnxo/5TFfA/8A7Ey5/wDRGs0AfoCnSnU1OlOoAKKKKACiiigAooooAKKKKACiiigCH/ltX5Y/sC/8pTP2jP8AuZP/AE+W9fqd/wAtq/LH9gX/AJSmftGf9zJ/6fLegD9UY/8AVrT6ZH/q1p9ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFQ/ak/ef9M+tTVWkh8zj+D5cfgaAPnX9oXUF+LHibwr8EdOuAx8UeZrHid7e4+e28O25T7RH+7uI5U+2TmKz+TzMxyXf9w1zcP7F+u694z+KTePvi14h8deBPGtpf2cfhC9jl+z6T59zHcQyW5nuJY/MtwuI3EY2YH+5XZ2fwb+Jei/Ezxz4u0rx34ZM3iK5t8JrHhe/uzZ2sCbLe3ixqkcYA8yZ3KRpvkuJT0wiHj74d/HbxN4F8S6XpvxK8HW+o6jpVxZW9zb+Fb+ynjldJBHJHcLqchgfL58wRvs4IQ9CAdB+zr8QdY8ZfDtLHxbGV8c+GLuTQPEhSB0jmv7fyx9ojBijzHcRvBdp5cezZcIK9hjk8wV8nfslfsu/En4M6xd+JfHHxAsPEmu6lo/8AZ2qWsFpJcSXlxBdzyWl5calOfPnkSCd7f/Vx/uyif8sEJ+sk6UAOooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvz8+NH/KYr4H/APYmXP8A6I1mv0Dr8/PjR/ymK+B//YmXP/ojWaAP0BTpTqanSnUAFFFFABRRRQAUUUUAFFFFABRRRQBD/wAtq/LH9gX/AJSmftGf9zJ/6fLev1O/5bV+WP7Av/KUz9oz/uZP/T5b0AfqjH/q1p9Mj/1a0+gAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArF1bXrHw3pN/qWq3cOn6bYQvPd3Vy+yKCNELySO7/wAAHft/Larj/iN4FtPiR4F8ReFNQuZ7bTNc0640u5ltmQSJHPHJHIY96ON+HPUHtQBd8I+LdA8c6Fba14b1mx1/R7jzBBqOmXKXFvJsfY+yRMocOmOvUGujrzP4D/B/Q/2e/hboPw+8Oz6lf6LpPnm3uNSkjkuP3k8k7hyiJ/HIeidCK9G+0f8ATNvyoAmopkcnmCn0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABX5+fGj/lMV8D/APsTLn/0RrNfoHX5+fGj/lMV8D/+xMuf/RGs0AfoCnSnU1OlOoAKKKKAIJLjy9+5GwK8W+M/7Wnwn/Z81fTtM+IPitfDl/qMD3UMK2s91LsB273jgjkKA4OzzOux/wC4a9mltvMfK8V+bn/BPn4R+Ef2ntW+LXx08d+G9M8T3eveJH0+x0XxFB/acWk2yRxz7IzJ8kh8ue3gT92nlpb/ACYSQx0Afcvwl+N3g341eE7XxN4K1mLXtHkuJLTzo98ciSx8OkkUgDxvyH2Pg7CH6V6RX5zeBfCenfsu/wDBUP8A4Q7wraNa+EviV4ce/wD7GsXa1s9OuIxcTBvK+cSfPYXOz7gjS8dE+RMP+iccXlx7KAPKPjZ+1F8M/wBnOXRI/iH4ik8PHWBP9gP2C6uvP8ny/M5gjfGPMj6+tef+HP8Ago1+z7408RaXoGh+PH1DVtUvLews7ddFv4/Pnnk8uOPL24A5I5PHNfPf/BUzUPD+i/Gb9l/UPFVvay+GbXX7yfVY7q2+0RSWYuNMM4kj2Hf+78zKYP8ASvYPgf4y/Y++K3jCGD4aaT8PH8T2Usc9pHF4Zg02980b5BJbfaLeN3eMR+Z+7+5sHSgD7BoqG3k82HNeI/Gj9sj4Rfs9eKYPDfj3xQ2hapcWaajHD/Zt3Pm3eSSMPvgjcffjf0oA9u/5bV+WP7Av/KUz9oz/ALmT/wBPlvX1L/w9E/Zo8z/kpL4/7AGp/wDyPXyP/wAE5fE+n+M/+Cjnxw8Q6PcLeaNq9nreoWdwFdPNgl1e2kjfa/I+QjtxQB+skf8Aq1p9Mj/1a0+gAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArlPiF44sfhz4I8ReJ7+G4udO0PTbjU7iO2Te7xwRySOE7b/AJO9dXXmHx+8XaX4D+EXijWNX0QeLLP7L9lTw79me5Gr3FwRb29nsSOT/XyyRxcxv/rORQB88+Cf+CgujfEDWNK8WaToVxpvwcW4TSdf8Ta9FcW0ulancGY26yGOOSDyE+zwJJIZMJ/alnkx7HD9v+y7+0Pq/wAYNW8Q6b4l0G28L6lcWlv4m8K2bSQCW+8M3G9LO4fy7iR/M3pJ5nAEfmx/89K8E+OXwfufCf7LOn/s5+GLW01LxrrWjX/jPxW+h2NviT7KReSfZ4IPs5P2i/8AsdpbgQPsgGNn7uuq8MfE7xl4m/Z68G/GbxNp2oWnxR+FV3eR+M9I+wT6fPPphSM38ElvJLbx+Y9ibLUE/g8yCPYn8FAH3bH90U6sLQdesNe0mz1HTb6DUtOuoUuIL22nSSK4jf8A1ciOnyOH4xg45rajk8wUAPooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK/Pz40f8AKYr4H/8AYmXP/ojWa/QOvz8+NH/KYr4H/wDYmXP/AKI1mgD9AU6U6mp0p1ABRRRQBUklTzOf4P8AlpXwP/wSLjbwf8LfiZ8N9WUWfjLw34xuDqun/wCsFtvt47cfvEJjc+ZZ3Kfu3P8Aq89xn74uLd5vMGfLP8ElfHHxu/4J2Q+NfilJ8Qfhr8RNY+DXiPVIHTXZdBWU/wBoOXRzIPLnjKO5QGTlw7xxyEbw7yAHGeMA3j7/AIK8eBH0HF8fBHgyRPEIx5f2EyRXnl/f2eZ/yELP/V5/1v8AsPs++/tKf7H/AH8r5u/ZZ/Yy0b9mm11jVJtWufGnxA16SR9W8ZajGUuZ45JPM2IDI5jTfiSTEheST5y/EaJpfFr9lN/ip+0J8NPilJ478QaD/wAIazgaHYufKuhkuNj7v3Bkz5dwcP58SIn7vGaAOr+Ln7Pfw8+O2q+GNR8deFrfxRL4flkl02K6eZIoZZDG8nmRpJskR/Ki+SRH/UivhH/gp18Jvh58A7L4bfEn4fabo/gTx/puuobGx0WO1tIp4oPMn+0m02bHeKWOAb9n/LURyeZ+7CfSH7Qn7BsHxW+Jl78SPA3xK8S/CXx9qcUNlqepaPNI8d3bxxj5fLSSOQP+6t+kmz/Rx+73/PWT8E/+CeEfg34rQfEP4l/EXWPjL4k0uCOHQ7jxBFIP7OKu7iT95PKXdC2U5AjdpHxvKOgB9mW+fIG+vEvjN+xx8Iv2hfFMfiTx94V/t/V7ewj06Ob+0ruDZbpJJIE2QSxg/PI9e4Rp5a4p9AHyn/w7B/Zm8z5fhmv3P+g9qf8A8k18if8ABOPwxp/gz/go18cPDmjW4sdG0my1rTrG13Oxigi1e2jjj3vlzhE7n3r9Yf8AltX5Y/sC/wDKUz9oz/uZP/T5b0AfqjH/AKtafTI/9WtPoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK+YPjbqyXX7RXgiHxNoGv3HgPwna/8JNDJp3hq+1eK/wBbkMlvBv8As9lPs+yQfaJf9Yn7y4tz/wAs6+n6gdGOf9r/AG6APkb4D/Fi1tda8b+PvGnhz4h6R4p8YaiVXS5fAOvyHTNJtDJHp9sRHFPAH2eZcP5Z/wBZeSDtRd/FDTfDf7SFn448L+GPG1zpHijTjpHjCFfAWswSRSW4kk0/UB/xLPMlfHn2rjzOktvxsgNfXUcf7v56iljeR/4Mf9NKAPm39kfULrStL8YeBbXSvE1t4Y8L6iV8L6pr2hX+mfadMuE823tA98/nSmzfzLT+D93Fb+pr6ZX7v/2OKgkif7qN8n+/ViNPLXFAD6KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvz8+NH/KYr4H/APYmXP8A6I1mv0Dr8/PjR/ymK+B//YmXP/ojWaAP0BTpTqanSnUAFFFFABRRRQAUUUUAFFFFABRRRQBD/wAtq/LH9gX/AJSmftGf9zJ/6fLev1O/5bV+WP7Av/KUz9oz/uZP/T5b0AfqjH/q1p9Mj/1a0+gAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK/Pz40f8pivgf8A9iZc/wDojWa/QOvz8+NH/KYr4H/9iZc/+iNZoA/QFOlOpqdKdQAUUUUAFFFFABRRRQAUUUUAFFFFAEP/AC2r8sf2Bf8AlKZ+0Z/3Mn/p8t6/U7/ltX5Y/sC/8pTP2jP+5k/9PlvQB+qMf+rWn0yP/VrT6ACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAr8/PjR/ymK+B/wD2Jlz/AOiNZr9A6/Pz40f8pivgf/2Jlz/6I1mgD9AU6U6mp0p1ABRRRQAVBNceX/A5/wBwZo+1J5mxDvevz28bfHP9oD9pz4/eOfBv7P8AqmleBPDvw/mk03VtW8QpBJ9uuzNJADh4LghN8E+wRp9yOQyODJHGgB+hMdykkkiDrH1qSN/MXNfFH7In7Q3xF1z4o+OPgL8arezvfiJ4SH9ojxFp6QfZLyzLwbC6RiNA4FxbvGdgOw4dEkjPmfalvL50e+gCaoJLpIxIW42USXIjEh/uV+aPxS/4KBeMvFP7YHw+8K/DXV4bX4VyeLLPw/c61bWsdxF4hk+0Wn2uOO4kj4SPz9mIP+enmeY6SR7AD9MkkEnK0+oLfHk4/ufJTvM/ebKAE/5bV+WP7Av/AClM/aM/7mT/ANPlvX6lSSfvI3r8tf2Bf+Upn7Rn/cyf+ny3oA/VGP8A1a0+mR/6tafQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFfn58aP+UxXwP/AOxMuf8A0RrNfoHX5+fGj/lMV8D/APsTLn/0RrNAH6Ap0p1NTpTqACiiigCBox5yPsr4B/4I1fvP2Y/Fa/P/AMjnedH/AOnPT/46+/Ps4+1eafn7DP8ADX5beDfivN/wS/8Aid4+8B+OvC2qXPwo8T6jPrnhGTQVjudiFxHJGTPs3v5H2dJA8mY/s4+Qi48wgHqPxe/ef8Fg/gW+/wCf/hDrj+D/AKZ6xX3r9p8tAjIBJ/zz31+f37Kv9uftbftZa3+0hqvhm60z4f6Tp0mh+Dnv5Nl4rg4kkjSMYdMS3nmbzIEkuRHG8nlEx++/Fj9qaX4UftEfDH4WjwHrutjxmZP+J1ZIfItP3nl8Jj9/5ZJkn5Ty43jk/edKAPOv21vir4m8eXg/Z2+Dz2+pfEPxKnla8/l+ZBoujvGftElxJ0t3kEkfaR9kn8Eklvv8e/am+F2hfBD4p/sO+B/C6yLoWj+KZI4ZJ5fPkmL3+mySSOf77vJI/HA3/J2A9t+Nv/BM34YftBfE3WPiDrmveMLLV9W+zmWHSb20jt08iKOCPYHt3I+SMfx18W/tVf8ABPv4ffAr4ufAbwvoeqeKLzS/HWvf2VqlxfXUDy28f2mzjBgdLdESTFxL9/eOBxxyAfswmNny18T/ALZn7RPx/wDhD8VNK0P4V/Cn/hO/DF1pMdzdahJ4e1DUvJuHllR4t9vIMfu0jOP+mlfSXwH+DWjfs+/CvRPAfh+4v7vRtJE7W8mpNHJcfvJ5JnyY44wfnkPRBxgV6HJH+830Aflf/wAN3/tsSYdv2c1dh93f4H1v/wCSK53/AIJea7q/ij9vL4r6t4l0/wDsvxFqOjape6nZeU8f2e6k1OzkljMb8qUkL9elfrW6L5qJu5CY+9/n+5X5cfsC/wDKUz9oz/uZP/T5b0AfqjH/AKtafTI/9WtPoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvz8+NH/KYr4H/wDYmXP/AKI1mv0Dr8/PjR/ymK+B/wD2Jlz/AOiNZoA/QFOlOpqdKdQAUUUUAFQSRt99P9ZU9FAFT7O/z/PJ7fPUkkLScpMy1PRQAyOMRxhe1RyI330//bqeigBkcflin0UUAQ/8tq/LH9gX/lKZ+0Z/3Mn/AKfLev1O/wCW1flj+wL/AMpTP2jP+5k/9PlvQB+qMf8Aq1p9Mj/1a0+gAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK/Pz40f8pivgf/ANiZc/8AojWa/QOvz8+NH/KYr4H/APYmXP8A6I1mgD9AU6U6mp0p1ABRRRQAUUUUAFFFFABRRRQAUUUUAQ/8tq/LH9gX/lKZ+0Z/3Mn/AKfLev1O/wCW1flj+wL/AMpTP2jP+5k/9PlvQB+qMf8Aq1p9Mj/1a0+gAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK/Pz40f8pivgf/ANiZc/8AojWa/QOvz8+NH/KYr4H/APYmXP8A6I1mgD9AU6U6mp0p1ABRRRQAUVXe7jTCdW37Ntcd4z+L3gr4bfZF8X+LdE8K/bPMNomt6lBZ/aRHs3+X5jgOf3if9/B60AdzRXK+GfG+h+OtKtNW8O6tZa/o12X+z6lpt3HcW8nluUIR0fD/ADpJz/0zkFdVQAUVzHirxp4f8G6Jeax4i1ix0PSbEoLjUNRuEt7aLzCETfI/yDJkTv8Axis3wb8YPA/xIkvP+ER8XaH4qFkIzdvoupwXYt/MzsMnludmdh/KgDuaKjjcyJlk2exqSgCH/ltX5Y/sC/8AKUz9oz/uZP8A0+W9fqd/y2r8sf2Bf+Upn7Rn/cyf+ny3oA/VGP8A1a0+mR/6tafQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFfn58aP+UxXwP/AOxMuf8A0RrNfoHX5+fGj/lMV8D/APsTLn/0RrNAH6Ap0p1NTpTqACiiigCrJE++THR6/MT9l34M+Gv2/PiB8U/jR8UxfeK/DP8Aaz6H4X0m7vXtJbS2RvOxJHbH5Ckdxbj93JsLyXDuC+JK/T+STy253V8A/wDBH2RdB+A/jjw3fj7F4j0vxjOb/Sp1KXlkPs1vGPPg+/F88E6fOPvxv6GgDK+Begv+x/8At/ax8F9I1C/T4bePtFk1/QNGhn8+OwuxvffIzjMeEs7yMeX5m9Ps/mb9nyfotHGsa4QcV8AfEMjxF/wWB+FTaRjVf7D8ITpqpsz5g0zMWp48/Z/q8/aLf7+P+PiP/nolfe8tz9nH3HIL0AfPfx1/Y58AftJfEbRvFHj+61zVLbQrKSzj8OLqJt9K2yEu8jog3iU748vHIm/yIwfuc/I/xM+Fvgz9mj9uD4E6f+z9cXGka9q+pnSfFnh3StRkvzHYCS1mkNxA7ySRpJbzSufM+QJbxyJsMfmV+i3xD8K2HxG8EeIvCupS3Edjrmm3GlzPa4jnSOeMxvsL5w+x/Svze+MHweu/+CVuteGvil8NdZPiHwlql1HoetaL4lggkv5uJJcRXkcAeCIpGfuDiSCAuJ0+RAD9S7P/AI90+TZx0pZLpI5Ah60W58yP/V+XXy5+01+yh8RPjz47s9c8MfHvxN8LdJh06O0fRdGjuBFPIJJH89/LvIvnO9E+5n92KAPqORxG2/tX5Y/sC/8AKUz9oz/uZP8A0+W9eox/8E4vjOHH/GYnjz5f+md//wDLGvEv+Cafh+/8If8ABQb4xaHqOrXHiDUdI0rVrG71e5LiTUJI9UtI5LmTe7nfIRvPznnuaAP1tj/1a0+mR/6tafQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFfn58aP+UxXwP8A+xMuf/RGs1+gdfn58aP+UxXwP/7Ey5/9EazQB+gKdKdTU6U6gAooooArNb/vt4+n+7Xwx8TP2Lfiz4N+M3iL4jfs2/EHT/BMvi/zJvEek+IJJJ7b7UZfMM8W+3nV95eQ/vEzGXk8t9kmxPvCigD5N/ZM/ZF174Q+KPE3xK+IviSPxp8XfEQkhvdTimk+zQQeYjmKP93H98xx9Y8RokccfyIfM6v4t/B34s+LP2iPhn4q8J/ExvDHgHQzJ/bXh0RnF3zk/u8eXP5qYj/eY8jBkjy5r6HooA+Qf2gf2d/jvq3xNv8Ax38GPjPceHZNRjgt7nwn4kJm0mEBMPLArRzpG58uL5PIzvkkfzfn8uuC8A/sJ/E74nfE7TfF37UPjfS/iNa+H4SNF0LTwfsckryGSSS4j+zxpsGE+Ty/3uyNJD5cflyffdFADI9/8VPoooAh/wCW1flj+wL/AMpTP2jP+5k/9PlvX6nf8tq/LH9gX/lKZ+0Z/wBzJ/6fLegD9UY/9WtPpkf+rWn0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABX5+fGj/lMV8D/APsTLn/0RrNfoHX5+fGj/lMV8D/+xMuf/RGs0AfoCnSnU1OlOoAKKKKACiiigAooooAKKKKACiiigCH/AJbV+WP7Av8AylM/aM/7mT/0+W9fqd/y2r8sf2Bf+Upn7Rn/AHMn/p8t6AP1Rj/1a0+mR/6tafQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFfn58aP+UxXwP8A+xMuf/RGs1+gdfn58aP+UxXwP/7Ey5/9EazQB+gKdKdTU6U6gAooooAKKKhkm8v+BzQBNRRRQAUVBJdCOTZsYtQLn95Imxvk/WgCeimRyeYKfQBD/wAtq/LH9gX/AJSmftGf9zJ/6fLev1O/5bV+WP7Av/KUz9oz/uZP/T5b0AfqjH/q1p9Mj/1a0+gAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK/Pz40f8pivgf8A9iZc/wDojWa/QOvz8+NH/KYr4H/9iZc/+iNZoA/QFOlOpqdKdQAUUUUAQSXHl9f7+K+MfjV/wUCXwL8XLv4f/DD4dar8avE+nwvJraaHJIDpvlskfl/u7ed5Cjv+87RvJsyX3pH9jyx/6Qv75k3en+f9yvgj/gkex8XfDL4n/ETUHe48Y+JPGFx/bF8vyfaykEdwPkH7tP3l3cH5AP8AW+gTYAe0/sn/ALY3h79o601rSrjSbzwT8QfD9zLHrPg/UpvMuLSNJSnmJmNDIgf93J+7DxucPj927/TMfT7myvgPxhI/gH/gr94HXQcab/wm3hGQ+ITnzPtvlxXgT7/+r/5B9n/q8f6r/bff972+I4fk/wBX/BQB8dftJf8ABQbTvhH8WU+GHgnwD4g+KXxGgaOWfS9MaSOONHtzOQuI5JJJBH5b4SMoEk/1mQ6VifDH/go9BrnxW0v4ffEz4UeI/hPrniCe2t9KXUEklE7TySIDIrx28kYkkRI0dEf59+/YENfZC6XYRa1calFDbpqMtvFbT3KKPPkSOSR4kd/vbEMk+AeP3knvXwB/wVCh074wa78KPgjoGnm8+KOtazHe2lx9kYxWWmyefBI8ki73Ebunmv5YPyWheQDy0yAfo7H90U6o41Ea4CbK8P8AjR+2R8Iv2evFMHhvx74obQtUuLNNRjh/s27nzbvJJGH3wRuPvxv6UAe3f8tq/LH9gX/lKZ+0Z/3Mn/p8t6+pf+Hon7NHmf8AJSXx/wBgDU//AJHr5H/4Jy+J9P8AGf8AwUc+OHiHR7hbzRtXs9b1CzuArp5sEur20kb7X5HyEduKAP1kj/1a0+mR/wCrWn0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABX5+fGj/lMV8D/+xMuf/RGs1+gdfn58aP8AlMV8D/8AsTLn/wBEazQB+gKdKdTU6U6gAooooAoyfJcbv+WfVk2D/P8A+xX5ufsD/FDwv+y3r3xh+Bnj7xFY+Fr/AEXxNJqFhqniSb+y4tShPlQeYEcbIv3cEE6J5n7xLjj93Hvr9KZEbG5P9779eM/GH9kf4WfH7V9N1Lx94Qi16/0+3NnBefa7q3nEZBJjMkEsZkTJP3+mXx980AfK3w+8Vab+1B/wVAbxf4YmjufCHw18Nvp661ZJJc2epzuLiPy0l+RI+b+52H94JEs3dPkfKfZPib49+A/APxA8O+BfEnimy0vxZ4j50rS5ifNuM8DJ/wCWe9wUTzNnmOCib3Bqf4T/AAa8K/A3wpD4Z8E6PDoOhR3ElwbWJ3bzJX+9I8kkjvI/AT526BcfcAqt4s+Angbx34+8MeOfEHhax1PxZ4bbOmatLF+8t/QbOkgR8yR+Zv8ALc70waAPnj9tr9tgfCW8T4cfDq+0q6+LGpRuVudV1K3s9P0KPyy/mXElxJHB5+w/u4JD3jd/+WaS5X7LMfwR/Z70m88Q+KPjp4N8d/FvXYYzr3iy+8WW93M6qI8W1vJJL5ggTCdfnk8tHP3I44/YviR+wf8ABP4zeNNS8YeMvBK634m1Ix/bL4atf2+/y40jjHlxzhOEjQfhXMyf8Evf2adj7Phemf8AsYdU/wDkigD6ptv+PeP935X/AEz/ALleJ/Gb9jj4RftC+KY/Enj7wr/b+r29hHp0c39pXcGy3SSSQJsgljB+eR69wjjEcYXtT6APlP8A4dg/szeZ8vwzX7n/AEHtT/8AkmvkT/gnH4Y0/wAGf8FGvjh4c0a3Fjo2k2WtadY2u52MUEWr20cce98ucInc+9frD/y2r8sf2Bf+Upn7Rn/cyf8Ap8t6AP1Rj/1a0+mR/wCrWn0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABX5+fGj/lMV8D/+xMuf/RGs1+gdfn58aP8AlMV8D/8AsTLn/wBEazQB+gKdKdTU6U6gAooooAKKKKACiiigAooooAKKKKAIf+W1flj+wL/ylM/aM/7mT/0+W9fqd/y2r8sf2Bf+Upn7Rn/cyf8Ap8t6AP1Rj/1a0+mR/wCrWn0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABX5+fGj/lMV8D/+xMuf/RGs1+gdfn58aP8AlMV8D/8AsTLn/wBEazQB+gKdKdTU6U6gAooooAKKKKACiiigAooooAKKKKAIf+W1flj+wL/ylM/aM/7mT/0+W9fqd/y2r8sf2Bf+Upn7Rn/cyf8Ap8t6AP1Rj/1a0+mR/wCrWn0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABX5+fGj/lMV8D/+xMuf/RGs1+gdfn58aP8AlMV8D/8AsTLn/wBEazQB+gKdKdTU6U6gAooooAKgmuPL/gc/7gzR9qTzNiHe9fnt42+Of7QH7Tnx+8c+Df2f9U0rwJ4d+H80mm6tq3iFIJPt12ZpIAcPBcEJvgn2CNPuRyGRwZI40AP0JjuUkkkQdY+tSRv5i5r4o/ZE/aG+IuufFHxx8BfjVb2d78RPCQ/tEeItPSD7JeWZeDYXSMRoHAuLd4zsB2HDokkZ8z7Ut5fOj30ANkufKEjujBEpVuA/SvnT9qr9rbR/2YpPDljP4a17xd4q8ULcW+haboUCf6RcR+Xsid878yPPH/q0k/3PXyj/AIJ7fH34rfGrx58bdG+K2oW/9o+E9Ss7SHSo7aAQabNJJeJcQI8fzyYMQQb5JMbOtAH3TRTEXYlQy3Pl71RGkkH8FAD/APltX5Y/sC/8pTP2jP8AuZP/AE+W9fqVJJ84f/lnX5bfsD/8pTP2i/p4k/8AT5b0AfqhH/q1p9Mj/wBWtPoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvz8+NH/KYr4H/9iZc/+iNZr9A6/Pz40f8AKYr4H/8AYmXP/ojWaAP0BTpTqanSnUAFFFFAEDRjzkfZXwD/AMEav3n7Mfitfn/5HO86P/056f8Ax19+fZx9q80/P2Gf4a/Lbwb8V5v+CX/xO8feA/HXhbVLn4UeJ9Rn1zwjJoKx3OxC4jkjJn2b38j7OkgeTMf2cfIRceYQD1H4vfvP+CwfwLff8/8Awh1x/B/0z1ivvY3Hlx/c/ef8899fn5+yiNf/AGtv2sdb/aT1fwzc6d8PtH06TQ/BpvnCXSOG2PJHHHxIMS3rSb/MCPOI0eTysp798VP2ppPhX+0N8Mfha3gTXtbHjIyEa5YofKtf4PuJ/rzH/rJ+U8iN45P3nSgD6Fx5lwHR/L/9nr4G/wCCcq+X+1F+2X/y02eMY/8A0t1Wvva3/wCuf+rr4I/4J1/N+1B+2Tz5iSeMI3/30+26rQB+gSLsSviX9s7/AIa4/wCFqWH/AAoBm/4Q/wDsmD7Xn+yM/b/Mnz/x+fvP9X9n9q+14pUlj3o/mCm3Fv5mHUL5ifcNAH5Z5/4KXybPn8uP/f8ADFcv/wAEuP8AhJH/AG9vix/wmmP+Ev8A7F1f+2tvl/8AH7/aln9o/wBX8n+s3/c4r9cWhHnfN+8/36/Lb9gX/lKZ+0Z/3Mn/AKfLegD9UY/9WtPpkf8Aq1p9ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV+fnxo/5TFfA//sTLn/0RrNfoHX5+fGj/AJTFfA//ALEy5/8ARGs0AfoCnSnU1OlOoAKKKKACoJI2++n+sqeigCp9nf5/nk9vnomhnljwk3lyVbooApfZ/lcKEO/+D/YqVI2xj7n8X7urFFABRRRQBD/y2r8sf2Bf+Upn7Rn/AHMn/p8t6/U7y/32a/LH9gX/AJSmftGf9zJ/6fLegD9UY/8AVrT6ZH/q1p9ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV+fnxo/wCUxXwP/wCxMuf/AERrNfoHX5+fGj/lMV8D/wDsTLn/ANEazQB+gKdKdTU6U6gAooooAKKKKACiiigAooooAKKKKAKv/Lz/AJ/26/LX9gX/AJSmftGf9zJ/6fLev1O/5bV+WP7Av/KUz9oz/uZP/T5b0AfqjH/q1p9Mj/1a0+gAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK/Pz40f8pivgf8A9iZc/wDojWa/QOvz8+NH/KYr4H/9iZc/+iNZoA/QFOlOpqdKdQAUUUUAFFV3u40wnVt+zbXHeM/i94K+G32RfF/i3RPCv2zzDaJrepQWf2kR7N/l+Y4Dn94n/fwetAHc0VyvhnxvofjrSrTVvDurWWv6Ndl/s+pabdx3FvJ5blCEdHw/zpJz/wBM5BXVUAFFcz4q8ZaH4H0e91rxFrNloOk2hj87UtSuo4LePzJBHH5kj8JmR9nPc1m+DfjF4I+JH2r/AIRHxfofikWfl/av7F1KC78gP9zf5bnZ0P5UAdxRUcbmRMsmz2NSUAQ/8tq/LH9gX/lKZ+0Z/wBzJ/6fLev1O/5bV+WP7Av/AClM/aM/7mT/ANPlvQB+qMf+rWn0yP8A1a0+gAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK/Pz40f8AKYr4H/8AYmXP/ojWa/QOvz8+NH/KYr4H/wDYmXP/AKI1mgD9AU6U6mp0p1ABRRRQBVkiffJjo9fmJ+y78GfDX7fnxA+Kfxo+KYvvFfhn+1n0PwvpN3evaS2lsjediSO2PyFI7i3H7uTYXkuHcF8SV+n8knltzur4B/4I+yLoPwH8ceG78fYvEel+MZzf6VOpS8sh9mt4x58H34vngnT5x9+N/Q0AZXwL0F/2P/2/tY+C+kahfp8NvH2iya/oGjQz+fHYXY3vvkZxmPCWd5GPL8zen2fzN+z5P0WjjWNcIOK+APiGR4i/4LA/CptIxqv9h+EJ01U2Z8waZmLU8efs/wBXn7Rb/fx/x8R/89Er73lufs4+45BegD88Pj54fP7Xv/BQLR/grq99eRfDfwDo0eua7opn+zpf3Ozf+6MeS+UvLOP94U2ILjy9hf8Aecx+018G/Dn/AAT38f8Awv8AjR8MU1Lwr4ZbV49C8T6TZ3kl3Je2bkz+XGtx18yKC43iST5HjtzHswZK7/4cY8O/8Fgvik+pIum/254Nh/sj7WRB/amyDTc+QH/1mDb3H3P+faT/AJ5vUH/BYKU658C/AnhvT1+1+ItV8Y2gsNLtl8y9vcWl3H+6gx5j/vJ4078yR93FAH6Bxx+XHXC+Mfjb8Pvh1rUek+LfG/hnwxqbwfaEtdZ1a3tJXjOQJAkjg7Pkf/viu9SQScrXy7+0x/wT8+H37VXj6z8V+Lda8S6fqFnpselxw6LdQRxGOOWSQORJBIS+Z3/zzQB6R/w1h8Ed27/hcfgH/wAKew/+OV+f3/BPfUrTXv8AgpZ8e9T02+t9Q0++t9eurS7tZRJHNFJrFs6SI4++pGOenNeuf8OWfgj/ANDP4/8A/A+z/wDkOvEP+CZfg3T/AIc/8FCPjL4T055p9P0LTNY0u2kuCN7xwaraRpu/2sJQB+t0f+rWn0yP/VrT6ACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAr8/PjR/ymK+B/wD2Jlz/AOiNZr9A6/Pz40f8pivgf/2Jlz/6I1mgD9AU6U6mp0p1ABRRRQBWa3/fbx9P92vhj4mfsW/Fnwb8ZvEXxG/Zt+IOn+CZfF/mTeI9J8QSST232oy+YZ4t9vOr7y8h/eJmMvJ5b7JNifeFFAHyb+yZ+yLr3wh8UeJviV8RfEkfjT4u+IhJDe6nFNJ9mgg8xHMUf7uP75jj6x4jRI44/kQ+Z1fxb+DvxZ8WftEfDPxV4T+JjeGPAOhmT+2vDojOLvnJ/d48ufzUxH+8x5GDJHlzX0PRQB8n/tc/sj618XvFnhj4lfDTxP8A8IV8XPDZjjstSuJJFtLi1EjnyJMI+3/XznOx/MEkkciOjgx8D8MP2LPix4u+Neg/EX9o3x7Y+NH8ItHP4b0nw4WggjuhJvEsgS3gT5HSM4CEybIvMfZF5b/d1FAEcaeXGielSUUUAQ/8tq/LH9gX/lKZ+0Z/3Mn/AKfLev1Mkyku/ZvXFfjp+zj8dPA37Pv/AAUX+P3iXx/rw0PR7q91/T4p/sk9z5lw+rxyABII3P3I5Pbj3oA/ZCP/AFa0+vlCP/gqH+zN5ab/AImc/wDYB1P/AOR6k/4eifsx/wDRTf8Ayg6p/wDI1AH1XRXyp/w9E/Zj/wCim/8AlB1T/wCRqP8Ah6J+zH/0U3/yg6p/8jUAfVdFfKn/AA9E/Zj/AOim/wDlB1T/AORqP+Hon7Mf/RTf/KDqn/yNQB9V0V8qf8PRP2Y/+im/+UHVP/kaj/h6J+zH/wBFN/8AKDqn/wAjUAfVdFfKn/D0T9mP/opv/lB1T/5Go/4egfszyNGifEd5Hf7oj0HU/wD5HoA+q6K+U/8Ah6N+zH/0Uz/yg6n/API1L/w9E/Zj/wCim/8AlB1T/wCRqAPquivlT/h6J+zH/wBFN/8AKDqn/wAjUf8AD0T9mP8A6Kb/AOUHVP8A5GoA+q6K+VP+Hon7Mf8A0U3/AMoOqf8AyNR/w9E/Zj/6Kb/5QdU/+RqAPquivlT/AIeifsx/9FN/8oOqf/I1H/D0T9mP/opv/lB1T/5GoA+q6K+VP+Hon7Mf/RTf/KDqn/yNR/w9E/Zj/wCim/8AlB1T/wCRqAPquivlT/h6J+zH/wBFN/8AKDqn/wAjUf8AD0T9mP8A6Kb/AOUHVP8A5GoA+q6K+VP+Hon7Mf8A0U3/AMoOqf8AyNR/w9E/Zj/6Kb/5QdU/+RqAPquivlT/AIeifsx/9FN/8oOqf/I1J/w9G/Zj/wCimf8AlB1P/wCRqAPqyivlH/h6P+zH/wBFKP8A4IdT/wDkanf8PRv2Y/8Aopn/AJQdT/8AkagD6sor5U/4eifsx/8ARTf/ACg6p/8AI1H/AA9E/Zj/AOim/wDlB1T/AORqAPquivlT/h6J+zH/ANFN/wDKDqn/AMjUf8PRP2Y/+im/+UHVP/kagD6ror5U/wCHon7Mf/RTf/KDqn/yNR/w9E/Zj/6Kb/5QdU/+RqAPquivlT/h6J+zH/0U3/yg6p/8jUf8PRP2Y/8Aopv/AJQdU/8AkagD6ror5U/4eifsx/8ARTf/ACg6p/8AI1H/AA9E/Zj/AOim/wDlB1T/AORqAPquivlT/h6J+zH/ANFN/wDKDqn/AMjUf8PRP2Y/+im/+UHVP/kagD6ror5U/wCHon7Mf/RTf/KDqn/yNR/w9E/Zj/6Kb/5QdU/+RqAPquivlP8A4ekfsx/9FLP/AIINT/8Akaj/AIejfsx/9FM/8oOp/wDyNQB9WUV8qf8AD0T9mP8A6Kb/AOUHVP8A5Go/4eifsx/9FN/8oOqf/I1AH1XRXyp/w9E/Zj/6Kb/5QdU/+RqP+Hon7Mf/AEU3/wAoOqf/ACNQB9V0V8qf8PRP2Y/+im/+UHVP/kaj/h6J+zH/ANFN/wDKDqn/AMjUAfVdFfKn/D0T9mP/AKKb/wCUHVP/AJGo/wCHon7Mf/RTf/KDqn/yNQB9V0V8qf8AD0T9mP8A6Kb/AOUHVP8A5Go/4eifsx/9FN/8oOqf/I1AH1XRXyp/w9E/Zj/6Kb/5QdU/+RqP+Hon7Mf/AEU3/wAoOqf/ACNQB9V0V8qf8PRP2Y/+im/+UHVP/kaj/h6J+zH/ANFN/wDKDqn/AMjUAfVdFfKf/D0f9mT/AKKUf/BBqf8A8jUf8PRv2Y/+imf+UHU//kagD6sor5U/4eifsx/9FN/8oOqf/I1H/D0T9mP/AKKb/wCUHVP/AJGoA+q6K+VP+Hon7Mf/AEU3/wAoOqf/ACNR/wAPRP2Y/wDopv8A5QdU/wDkagD6ror5U/4eifsx/wDRTf8Ayg6p/wDI1H/D0T9mP/opv/lB1T/5GoA+q6K+VP8Ah6J+zH/0U3/yg6p/8jUf8PRP2Y/+im/+UHVP/kagD6ror5U/4eifsx/9FN/8oOqf/I1H/D0T9mP/AKKb/wCUHVP/AJGoA+q6K+VP+Hon7Mf/AEU3/wAoOqf/ACNR/wAPRP2Y/wDopv8A5QdU/wDkagD6ror5U/4eifsx/wDRTf8Ayg6p/wDI1H/D0T9mP/opv/lB1T/5GoA+q6K+VP8Ah6J+zH/0U3/yg6p/8jUn/D0P9mX5P+Lldf8AqA6n/wDI1AH1ZRXyp/w9E/Zj/wCim/8AlB1T/wCRqP8Ah6J+zH/0U3/yg6p/8jUAfVdFfKn/AA9E/Zj/AOim/wDlB1T/AORqP+Hon7Mf/RTf/KDqn/yNQB9V0V8qf8PRP2Y/+im/+UHVP/kaj/h6J+zH/wBFN/8AKDqn/wAjUAfVdFfKn/D0T9mP/opv/lB1T/5Go/4eifsx/wDRTf8Ayg6p/wDI1AH1XRXyp/w9E/Zj/wCim/8AlB1T/wCRqP8Ah6J+zH/0U3/yg6p/8jUAfVdFfKn/AA9E/Zj/AOim/wDlB1T/AORqP+Hon7Mf/RTf/KDqn/yNQB9V0V8qf8PRP2Y/+im/+UHVP/kaj/h6J+zH/wBFN/8AKDqn/wAjUAfVdFfKn/D0T9mP/opv/lB1T/5Go/4egfszyNGifEd5Hf7oj0HU/wD5HoA+q6K+U/8Ah6N+zH/0Uz/yg6n/API1L/w9E/Zj/wCim/8AlB1T/wCRqAPquivlT/h6J+zH/wBFN/8AKDqn/wAjUf8AD0T9mP8A6Kb/AOUHVP8A5GoA+q6K+VP+Hon7Mf8A0U3/AMoOqf8AyNR/w9E/Zj/6Kb/5QdU/+RqAPquivlT/AIeifsx/9FN/8oOqf/I1H/D0T9mP/opv/lB1T/5GoA+q6K+VP+Hon7Mf/RTf/KDqn/yNR/w9E/Zj/wCim/8AlB1T/wCRqAPquivlT/h6J+zH/wBFN/8AKDqn/wAjUf8AD0T9mP8A6Kb/AOUHVP8A5GoA+q6K+VP+Hon7Mf8A0U3/AMoOqf8AyNR/w9E/Zj/6Kb/5QdU/+RqAPquivlT/AIeifsx/9FN/8oOqf/I1J/w9G/Zj/wCimf8AlB1P/wCRqAPqyivlH/h6P+zH/wBFKP8A4IdT/wDkanf8PRv2Y/8Aopn/AJQdT/8AkagD6sor5U/4eifsx/8ARTf/ACg6p/8AI1H/AA9E/Zj/AOim/wDlB1T/AORqAPquivlT/h6J+zH/ANFN/wDKDqn/AMjUf8PRP2Y/+im/+UHVP/kagD6ror5U/wCHon7Mf/RTf/KDqn/yNR/w9E/Zj/6Kb/5QdU/+RqAPquivlT/h6J+zH/0U3/yg6p/8jUf8PRP2Y/8Aopv/AJQdU/8AkagD6ror5U/4eifsx/8ARTf/ACg6p/8AI1H/AA9E/Zj/AOim/wDlB1T/AORqAPquivlT/h6J+zH/ANFN/wDKDqn/AMjUf8PRP2Y/+im/+UHVP/kagD6ror5U/wCHon7Mf/RTf/KDqn/yNR/w9E/Zj/6Kb/5QdU/+RqAPquivlP8A4ekfsx/9FLP/AIINT/8Akaj/AIejfsx/9FM/8oOp/wDyNQB9WUV8qf8AD0T9mP8A6Kb/AOUHVP8A5Go/4eifsx/9FN/8oOqf/I1AH1XRXyp/w9E/Zj/6Kb/5QdU/+RqP+Hon7Mf/AEU3/wAoOqf/ACNQB9V0V8qf8PRP2Y/+im/+UHVP/kaj/h6J+zH/ANFN/wDKDqn/AMjUAfVdFfKn/D0T9mP/AKKb/wCUHVP/AJGo/wCHon7Mf/RTf/KDqn/yNQB9V0V8qf8AD0T9mP8A6Kb/AOUHVP8A5Go/4eifsx/9FN/8oOqf/I1AH1XRXyp/w9E/Zj/6Kb/5QdU/+RqP+Hon7Mf/AEU3/wAoOqf/ACNQB9V0V8qf8PRP2Y/+im/+UHVP/kaj/h6J+zH/ANFN/wDKDqn/AMjUAfVdFfKf/D0f9mT/AKKUf/BBqf8A8jUf8PRv2Y/+imf+UHU//kagD6sor5U/4eifsx/9FN/8oOqf/I1H/D0T9mP/AKKb/wCUHVP/AJGoA+q6K+VP+Hon7Mf/AEU3/wAoOqf/ACNR/wAPRP2Y/wDopv8A5QdU/wDkagD6ror5U/4eifsx/wDRTf8Ayg6p/wDI1H/D0T9mP/opv/lB1T/5GoA+q6K+VP8Ah6J+zH/0U3/yg6p/8jUf8PRP2Y/+im/+UHVP/kagD6ror5U/4eifsx/9FN/8oOqf/I1H/D0T9mP/AKKb/wCUHVP/AJGoA+q6K+VP+Hon7Mf/AEU3/wAoOqf/ACNR/wAPRP2Y/wDopv8A5QdU/wDkagD6ror5U/4eifsx/wDRTf8Ayg6p/wDI1H/D0T9mP/opv/lB1T/5GoA+q6K+VP8Ah6J+zH/0U3/yg6p/8jUn/D0P9mX5P+Lldf8AqA6n/wDI1AH1ZRXyp/w9E/Zj/wCim/8AlB1T/wCRqP8Ah6J+zH/0U3/yg6p/8jUAfVdFfKn/AA9E/Zj/AOim/wDlB1T/AORqP+Hon7Mf/RTf/KDqn/yNQB9V0V8qf8PRP2Y/+im/+UHVP/kaj/h6J+zH/wBFN/8AKDqn/wAjUAfVdFfKn/D0T9mP/opv/lB1T/5Go/4eifsx/wDRTf8Ayg6p/wDI1AH1XRXyp/w9E/Zj/wCim/8AlB1T/wCRqP8Ah6J+zH/0U3/yg6p/8jUAfVdFfKn/AA9E/Zj/AOim/wDlB1T/AORqP+Hon7Mf/RTf/KDqn/yNQB9V0V8qf8PRP2Y/+im/+UHVP/kaj/h6J+zH/wBFN/8AKDqn/wAjUAfVdFfKn/D0T9mP/opv/lB1T/5Go/4egfszyNGifEd5Hf7oj0HU/wD5HoA+q6K+U/8Ah6N+zH/0Uz/yg6n/API1L/w9E/Zj/wCim/8AlB1T/wCRqAPquivlT/h6J+zH/wBFN/8AKDqn/wAjUf8AD0T9mP8A6Kb/AOUHVP8A5GoA+q6K+VP+Hon7Mf8A0U3/AMoOqf8AyNR/w9E/Zj/6Kb/5QdU/+RqAPquivlT/AIeifsx/9FN/8oOqf/I1H/D0T9mP/opv/lB1T/5GoA+q6K+VP+Hon7Mf/RTf/KDqn/yNR/w9E/Zj/wCim/8AlB1T/wCRqAPquivlT/h6J+zH/wBFN/8AKDqn/wAjUf8AD0T9mP8A6Kb/AOUHVP8A5GoA+q6K+VP+Hon7Mf8A0U3/AMoOqf8AyNR/w9E/Zj/6Kb/5QdU/+RqAPquivlT/AIeifsx/9FN/8oOqf/I1Ryf8FRv2Y/8AopO//uA6n/8AI1AH1fRXyn/w9G/Zl/6KQ3/gg1P/AORqP+Ho37Mf/RTP/KDqf/yNQB9WUV8qf8PRP2Y/+im/+UHVP/kaj/h6J+zH/wBFN/8AKDqn/wAjUAfVdFfKn/D0T9mP/opv/lB1T/5Go/4eifsx/wDRTf8Ayg6p/wDI1AH1XRXyp/w9E/Zj/wCim/8AlB1T/wCRqP8Ah6J+zH/0U3/yg6p/8jUAfVdFfKn/AA9E/Zj/AOim/wDlB1T/AORqP+Hon7Mf/RTf/KDqn/yNQB9V0V8qf8PRP2Y/+im/+UHVP/kaj/h6J+zH/wBFN/8AKDqn/wAjUAfVdFfKn/D0T9mP/opv/lB1T/5Go/4eifsx/wDRTf8Ayg6p/wDI1AH1XRXyp/w9E/Zj/wCim/8AlB1T/wCRqP8Ah6J+zH/0U3/yg6p/8jUAfVdFfKn/AA9E/Zj/AOim/wDlB1T/AORqP+Hon7Mf/RTf/KDqn/yNQB9V1+fnxo/5TFfA/wD7Ey5/9EazXrH/AA9E/Zj/AOim/wDlB1T/AORq+aR8cvA37Qf/AAVW+DHiX4fa7/wkGk2vhu80951s57by7hLfVJCmydIz9yROelAH6fp0p1RxypNHvRt6etSUAFFFFABRRRQAUUUUAFFFFABRRRQBUFqfPeTv/BXzf4k/4J2/ADxp4k1fXta8AG91fWruW/v7k63qEfmzyOZJH8tJ9gy5zgV9N0UAfKn/AA67/ZlP3vhnn/uPan/8k0f8Ou/2Y/8AomX/AJXtU/8AkmvquigD5U/4dd/sx/8ARMv/ACvap/8AJNH/AA67/Zj/AOiZf+V7VP8A5Jr6rooA+VP+HXf7Mf8A0TL/AMr2qf8AyTR/w67/AGY/+iZf+V7VP/kmvquigD5U/wCHXf7Mf/RMv/K9qn/yTR/w67/Zj/6Jl/5XtU/+Sa+q6KAPlT/h13+zH/0TL/yvap/8k18h/wDBTD9j/wCEH7OPwM0LxH4B8Hf8I/q914lt9PmuhqV3cFoHtruR49k8roOYk5r9Z6+Hf+CtXgHxJ8SP2efDml+FPD+q+J9Vh8V29zLYaNZSXdwsX2O8QyeXHltmT196AK3wB/4J3/s9ePPgT8OfEmvfD/7brOteGtN1C9nGtahH588ttHJI+yO4A++57V6B/wAOu/2Y/wDomX/le1T/AOSa9Y/Zp0a88P8A7Ovws0rU7KfT9R0/wrpdrd2dxGUkhljtIkkjdOoYEHj2r1OgD5U/4dd/sx/9Ey/8r2qf/JNH/Drv9mP/AKJl/wCV7VP/AJJr6rooA+VP+HXf7Mf/AETL/wAr2qf/ACTR/wAOu/2Y/wDomX/le1T/AOSa+q6KAPlT/h13+zH/ANEy/wDK9qn/AMk0f8Ou/wBmP/omX/le1T/5Jr6rooA+VP8Ah13+zH/0TL/yvap/8k0f8Ou/2Y/+iZf+V7VP/kmvquigD5U/4dd/sx/9Ey/8r2qf/JNH/Drv9mP/AKJl/wCV7VP/AJJr6rooA+VP+HXf7Mf/AETL/wAr2qf/ACTR/wAOu/2Y/wDomX/le1T/AOSa+q6KAPlT/h13+zH/ANEy/wDK9qn/AMk1H/w67/Zmjkj/AOLa/wDle1P/AOSK+r6hkk/ebKAPxh/4Jafsz/DT9pRfiaPiJ4YTxANGOmfYP9NuLTyPM+2eZ/x7yR7/APVx9a++P+HXP7Mf/RM//K9qf/yTXz7/AMEffhZ44+Ff/C3P+Ev8G694VN+NJNqNa02Wz+0eX9s8zy/MCf8APSP86/SxOlAHyt/w67/Zj/6Jl/5XtU/+SaP+HXf7Mf8A0TL/AMr2qf8AyTX1XRQB8qf8Ou/2Y/8AomX/AJXtU/8Akmj/AIdd/sx/9Ey/8r2qf/JNfVdFAHyp/wAOu/2Y/wDomX/le1T/AOSaP+HXf7Mf/RMv/K9qn/yTX1XRQB8qf8Ou/wBmP/omX/le1T/5Jo/4dd/sx/8ARMv/ACvap/8AJNfVdFAHyp/w67/Zj/6Jl/5XtU/+SaP+HXf7Mf8A0TL/AMr2qf8AyTX1XRQB8qf8Ou/2Y/8AomX/AJXtU/8Akmj/AIdd/sx/9Ey/8r2qf/JNfVdFAHyp/wAOu/2Y/wDomX/le1T/AOSaP+HXf7Mf/RMv/K9qn/yTX1XRQB+Lf/BVL9mX4afs2L8L1+HXhn+wP7aOqHUD9turkzmL7J5YzPJJj/WydK++f+HXf7Mf/RMv/K9qn/yTXz7/AMFiPhX43+KH/Cp/+EQ8HeIPFf8AZ/8Aa32r+wtMnvfIEn2Py/M8tDs3+XJ1/uV+lSSCTlaAPlf/AIdd/sx/9Ey/8r2qf/JNH/Drv9mP/omX/le1T/5Jr6rooA+VP+HXf7Mf/RMv/K9qn/yTR/w67/Zj/wCiZf8Ale1T/wCSa+q6KAPlT/h13+zH/wBEy/8AK9qn/wAk0f8ADrv9mP8A6Jl/5XtU/wDkmvquigD5U/4dd/sx/wDRMv8Ayvap/wDJNH/Drv8AZj/6Jl/5XtU/+Sa+q6KAPlT/AIdd/sx/9Ey/8r2qf/JNH/Drv9mP/omX/le1T/5Jr6rooA+VP+HXf7Mf/RMv/K9qn/yTR/w67/Zj/wCiZf8Ale1T/wCSa+q6KAPlT/h13+zH/wBEy/8AK9qn/wAk0f8ADrv9mP8A6Jl/5XtU/wDkmvquigD4V+PX/BO79nvwL8C/iL4i0X4eLbato3hvUtQtJX1m/lEUsdvI6Pse42dUrz/9hX9hH4HfGf8AZR8FeMvF/gX+2PEepC++1Xn9q31v5vl39xHH+7jnRB8kaflX2n+01ptzrX7OnxT03TrWa+v9Q8Kapa2tpbo7yTyyWcojREHcnjivPf8AgnX4V1zwT+x34B0XxHo2oaBrVn/aH2jT9UtHt5499/cSJujcBx8jg8+tAGb/AMOu/wBmP/omX/le1T/5Jo/4dd/sx/8ARMv/ACvap/8AJNfVdFAHyp/w67/Zj/6Jl/5XtU/+SaP+HXf7Mf8A0TL/AMr2qf8AyTX1XRQB8qf8Ou/2Y/8AomX/AJXtU/8Akmj/AIdd/sx/9Ey/8r2qf/JNfVdFAHyp/wAOu/2Y/wDomX/le1T/AOSaP+HXf7Mf/RMv/K9qn/yTX1XRQB8qf8Ou/wBmP/omX/le1T/5Jo/4dd/sx/8ARMv/ACvap/8AJNfVdFAHyp/w67/Zj/6Jl/5XtU/+SaP+HXf7Mf8A0TL/AMr2qf8AyTX1XRQB8qf8Ou/2Y/8AomX/AJXtU/8Akmj/AIdd/sx/9Ey/8r2qf/JNfVdFAHyp/wAOu/2Y/wDomX/le1T/AOSa+QviV+yH8JfDn/BRz4V/Cyw8Ii18Ca14anv77TP7SvPnuEj1GTzPN8/zBzbwfx/wV+tFfDnxa8A+Jrz/AIKofB/xZb+HdXm8KWHhSeC716PT5XsrWTy9UHlyT48tD+9j6n/lonqKAO3X/gl7+zK/3/hn/wCV7U//AJJpf+HXf7Mf/RMv/K9qn/yTX1RG/mLmn0AfKn/Drv8AZj/6Jl/5XtU/+SaP+HXf7Mf/AETL/wAr2qf/ACTX1XRQB8qf8Ou/2Y/+iZf+V7VP/kmj/h13+zH/ANEy/wDK9qn/AMk19V0UAfKn/Drv9mP/AKJl/wCV7VP/AJJo/wCHXf7Mf/RMv/K9qn/yTX1XRQB8qf8ADrv9mP8A6Jl/5XtU/wDkmj/h13+zH/0TL/yvap/8k19V0UAfKn/Drv8AZj/6Jl/5XtU/+SaP+HXf7Mf/AETL/wAr2qf/ACTX1XRQB8qf8Ou/2Y/+iZf+V7VP/kmj/h13+zH/ANEy/wDK9qn/AMk19V0UAfKn/Drv9mP/AKJl/wCV7VP/AJJr5D/4KYfsf/CD9nH4GaF4j8A+Dv8AhH9XuvEtvp810NSu7gtA9tdyPHsnldBzEnNfrPXw7/wVq8A+JPiR+zz4c0vwp4f1XxPqsPiu3uZbDRrKS7uFi+x3iGTy48tsyevvQBW+AP8AwTv/AGevHnwJ+HPiTXvh/wDbdZ1rw1puoXs41rUI/Pnlto5JH2R3AH33PavQP+HXf7Mf/RMv/K9qn/yTXrH7NOjXnh/9nX4WaVqdlPp+o6f4V0u1u7O4jKSQyx2kSSRunUMCDx7V6nQB8qf8Ou/2Y/8AomX/AJXtU/8Akmj/AIdd/sx/9Ey/8r2qf/JNfVdFAHyp/wAOu/2Y/wDomX/le1T/AOSaP+HXf7Mf/RMv/K9qn/yTX1XRQB8qf8Ou/wBmP/omX/le1T/5Jo/4dd/sx/8ARMv/ACvap/8AJNfVdFAHyp/w67/Zj/6Jl/5XtU/+SaP+HXf7Mf8A0TL/AMr2qf8AyTX1XRQB8qf8Ou/2Y/8AomX/AJXtU/8Akmj/AIdd/sx/9Ey/8r2qf/JNfVdFAHyp/wAOu/2Y/wDomX/le1T/AOSaP+HXf7Mf/RMv/K9qn/yTX1XRQB8qf8Ou/wBmP/omX/le1T/5JqP/AIdd/szRyR/8W1/8r2p//JFfV9QySfvNlAH4w/8ABLT9mf4aftKL8TR8RPDCeIBox0z7B/ptxaeR5n2zzP8Aj3kj3/6uPrX3x/w65/Zj/wCiZ/8Ale1P/wCSa+ff+CPvws8cfCv/AIW5/wAJf4N17wqb8aSbUa1pstn9o8v7Z5nl+YE/56R/nX6WJ0oA+Vv+HXf7Mf8A0TL/AMr2qf8AyTR/w67/AGY/+iZf+V7VP/kmvquigD5U/wCHXf7Mf/RMv/K9qn/yTR/w67/Zj/6Jl/5XtU/+Sa+q6KAPlT/h13+zH/0TL/yvap/8k0f8Ou/2Y/8AomX/AJXtU/8AkmvquigD5U/4dd/sx/8ARMv/ACvap/8AJNH/AA67/Zj/AOiZf+V7VP8A5Jr6rooA+VP+HXf7Mf8A0TL/AMr2qf8AyTR/w67/AGY/+iZf+V7VP/kmvquigD5U/wCHXf7Mf/RMv/K9qn/yTR/w67/Zj/6Jl/5XtU/+Sa+q6KAPlT/h13+zH/0TL/yvap/8k0f8Ou/2Y/8AomX/AJXtU/8AkmvquigD8W/+CqX7Mvw0/ZsX4Xr8OvDP9gf20dUOoH7bdXJnMX2TyxmeSTH+tk6V98/8Ou/2Y/8AomX/AJXtU/8Akmvn3/gsR8K/G/xQ/wCFT/8ACIeDvEHiv+z/AO1vtX9haZPe+QJPsfl+Z5aHZv8ALk6/3K/SpJBJytAHyv8A8Ou/2Y/+iZf+V7VP/kmj/h13+zH/ANEy/wDK9qn/AMk19V0UAfKn/Drv9mP/AKJl/wCV7VP/AJJo/wCHXf7Mf/RMv/K9qn/yTX1XRQB8qf8ADrv9mP8A6Jl/5XtU/wDkmj/h13+zH/0TL/yvap/8k19V0UAfKn/Drv8AZj/6Jl/5XtU/+SaP+HXf7Mf/AETL/wAr2qf/ACTX1XRQB8qf8Ou/2Y/+iZf+V7VP/kmj/h13+zH/ANEy/wDK9qn/AMk19V0UAfKn/Drv9mP/AKJl/wCV7VP/AJJo/wCHXf7Mf/RMv/K9qn/yTX1XRQB8qf8ADrv9mP8A6Jl/5XtU/wDkmj/h13+zH/0TL/yvap/8k19V0UAfCvx6/wCCd37PfgX4F/EXxFovw8W21bRvDepahaSvrN/KIpY7eR0fY9xs6pXn/wCwr+wj8DvjP+yj4K8ZeL/Av9seI9SF99qvP7VvrfzfLv7iOP8Adxzog+SNPyr7T/aa0251r9nT4p6bp1rNfX+oeFNUtbW0t0d5J5ZLOURoiDuTxxXnv/BOvwrrngn9jvwDoviPRtQ0DWrP+0PtGn6paPbzx77+4kTdG4Dj5HB59aAM3/h13+zH/wBEy/8AK9qn/wAk0f8ADrv9mP8A6Jl/5XtU/wDkmvquigD5U/4dd/sx/wDRMv8Ayvap/wDJNH/Drv8AZj/6Jl/5XtU/+Sa+q6KAPlT/AIdd/sx/9Ey/8r2qf/JNH/Drv9mP/omX/le1T/5Jr6rooA+VP+HXf7Mf/RMv/K9qn/yTR/w67/Zj/wCiZf8Ale1T/wCSa+q6KAPlT/h13+zH/wBEy/8AK9qn/wAk0f8ADrv9mP8A6Jl/5XtU/wDkmvquigD5U/4dd/sx/wDRMv8Ayvap/wDJNH/Drv8AZj/6Jl/5XtU/+Sa+q6KAPlT/AIdd/sx/9Ey/8r2qf/JNH/Drv9mP/omX/le1T/5Jr6rooA+VP+HXf7Mf/RMv/K9qn/yTXyF8Sv2Q/hL4c/4KOfCv4WWHhEWvgTWvDU9/faZ/aV589wkeoyeZ5vn+YObeD+P+Cv1or4c+LXgHxNef8FUPg/4st/DurzeFLDwpPBd69Hp8r2VrJ5eqDy5J8eWh/ex9T/y0T1FAHbr/AMEvf2ZX+/8ADP8A8r2p/wDyTS/8Ou/2Y/8AomX/AJXtU/8AkmvqiN/MXNPoA+VP+HXf7Mf/AETL/wAr2qf/ACTR/wAOu/2Y/wDomX/le1T/AOSa+q6KAPlT/h13+zH/ANEy/wDK9qn/AMk0f8Ou/wBmP/omX/le1T/5Jr6rooA+VP8Ah13+zH/0TL/yvap/8k0f8Ou/2Y/+iZf+V7VP/kmvquigD5U/4dd/sx/9Ey/8r2qf/JNH/Drv9mP/AKJl/wCV7VP/AJJr6rooA+VP+HXf7Mf/AETL/wAr2qf/ACTR/wAOu/2Y/wDomX/le1T/AOSa+q6KAPlT/h13+zH/ANEy/wDK9qn/AMk0f8Ou/wBmP/omX/le1T/5Jr6rooA+VP8Ah13+zH/0TL/yvap/8k18h/8ABTD9j/4Qfs4/AzQvEfgHwd/wj+r3XiW30+a6GpXdwWge2u5Hj2Tyug5iTmv1nr4d/wCCtXgHxJ8SP2efDml+FPD+q+J9Vh8V29zLYaNZSXdwsX2O8QyeXHltmT196AK3wB/4J3/s9ePPgT8OfEmvfD/7brOteGtN1C9nGtahH588ttHJI+yO4A++57V6B/w67/Zj/wCiZf8Ale1T/wCSa9Y/Zp0a88P/ALOvws0rU7KfT9R0/wAK6Xa3dncRlJIZY7SJJI3TqGBB49q9ToA+VP8Ah13+zH/0TL/yvap/8k0f8Ou/2Y/+iZf+V7VP/kmvquigD5U/4dd/sx/9Ey/8r2qf/JNH/Drv9mP/AKJl/wCV7VP/AJJr6rooA+VP+HXf7Mf/AETL/wAr2qf/ACTR/wAOu/2Y/wDomX/le1T/AOSa+q6KAPlT/h13+zH/ANEy/wDK9qn/AMk0f8Ou/wBmP/omX/le1T/5Jr6rooA+VP8Ah13+zH/0TL/yvap/8k0f8Ou/2Y/+iZf+V7VP/kmvquigD5U/4dd/sx/9Ey/8r2qf/JNH/Drv9mP/AKJl/wCV7VP/AJJr6rooA+VP+HXf7Mf/AETL/wAr2qf/ACTUf/DsD9maOT5Phl/B/wBB7VP/AJIr6vqBpCJsH7lAH4yfsm/sz/Df4m/t2fGj4ceJ/C6at4R0EawNPsZL64jeH7PqkFvF+8jkD/6tz1Nfe3/Dr39mOT5/+Fa7/wDuPan/APJNfPn7Ffwz8Y+F/wDgoz8dvE2s+FNd0Xw3q4142Orahps9vaXfmaxBJGY5HQI+UBNfpbH90UAfK3/Drv8AZj/6Jl/5XtU/+SaP+HXf7Mf/AETL/wAr2qf/ACTX1XRQB8qf8Ou/2Y/+iZf+V7VP/kmj/h13+zH/ANEy/wDK9qn/AMk19V0UAfKn/Drv9mP/AKJl/wCV7VP/AJJo/wCHXf7Mf/RMv/K9qn/yTX1XRQB8qf8ADrv9mP8A6Jl/5XtU/wDkmj/h13+zH/0TL/yvap/8k19V0UAfKn/Drv8AZj/6Jl/5XtU/+SaP+HXf7Mf/AETL/wAr2qf/ACTX1XRQB8qf8Ou/2Y/+iZf+V7VP/kmj/h13+zH/ANEy/wDK9qn/AMk19V0UAfKn/Drv9mP/AKJl/wCV7VP/AJJo/wCHXf7Mf/RMv/K9qn/yTX1XRQB8qf8ADrv9mP8A6Jl/5XtU/wDkmj/h13+zH/0TL/yvap/8k19V0UAfKn/Drv8AZj/6Jl/5XtU/+Sa6L4Z/sI/BL4O+MtL8W+D/AAT/AGN4k04yfZboaxfy+V5kbxSDZJO6HMcknbvX0TRQA1OlOoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACoPK8xpA3MbikmufL+VUeRvRBTvtH/AEzb8qAHp8kfzGn1D9o/6Zt+VPSQScrQA+iiigAooooAKKKKACiiigAooooAKKKKACoHjDuH/wDZqnooApiOSXO9z8//ADzf7lWY08tcVFJdLH9B9/n7lWKACiiigAooooAKKKKACiiigAooooAKKKKACiiq8lwkWS/RP46AHSB/4Hp8e/8AiqP7Sn/PN/8Avil+0Bvu80ATUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVD5n7zZsoASTzNsmxU8z+DNSp0psMnmJuK7PrUf2qNZJEPVE3vQBYoqD7Smzf5b4/3Kkjk8wUAPooooAKKKKACiiigAooooAKKKKACiioftKeZ5f8AH6UATVXkjaQ4/g/3qdJdJH1pJLny/wDlm5/CgCVOlOqD7R8ufLf8qj+3JtxtPmf88+9AFuimRyeYKfQAUUUUAFFFFABRRRQAUUUUAFFFVpLqPzzB9+XZv2UAWag8rzGkDcxuKPtCf7X5UfaUP3P3n0oAkT5I/mNPqD7Un+3/AN80v2lPM2d6AJqKZHIJIw3an0AFFFFABRRRQAUUUUAFFFFABRRRQAVA8Ydw/wD7NSfao1kkQ9UTe9L9pTZv8t8f7lAEQjklzvc/P/zzf7lWY08tcURyeYKikulj+g+/z9ygCxRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRUMtzHbj949I1wkfB+/QAsgf8Agenx7/4qiW4VfL3rseTtSrcrJHvVXI+lAE9FQ/aP+mbflT45BLHuXmgB9FFFABRRRQAUUUUAFFFFABRRRQAUVDNcpb/fOKPtKeZs70AJJ5m2TYqeZ/BmpU6VElykmzG75+lNW7R9/DfKm/laALNFQfaU2b/LfH+5UkcnmCgB9FFFABRRRQAUUUUAFFFFABRRRQAUUVF5kdAEtV5I2kOP4P8AepBeR/mdqc/fp32hP7tAEqdKdUH2j5c+W/5VH9uTbjafM/5596ALdFMjk8wU+gAooooAKKKKACiiigAooooAKKKKACoPK8xpA3Mbijzv3mz5/wDvil+0f9M2/KgB6fJH8xp9Q/ak9aPtKeZs70ATUUyOQSRhu1PoAKKKKACiiigAooooAKKKKACiiigAqDy28zfj/wAeqeq8l0sf0H3+fuUARxxvGEQbZI/96rMe/wDip9QyXSRyBD1oAmopqtvFOoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOY8aeINO8E+F9a8Ratd/YNI0uzlvr24KF9kEEfmSfJ/H8iSe9fmj8Av2R7n/AIKGaLqfxs+OPibXo7nWruS10LT/AA7NbxW8FjAZEITzBPsjEm+NI/kfMUkjmQy76+9/2rJEX9mv4vOJMunhHWD/ALn/ABL7ivKf+CYsO/8AYb+HGd/mKmpo+Hx/zFLygDz79gfxl4s8B/Er4jfs3+O9eOqaj8P/ACpPDc7QYuLjSHABzIHdEjxLYSRxl/Mj+0bOUj2R/d9v+7t0FfAfwf2f8Pg/jom75G8HWZ/8haPX33bbPITY/mR9jQBPRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABUP2lPM8v+P0qavz5/wCClP7R9lot9pPwFbVV8F2fiuzj1DX/ABrcW9xOmm6YZZEZIIIP3kskht3jI4TZJsP+sLxgHy3/AMFBfjr4h/ai0NvHXhi5uo/gf4c1uPw1ZR3TBf7V1NoJbiTUBBsDooi2IPN5CSDZgyTon7SW+BH8p31+On7a3x8+A/iD9kPwH8KvhD4pOsHwzqto6Wx0mezMkEdncxyXMnmW8cbySSSZcjkvI74r9Q/gn8d/A3x+8NXXiDwDrkmv6PBevp8119lntws4SOQpieNHOEkj5HHIoA9OopkcnmCn0AFFFFABRRRQAUUUUAFFFFABRRRQAV578b/F998OfhD478W6WIf7Q0PQdQ1SCOdNyPLBbySR78c7Mx/rXoVeQ/tDfGyy/Z7+D3ib4h32nTaxa6JEki6faukUk0kkscEALn7qGSTBk7Ju+RyKAPz++Av7BOj/ALZ3wd/4XF8RPH/iS6+IXjCbULhbqNYDbwGOd7ePzIvLzIAYf9XHJGPLxGmzy819K/8ABMv4xeMPjP8As2HUfF98mt6tomqPosF9IgNxdW8cEEkf2iTP7yT9+6eZx9zL5feT8tfBv9gf4o/Er4C3vibRviR/wqDR/F1qby1+HegXV/Jpdzby2qeW93I95IU+0R4Zw4nKI44z+5T6V/4J0/Ff/hIfAviT4V3Xg238A658NdTk0/UNM0m5kuLOKSe5uZMxyS3EsnEsVwjpvcdGSTY+yMA+1osbPl2/8A6VJUVv/q6loAKKKKACiiigAooooAKKKKACiiigAr4A/bgh/aE8eD4p+HLSLS/CHwR0zQp9XfxFZvv1TVYoLFJ5bDHnkoJLj92f3cf7sH/WDKSff9eSftXZ/wCGYPjP/wBiVrH/AKRXFAHl3/BLz5f2GPhmPfU//TpeVzX7QX7Cuv8A7TXxyn1Txl8T9Rj+FkMFu9j4N0uPZJHcJFKknzvmPO+QSeeY5JD9okj/AHYjRz03/BLn/kxX4Z/9xP8A9Ol3Xu/xI+IWh/C/wjqvirxNqcOkaJpaefcXlw+1IxkDqM/OT8iJ1dyEHLigD8yvjx8A9R/4Jj634O+Kfwv8X+IL3wjPrlvY674b1O/QPqBEc8mJNkHlvG8AuI8yR74HJdN+/wDd/rHb48mPy/uYr89vD+jax/wUo+LXhrx3e2mr+HP2efCc8V3pui6ytuz+JNTjf95J9n+dPs6f6mTLyKQjpHh5Z/L/AEJt87Bv+/QBNRRRQAUUUUAFFFFABRRRQAUUUUAFeW/HrWviDoHwv1y/+GWj2niHx2hgTS9J1N0S3nJlj8znzI/+WfmP/rP+WdepVUkjf7RvR/4KAPyo8A+H/iVoP/BTj4Pah8W9di1Dxp4i8P3es3Gn2IP2fRYzaanHHYRYP/LNI+dn/LSR/wDWf6x/0W+MnxI074K/C3xd4yvhatDoemzX4tZLpLVLu4RP3dv5nZ5H2R52dZEwD0PyX8Zv+Ux3wL/7Eu4/9FaxXqX/AAU+Z4/2I/iS7f6sf2Yf/KpZ0AfHfg39l3wN8bPDuifET9qj4+y6b408X6amsabpN9r1hYSWFhJPO8Xl/aHkzBKH8yNI440jxIlfoD+zV+zzZ/sz/DOTwTp/ibWPEul/2leX9u2suGNrG8uVgjROiAAbx0eSSWT5PM2D5j/Z7/4Jw/Cb4ifs9+Edd8fRap4w8XeJ9As78a1LqU9vLYRyWcfkW9uiSeX5dvH5aR+Ykn+r6eXsjSb/AIJg6pr3hO8+N3wZu9R/t3T/AIfeIvs+nXVwjh2Lz3EcgA8x0jjL2nmhB9ySeUkvmgD7/tuYfM+V9/z/ACd6sUxG3oKfQAUUUUAFFFFABRRRQAUUUUAFcz4w0fVNY8L6vp2kaqND1i7tXisNW+zJcfYZzH+6uPIk+STy5AH2HriumqB7iOLO87AtAH526H/wSN8PeKrdtW+MHxP8XeL/AB5eeU93f6ddR+Uv7iOMReZcRyyT+XsIEhKZj8v92mKtfsG6342+D/7SXxJ/Zx8Y+JLjxfZeGdOg1TRtSkndvsUEYt40t443DuiPBd2/7vzNkTxuI9+/zD77+03+114S/Zsl0vS7jTr/AMVeONfPl6V4P0ZUkurqR8pF5n9yOSXEe/Du5z5aSeW+zmf2Lv2bPE/wrm8Q/EP4p60fEHxm8abZtXuJI43OnW6ci0jkQc/8s9/l/uv3cEcY2RpI4B82eCfg3L/wU9+KXj7xv458Vasnws8MahJ4f8Hw+HTHAlxHvEhk8ucSOknkCB5C8e9zPHgp5Hl13n7Kv/CRfsm/tZa3+zdqfiCa+8A6rp0mt+DBqNuJLgyZ8wx7ovkjGyK88zfs3yWnmJ5fn/vLP/BGMZ/Zb8T7lV/+K0uP/SPT6X4xyeX/AMFhvgXn5B/whdx/q2/6ZaxQB9/23/HvH9Kmpsf3RTqACiiigAooooAKKKKACiiigAooooA+Lv2gv2Fdf/aa+OU+qeMvifqMfwshgt3sfBulx7JI7hIpUk+d8x53yCTzzHJIftEkf7sRo5+Z/jx8A9R/4Jj634O+Kfwv8X+IL3wjPrlvY674b1O/QPqBEc8mJNkHlvG8AuI8yR74HJdN+/8Ad/pr8SPiFofwv8I6r4q8TanDpGiaWnn3F5cPtSMZA6jPzk/IidXchBy4r4l0HS9X/wCCknxW8M/EHUbTVvDn7O3hOe3udP0XWUgZ/EmqJJ+8kMHzp5A/1D5eQYSRI8PLP5YB+gdvKkcccfSTH+rr8YP+Cgvx18Q/tRaG3jrwxc3UfwP8Oa3H4aso7pgv9q6m0EtxJqAg2B0URbEHm8hJBswZJ0T6i/4KRftJWmh3mlfAV9S/4Qmz8VWcd/4g8aXkFxOmm6YZ5Y3jgggzJJJJ9nePHCFH2f8ALQvH87ftrfHz4D+IP2Q/Afwq+EPik6wfDOq2jpbHSZ7MyQR2dzHJcyeZbxxvJJJJlyOS8jvigD9i7fAj+U76mrzH4LfHbwN8fvDd14g8Baw+v6Pa3UllNefZZ7fZOEjkKfv0Rz8kkfI9RXpccnmCgB9FFFABRRRQAUUUUAFFFFABRRRQB5d8evB3i34gfCXxNoXgXxMfCfiq+tDDYa0R/wAe78b+esfmIHj82P54/M8xOa+On/4I7+DNT0m+n8RfELxdrnji68+efXj9njtbi5keRxJJA4eeTqPMzcZk5+dM/J+iEl0kfWvk39qT9sCHwJr0nwg+HdpfeMfjhrtl5ekafpMcLjSriRf3c948mUTZHmfyzGfkjzJ5ccnmUAcb/wAE4fiZ46161+Kvww+Ieq3XijXfhvrn2H+3bm9kuXnSSWeOSJZHj8x0jks5XR5Dv/eInyCMV4D+zX+zbaf8FMo/GHxh+MPivX21VtVOjWem6DJBb2+nQxQRy+XH5scp8v8A0gBEGMeXI7vI8hNfXPwD+DFr+xD+z94x8S+KNRuPF/iopc+LPFWuW6+ZcXskcRkkjSSTY86IPM2ee/zvJJJ8nmbE+UfgH+zj8Sf2rrjxX8avC/jOb9nPR/F+pTXEVl4TvL67k1Z1uLh5Lm7P2yMb0kkeMYCITvIjj/jAPZf+CbPjPxdb3fxi+D2ua7L4l034XatHoekarKnl3At/MvIvLfMhxEPsibEyXj8zy9+xE2feVtH5cCCvz4/4J5+Irv4S+OPH37NHiDwfYeGvFPhrGtzX+g3089pqKmK0iNxJ5kkjpJIj28g2bExIf3cDx/P+hK/d/wDscUASUUUUAFFFFABRRRQAUUUUAFFFFAEDRvu42f8AfFfFfxQ/4J0237Q3xC8QeI/ih8W/FXiSzuLiSbQdH0+KOzt9GgkkGYkEnnp/q44EMkaRl/K3vvL19pyXHlvs2SSfRK8b/aW+DPiX45+CdN0Twp8SdX+FmqW+opfS6voySCaaPy5IzATHLH/fH8f8AoA+XP2JZvEPwH/a0+K/7NVp4jn13wB4e07+39J/tO3zcWTubSTy0wf9Xi8w4HDyRiRBGZJM9/8AtBfsI69+018bptU8Y/FPUl+FsNvb/YfB+mxeXJHcJDJHId774wRJIJPtBjkkPnyR/II0c+U/sbrd/sa/tH337NniLwrpNw/iWOTV9I8Z6QjpcarHGk8qPe+ZI+xBHBPGkcePLkjfiTzTOfu/xv468O/CfwPqnifxTfRaLoWmg3N3d3TkovPHIz85OESPu5REySlAH5m/Hj4B6j/wTH1vwd8U/hf4v8QXvhGfXLex13w3qd+gfUCI55MSbIPLeN4BcR5kj3wOS6b9/wC7/WO3x5Mfl/cxX57eH9G1j/gpR8WvDXju9tNX8Ofs8+E54rvTdF1lbdn8SanG/wC8k+z/ADp9nT/UyZeRSEdI8PLP5f6E2+dg3/foAmooooAKKKKACiiigAooooAKKKKACvGP2j/hf4p+MHgNPDfhL4l6h8Lrye8jkm1bSrMy3DxxxtmBCkkbx/P5b70fP7vZ0c17PVS4xIroRv4/1f8AfoA/LP8AaQ/YI8PfsY/Cy8+M/wAK/G/izS/FfhW6s7i3kvrm3uY3SS4S3kj2RwR/89xnf5iOnmRun7zI+3P+F+Dw/wDsk2Xxk8QLYRXTeDofEc2npP8AZLee7ks0kFvG8m/ZvlkEaZ3n50+/XyH+1z+xr480nUNf+Nj+NLX4xWHhrUbzxLb+AfHEdw2n2Ng5kmlSP/TMSJH5cR8r92kiW/R/9W/dftUfGK1+PX/BL/XviDaadcabaa7a2LPa3EwkMEseswRvHkfIR5iS/vMJkBPkB+RADwrwb+y74G+Nnh3RPiJ+1R8fZdN8aeL9NTWNN0m+16wsJLCwknneLy/tDyZglD+ZGkccaR4kSv0B/Zq/Z5s/2Z/hnJ4J0/xNrHiXS/7SvL+3bWXDG1jeXKwRonRAAN46PJJLJ8nmbB8x/s9/8E4fhN8RP2e/COu+PotU8YeLvE+gWd+Nal1Ke3lsI5LOPyLe3RJPL8u3j8tI/MST/V9PL2RpN/wTB1TXvCd58bvgzd6j/bun/D7xF9n066uEcOxee4jkAHmOkcZe080IPuSTykl80Aff9tzD5nyvv+f5O9WKYjb0FPoAKKKKACiiigAooooAKKKKACovM/ebKlrjPiN40s/h74H8SeLdSha4sPD+m3GqXCW/+vdII3kcJ74R6APGf2vf2mD8FvCWk6F4StZtT+JnjmeTR/CVrbmJY/tj+XH57yS/uwkbzwPh/wDWGSMfcMjx/NX/AASn0HVPC/xM/aW0HxPejWPEOn63YWWpX/mPN9ruo59TEsnmSfPJvdCcvyc89a4r9nz9q/4O698cvEvx7+MHj620nxhqEEmnaD4Rh0nUL+Lw9p/TcJzbuvnyZk/1WExPPx+/8uO/+wT+018N/D37UPx7/tHxG1n/AMLJ8YW//CKn7Ddn+0vNvL0x/wDLP93/AMfNv/rPL/1h9KAJvBvwdn/4Ke/FH4h+PPHPi3WF+FnhjUZNA8Hx6AIrbz0EgkeXZPveM+R5Lyb498hnTn9x5dd/+yr/AMJF+yb+1lrf7N2p+IJr7wDqunSa34MGo24kuDJnzDHui+SMbIrzzN+zfJaeYnl+f+8s/wDBGX5v2XfE7FFfd40uPv8A/Xnp9L8Y5PL/AOCw3wLz8g/4Qu4/1bf9MtYoA+/7b/j3j+lTU2P7op1ABRRRQAUUUUAFFFFABRRRQAUUUUAQPcIJPLz89fi5/wAFBfjr4h/ai0NvHXhi5uo/gf4c1uPw1ZR3TBf7V1NoJbiTUBBsDooi2IPN5CSDZgyTon1J/wAFJv2kLLQNQ0n4ENqcfgqz8V2cd74g8a3FvcTppumGWWMxwW8H7ySSTyJIz0TZJs/5aF4/nT9tb4+fAfxB+yH4D+FXwh8UnWD4Z1W0dLY6TPZmSCOzuY5LmTzLeON5JJJMuRyXkd8UAfsN9pSKNPvyV+VX/BRb4665+0BpvxB8PeBpruy+HfwvkgTxvdySiD+07+a8jt7azSIp5jiCQTv8/wC73pIf+WcDyer/ALVv/BRfwZ/wpm1j+FOvLfzeNLu88PR+KrmO8srbQvLjtzcXJAjFx5kcd5GU8uP3+cxiN/DPil8b/wBnbwT/AME+db+C/wAN/G8fiTXrgWc8k8mh3dnLqd59vt5555N9uicRxnZ5j58uOOPL7BkA/SL9kuPZ+yz8Hdv/AEJ2j/8ApFFXrVfMP7Cvx68EfFL4E+DvDfhXXf7V1nwb4b0fT9ctfsc8X2Sb7J5YTfJGiP8APBKPk3/c9xX04rbxQA6iiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCuEcsc7Hj/gr82vCfwY/am/Yn17xR4S+B2gaH8SPhtqF5/a9hL4glt45rWQp5bxyZubc+ZiOPeRmM7I3QRl5I6/S2oPL+b1/9koA+T/2Gf2Y/FXwN0Pxh4t8f6suofEv4gXkesa7awmP7PaS75ZPL/dpgyF7iQyPH+7GQiDEYkf6ziVgvzNvPriiNPLjRPSpKACiiigAooooAKKKKACiiigAooooAKKKKACvO/GfwR+H/AMRtbXVfFngjw34nv4YEt4rzW9JgvZY4g7v5Y8yM7E+c/ma9EooA+Bv2+v2JbPxx8I9E0z4LfCjw5B4vTXo7i6Gj2lhpcj2YguPMDyHywyeYYPk3/wDPPjivsXwb8OvDHgHT5LTwl4e0nwtp00n2h7LRLKO0ieTCDzNkY2MdiIM47V1skfmL9wSf9dKlTpQBHHF5ceypqKKACiiigAooooAKKKKACiiigAooooAK8t+Pfwf0748fCvxX4F1SbyrLWrQ28dxs8z7PcZR4JymU3+XKkcnl78PjFepUUAfmZ4N8N/t3/ADwRL8NfDWgeG/GGladbfZNI8SvfwXElojxR4SA3FxAdkB3bBcQPgjZ88WwV9EfsP8A7K2p/s0+FfEs3ijWIPEnj/xVfte63rdrdXEok8sny4jJIPnfc9xI8hRHJnIO/wAsPX1JJvw+wc/79Sp0oAE6U6iigAooooAKKKKACiiigAooooAKKKKACvMv2iPDupeMPgX8SPD2jWgu9W1rw1qGnWUW9E82eW3ljjj+f1L/AM69NqHy38zfQB8//sG/DHxN8G/2V/BXg7xhpp0XxDpv29bqxM8dx5fmX08qfvI3dD8kidCa+Wv25vgx+0h8cvjd9n0r4d2njX4R6H5cul6Jea1DZ2moXElv+9uLhI723n8yOSSRU5TAj/6aSeZ+kluHWP8AeffpZI/M/joA/PWz+I37emk6ZaafZfAT4d6bp9okccFna3cEUcccY+SNETVPuADGzpX6E20nmQ7w/mUmxtr7Pvb81MnSgB1FFFABRRRQAUUUUAFFFFABRRRQAUUUUAfGvxK+CHjbxB/wUk+FnxSsNE83wLoHhyfTb/V/tUCeRcPFqeyMxl/M/wCXmDkIR+8r6W8e+B4PiP4L8ReG9RuLiz03X9NuNKupLeU+b5M0RjLx7xsST5z1Q811txG8g+R8VKq7BQB+amgfDP8AbK/Zd8CyfCj4caJ4V8f+D4PtZ0rxHmBLuyWeSXjyp7iJBJkvPseOdB5+zzJOg+hv2Lv2Ub39nXwjq19r+pDX/iX4mvWvfEutR38k0VwfMkMYjd0B/wBXIZDlN5kkk/eFCmPqCSL94joiVJGvloiUAEcYjjC9qfRRQAUUUUAFFFFABRRRQAUUUUAFcb8SLzxJpvgzxHe+EbK3v/FNtptxJpVnc/6u5uxHJ5Ecnzp8hkwOo4PWuyqHy38zfQB+Sfww+D/7YHw++JGrfESf4JeG/GvxD1K4mlk8U+JtXt57iBZBGjpDHHqEcEaeXH5Y2R7wjugfZ8lfYn7M/jr9qHxN481Cz+NPgDwz4Q8Mx6bLJbXei3Eck73nmx7IyBe3HybHk/g/uV9Txxv5f7x/n/6Z0eWxJ+fKNQB+e3ij4F/tBfsy/HXx143/AGe9M0jx/o/xAuJNR1jSdflgQ2F4JZJDkmS3yM3D+X5b9JJEkR9iSHvP2Pf2bfiXoPxU8Z/Hf4w3Vtp/xK8WQHTBoGnCNrbT7PfEQZDGZN7gW0CIA5/dpl5HkkOz7J2v/s/99mrKdKAGQx7I9v8ANi386loooAKKKKACiiigAooooAKKKKACiiigD81P25vgx+0h8cvjd9n0r4d2njX4R6H5cul6Jea1DZ2moXElv+9uLhI723n8yOSSRU5TAj/6aSeZt6f8Rv29dJ0u006x+A3w702ws4447e0tbqJI444/uIiJqn3Bjp0r9CpInk/jwKZJG/lvsHz9vm+9QBwXiz4L/Dz4lavBq3i7wP4a8ValDD9mS71vSYL2REjd/wB2HkjOBvc8fWvkz9vr9iWz8cfCPRNM+C3wo8OQeL016O4uho9pYaXI9mILjzA8h8sMnmGD5N//ADz44r73TpUUkfmL9wSf9dKAOS8G/Drwx4B0+S08JeHtJ8LadNJ9oey0SyjtInkwg8zZGNjHYiDOO1ddHF5ceypE6U6gAooooAKKKKACiiigAooooAKKKKAPIv2irr4hWHwl8Ut8JrK1v/H8kUcelQ3LRgGR5ESST95IkYeOJ3cbyRlUyH+5X56/Af4W/te/s53eran4c+BfhXWPFOsiQ6t4s8Q6vHd6rqJeQyvvk/tTA/eOM+WiGTy4y+Xr9YJIRh/9v79L5b+tAHzD8CJfjZ8XvDnjrw9+0b8PtF8L6HqFnHp9naaHPxfQTxzpdxySR3c7p8nlf88+vWvmv4efCr9sj9ji3v8AwT8PNJ8M/FjwPJO11plzqt0saWOZZPkSOS4t3gkkOySSMGSMO3yPvMhP6W/Z/wDWf9NP9un+X/nf9ygD40/Yf/ZS8ffDHxb4x+LHxi1W3174oeLkt4WCTO5srf8AdySo5GIi/mJEnlxoUjFsgjk2Px9oRxiOML2oRdiU+gAooooAKKKKACiiigAooooAKKKKAKklqZJvMX92a+Dda1L9u34U6je6NpGm+CfjHYNcS3Fr4kuYYLCVEc7I4ngFxbIknG8geZ/rz+8k6D79qvcW/mYdR+8T7lAHxX+y9+yz471b4vXfx++P1w8vxLlE1tofh2ynBtdCtX8yMjEbvH9x5NiB3AEjySGSeQmPzD9uD4M/tIfG742Jb6V8ObLxn8I9C8uXStEutXgtLS/uJLf97cXCJeW85kjkkkCcpgR/9NJPM/Slc7fmqOSPzP46APz1s/iN+3ppOmWmn2XwE+Hem6faJHHBZ2t3BFHHHGPkjRE1T7gAxs6V+hNtJ5kO8P5lJsba+z72/NTJ0oAdRRRQAUUUUAFFFFABRRRQAUUUUAFfPX7UGg/G+6s9E1r4J+JtM03UdFme41Pw7rNpG9trsfyPHF5uC8cmYvLwDHv+0f6yPZX0LUXz+Z7UAfnJ4v0L9tr9pHQ4vh7408OeHvhZ4M1iXyta8QaNcxySR2ez97A6JeyvJG/pHgv9x5EjeSvrfwz+zj4T8G/s/P8AB7R5dQsvCT6Xd6JI7XO+5eOcSfaJ97jZ5xkklk+5s5ICBMAevRxv8nmf6z/fqxHGI4wvagD81dA+Gf7ZX7LvgWT4UfDjRPCvj/wfB9rOleI8wJd2SzyS8eVPcRIJMl59jxzoPP2eZJ0H0N+xd+yje/s6+EdWvtf1Ia/8S/E16174l1qO/kmiuD5khjEbugP+rkMhym8ySSfvChTH1BJF+8R0RKkjXy0RKACOMRxhe1PoooAKKKKACiiigAooooAKKKKACsTWNCtPEGm3un6lBDfadeRyQT2s6eZHLG6bHjkT+MH+tbdFAHkTfso/BKP51+DngP8A8Jmw/wDjdfNP7If7Hz/D344fG3xF4z+GGgWuh3XiWPUPBFxNb2N19khF3eOkloieZ9lwjWmOI8bE/wCefH3d5f7zfUEcA8t/kQf9c2NAH59+LvgX+0H+zJ+0D4/8dfADT9I8faD8QLl7/WNJ19oEFldiV5OXee3JXNxL5flv0d0kQ+XHI/efse/s2/EvQfip4z+O/wAYbq20/wCJXiyA6YNA04RtbafZ74iDIYzJvcC2gRAHP7tMvI8kh2fZvlvvTY/7upU6UAMhj2R7f5sW/nUtFFABRRRQAUUUUAFFFFABRRRQAUUUUAed+M/gj8P/AIja2uq+LPBHhvxPfwwJbxXmt6TBeyxxB3fyx5kZ2J85/M18lft9fsS2fjj4R6JpnwW+FHhyDxemvR3F0NHtLDS5HsxBceYHkPlhk8wwfJv/AOefHFffNQSR+Yv3BJ/10oA8sm/Zt+E02l2lh/wq/wAEyadbyvcQWMnh608qKSQIJJI0MfyO/lxof+uUf9wCvEP2wv2OfDPif9nvxTpXwt+EvhO38dTmzGmSaVpNhYXAP2y3eQxzkR7P3Yn4319jp0qKSNzJvR8e1AHiv7LvwT0/4N/CDwjYW/hTR/C3ieTQtMt9dk020giluLyC3Ak+0SR/69xIZfn5/wBY5zXt0aeWuKfRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFeFfH79qjRf2fvEHhTRL3wp4v8AF2s+KBd/2dpvhHTo765f7Okbyny/NR+kmeM8RydMUAe60V8mr/wUE8N6H/pfjH4V/Fr4eeHIzm78SeJ/CEsWn2Y6J5rxvI43v5cYwh+eQV9XpIJOVoAfRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFQyTeX/A5rxn4vftTeBvgz438EeDtflup/FHjDUrfT9P0nTo45Z40nl8tbicF/kg8z5P77kPsR9j7AD2yiuT+IHjqz+HvgDxH4u1KGeTTtC0241O6ggX995cEbySbeRzhK+cdL/4KDWGtabaajpfwE+OWqadeQxz2t7aeDRNHOjjejxyC4w6Y5BHXNAH11RXh/wARP2mNC+Ffwx8PeMtd8OeJw2vTWVnp/hmHSt+sT3l3GJEsxBvws4G/ejuOYnAySgfG+En7Z3hP4qfEQeA73wz4u+Hvi+W0+32Oj+NtKGm3Gow/PveBPMffjZIcdcI5Gdj7AD6JqCS58v8A5ZufwqSOQSRhu1eb/FL4hf8ACu7GwAsJdX1bxBqceiaTp8Sy/wCkXciSOPMkjjfyIESKSSSTH7uKKV/3j4QgHpdQ+d8+zY9eG/HL9rTwp8CNe8PeHL3SfEXi3xZrpkksfDPhGw+3alJDGju9x5W9P3fyde+HxkJJsg+Cf7WHhf47eKNe8PWWna94N8XaEEkv/DHjCw/s/VI4ZNhjl8jzH3x/vB9PMj+5vjLgHvkciypvTkU+vNPhX8SV8f6Xq3maZeaVrui6jPous6ZPHJi3vY0jf93JIE86B43ikjmwPMjlQ/ITsHpdABRRRQAUUUUAFFQSSYHEbyV4t8E/2pPBHx78XeOtC8Ez3Wow+DZ7eG/1XEZsp3n805t3DkyIhgkTfgJ0KeYmHoA9worwr49ftQ6P+z7rXg7RL7wj4v8AGOs+Khef2bp/hHTo765zaxxvL+7MqZ/dyZ/d5+4/pWb8Mf2tD8UPG2neHF+Dnxa8Ki8Lgar4o8LGz0+Dy45JP3kvmnZny/LHH33QUAfQ9FfPvxi/a50L4R+PNK8GReD/ABn478VXumtrD6T4L0g39xaWfm+WlxKPMQBHkBHGcfx7MoH6H4D/ALSfhT9oTRdVufD0epWGp6LeNYax4f1q2EGpabMJHTZPBuOzOwkHkcOn+sjkRAD2GoJLny/+Wbn8KPtHHyI7153ovxOXxN8UPEPhfTdNuHh8NxW41fUboSJHHd3EUcsdpF8nlzSCAiSQpJ+78+3AEnmP5YB6PGdyfd2e1MkufL/5Zufwr5I1z/goh4ItbjxFP4e8FfEXx34a8OSywX3jDwpoIu9GLRxeZLi489BsjD/fOE/jHyFHPsbfGHT/ABB8JY/iL4Ftl8Z6NLaNq0ceku5lvbeM/vY4kVPnuNiSIkD7H8xEjk8vLlAD1lW3inVzXhPxXp/jjwrpGvaPL9t0fVrOLULW68sp50MiJIjbHwfnR66KOTzBQA+iiigAooooAKKw9c12w8O6ddanqN3b2OnWkMlxcXVzKkcUMacySO74ConXPavPvgD+0V4V/aW8O654g8HR350XStYuNHNxqFt5H2iSNIpBLEmS/luk6EeYEf8A2BQB67RXzr8Z/wBsTRfg/wDE628CDwF4+8ba/No0eui38G6Kl+Y7V55LfLoZUcfPGO2PnT6VrfBn9pr/AIXF4oudDHwp+JngrybV7z+0fGfh77BZvh44/KSQyHMv7zOwdkf0oA90or5O/wCHgnhvWGa88HfCn4ufETw7N/x6+I/C3hCWXT7zs5jeR43Ox/MjOUHzxvjPWvd/hf8AFPwx8ZPBem+L/CGp/wBraBqXmizuzbyQeZ5chjkIjkRHwHQjkUAd1Vc3I3lFRpHWlkufL/5ZufwrzLw78WLDxN/wnGppG2k+FvDF1c6fJr2qO9rFPPaFzev+8REFvBJ+78/zPnkiuBwkYeQA9RjkEkYbtUclz5f/ACzc/hXyD/w8w8ALpP8AwkP/AAgPxKHgH7X9m/4T1fDDf2D5f2nyPtHn+Zv8vzP+mfmdvL3/ACV7l4r+LmneG5vA2qrAureEvE11BYQa9pcr3cUc91s+xSSeWjxm3lf92J9/ySSW4wUld4wD0+M7k+7s9qkqG3i8mPZU1ABRRRQAUUUUAFFeHftHftTeCv2V/B9rrfjK5uMXk5hsdN01UkvL5wR5nlRvIn3A253chOAM75ERvbo5PMFAD6K4D4x/FjQvgf8ADnX/ABx4ja4XRtGhjlm+yxb5Hd5PLSNE/vu8iLzj74yR1p/hX4naJ4q+GujeOXuG0rw9qmjQa2ZtUeOAW1rJF5+ZjvKJ5cZ/eHJHvQB3lFfHv/DzLwB/Zv8AwkX/AAgvxM/4V/8AbPs//Ce/8Iwf7C8vz/s/2jz/ADN/l+Z28vzP4PL3/JX1Ro2uWHiTSrTVdKvINS067hjuLe9tJPNjnjcZjdHTh0Of60AannfPs2PT45FlTenIrhfin4/sPhX4R1PxPqcF5fWdn5axWWmWr3F3d3EkkcMFvBGn35JJJI40/wBtx07bWlX+oQ6Xatq9taWF6UQ3Udtdm4t4HwPMRJXEbOgORvMadjs7UAdHUH2n95s8t/yryPRf2lfCniD9oDX/AIPafHfyeKtB0hNY1OTyAlrFG8kQ2b8+Y8my4ik+SMx4f/WZ4GxB8TA3xY1DwHf2U2mai2mf21pd2BI1tfWilI5/3uwRxzwTvHvi+f8Ad3EDg/PIkYB6RHIJIw3an1Bb/wCoj/d+V/0zqegAooooAKKKhkm8v+BzQBNRXifxe/am8DfBnxv4I8Ha/LdT+KPGGpW+n6fpOnRxyzxpPL5a3E4L/JB5nyf33IfYj7H2dl8Tviv4a+D/AIJv/GPjG/bRvDem+X9rvZLeSXy/MkSND5caO/LyIOnU0Ad1RXyfL/wUE8NaTI03jD4WfFn4feHbc5u/EnijwfLHp9n/AHPMdJHf532RphD88iV6l8bvj6Pgm2ibPh54+8frqYmGPA+hHUTZ+WY/+Pj94nl7/M+T12P6UAevUV8ZeMv+Clnhn4e6aNR8V/B34xeF9PlnW3jvta8MQWkDyf3PMkuQm/5H49B7V9kwyeYm4rs+tADJLny/+Wbn8KnrzP4reP8A/hXtjpzC0k1TVdf1KPQ9I0yIyL593IjyZlkjR/IgRIpJJJMfu4o5X/ePsQ6nxA+JGg/C/wAI6l4n8SahHo+g6XB9pur+5fbGnI9i5cn5ETq7kIBkigDuKK84+Bfxo0f4/fDDRvHvh+0vbLRtW+0fZ4tSjRLhfKnkgfeI3dPvxnGH6V0fizxhpPgnwrrXiDWZ/s2maLaT399Ls8wpBFGZJH2p1+TNAG7Jc+X/AMs3P4VPXjvwl+M1l8fvgxp3j/wdYzfY9YhuP7PsPEDraO8kcskAjnkj8/YjyRcEeZx6/crp/hj8SNP+KvgfTvE+lWd/ZwXQdXsNUtzb3drNHLJBPBPG/KSRzRyo/uh60Ad3RUaSCVA6HepqSgAooqCSTA4jeSgCeivDvgr+1J4I+P3jDxxofgie51b/AIRCe3hvdT2I1ndvOJf+PeTzP3gBgkTfgJ0MZkj+evVdc12w8O6ddanqN3b2OnWkMlxcXVzKkcUMacySO74ConXPagDcoryL4A/tFeFf2lvDuueIPB0d+dF0rWLjRzcahbeR9okjSKQSxJkv5bpOhHmBH/2BWJ8dP2svCfwH17QfD17pPiHxZ4t1wySWXhnwnpov9SeGOOR3uDFvT938jc55w/GEk2AHvFFeHfB39qXwf8ata1HQ7CDVfDPjLSYUuNU8KeLLF9P1XT4HxtkeJ+qEeW+ULgCSLfs8xa9p+0dPkf34+7QAslz5f/LNz+FPjO5Pu7PavItX+OWl6b4l8bpNDdWug+BNNW88Qa1PFP5VvI8Edx9nj2RyfaHjt/38vl/6sSW+N/mSeX5lH/wUA8NJb/2j/wAKr+LP/CG/8fP/AAmn/CHyf2P9gz/yEPM8zzPs/l/vc+Xv8v8AgzxQB9XUV5l4i+Pvgfwh8IYvijq+tG08DSWtpfrqwtJ5N0Fw6JbyGNI/M/eeZHxs7+leOS/8FBPDWkyNN4w+FnxZ+H3h23ObvxJ4o8Hyx6fZ/wBzzHSR3+d9kaYQ/PIlAH1TJc+X/wAs3P4U+M7k+7s9q888efERPh7rPhY39jNPoes6guitqFv5j/ZLud447PzEVDthkk/d+Z/BJJbj7kkjx+g28Xkx7KAJqKKKACiisPXNdsPDunXWp6jd29jp1pDJcXF1cypHFDGnMkju+AqJ1z2oA3KK8i+AP7RXhX9pbw7rniDwdHfnRdK1i40c3GoW3kfaJI0ikEsSZL+W6ToR5gR/9gVi/HL9rLwn8B/EGgeHbzSfEXi3xjrheSx8LeEbAX2qPAiSO9wYN6fu/kYZ6kh8A+XJsAPd6K8J+B/7WnhL45a1r+g22m694O8W6IY3v/Cvi6xFhqqQyIhS4Fv5j5jO9B6jfHkfvE3zftGftTeC/wBlfwfaa540ubhjeTGGy03T1SS8vpAR5gjQugGwHc7khBwM75ERgD3CimRyeYKZJIYhwjyUANNyN5RUaR1qWOQSRhu1eQWfxs07UtN+IXiOaK40zwb4MuLm0utcuI54/tEliJDfvFDszJBE/wC78yPeZJIp0Cfu0eTyPQv+CjHgq7k8LT674H+IXgLw74knihsvFfivQo7PRlaVPMjzc+efkcAkSdP4z8mSAD6+orh/iF8TvD3wv8K6j4n8Tanb6PoemwtNc3lweEweBsHzu7kfIiAl+g6ivG/Cf7bVj4n8beHfDV98I/i14Qk168Gn2l/4i8KPb2pn8qSTYXjlcj5I5OcEJtLvsSN3AB9KG5G8oqNI61LHIJIw3avN9e+JB0H4naF4U1Gxnhi8SRzR6RqsIkkt3u4EkuJLS4wmIJDB+9jO/wDeeRcf6vy08z0W2/494/pQBNRRRQAUVXkuBHjgff2fer5r8Yft0+FPDvxC17wd4f8ABPj34n6xoGxdafwDow1S30y4bzP9Hkk81MSfu349fk++jogB9OUV5t8IvjZ4O+NXg2HxV4G1y31zQJJ5LX7RESjpJH95JI5MPG/IfDjlCH6OK8G/4eZeAP7N/wCEi/4QX4mf8K/+2fZ/+E9/4Rg/2F5fn/Z/tHn+Zv8AL8zt5fmfweXv+SgD7CqHzvn2bHrN0XW7DxBptrqWl3sGpafdwxz2t7ayLLFPG/KOjocMhz1rM8ZeK9N8D+Gtc8R6tdfYNL0i1k1C7vPLeTbBHGXkfYnL4SM/l+FAHTwyeYm4rs+tSV4H4y/aYsvhT8IdA8b+L/DGv2d/4gv7ey0vwnp1o93qlxPc/vLe3MX7vZceTzJG+NjxyRoZMR+ZS+En7Z3hP4qfEQeA73wz4u+Hvi+W0+32Oj+NtKGm3Gow/PveBPMffjZIcdcI5Gdj7AD6Jorxv46/tJeE/wBnzRtJvPEKX2o6rrN4mn6R4d0eNbvU9SuCYxst4d43EB0JyQPmQZ3yRo+H8LP2wvBfxN8ZxeDbzSfE3w+8b3MDXdr4X8b6VJpl5d26Dm4gBzG8f+s43+Z/o8h2YTNAHvP2n95s8t/yqSOQSRhu1ebWfxMD/Fa+8CalZzadqJ07+2tMvF8xra/s0KRz/vDHsjngndN8X/POe3fJ3ukfotv/AKiP935X/TOgCeiiigAooooAKKg+0fNjy3/Kvk6b/goh4COsaydB8LfEDxj4T0W8+y6j438P+H/tuiW2xFe4kNxG/McYfLkIeDvTemwkA+uKK8jv/j74fPwZh+Jvhiy1j4gaFNDDc2dr4Ptftl7dJJJ5X7uD5CXTrIj4MflyZGYyK8i1L/goJY6JpN3quo/AT45aZp9lDJcXV5d+D0hjgjQb5Hkd7jCJjnnsKAPrmofO+fZsevPfgP8AGjR/2gvhbo/j7w/ZX9ho2recLa31WNI7keXPJA4cI7gfPGe/pVv4p+P7D4V+EdT8T6nBeX1nZ+WsVlplq9xd3dxJJHDBbwRp9+SSSSONP9tx07AHdRyLKm9ORT65zSr/AFCHS7VtXtrSwvSiG6jtrs3FvA+B5iJK4jZ0ByN5jTsdnavP9F/aV8KeIP2gNf8Ag9p8d/J4q0HSE1jU5PICWsUbyRDZvz5jybLiKT5IzHh/9ZngAHsdQ+d8+zY9R/bk/uP+VeOfDH9ozwr8YPiJ8RPC3hr7dLe+AbuGy1a8nt/KgeeTzE8uD+N/LkgmjO9ByMpvGKAPao5FlTenIp9ea/C34px/ELSdSMmnXWl6tompzaFrGnTRyZtr2MI/ySSInmRSRyRyRyYG+OWM/I5MdelUAFFFFABRRRQAUV5f8cvjp4W/Z18C3/i7xpqIs9Jt/kiijIa5u5zkpBAhI3yHHA+ruURHcedeBf22PB3iTxhpnhnxF4b8afC3Wtcl8jRLbx5oclgmrS5/eRwOHePeP3Qw5TLzxhPMMlAH0rRWDrGu2Ph/TrnU7+6t7HTrSGSe4urmVI4oY4+ZJHd+EROvtXAfAH9orwr+0t4d1zxB4OjvzoulaxcaObjULbyPtEkaRSCWJMl/LdJ0I8wI/wDsCgD12oJLny5NmxjR9o+XPlv+Vec6p8SEHxStPAml6ZdXWqf2cdZ1a58qSK2sLMmSKA+Z5Z8yeWWORI4sj93BcSH/AFaJIAem0VzHijxhpfgTwvrWv6xMbLTdFs59Qu5AnmbLeCPfI+xP9j+lcJ8N/wBorRviz8B4/ixoGha7c6TNa3d5Bo7Wkb6jOLeWSIxxxJIUeR3gOwb+cjkUAexVBJc+X/yzc/hXy1/w3yf+jdPj9/4Q/wD90Vs/Cn9rzR/j58FfEXxG+H/hrXNSt9EvHtrjRbxETULkxRwTy/Z44JJBJJ5cjmOPKeZInl5j3+YAD6RVt4p1cz4X8Xad4u8L6X4h0SU32japaR31pdiMxieCRBJHJhwmN4cHp37V0ccnmCgB9FFFABRRRQAUV5x8Xvi9ovwa8LtrWuy3Mm6ZLOy03T7f7RealdyHEVnbRjl7iTPCexc4RHI88+Fv7YGnfFL4gWvg6b4b/EvwLqV9ZzX1pN4w8Nmyt7hIDGJcSJI+3HmxfO4EfzImd8kauAfRVFeD/HH9rTwl8C9b8P8Ah+60zxB4v8Xa75klj4Z8I2Av9SkgSN3e4MG9P3eUYZ7kPjPlybHfA79rTwl8cta1/wAP2um694O8W6J5b3/hXxdYiw1WOGREKXAg3vmP50HqPMjyP3ibwD3aoJLny/8Alm5/Cmi4BjR0Hmbxu/d15/o/xQj8SfE3X/Dmm6fMY/DkMCanqNwJEjF3cRx3EdnB8nlzyC3/AHkmyT935lv/AKzzH8sA9FjO5Pu7PapK+O/Cv/BRnRfGHh+z1nw/8DvjRr2j3QPkajpPhOO4t5fn2P5ciXGPvg+/FfRnw1+Iv/Cx/AWl+JG8Pa/4T+3NIDpPiax+x38GyWSP95Fn5M7N/U/IQe9AHcVBJc+X/wAs3P4V4lq37VHgbw/8fvDnwZa4u77xxrVvNdPb2aLMumeXbvcbbkl8o8iJJsRA5wUJwjoT13jz4iL8Pda8LNfWU02jaxqSaG+oQeY5s7qd447bzY1Q7YZHzH5mfkkktx9ySR4wD0KM7k+7s9qkqG3i8mPZU1ABRRRQAUUVFJJ5VAEtFfMPjD9uzwl4Z+IGveEPD3gzx58TtX0Py01iTwFow1S30+d/MxbySeamJP3Z49fk++kiJ6X8E/j14V/aC8B2HjHwfffb9LucRS27jy57S46yW8yc7JI+OOhBDjMbo5APU6rm5G8oqNI60slx5XRHf6CvHLj482LeGfib4sGnagPC/gY3sD3ypLHJqVxYJJJei3jk8tJI43TyvM8z95JHcJwkYkkAPZ45BJGG7U+vkbTP+CgVlqemWWoWHwE+OV/p97FHcWl1ZeDhLHcxum+N45BcYdCmDx1FfSnhfxMnifw1o+sjTtQ0ptRtLe5bTtUh8i8tfMQSeXcR5+SRN/zpnjFAHS1XNyN5RUaR1ryHxF+0f4S8MfHjwZ8IrpdTuPGPii1nvbaKGD/R7eGNJH3zyO4xv8i4CCPf/q+cfJnc1v4j/wBhfEnw/wCGNSsLi2i8TQTDSNRijkkie7gR7iS0uPkxBIYP3kf7z955FwP3flp5gB6PHIJIw3an1Dbf8e8f0qagAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK+Jv2zfHjfDX9qr9mTxMPD+u+KRp//AAlGNJ8MWIu9Rn32FvHiKPeN+PM3/QV9s186fGL4a+J/Ev7VH7PvjDS9OF34e8JnxF/a98JI0Fobuwjit/3buHk3yAj92DjvigDyn4rftMeJfjZ8L/GXgPwh8APi7Fr3iTSLzS7ebxTosOkafGZbeSOV5bmSQpGETe4H8b4j43ivq74S+Bz8M/hb4P8ACD3n27/hH9Hs9K+2GLy/P8iBIxJs/gzs6V1Aj8zzP+Wnz/36sp0oAdRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAV5IBJ/AnXd+NfD/7W/wd8J/C7VPhJe+FNDg0zUfFXxx0LVtZujJI8l3dyG5yTI+87MmTEYOxPMfCfPX3RXzp+1r8N/EnxMb4Ojw3p39pHw98SNF8QaiPPjiNvY2/m+fcfvHG8LvT5E+fngGgD0j45eErnx98HvHXhSwmhg1HXtCv9KtXu3/crNPbyRx7/wAx618s6LB+158APhXpGnweHvhj468OeD9Ns7ZtH0KXU/7Y1Kzt4445I4DJiMy+WD0j/wByN3Ijr6s+Ko8aS+C9RPw8XQH8XMka2H/CUpP/AGeP3ieYkvkfvMeWJcf7fl183+KPjB+1R4q0OfRvDP7Pdh4D1rVB9ng8SXnjKx1CLS/MJ8y4kt4497+Xlz3+fHySf6twD374N/EzQfjl8MtH8Z+FJrmTSdWhEtt9sjEckTpK8ckboP40eORPkJT5P3bkYevl6z8ceJ/G37XXww1T41+A9S+Cknh+1urbwjsvI9S07VdTvxJFJbz6lH+4SQwQfu7bYJHcEmT/AFcb9rYfD/4nfsj/AAf+GXg/4ReGrH4saPpEd5beILbU7+PTL+SSaQzxz28j/u4o/PklykgkOzyh/fkGXH4O+Mf7THxM8HS/Ev4faf8ACb4f+B9as/FFnaWWqx6vqGq6pG8vlYnhxHHb/Pvk3x7+Ov7zMYB9lxn5Plbf718q+KZ08Wf8FEPCGg6ha2ty3hL4dX3iPSrovJHMl5d3sdlLvwdjp5EZA+Q48yQ/3Nn1Pbr5UMae1fMnxSto/hz+2P8ADHx/c2/+g+LtGvPh7d3l3qcdvbWdxu+32QRMeZJJcPBcQYHfyv48JIAc/wDBnR4dY/b8/aS1m7nmudR0PS/Duj6TPLcyOLO0uLcXFxFHHnywHuI1k6ff3/35Ms+NdlHoP/BQD9mzXLC6uLa/1vTfEWi6rNFdOEu7S1tfPit5IwQhAnld+n39h/5ZpiT4s/DP4mfCf9oaX40fCLw3B42g8S6cml+LPBkusnTmuLiL/j2v45ZJPJzGkccX3OE8zg+fJJGz4R/DL4m/FX9oqP4zfFrw5b+CYPDOnyaN4R8H2+sf2k8Ekw/0nUHnSTyy7o7x/c+dAMp+6jeQA0/C7ReD/wDgoV4y8P6bp9tDB4s+Hun+ItTmLSGWS8s9Qks4PL+fYiGCRB5eP+WcZ6l9/wBVW6iOBET+HivmL4Y2EHxG/bJ+J3xCtoSbHwto9n8PrS8tr6C4t76fzDf6hvjT545IJJrSP0z5nU8R/T1t/wAe8f0oAmooooAKKKKAOG+Kvws8N/GDwPqnhDxXp/8AamgakYPtVmbp7fzPLkSSP95GQ/344+/avnj9mXRrLw7+2d+1Ho+lWkGm6dZxeELe1tbNEgjgjTTJNkaRjomPSvsCvnH4Q/DnxR4X/as/aE8X6jpj23h/xWfDg0i+WSOQXX2azkguPkR98eyQ/wDLQDjkUAUf2n/g38TvHHxa+EPj/wCF914TttY8FHVvMt/F0lwLeT7XBFAcJBGXf5A/8ac+X1rm/D/x++LXwr+Kfh7wt8edA8OrofjKWKw0bxf8Pftcllb6m8hjS0uxPmRPMDx7HAx/vp5hg9C+NHjH41+B/FNtffDz4f8Ah74i+EpLaOKfSP7a/svVYLzzJP3/AJkv7j7P5ccaeX/rN59BXk3/AAg/xp/ae+LHgTUfib4Ni+EPw88C6laeJLfR7LVLXWLzWdWjeTyJDcRj91BHn5xjP7w/f3+ZAAfTPxP8TeJPDHgnUtV8H+Fm8deI7cxfZNA/tKOwN3vljEg+0SApHsjcv7+XXzl+xx4jOrfF74y6542sdQ8E/GDxNe2k+peDdSh8tLfTLMPZ2lxaPz9sj4cSXKYjMnSONPLeTqviR8Sf2hPBfxG1q38P/BzSfiN4HaC0k0m603xNBpNxaSD/AF9vcfaN/mOXxs8uNMIU6vwifAr4Z/EXxN8V9S+NvxW03TfCHi+90Z/Cuk+FtGmS5Sw0v7YbhJLufzHSe4L7P9VsTZzje/lxgH0h5YWT5ev4+n/j5+Svh34D+JJrr/gnX8R/iXYJ/YPinxVaeLPFmoX2jzyxBNQd7v8AeQO8m+PYLe3QbH6x56/OfuiTep3fONjdP79fKH7JvgPRF+EnxC+AGsWBksPB+tanoE9pcamkt7d6Rfb7u2u5DBs8vz4LvZxjmOTpyiAHoX7G/h/T/B/7KvwjtNPVbC0k8O2F48TPvDT3EX2id9+f45J3f8a85/4J92I8MeEfi74T08TJoXhn4oa3pGkWUlzJLHY2cZjKRx+YT8nmF+Om95H6k1x/w7P7Uf7Nnw1ufhdpPwwsPivaaGtxZ+HfGjeJ4LWOazID23n2c8hk/dmTy/LSSPEcYjQ4jSR/Zv2Zfg/a/sx/A97PxZ4kt9T1x57jxB4p8RXl0/2ae+fElxcSPPJ/AkaJ5kmzPkeYUQl6AOb/AGE5k07wN8SfCFhYWmm6B4E+IOu+HtEt4hIXS0inE8fmO7uz4N06Z67NnfJP1WnSvmz9iPwxPY/BifxfNYzaJdfEfXr/AMbz6XJcpcx26X0++3jjkjA+Q2gtz67yen3K+k4/uigB1FFFABRRRQB5p8Wfg/4O+ONnpWleNNDt/EmlaXqEGq21neNJ5X2qMSIjyIhG9Ajyfu5MxvvwRXjX7BP3f2iv+yzeIf8A22r6lkl8ppHKfJGK+e/2Rfh74k+HK/GQeJNI/stvEXxI1fxDpqmeN/tFjceR5U/yO+37h4OMcUAc18Zvgz8a1/acs/iz8JrvwJIV8GJ4XurfxrJfcj7a9w8gS3jH/TIcv/z0+TpUvwl/aC+Iei/Gq2+FHxy0LSNK8V6vHJeeGNe8KC4fRtZjjj8y4tx5nzxzxYf/AFmPon7s3G58UvH3x+8E+ONQ/wCET+FGgfFDwfcmD+zRp/iL+ydQsDHHH5v237QDG/mSOfL8r/lnH+8rkvhr8O/ip8Yf2htE+Knxg0OD4c2fgeC4tfC3g3T7+G/lkuLuAR3d3cXUeQY3D7I4xg5iHCbHM4B7l8WPipoPwd8KpruvTTGLz0sbHTrOB7i91O7f/j3s7eH77zyFfkH+/nH364n9lT4T+JPhn4Y8U3/ii2t7LXPGXie/8XXWkwz/AGj+y5rsx5tDcf8ALeSOOMfvEREzkDeBvPz54cvf2kpvixqPxK8Ufs0f8JTrsPmWnhaE+PNNgtPDtg/347dDv3zy/wDLS46unyII4/3Z+svgt4x8eeNvD89z8QPh/wD8K61iO7MC6THrcGp+ZB5aP9o82D7mZPMj8v8A2PegCz8Z/GWo/Dn4N+OvF2mxQ3Oo6P4f1DVbT7Yj+X5kFtJJFvj+v3/udfy+NPitYJ8Nv+CP9nF4bM+hR3PhjRZ54re4fMovLi0e8Tfv3+XJJd3G9P8Apo6cJgV9xeOvA9r8RPAPiDwpqcksFjrmm3Gl3k1v/rYo54HjkKb94zh//wBdfN/wn8D2f7Sn7DMPwu8SWsGj6jp9kfBOr20d6l9JpGp6a/kRyOY5E+YSW8E/l9P3g5dH3kA+h4/hb4cb4Zx/Dr7Af+ELXRv+EffTPPkz9j8jyPL8z/Wf6r5N+/P418W/CnSl+If/AAR/vbbxOs2rrbeEtZuY2ubqTej2VzcSWfIP3I/s9vsH3NkYTGzityTWv2wj8ID8KZfhjYyeI/sn/CP/APC0v+E0j8vyv+Pf+0fs/wDx9+Z5f7zzM+Z5n7zy/wDlnXYfFjwLZ/s1fsKy/Cnw5bW2tanqWmr4P0m1a6+xtq+p6lJ9nkkTzXkAcvcT3Hl+Zjakg+RE3oAfQfwP8Y3nxG+DHgPxbqcMMN/rmg2GqXMcC7Y0knt45JNmT9zLn8q9Brlvh74PtPh/4C8O+FrCSaax0PTrfTIJLpw8zxwRiNHfj73yf56V1NABRRRQAUUUUAfCn/BR34MeEfD37Ofxs+I1noVtF4w1+30m21HVy7tPIkWoWccaIXz5abEj3iPG/wAtCegNfZ+s69Z+G9LutR1W7h0/T7OGSe7vrmRYbaCNE3ySSO5+RPU9q8S/bq+Gfib4yfsp+OPBnhDS21fxLqJsPs9mJ47fzfLvLeWT95KUQfu43717D4u8I6Z458M634e1i1+2aPrNnPp17EHeN57eRCkkfmIQ6Z3uODnr0oA+C/jBp+pfte+Afif8Yr/VI5vgt4b8Oa43gTQVtEH9rXkdhcW8mr3kZL48uTzVg37JE2I+yDDiff8Ajvq13oP/AASN0y5s7mWzebwN4YtnaCUxl45PsMcicY/1kckiPz9yuh+Kn/BMf4Gp8MvF58GfDM/8Jguk3g0Uf27ff8fnlSfZ/wDX3Hl/6wR/6z5K0Phv+wT4H039lLVvAsnhs+FvEPjPw3YW3ii6+2z3fl6tBH5kc+z7R5Z8i6LPsjKRv0z5dAH0d/wrDw3P8N/+Fe/YD/wha6R/wj/9lJNJ/wAefkeR5fmf6z/VfJv35/GvGv8Agmxq17rX7FHw0ub+8mvp0gvLdJZnZ3VI7+4ijj/3ERI0HbCV5f8A29+1/J8IB8LH+F9i3iH7H/wj3/C0P+E0Ty2j/wCPf+1Ps/8Ax9+Z5f7zzM+Z5n7zy/8AlnX1L8AfhLpnwH+D/hfwDo0nnWui2v2eW5JcG5nJ3zzhDI/l+bK8kmzfhPMoA8f/AGnrgeKP2lP2ZvAmraVFcaFqGvan4gkkMjxzrd6Zp8j2hjkjkTA33BfHrGnbeh3P2k/jbqPhy40z4Z/Dq/s1+N3jFjb6Db3cWI7KD/WXGo3Ac/JHHDHL5f3/ADJI9gjk8uREpftWWcXg/wCIHwW+L88IltfBfiR9O1Ga4v4LO0sdO1aP7DLeSvIPm8uR7TgHp5mePnj6X4vfsZfCX4/eJrTX/iB4P/4SHWLW0TT47v8AtK7tswCSR+UgljT78jv0/jPtQB88/s//AAbsPgT+3RYeFYNTuNfvW+E8mo6t4ivY/wDTNWv59e8y4uJz1LyE7P3hdxHHGhdyMn1D9r+8Twb8Qv2d/G9nZpf69b/ECDw7byXU0mI7TU7a4t7tRGHQb9kcZQno8Y9XEnln/Dsb4bH9qRz/AMK0V/g//wAIdj5dbuP+Q99tz/z8faMfZ/8Atn+NexftCaba/Ez49/A74fQQC4/srWZPiBqU1nfwR3Nlb2Eey23xPl3juLu6jj9f3cnu8YB9NW/+r+bf/wBtKnqG3j8mCNKmoAKKKKACq8kAk/gTru/GrFFAHwt+1n8HfCvwr1T4T6j4Z0K30y+8UfHHQdY1i8DSSSXVy5ucu8jk/Jy5EYOxDJIQPnr7akPlNyXk/uR/368D/a1+G/iT4mN8HR4b07+0j4e+JGi+INRHnxxG3sbfzfPuP3jjeF3p8ifPzwDXffGLxB438N/DrW9S+Hvh638V+NI4Yzpuiz3QghmnkkSMtI7lAEjR/MKb03hCAUPNAHm/7UnjaPVtA1P4OeFrYa/8RPH+kXmmxadHciOPTLKaM28mp3kmw+Vbx+ZkcF55NkcYfPyesfCjwe3wv+GfhHweb7+1G8PaTaaMbtI/LE4ggjj8zZv+TOOnvXyH8FNW/aF+E2l6nPd/syXHiTxt4hnF74i8V33xE02O81e5CccIh8qGPlILeP8Adxpx/fd/fPjNJ8T/ABJ+z2tr4M8Opo/xK8Q2MFhPG1/GkXh5rjH2u4e4SRHIt8ybHt/MfzPLcRvQB55oYuv2pP2rrnVHSCT4WfB7U57GzPnl/wC1vE/loJJJLR4/uWYdxHJwRJ+8jkkDvs+ubdvMhDetef8Awd+EehfBL4Z6B4H8LxTRaJo6mOBLubzJJA7u8kjn/ppI7v2+/jGPkr0ONPLTGd9AHyr4pnTxZ/wUQ8IaDqFra3LeEvh1feI9Kui8kcyXl3ex2Uu/B2OnkRkD5DjzJD/c2exeNPgr4L+IXinwx4k8S6JBq+reFbh7jRZrlpHS0kl8sO+zOyQ5ijfMgfy3QOOea8m+KVvH8O/2xvhh8Q7yAmx8W6PefD66vLnUo7e3s7jd9vstkf8ArHkuHt7iDYOCfK/j+ST6aMoUfKj/AH/4EoA+W/8AgmDcJD+wt8Nc7v8AmJ/+nS7rmdUu5v26Pi21ro+uQT/s9eB9Tjj1WO1ijmHirWYSJ/sj79/mWEeYM5j2SOT5fmfu5IvR/wBhb4X+KPg9+yr4F8I+LdKOkeJ9MW/FxZyTpJ5ZkvbiSP8AeRl0/wBXIPzrnpP+CYn7M0fyL8Mnk/7j2qf/ACTQBF/wTFk8z9hz4YsvzyZ1NPL3/wDURvKsfs2XlvoP7SP7TPgbSLKC18P2niDSvEIMbyfaHvNSsI5Lsu8j8jfb+Zs7eY46DZWH+wH+yFpv7Pnw30fxD4g8Hvofxfmsry01qddQe4Bge8MkcYSOSSD/AFcdv9wb/k+tdH+yjaQ+MPG/xo+K1tEyW/jfxLHp+m3VvqUF5bXmmaTH9jjvI5I/+ekiXP8A5D/66OAfT1v+8t0Ozy/ap6Yjb0FPoAK4b4q/Czw38YPA+qeEPFen/wBqaBqRg+1WZunt/M8uRJI/3kZD/fjj79q7migD5E/Zk0Wz8N/tnftR6XplnBp2m2cfhG3t7OziWKKCNNMk2IkacIgHTtXuHxQ+DPhD43afpGleNdBtfEGl6Xfw6pa2V07rH9rjEgSSSMcSKEd/3cm9H8wh04rzz4R/DTxL4V/aq/aE8Xappclt4c8WN4dGj3wnjf7X9ms5ILj5EfemyRwPnA45FfQXmfx9/k30AfLf7BP3f2iv+yzeIf8A22rhfjt4/uPBf7cHhjUfhZo118UPik3hW40fXvBcc0dtBaaX5n2uO5kvCdlpP5rp8kkbiSOQD928kRk9a/ZL+G/iX4bzfGZPEmkSacPEvxJ1nX9N23MUnn2Fx5XlT/JJ8mdh6/P7VzPxC8CfE74M/G7xH8UvhH4Y074j2Pjg2UPijw1qN+mn3kD2du8FvJZXD/u1jIIEkciSPlPk/wBYfLAOP+AvxEu/Gn7b3ii/+KukTfC34rr4Yt9G0DwZc3EdzbXWj+Z9qnuI7xP3d3OZUfiPy9iI/Ehjk8v7VZCZvk+5/wA9Onb/AMfr5Y+HvgP4pfG748eGfij8WPDNj8OLbwN9vi8MeHNN1FL+5nN3aRx3FxeXCPsMYx+7SOON8v8APxGDJ9U+czYfY8ex/noA+Yf+CeV9H4q/Zvg8cmwtrPXfHWv6z4k1uO1kfypbuS/njzHHI7+WmyCOPGf+Wfc5evTfjZ8bYPhLYaTaWmn3Pi3xjr832Tw74X0+SMXOrXAQk4OR5cEYHmT3D/JGnqSBXkf7KL3Hwr+D/wAQfhZpGjvqnif4aazqdppOiy63bi71a2mMl/p0ksg+S3NxHc7N/wD0zkPGx0TzT4X3f7THgbxVrPjbxB+zT/wmPxF1k+Tda/L4+023itrIP+60+ztzv+zwJ1Pzu8kmZJHfoAD6T/ZQ+DOo/s8/ALwt8P8AUdRt9Z1DS4ZBPLAjpbPJPPJPIIy/LhDK6g4QuEyUjziue/ai8bR6t4e1L4P+FbYa98QfiFpF5YRadFcCKLTLKaM28mp3kmw+VbxmTjq88myOMPn5Om1bx98VZPgDe+IdN+GNpbfFVoW+yeCbnWoLmJJ/tHlxyS3S7EkQR7J+Nn9zeh+cfOnwZ1b9oX4P6bqFxdfsxTeJfG2v3Ed34j8WX/xD0xLzWLkJwMCMiKCMDy44E/dxJwMne5APVvjr8I9N0H9gPxT4D1j/AInth4b8BNCZ1zbme4020D29xsR+P3lukmzeR+72HeM17H8D/GN58Rvgx4D8W6nDDDf65oNhqlzHAu2NJJ7eOSTZk/cy5/KvH/2pvGGsQ/sn61Z3vh+C08ceNtMt/Dlp4bk1WNFGp6mI7b7PHOf3c8kRkkk44KW78omXr3j4e+D7T4f+AvDvhawkmmsdD0630yCS6cPM8cEYjR34+98n+elAHU0UUUAFeafFn4P+DvjjZ6VpXjTQ7fxJpWl6hBqttZ3jSeV9qjEiI8iIRvQI8n7uTMb78EV6XVSSXymkcp8kYoA+Wv2Cfu/tFf8AZZvEP/ttWf8ABXR01z9vj9o/V7+a6n1fRNL8O6RpU0l05+xWdxafaLiKKPOwIZ4kk+59/f03vnsf2R/h34k+G7fGWPxFpR0weJPiTrHiLTj58chnsLjy/Km+RzszsPXnpxXGfFj4a/E34WftES/Gj4QeHIPG0fibTItK8WeEbrVzp0txPBkW9/HJLJ5GUSOOMjZwm/YD57yRgEXxqsY9D/b2/Zx1nTWltNU17TfEej6lPa3Umbu0t7T7RbwSR79j7JZDJ/v+Wf4ErmP+CjXwb8G+HP2cPjZ8QrPQraPxlr0OkW+oavI0ks8kcN/ZxxonmE+WNiJvEeN/loXzgV1Pwk+GfxK+K37SEHxe+LPhmPwVbeGdOfSPCPg+LWxqjW8kiD7TqEk8cnl73SRo/ufOPL3gGON5O5/bo+GHiX4w/sp+OPBnhDSpNV8QaibP7PY+fHB5my/t55P3kjhB8kb9TQB9EpnZ81ee/HDxdffDn4PeP/FmlwQyaloeg6hqsK3IcxmSC3kkjBH/AACvQ06Vx/xA8E2XxD8D+JfC+oPNDp+u6bcaZPPbuBJDHPFJG7pv+4+JD69qAPNf2OfDeneDf2U/hHZaZAbO0n8NafqDo07fNPdRfaLhuT/fkkf8e1eKftzeJvGXiDTr7wB4k+G2r6X8DL3UbMa18R9BlTVZ4LBAl5LILBP3lukckAje4k8xERHIjcvGldh8E/FnxCu/2I7C08DaNof/AAtPwbYDwpP4d1e9F5breabMLS4t5HgKbZJI4PMQFwgM6Zfy/wB5XP8AjrxH+0p8ctBvPAFx8ENL+FPh3xJBcabrniXVvFNvrMVnYzwSJcPHbW5jkM+H+TOY9+d4wd6AGf8AtmePZJPi5+zJDoGh3HxK0O+1LUNf0/RdFuExql/b2cZ0u4F12gjkuvMeXeY/LMjukgTFXvE/7Qvx2/Z31TR9e+Ouh+C774WXsosdS1z4eC+kk0N5HTy7m5juMu8Dnen7sf8Aj/lxydv8Wf2adZk8H/Cl/hHqljpnjv4VPHZ+Hr3xIJZre4s/swtLu0uPLHyCSBI/3oTfmP8Ad+XvMg84+InhL47/ALYlrYfDbxh8O4vgh8Nry5F/4mvRr9nrN5qMcckckdpbmP8A1DmTZJvePjAP/LPy5wDu/wDgoTdJ4b/Zxm8dGwh1LXPAmt6N4k0Zbtpfs8d5HqEUY8yON08wbJHQjP8Ay0/g6j6oj3pH8/L18xfts6bD8QPBPhX4RmH7TcfEbxJY6ZPbW+owWtxBp9pIL7ULyJJB+88uK22H0MkfUkJJ9PRf6ugCWiiigCpMvmM4/v8A7uvzw/Zd/aC8FfsKeB7z4L/Ga3T4feK9Bv3n/tW1sbi8s/EcM8kjpeRyQW+T+7CR/vBwkcY++kkcf6KSQiR/m6V8y+MPjD+0T4T+IHiXStM+AFj418MW94Do+r2XjO1sQ9mY4wPMjkj8zzPMEmQEGM7E37PNkAPMf2GfH9348/aD/aXv38Kaz4BsZtT0i7i8KatbPbS2kktrcCS8lt8Dy57nyI5ZP9//AFkn3z2v7bPjH4p2vgvX/CPhX4XX/ijwn4g0UWOpeJ9JnS8u7JLqT7PcRwaWhSW7mSD50IkRP3uX+SN66f4K/B/xr8M/h/451m+u9D1f40eMNT1DVb7UWkuLjShebZE0+28zyxcfYYESNPLf/V75dh+5XDp8aP2ttW0PTNNtf2ddB0TxDcrAk+t6t4vguNPt3PliWc2cbidY8eZ+7SR3Tj754cA96/Z7uvB9x8F/BA8D6uNd8Jw6RbWem6iJd7TwQR+UN/yJiQbCHj2IUfeCiEYryX9va6iuvAvw78G6jp9tqegeOviHoXhvV7e4Mgb7I9x57+W8bpscmBEz/cL+uR6n+zr8GbL9nf4M+Gvh7pt/cavBo0MgN5cr5TTSSTPNI+wE7ELyPgegA+brXAftxeF3uPgzB4ztNLuNb1D4d6/Y+OIdJjuYrSO7SxkP2lJXdPufZJLjpz+7jxv+44B9EfZf3kn7z95Xw7p/jjxP42/a8+GGrfGvwHqHwUk8P2t1beEFS8j1LTtW1O/EkUtvPqUf7hJDDAPLt9gkdwSZP9XG/ufxg8efFDT7HwZ4g+EPhHQfiZ4fv/Ml1W0XWI7S4lhdENncWdy58jy+MycSZBj2d3Hlsfg74x/tMfEzwdL8S/h9p/wm+H/gfWrPxRZ2llqser6hquqRvL5WJ4cRx2/z75N8e/jr+8zGAZ37SGoH4CftbeEPj54o0BNb+G6+GP8AhE7vXbMefceHLyS5keO/ePy+I5BJ5HmJ/wA9JB1Mccnnnx5/a18LfGz4pfs9S/C+01bVNMsPiFp8M3xAi0y4tIIWnPlz6PHLJGjs9xFJ5kifIhRI+H58v65+OPjL4p+CbLw9dfDT4eWXxGc3ckeq2FxrEem3CwCA7PLkk/d48zYXfP8ABs8s+Z5kfmHhnwn8Uvj58YvBXi/4reB9N+HnhTwc11daV4S/t5NWlvtXdESK/nCR+R5EaSSeX0njmyc4kxQBa/a8uE8G+O/2ePGljbw3uu2/xBg8NW09w8n7uz1S3uLe7QIkiAyfImzP3DGD03g/VFv/AKv5t/8A20r5i/aCtofiZ8efgX8Oo7c3LaXqsnxA1O4tb2CO50+302Py7MvAR88c93cRx5H/ADzl2d3j+nbb/UJ8nl+1AE9FFFABRRRQBha5q1r4f02+1bU7y00+wsoTcXF3duI44I05d3cnhAN3Wvzs+AHxn+Kfw7+BevaR8DvhHqPxQ+GGg3Gpx+FPF2oXUenXF3B5kk+XsG/eXmyeSRMweWZcbPLjkyifoF8RPAlh8SPBHiHwrqjTw2Ot6dcadcPA43xpPA8DlMjrskevk7w/rv7UfwL8G/8ACvNG+Deh/EODw3YR6T4b8XWPiKCwtp7SO3jjt5Liwml8x5P3Y8z95H3SM/8ALRwD0P8AYNufBEP7KngvT/h74nm8S6LpsEkc897FHBcwXbvJPcRzxDPluJJW/d7ziPZ+8kBEkmP+1hrGufFnxlon7Onhq4FpN4ps/wC2fGmqR30ltcaV4bjuI45RbnYUeS4PmQY/ecZEkeyTzE7f9n74T6n8DvAfie5vy3iXxZ4i1rUPF2u2miosdvJf3ABktbMTyJiP90kcckr/ADnLvsz8lP8AZT+Cuu/DvRdf8aeOo93xX8fXv9qeKPKvpJ7e02PJ9jsoOuI4I38vq/O/948aR0Ae4aHoth4d0iy0nTLWHT9PsYEtrazt08uOCNAEREQdEAHFfNX7T1wPFH7Sn7M3gTVtKiuNC1DXtT8QSSGR451u9M0+R7QxyRyJgb7gvj1jTtvQ/U1tEtrAkEaeXGg2JXzR+1ZZxeD/AIgfBb4vzwiW18F+JH07UZri/gs7Sx07Vo/sMt5K8g+by5HtOAenmZ4+eMAu/tJ/G3UfDlxpnwz+HV/Zr8bvGLG30G3u4sR2UH+suNRuA5+SOOGOXy/v+ZJHsEcnlyIniP7P/wAG7D4E/t0WHhWDU7jX71vhPJqOreIr2P8A0zVr+fXvMuLic9S8hOz94XcRxxoXcjJ+hvi9+xl8Jfj94mtNf+IHg/8A4SHWLW0TT47v+0ru2zAJJH5SCWNPvyO/T+M+1fO3/DsX4bf8NSbz8NA/wf8A+EOwdmt3H/If+25/5+PtGPs//bP8aAPU/wBor4k+IPHvjGD4BfCfxTBpHj++iF74j1hVMkvh3R+BJcDDx4u5DJB5cceXAkMn7v8Adz1yn7Gfw50b4N/tLftIeDvDtqlvpGhWfhGzgAVEe42aZLmWQoiJ5sj5kkfAy7ue+a9P+I37CfwU+M/jbUfGPjHwUmueINS8s3l9/a9/B5nlxpHGPLjnEePLjQfhXi/wX/4J2+B/A37S/wAQfEF18Pxp/hXSrvQ77wBdf2zPJ5VxHBvvDs+0GTi4Ef8Ax8e2zigD0Xw9InhP/gob4w0DTLKGC38WfD3T/EOp3TyvLLLd2eoSWcD/ADyY/wBRIoPH/LNP9vf9UW6iOBET+HivmX4Y2Nt8R/2zPid8QbWBfsHhXSbT4fWl5aX0VxBfT+Yb/UN8Y+eOS3kntIvTIk6niP6btv8Aj3j+lAE1FFFABRRRQB8gf8FDvEGiaF8OPB9/c6pOvj7TfFVhrPgvw/Z2Zu5dX1S3ceXbyW6OHeD98d7xumzzI8b32RyeWfGb4v8AizxV8S/gxZ/tAfDm5+B/gKx8UJrVrrsOsW+tRT6vaRubO3uLiM+XZwfvJC8kkbl/L48tEkkj+g/2nfhF4s8Tat4T+JPw7ksp/iV8P/7QudF0vW1J0/VRdweRcW8mx43jk2JH5b7xGP4+H3p5f400b47ftcaenw08cfC+1+EPw7v5I5PEOrP4jt9bv7hYLiCeOKz8jCwSb48ZkR0w/wDseXIAfS3xK+Cfg34zafpumeNdAg8RaZp+pR6xbWV5NIYvtkYkx5gB/eJiWQeW+YyHxs4rxj9gn7v7RX/ZZvEP/ttX1J5nlqXZGQ/Jvr57/ZM+HviT4bSfGVPEmlvpn/CRfErWPEWm/vo5ftNhP5HlTfu3Oz/Vn7+D+dAH0D5Xlxx7I0/66f3K+Xv2QXj8RePP2iPGd3YWtjrd18Qrjw3cS2W9I5bPTLeC3s/3fmHY/wC8kc45cyH/AGMfUixviN1RfMVMfPXzN+zvpsPwr+Onxw+HEkX2KXUtYj+IOk3F/qEElxqUepRiO5IhjQFI4Lu0kjz/ANNY8/wPIAcbfXE/7dHxWW30PWrab9nrwJqMUerJbJFKPFerwuJ/svO/zLCIGDPybJHz5fmfu54Oj/4JhSSN+wx8N3SFZJY/7TCDf/1EbmpD/wAExf2ZcJt+Gzyf7H9van/8k1ifsB/sg2P7Pvw70HxD4h8G/wBifF67tLzTtau/7Sknzb/bTJHHsjleD/VwW/8Aqxnj/foA6/8Aa4+JXibTPD/h74cfDt4F+I/xKlvNK0ma4u5LdLC3S3eS81DzkxzBH5ZTDh8yb0STy/LPsPwv+HOi/B/wHoPgnw9GYdF0W0is7dWRElfAwZZPLRAXkcNI74+eSSQ968m+APwg1+b4neOvjJ8Q7C40rxpr1zJpWi6XPqHm/wBleH0kj8i3eON5I455JIvPkEckib3+TZvkSvbtY1C28PWsmpard2+nabYRyXVze3UxijjjQOS8j5xsRM/f46v/AAUAfOn7Cl1baf4A+Ivg/S7K10zQfA3xB17w7o9vH5nmfZI7j7QnmvI+99huz15wg5ya+r06V83/ALFPhm5tfgzc+Mrmyn0e9+JGvX3ji40+4uUvI7ZL6ffbxxugHBtBbnnneTnH3K+kI/uigB1FFFABRRRQB8HftBeLvGC/t9eDtG8OeHD4u17TfAlzf+GLa6dotP0nUbu8ktbjUb+SPD/Z0tY2TZ8+9zGkYEkm+uw8N/Hr4vfCD4seGPCnx58PeGY9F8XSJpuheLPAaXkllDqDybI7O8Wc+YHk/d7HwB/vjzHg6j4+/Cnx7ZfFrwt8XfhWdKu/Fek6dPpGt6HrEskKeIdLd/PFpBJh/s86SISj7AD548yTy49j8G3gT40/tPfF7wPqHxO8HRfCD4feBNStPEEOj2uqWusXmtatG8n2djcR8RQR/wAadfn/AI94kgANT4J6Sdc/b0/aT1bUbi4u9W0TTvDukaVcyXcjC0sbi2+0SxxRnKAGWKOT7n39/wDz0fMPxqsY9D/b2/Zx1nTWltNU17TfEej6lPa3Umbu0t7T7RbwSR79j7JZDJ/v+Wf4Eqb4rfDL4n/Cn9oSX4z/AAm8O23jmDxLpyaX4r8ISay+nmaeEf6NfRySSCHKJHHBzHwivx+/kdGfCb4Z/Ez4rftJ23xe+LnhuLwTaeGdNfSPCHhCLWRqjQSyRj7TqElxHJ5Zd0keP7nzjy94BgjeQA+svLDSe+/3Hb/x/wC5XzP/AME77xPFX7ONp46NnBYa74613WfEmtLZu/lSXkl/PGWjR3fy02RIn/bMZyea+mz/AKNFG534SvlH9lfSdQ8EfB/4hfBzQraxtPFHw81fU9M0q28QahHd/aobgyX2lXV5HbplI5BeAPs5/wBHk9HRADz74R/Cf9rb9m34M6X4L8Mf8Kf1+00OC4k0+3mm1J7y6Mk8lx5YkPlR5kdzH8/lp/q8v1NfSn7O/wAdtL/aG+H58S22maj4e1WwupdG1nQ9WikSfS9QjKebBJnZvMeU+fAOCPuPvjHk2pfGT9qrTbK+022/Zy0rVNYiSSCPW4PHFr/Z09wM4uI7eTZOLcuN4gdw+z5CUr0b9lb4C6p8C/h/qlvr/iQ+JfGXiTWbrxH4g1FIkS2bU7jZ5/kJHGhEf7sAZ7jfsTPloAeL+Kvg74U+Bn7WH7J/hbwJo8XhzR/M8XT/AGSGSSTe76dFvd5HzJI/CDLv0jQdq9u/bM8M6f4o/ZS+Lllqtt9sto/DeoagI2bZ+/t4vtEDnZ18uSKPr/zzrH+MPwz8T+JP2pv2e/GWm6S174f8JjxEdbvVkiQ2pu7KOO3HlmQPJl+P3YfFS/tmeKn0n9njxdpVlYxahr/i2P8A4RLR9NmvY7L7Zd6gVtIwkknyO6b3k2cZSN+iZegD0n4H+Mbz4jfBjwH4t1OGGG/1zQbDVLmOBdsaST28ckmzJ+5lz+Veg1y3w98H2nw/8BeHfC1hJNNY6Hp1vpkEl04eZ44IxGjvx975P89K6mgAooooAKpzfu5o3EO8/czVyq8sG/ft4ymKAPkr/gmLYxSfsk+HPETPcz694m1HU9W1i9up5J5b66N5JAZ5HfPzlLeP8snl6g/Zl02Hwr+1p+1ToOlm4TRRqeg6smny3Uj263l/aST3k/lyPw8kmM/SNOiDHNeAfB/xv/Y91bxV4H8BfDCD4ufC671CXWPDZbxUmlyaJBMW8ywkS8eTeiHBBTj53kcl5Nkfp/7InwH8V/D2z8YeMfiPLBJ8TviFf/2zrf2GeeSLT48H7Pp8ZeSRHSASSjg4G/y/3iRo5APUvjj4wvPh58HPHfizTIoX1DQvD+oalardhihmgt5JEyD2+SvGvhF8J11r/gnrofgjw5DDpcnif4eOkLXkz/Z47q/s/Mkkcne4Hn3Ej8DgcCvevH3gmz+IfgXxL4T1FpIbPXtMuNKupoH/AHkcc8Ukcjpv/wCulfP3wB8ReOPEn7HWhaP4PsPC+l/EzwjAPB15pfiS9N5Z2t5p88dpcR3H2QeZ+8ggeUIP+ekfLp85AOO0m3/a9+APwt0ezt/Dvwu8deHvB+mWcDaPoL6n/bGoWcCRxvFb+ZiPzfLjPSP/AHI3ciOu/wDFX7ZXhaT4E+GPHfg2b+0fEvjctpvgvQLqMpLf6q8pt/Lnj81AI453CSyeZ5afwSP5ke/mfEvxW/an8WaPc6L4Z/Z607wDrOpN9nh8SX3jWw1CHTC8g8y4e3jjzJs/ednwf+Wcn+rfodE/4J//AArl+Cvw68B+M9Mk8c2/g2K6NpeXN5cWeJLuQTXLbLeRMI8mMB9+xRjPU0AeIaD8Db/4R/tXfs13vivxCvi74j+KLzxZqPibxGIUDS3A0uONLe3+QH7PABsjR+BlyI4wRGnt3/BQq6tvDn7N83jo2MN/rHgTXNH8Q6Ktw8pt472PUI4x5kaGPzAUkeMpn/lp/B9+vJ/iD/wTI+Gkfx0+FS+FvhqV+HI/tceMM67dAH/Ro/7P+/ceb/r8/wCo/wC2nFemftYeBdJvPhL8O/gFotiU07xhremaBBp9vq0cdzZ6PY7Lu7uI/P3+Z5UFps5/56R9fuSAH1lHvSP5+Xqaoov9XUtABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVVkjk/eOmzzP8AlnVqofO+fZsegB8cYjjC9qfUEdz5n/LNx+FSRyeYKAH0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABUMluJGyamqKSTyqAGeXt8v/Y/vtTJLdzbyJHsjkepftA9Kh+2J8nySDP8Ayz2UAKY3M+/5Pko+zv8AvP8Ab/26t1CJsu6bPuUASR/dFcv4w8Jaf4y0e707U7Y3VnMpyoeSORHR0kjkjdPnjkSREeOSMh0dEdCCK6eOTzBTPtA83ZQBB9ldJEKJEmxNie1Oktnkk35o+3J+7+R/3ntUvm8fP+7oA5jwz4Q07wpodjpelW7WtnbMH8mR5JS7yP5kjySOd8kjyO7vJJl3kcu5NdWq7BSRyCSMN2p9ABRRRQAUUUUAFVJIn/ebP4/9urdQibLumz7lAEM0L+fG6bPkT+Ol+z/6z/pp/t1L5h/55vR5h/55vQBFJG8mx8J5g/8AHKsrnb81ReaD8648v+/T4ZPMTcV2fWgCNofn3Hn+5x9yuc/4Q/Tl8UR+IDaIup/Yf7PeSJ3RZYhJ5kaSJnZJ5bl/L8zJj82Ty9nmSb+rqu1yBN5YRi1ABMrLHhQv/fRSuZ8S+EdN8V6Ve6Vq1qL7Sb5la8svNlVbpA4OyQA/PGcBJIn+SRCUkBjyldP9o/d70R5Kb9qVW2YaQ/7C0ASxp5aYzvqSmRyCSMN2p9ABRRRQAUUUUAQ/Zx9o8zNQxW+V2OkPP3/LFTed8+zY9JHdGT/lk4/CgCFY5I9gHPHzycj/AMcqcxuv3DT45BJGG7VH53zv8jfJQAscdRfZ8/f2SR1L5h/55vT45BJGG7UAVZLMyQokreZ/fkHyGsC18H6bpuu6jqtjbGz1DVPIfUJI5HRLiSP93HIUPyeZswhk/wBZ5ccSZxHHs6yoftKeZs70ARSW7/Z9ibN9c9q3hPTta8QaVq95YrdXumfaDaSmR9kTSII3k8vOzzDGZE8wjekckqIQJJM9LJciKPeyMPwo+0/6z5G+SgB8cZSPazb/AK1JTI5BJGG7U+gAooooAKKKKAKklv5kh/uP1qxGnlriopp/LkCbDju/ZaWO58z/AJZuPwoAT7OPMd+oP8FN+y/vPM/5aUkl8IYPOZGCVL9o/wCmbflQBFJbv9k8uPZHJVuofMP/ADzenJIJUDod6mgDI1zw/YeJNNvdP1Sytr/TryCS3ns7uASRTRv99HjPDjA/Wk0HRY9D0XT7CFrlobWCOCP7VcyXEgRAOHklJdzx99/nJ571qPceW+wo3t/tUC56bUaRP74oAdJF5j1zdj4N02x8QaxqsVghv9TaJbm6ld5HlEajykG8ny44yZH8tMJ5kkkmPMkkJ6TzD/zzem/bEZQ6fPH/AHx0oAljjEcYXtT6ZHIJIw3an0AFFFFABRRRQBDJbiRsmm/Z8Lt3Zj9H5p8knlUnm/7FAEMlvJLwdhj7xyDfUz24bpSR3HmLny3H4U9JBKgdDvU0ALGvloiU+q8k/l5+X6f7VSxyeYKAOZ8YeFdO8X6Peafqts97azjIjDyROjxuskbxuh3xyI8aSRyJiSN0Docit77OOPkj+Xp/sVL9oHm7Kj+3J/cf8qAHW8Zjh+ZEjP8A0zp0keXzSSXPl/eRqnoA53UtBj17Q7mxvnuIhcxSRySWN5LbyJvHPlzxlJEP+3GUNS6ToNp4e0ux0jTrO2stKtIUtreygiVIoIkTYkaJjhBhMDtW7RQBBbxmOMI58x6noooAKKKKAKklv5gk+Rf3n+2ak8sSPvP3/wD0Cl8759mx6j85PO27G3//AKv/AIugBsdvgfMkGz+MIlL9nciMvskkSpPtP7zZ5b/lSfaeI22N89AALcb5PkTY/WmLbyR9kk+oq3RQByjeDtObxIuu/Y0XVhafYWuLeV0863EnmRxypnZJ5bmTy94Pl+ZL5ezzZM9LHH+7/wBuke6jSYR/xmo5L9Irfz9j7KAJPswxIn8D1FJbyS8HYY+8cg31I1wu/wAsKx/3BUscgkjDdqAOVvPCuna94h0rV76zjubnSjcfYnmd8QtIgjZxH9zzNnmR+ZjeiSSIMeZJnqY4yke1m3/WpKKACiiigAqH7OPtHmZqaofO+fZsegCGO3wPmSDZ/GESlEb/ALv50k2VJHc+Z/yzcfhSfaeI22N89ADPs37yTeiGN6BbvtCP+8z9+SpfMP8Azzemi4UfwSJ/wCgCWNPLXFV7i387GX+TfmpPtP7zZ5b/AJVJHIJIw3agDmLPwfpul+INR1iytRZX+reSdQkid40uJI08uN/Lzs8zYQhk++UjiQkiOPZvx24j+fYnmf8AodSyXKRffpsl1tEhCMXQfc9aAE+znaiE70/j8zndTI1m53hfn/2zVmOTzBUUlx5e/CF3HYUAc63hPT28VHxC9qr6ubL+z47hneTyrfzPMdI0JxHvfZ5mwfvPKi358uPZ08cYjjC9qr/bo/3n/TP79TxOZEztKUASUUUUAFQSb8PsHP8Av1PUElx5bY2GgA8sbst8/wDBUEkDNblE/dO4znf9x6sfaP8Apm35VFJdeXDv8l/pQBZXO35qrSWwebzCieYPuGrEcnmCopJ/Lz8v0/2qAOa8M+FLLwbpFppWi2a2Wj2peK2tQ8jLbo8mdic/JHGPkSNPkjQIibI0xXRfZ/8AWfJ/rP8AbqxHJ5gqJ7jy32FG9v8AaoAj8tvOTlfl/wA//F1J9n+dx8pjP8GKVblZPuq5/CiO58z/AJZuPwoA5zTfCunWeuazqsdkp1DVGjW5uJXeR5FjjHlJlz+7jT95+7T5N8kkmPMkkJ6eOMRxhe1V5L5Io95R/wAqJL6OH728fhQBbopkcnmCn0AFFFFABUEm/D7Bz/v1PUUknlUAQyW/X/loP+edWI/ljUURv5i5qKSfy8/L9P8AaoAsVia54fsPEmm3un6pZW1/p15BJbz2d3AJIpo3++jxnhxgfrWr9oHpUSXXmL/qXB/uUAZ2g6LHoei6fYQtctDawRwR/armS4kCIBw8kpLuePvv85PPetaSLzHp8cnmCm+Z+82UAOjTy1xVe4tfOJBb92/346dHceZhtjbT14+7UsMnmJuK7PrQBy3hXwjp/hHQbHS9Kga0s7dg4iZ5JS5d/MkeSRyXkkd3keSSTLvI5dyc11arsFRyTeX/AAOaha/SMOdjfI/l0AXKKZHIJY9y80+gAooooAh8t/M31HHG/wDHs/26tVD53z7Nj0AR/Zud/wAlNjt8D5kg2fxhEqb7R/0zb8qSO6Mn/LJx+FADoUeONQ7b39a53WPDNjqWvabq88AGq6a0i2V5GzxyoJUKSI5QjfG+EJjfKb443+/HHs3/ALTxG2xvnqxQBUjtvL8v5Eohjcom9Fj/AOub1bqCS5WMSfL9ygBY4/LjrmvFnhDTfFmlXmmarYfa9JvGj+2WfmSLHdjcMpIIyPMjIGx43+SSPKSApkHpJLgRxlyj/LS+Yf8Anm9ADo08tMZ31JVOS+8u385oXwE31L9p/wBZ8jfJQBPRTI5BJGG7U+gAooooAh8t/MznioY4H8uTeF8yT/aNTPN5bhKT7T+82eW/5UAEsTtJGy7fl9aQW43yfImx+tO+0f8ATNvyqagCrHa+T/00rnl8H6f/AMJV/wAJCLJRq32H+z3mikdPOtw5kEciZ2SbHL+X5gPl+bLs2eZJv6uoJLlYxJ8v3KAImjaKN/Kiz/wPZVpOlRSXAjjLlH+Wl+0f9M2/KgCOaN9xdf8AWfwVzlx4TsNY17SdXurBJ7rSTcGxed3xbmRBGZBH9zzPL3R+ZjeiSSJnEkmeikuvLg37H/74qT7T/rPkb5KAHxxlI9rNv+tSUyOQSRhu1PoAKKKKACiiigCHy/3lPRdiUx5vLcJT45BJGG7UAV7i387H+/muc0/wlp+leINV1m2to7fVdT8s3M6Z/eMimMSbB8nmeWIk8zG9444EckRR466oXm8twlAEUltJ9j8tJPMk/wCeklW6h84bfl/ef9c6T7SmPk/ef7lADJo33F1/1n8Fc9L4LsE8Uf8ACR/ZFfVfsn9nJcTSPJ5NvvEmyNM4j3uE8zZgyeXF5m/y49nS+Yf+eb0xrxIxlwyY+9kdKAJo4xHGF7U+o4nMiZ2lKkoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACs+5fynwnLyPjzP7laFfI//AAUT+Iup+G/gPqfhDwvZ6jq3jrx5G+h6TpOk2iXt3cQkF9Q/c/6zyvs6OjyRh/LMkf3Mo9AGr+zX+2NYftD/ABC8Q+HYtDj0iy+wvrHhq/F893/bulx39xYSXhjMUZt8SW8f7uT5/wB5X07FL5ke+vy6+J3xel8Pr8BPEPhj4S/HLQIPg5cRwT6h4h8IRpDJoH2ZIL8SHJHnfZ4APM/doMyH5PkKfphouuaf4g0az1LTrqK90+8t47m1vLeQGOeOTmN0cf3wR+dAG3RTI5PMFPoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAIftA83ZXzF8XP21/Cfw/wDil4P8D+H7FvHGs6v4gs9A1e60u7BttCeeeSFBdTokifaN8c5S0++fIkPyYTf9MyxvJ9z/ANDr5C/bO8J6L4Tb4Ef2Lo2n6SNT+N+gahemztEgNxdSfaPMuJSg+eSQjlzzwOaAPor4peM5vhn8LfF/iyOyS/bw/pF5qi2XmeX5/wBntzJ5efn5+TFfN/hj9qT9oLxt4T0bxJpP7L32zQ9Vs4L+zu/+FhWMAkt5I/Mjk5jDplHH36+kvih4Ij+Inw28X+DDefYD4k0e70c3Gze8P2i3kjMn+3x/6BXyzD+zz+0z8IvhrYWvgb49Wfi4+F7OC30nwfqfg+zs4L+K32AWZu/MMiDy49nmeZn/AKaR/wCsAB9Q/wDCxLXw38N9O8SePptO8CObK3k1aLUtSh+z6bcPs8y3+0cRv5cj+WD/ABnGM15d+zr+1fYftMeO/iPo2iaDe6doXhg6bJbalq4eKTV7e7jlkjuBbugMUbpGHj6mSOSNz5f3K3fg/wCOvDH7X3wC0DxPqPhe2m8O+IYM3eh63DHeRb4LiSOSNxjZIiSxZjcj+4+yMjFcJ+zzv/4bm/a13p+8/wCKT+5/2C5KAPqxM7PmryT4yfE2bwPeeF/C+kx29/4u8Zak2m6TZ3DofJ2RmS4vpI/NjkkgtoYzIUjO938qPenmBx62i7Er5Z1jU5tV/wCCjPh3Rb8w31lonwzuNX0qGaCOQ2l3capHbzzxyY37zBGkfX7m8ceY+QDW+On7TmqfDf4haB8PPAHw/vPid8Qb60k1dtFgu/7PgsbCPzI/tElzIhRN7jy0Tpnvl4xIfBL9pLUviF8Rta+HfjX4dXnw0+ImlWserroNxcpfwXunSSRg3UF5GnlviR9jrz8+MPlJPL5H4E6bp/8Aw3l+1VqssMCXlrF4WtorySMb4YJLAmWMP2RzHHkZ/gQ/wDDfjlo1lD+3h+yvq6WUP2y5i8TW73kcf7x449O8yNN6D50TzZNg/wCmj+poA9m+DfxWm8bzeKPDusQw2Pi/wjqJ03V7W3mTy7jfGk9veRR+ZJJHBcQyeYiSHMZ8yPL+VvPrUcnmCvlXT9Qk0X/goxrejW3kW1jrvwzs9X1NILOOP7bfWupyW8c7yEby6QSunX7hT/nnHj6rj+6KAHUUUUAFFFFAHNeMPGmh+A9Hn1fxFq9loWk2pj8/UNRuo4LeHe4Qb5JDgcuOteJ/s6/tW2P7THj74i6Noeg3WnaJ4YfTJLbUtWDxS6vb3ccskdwLd0BijdIRJH3eOWNz5Z+Sva/FHgrRPHmk3OleINIsNd0i6KfaNO1G0juLefY/mR743GDh/n5HavnX9nl2/wCG5P2tN22OT/ik+Pv/APMLkoA3/wBor9o7xR8GvHHw88J+E/h4vxE8Q+MhqH2axGuR6Z5P2SKOWT55IyhHlySff2f6vvS/Dj4ufG/xZ4y0zS/FX7P/APwgmgXZnW78QR+NLHUzajy5Hz9nijy+ZEjj9vMqf9oz9m7xT8YPHXw48XeEfiEPhzr/AIJ/tD7JdLocep+Z9siijk/dySIi4SNxzv8A9Z2rzFvHHxm/Zj+K3gaw+Jvi+D4y/Dzx1qVt4at9Xt9KtdIvNG1aV38iIwRn95BJj5znI8s/c2bJwD6B+LXxy8J/BrRYdR8Q3ub6+Z49I0O2xJqmqz5SMW9nb/fkkMkkfThPM+fYOaq/su/HCT9o74G+GviIdG/4R8aybjGmrdfaDEIriSA/vPLTOfK39O9dlqng3S9Y17Sdcv8ATNPu9Y0hbg6bqE9rHJc2PmARyGCRxmPfGMPjrXgX/BL3/kxn4bf9xP8A9Ol5QB9SSXHl9f7+K8m8H/FQ/E74m+NdE0q3s5PCXhOUaPqGpM8c/wBv1R0jklgj2S/uxbo8aSeZGTJJK6Dy/s7+Z6rJC8kwdHcCvgv4K6hP4k/4JbePPFV+sD654l0PxbrOs3ttbJG19dSPfiSaTy9qb/3afRI0ToBQB01t+258RPHGmeIvE/wq+AGr+Pfh1aT3MVl4lm1+Oxk1URf6yS3sJInnkQv5kcYQnfjZhJB5ae4eGPjEPjB8B7f4kfC+2/tyfULOS80zTNQT7O928cj+ZYOS4SOTMckAkJdI3PmYkT79T9kLS7LRv2X/AITW2nwQ6dDN4T0y5dLWGOPMktukskh46vJJI/8Avu/NeY/sA6PZaXpvx40rTbaLT9Ps/i3r9raW9mnlwWsUYt/LSOMDYEATHGPSgD6C+FPxU0T4tfD7QPGOgyO2i67bi9tiZUlkQPy0cmyRwJI3zG6A/I42dq72OTzBXyx+wtqUn/CP/GLQ4Ugg0bwv8Tdf0fRtPs7aOKOxtBPHP5EaRj7m+eT6V9R28bxx/Py9AE9FFFABRRRQB598T/il4S+DPhe58QeLfEen+HdIjO0TX1xs82TZvMcSdZJNifJGmScGvPf2X/2ip/2lPDPivXD4X1Dwm+g+Jbvw+NN1eRvteYEjffPHs/cSfv8AY8fz7COtes634P0fxTcad/bOjafqyWN1HqNiNStknNpdx/6ueLeh8uQZf9598Z4r55/YJ+7+0V/2WbxD/wC21AH1L9pji37/AN3/AB189fs8/tYaL+0p8R/itoHhrTFXSPBt5Z2kOsvfJcJqyyG4jkljjT5Nn+jny38x96OjnH3K8o/aw+N3hv4lfEf/AIZ2n+JVt8NNPjhW98ceIr29isS1hIkZGj2rzjEk9wJ43dxsRIxg+Z+8hrM/ZT+Inwm8J/tWfHHRNC8X+F10C7j8I6R4Yt11mCUX32bT/ISO3keQ/aDG/lx8PI+8epoA7eT9srxl8RPGHiHT/gb8I7r4veG/D8qWV/4oXxDbaTZy3h8wvb28kiYuI4/3f7yP1/uOjv7N8A/j9oXx+8K3evaDaaxpcunX8+k6ppOvWptbvTryE/vIJk5+f54zwTwezh0HzJ8EPGnjv9iPwxcfBvxZ8KPGXxE0HQZ3n8OeLPh3oJv4tQs7ieSf/SIzJiCeOQvlM9x6JJNc/Yj1zxv4p/al/ad1Tx34ag8JeKZZ/DyzaHbXaXi2kYtbj7OhnQujv5CQF34y5zhPuAA+5vtH/TNvyrxHwZ8erDxl4Q8d/EG5NtY/DTRZ7yOx1LCXb39tY+Yl5qGYHk/cO6SRxxiPfst3fJ89Ej6P4+eJNQ8D/AP4heINFufJ1bSfDupahY3SRJJsuI7eSSOTZjYfnHcc/nXx58etHt9H/wCCPmlWtnZQWdu/hfw5N9nhh2Hz5Lmzkkfj+OSSQuf996AO0b9uj4n/APCCp8SU/Zq15PhVj+0P7bfX7b+0H0/zP+Pv+z/L8z/V/vMfc2fP5nl/vK9s8dfG6w8I+E/AvxLt2t9S+HerSWcGoaq5+yPY2l8Y0s9Qd7iSP9xG8kaSR7PMxceZlPKkjk9K/wCEX0JfDY8NPpGnNojWn9npo32aP7L9k8vy/s3kf6vytn7vZjZ7dq+GPgPpdnr3/BHi/tNQtY7y3HhXxFc7ZEDxpJFcX8sb/wC+kkaP/vhOlAH6GxqFjwq7PapK83/Z78TX/jX4D/DbxBrM/wBr1fV/DemX95MU2eZPJbRySPj/AH3r0igAooooAKKKKAPlv9q79tLwd+zXpt6sUJ8Z+NLYI914Y0272NYwlox9pvZIw/2SP/SIvLLjLvcR4HV0+lpN+JPL/wBZ/wA9K+Q/+CkvhXRtC/Y6+Mmt6fpNnY6zq40gajqdvAkdxfCPULWOMSyD55PLQ7Bv7dK+uncfaCjOwkTn7/8AB60AfHWrftpfFrQfC99411D9mbxFp/w6sp5JbvUrnXLePVIrBJihuJNM8vzkkEabyM7AuX8zYPMr6G1T4y+EdJ+EX/Cy7vxBBaeCZrOHU/7amDxj7LLGjRyeXjeZHDoEj2by7xpszXj37X3hn48+M/Dmq6J8PLPw7q3gvVtMSw1rTTdmz8QXKSSFLyGznuENmieRIo8yRN4/efxpHUHiDwT4X/bC/YPi8NfCu+fQfC+r6Ja22gpqcEh+y/YbhMW8n35MiS3+zvJmTp5ieZ/y0AOb0/8AbX+IFz4LHxFvf2efFFv8JfImvY/E9nqtnNqhsAzmK8/sw+W4EmI5JPn2CPMgLpyfrXwb4o0zxx4R0TxHo11JfaRq9pHqFjcSRPGZIJkEkb7H+cZRxx/Lt8oWH7Xnxf1Lwd/wjsP7OnjGH4vRw3Fmy3GnpB4W+0R7/wB4L+S4CGDCbxz+8/1aSciSuq/4Je/8mM/Dbd/1E/8A06XlAHq/xs+KFv8ACDwe+sz2A1nVb67t9M0XQlu47R9U1C4lSO2t1kkPB3vkv/yzRJH2Hy683+O37QXjL4LeJ/hh4O0HwFa/Enxp4ugv9sdjqcegR77OCKWTyxP5oSMh5H2SScbOr1m/tGavcXn7WH7Mfhi7WG90K71TW9XfT7y1SSM3dpp3+iTh3JKvGZ32Yx+8IfqEx0f7Q37Nvif4xeNPhv4t8IfEQfDvX/BJ1BLS9j0OPUxJ9riigciOSRETCRv1D/f+lAEXw4+Lnxv8WeMtM0vxV+z/AP8ACCaBdmdbvxBH40sdTNqPLkfP2eKPL5kSOP28yuvm+JD+HPjxa+A9djhhi1zTZNT8M6grohuzb7EvLGRDIXklQSJcIUQIY5ZPkBt/Mk8Jbxx8Zv2Y/it4GsPib4vg+Mvw88dalbeGrfV7fSrXSLzRtWld/IiMEZ/eQSY+c5yPLP3NmyfqP2xrx/CviT9nfxBpcccGtL8T9N0eLUPJQyR2l5FcQXlvH5gOElT06+XGf4EoA+qY4/LjqaoLP/UCp6ACiiigAqH7QPN2VNVWWN5Puf8AodAHzL8XP22vB/gH4n+EfBWg2beNdW1fX7PQtWutLvR9j8Pm4uHiAup1WRPtG+OfZbcORBL/AKv5d/u/i7WP+EV8J6nq8OmXmq/2VZz3IsdJg8y6uPKjc+RBHx+8PRB718y/tneE9F8Jt8CP7F0bT9JGp/G/QNQvTZ2iQG4upPtHmXEpQfPJIRy554HNfWckaW8uXbnzI/nNAHx1cftr/EnwHpegeKvil8AdX+HPgC8mgi1DxNDrcepTaak6fJLcaekQljQOIw+/50yUAMmEP2dHdJuKfMH3/c718VftraX8WNYt9STXNE0DxT+zzp19b6r4h03Qb17TxJLp1rH9ouDJJORB5aTxl9lu6TugjQOm93HW/tMfta6H8N/hj4Sn8P6/Gde+JUCw+FNQvSbaxsVnEeNTvJJ4n8u3t0nSQh4yTwPLxveMA6TxX+1jo+i/tbeD/gXaaf8A2rrGs2dxd6jqS3ypHpOy3lnjjeMb98jpBv2P5exJI3+fzMD6Jtv+PeP6V+Yujj4Q/Av49fsyxaH8XPD3i23tbvxVqvinxZeeIbebz9Qu9OiT7RcSeY6QCR49kcZPOzrI+9z+kmh6rYeINJtdS0q5tbzTryGO4tLmzlSSCaNxvSSOROHR8g57/jQB598aPie/gm58L+F9Jgtr/wAX+MNRbTdJtZZIyIVSMyz38kZljkkit40kkKRne7+XGHj8zeOI+O/7Tmq/DT4geHfh34C8A3vxM+IGqWMmpHR4LsaZb2OnoZI/tMlxInlpmRPLH+4fuGSPflazqU2uf8FHdD0S+WG+s9B+GlxrGlxzW8b/AGW6uNTjt7ieOT7ySGFI4+P4N443nPnnxi8QeKfFH7aFha/AvR7e6+KXhfRG07xdr3iZZ4/D1tps+bi0s7hRmR5zIRLHJblDzz5ieZ5AB7J8Gf2jG+Ifj/Ufh14s8Ca18NPiVY2A1i40PUHjvLO7szL5fn295F+7nHzx+YfkIcmP5/Lkrq/gz8UrjxpP4q8O6zHHZeMPCWqf2Xq1vFIn7/cqz295FH5kkkcFxA4dI5CXjIlj3v5ZevnD4O+IPFHh39szV7P47aRbWnxR8TaAml+D9d8NvL/wjtxpsH+kXFhBlPMjnEm+R5Jy744Tyk8vz+/0vUptL/4KMa5olrDFa6frnwys9Z1GOK1jEl5d2+qSW8FxI+PM3pBO8fXpjr5ceAD6qjk8wU+mx/dFOoAKKKKACua8YeNND8B6PPq/iLV7LQtJtTH5+oajdRwW8O9wg3ySHA5cda6WuZ8UeCtE8eaTc6V4g0iw13SLop9o07UbSO4t59j+ZHvjcYOH+fkdqAPEv2df2rtO/aX8c/EjSNG0G603QvC50yS21PWA8cur213HLIJxbug8uN44Q8f9+OWNzsPyDofjx8YfGfw1vPC+meBPhfqnxN8Qa01xiG1vEsrOxjjQOWnvHQpGXP8Aq/M+/wCW461wf7PG7/hun9rXH/UoZ/8ABXJX0L4wj1uTwvrK+HWsH8RSWU402PVlf7H9o2fu/tHl/P5fmbd/l84NAHifwL/aX1X4h/ErXvh144+H+ofDD4g6bapq8WiteJf2t3pj7P8AS0u44/LkxO5jfZ3kxlzHJ5bviJ8ePiXpPjjU/D3w4+BGu+OxpQjF/quoapaaHp7b40eMWc8u/wC1bMyJJgfu5BXmfwf1Hxb4b/a6vm+O2m6Zb/Ezxdo50jwbrfhmUS6NPp9mguLyzjgP+kRyb38x5Ln7/lukfl+WnmfUfxE+IGh/DfwdqfifxBrUGi6HpsfnXl/MdqDCgY+6fnPybEGS7kJjJFAHA/A79oqfx54k1jwX4z8G6j8M/iHotrDqF1oGoahb3sU9pO8gjuLO4jf/AEqMeWgkkCfu5JPL5Ne5SXQjx8jH59n/ANevnP4K+BNf8ffGS++PfivSJ/Cl7qGh/wDCN6F4XnA+2WukC5Nx59+c/JdySYPkR/6hMI5kfOz6H+zu3lkSSp8+W560AeR6N8arfxX4z+IEcMmn2fgDwIr2mr63eSxyR3V+IUmuY0dJP3EdnE6JJ5iEu8rp8n2d/M8e0X9tTxv8Q21LxJ8OfgJrvjf4UWt7NFH4oh1aG0uNSig/4+Z7PT5YxJOc+YETzP3nl7Pkk3olL9j7wzN8cP2BbyDUL62sNe+I0XiJ9W1qKzjHn313d3kUl3JHH5e9/wDV8f3IkjGwVnfCP9oL4nfBbwDp3wn8RfAjxx4m8YeGVj8PaTrHhexLaBqsEcccdlcPfyPi3R0x5jEOI+XOz/VIAe/+Hfi8vxn+Bdr8RvhfarrM97Z/bNO03Ul+zyX0kMhD2byb9kcnmRyxeZ88cb/vP3kf+s6n4U/FTRPi18PtA8Y6DI7aLrtuL22JlSWRA/LRybJHAkjfMboD8jjZ2r5l/wCCb11r2qfD34x3Pi2yh0nxRN8TdYfVbSzfzI4LzyrR5405k34k8zu/Suy/YX1SZfD/AMYtFjihg0Xwt8Tdf0bR7Czt4447GzE8c/kIkY6b55P0oA+pY5PMFPqC3jeOP5+XqegAooooAK87+KHxR8I/Bnwzc+IPFviSw8OaTHuVJr64C+bJ5fmeXEmcySbEOyNMk4NeiVy3iLwdo3i2TT/7b0fT9XXTbqO/sTqFrHObS7jz5dxHvT93IOcSDp2oA8p/Zf8A2h5v2kfDPi/Xl8M6j4OXRfE13oH9m6vMwu/3CRvvuEx+4k/e7Hjy+wp1rK+JPxz+J2iePtY8NfDv4CeIPHZ03yzfatqGp2mg2P7yJJIhZzy7/tfJl8zujgfhh/sE/d/aK/7LN4h/9tq918e/ELQPhl4O1TxP4k1aLRdF0yHz727ucjy8rgc4+/wETrvciPlyKAPPfgr+0BdfETxVrXgvxb4J1D4a/EfR7WDU5/D9/f212k1tPJIn2iznjf8A0qOPywJJNgEcknl8mvM9J/a8+MPjLxF41svAn7PH/CX6V4U8R3/hq41X/hN7Oy82e1kx/q54PM+40b9/vnmut+DvgXxH49+MmpfHrxlpF34P1DUvDy+G9A8MTbRd2mkfafP8/UOfku5JD5nlRnECfI++TpyNt+yT8XPB/iTxteeA/wBof/hC9J8XeJdQ8RtpC+DLS82XFyd5HnySFz8iRjsPk+51oA93+DHi7xx408O3l74/8Af8K21VLzyI9I/ty31PzICkZS48yLhMyeYnl/8ATPPOa9Jjk8uP7n7yvm/9lX4x+NfHs3jf4dfE3S4IPif8P5LSz1rUtPlT7FqkM6SPbXcYThJJI48vH8g5H3P9XH6V8fvE+o+Dfgf8RfEeizfZdY0jw9qV/Yz+UH8maK3kljfY+UkxIidR/OgDO+D/AMU2+MTeI/Emn20J8HLqcmm6Fc27xXD6olrLJBc38ciSOnkPJ5kaJjfst/MyftCJH5zb/tseFvEH7Qfgv4ZeEoT4o0/X2vEn8X6dck6dDPb2huDb28iCRLqTZ5fmCNx5fnx/x7wnbfsj6DbaD+y78IorO0trK2bwpptw1vbR+UPMkgjlkfCdXd3kd+Mu78nrXk3xX8J6L4L/AGwP2RtD8OaXY+H9JgPi/wCz2Ol2kdvbwb9Pjc7Ik+QfO5f680AfX8FxGnlx+v3K+ePFX7XWlaN+1j4N+BWnaU2sa1rNtc3epXyXyRjSdkEs0cRTku7pA77H8vCSQP8APvxVP9sL9pa0+AfhjTNHs9Rj0nxj4zuH0fQbrUJEistOnLpG+oXcjxSIkFv50chBD78/c+/Iny7o/wDwqH4F/Hz9mWHQ/i5oHiy3tLvxVqvinxZeeIbebz9Qu9OiT7RcP5jpAJHj2Rxk/wAHWR97kA+4fG3xLl+GvxI8EaZq1vbW/hjxfPJo9pqvmRwyWGq+XJLbwS+ZJ+8+0xpIkflplJLfZ+8+0J5frkcYjjC9q+Sf2/PElnD+yNrPjnw1c2F7eaLd6Jrvh/WoI47oQTi/tjb3NuxHln93LJyP4JCOUfFfWkX+roAlooooAK+W/wBqz9tTwf8As06berDEfGnjW32PdeGtMvNrWMB8sfaL14xJ9lj/ANIi8vzBl3uI8cZdPqSvjf8A4KT+EdH0L9jv4xa7p2l2VnrOtf2SNS1K2tkjnuxHqNtHH58g+d9ifIM9AfrgA+mvFmst4Z8Mazrkenalq7afaT3hsNKi+0Xk5jjZ/Lii3/PIdnlon9+vnP8A4aW+O3l/2v8A8Ms+IP8AhEc/bfO/4Sa0/tb+z879/wDZ+PM+1+X/AMu/mb/M+SvqlowssryPsHyOZPuV478YvjVqHg7U9L8FeDLCHxT8WdfjeXTNHmd47PT7YHy5NQ1Agb47ON/+2k8g8uPnlADs/hT8U9G+MHgHw74y8NTPeaPrVpHeQjejSISBvjk2SFEkjOY3Ts4I7V45D+3D4T179onwX8NfCdmfFVjr7XqTeL7G6D6dDPb2hufIt5I0kS7fyxH5gRx5f2iPq+9E9E/Z7+CsH7PfwX8MeA9J1V9ag0SF0a9vIvLe5kkuHnkfYn+rQyO/ljL7ExzJya8V+LXhXRPBv7Yn7I2i+HNJstA0iH/hLlgstMtkt7eDOnxv8kafIPncnp1oA+w7b/j3j+leY/Gz4oW/wg8HvrM9gNZ1W+u7fTNF0JbuO0fVNQuJUjtrdZJDwd75L/8ALNEkfYfLr1GNPLXFfKv7ReqT3f7WH7Mvhm4MN54futV1vV5bC6tI5I3vLPT/APRJg7/deIzyOmMfOd/UIQAeveN/iT4e+DPgFNa+IfivSNDjgtxHcagw+yxz3CR+ZJ9nt5JJJJJDsd0jBkf/AK6d+R/Ze/aHm/aS8N+LtfPhu+8Gpo3iS68O/wBm6rL/AKZ+4jjk3ypx9nl/e4eP5+Yzya9Q1zwjo3iaTS11nSdP1SPTbqO/sDf2kc5s7uPf5c8G9P3cqdpOozXz5+wT939orf1/4XN4h/8AbagC98Y/2mPHvg748Wfww+H/AMJf+FiavL4bi8TO48RwaX5Fv9seCRMSR7HwRH/H/wAtOldR8I/ij8X/ABp4iu7Lx98Dz8NtHjtPNTUH8V2mrm4n8yNBF5MCBx8nmPvPH7vHeuY+M37Mfjbxl8dYPin4D+LR+G+sw+Go/DDoPDUGr+fB9okuCf3kmBmQp/Bn93161zPw8+InxT+Dv7QmkfCL4t6xbfEjS/GsN3P4Y8X6fY2+nyB7W38y7s7uzTAREQ70I3/6wcyb8W4B7b8G/ipL44uPFHh7WIYNP8XeEdSOl6ra28sfl3G9FmtL2KMSSSRwXEMiuiOcxnzY8yeVvr1eOTzBXyppd8+k/wDBRfxBounxQ2mm678M7XWNTFvAge7u7fVJbeKeSQfvPMSCd4+vTYMfu48fVkf3RQA6iiigCH7QPN2V8w/Fz9tjwj8Pvid4Q8E6BaP401bVfEFnoOrXWk3oFnoH2iWSEC7nRXQ3G+OfZaffPkSH5MJv+mpY3k+5/wCh18hftneEtF8It8CP7F0bT9JGp/G/QNQvTZ2iQG4upPtHmXEuwfPI+OXPPAoA+wPOx8qpvH+xXzHD+3D4T179onwX8NfCdmfFVjr7XqTeL7G6D6dDPb2hufIt5I0kS7fyxH5gRx5f2iPq+9E+l/Lmj/jR41/56V8hfFrwrong39sT9kbRfDmk2WgaRD/wlywWWmWyW9vBnT43+SNPkHzuT060AepftGftEaJ+zn4Us7u/tpNb8TarP9g8OeF9NG+81i8d9ogjTZnywXj3yf7nG940fhND/ar8XeHfGXhnQPjH8GtS+Ftv4r1KPR9A1W31aDXLGS9kBH2e5ktyDC8h2JHlD/y0P3I3wn7XngPx5p3ir4c/F/4eaWnjDX/hncahcz+FZo5BJqtpd26R3AhkT/lvHHGdmUO/eMb3j8uT56/bn/aQ8Y/FT9mLxZp+ifBrxx4W8JR3NjJ4k1nx9YR6YYY/tMZtxaReZuneSdIxIU/1f/bXegB+mNvN5sEb/wB+vKfjP8Sp/BNz4V8NaRDbXvi7xlqZ0vSLOWVG8vbG0lxfyoZI5JILaBGkdIyHdzHHvTzA9etx/dFfK2sajNrH/BRrw/o+oJDfWmh/DO41jTI5YI3NneXGqRW888cmA4JgjSPr9zzBx5kmQD1T4ufGrwz8F9Ht9Q8RagEvbkvHpOg26eZqmsSkpGltZ22fMlkLyQD5OnmDfs61U/Zf+Oj/ALRnwL8OfEU6P/wj66ybjdpq3f2jyPKuJLc/vPLTOfL39O9dvq3g3Stb17StbvNJ0+71PSFn/s7Ubi1jkuLEyoEk8iRxmMuBh/XZg187f8Ew93/DD/wt+TeM6p+8/uf8TG8oA1fHf7SniuXxvrWi/CH4Z3nxcbQpfseu6lFr9ppNlp95nJs455wRcSIBvkSP/V+ZGjnJ2J33wr8ceMPiR8ObzVNc8FSfC3xckt7ZLY628WpJBIkpjjuAYpIzLbsU3f8ALLzNhKEp5cknxf8AsReDfjz8VP2dNA1Pwz8QtP8AhPpFxeX97NrB0S31vVPFd5JeSfaL28knf5PLwkCZJkk8uTzPk8uvpj9lT4ueN/G0vjb4e/ErToLb4n/D2e3tNU1WzdH07VI7iMvbXkaLjY8kaF3jwmPMB/d7/LjAPSPgj8Vrb4reAxq66a2h6xa6hcaTrWgi7hvJdL1CCUx3MEkkfyHD/OH/AI43jkwN4A9OjkEkYbtXyr+z5fzab+1R+0z4X09rex8PWWq6Dq0Fja26R/6Zeafm8uHON7vL9nj3knqHf/WFyfqa3Hlx8v5n+3QBPRRRQBzXjDxpofgPR59X8RavZaFpNqY/P1DUbqOC3h3uEG+SQ4HLjrXiP7On7WGn/tL+PPiLpGh6DdadoPhiTTJbbUNV3wy6tBdxyyR3At3TMUZSESR5JMkckb/u+Ur23xR4K0Tx5pNzpXiDSLDXdIuin2jTtRtI7i3n2P5ke+Nxg4f5+R2r52/Z53/8Nzfta70/ef8AFJ/c/wCwXJQB7V8Ufit4S+Dnhi58ReL/ABLp/hzSYVYLPeTiPzX8tpPLiQHM8myP5I0y5A4FcP8Asu/tBSftMeG/FWv/APCM6h4TXQ/El34e/szVpf8ASwYI45N8sfHkSfv9jx5k5TrXqniPwfo/iifThrOkafq66bdR39j/AGhapObS6j8zy7iPf/q5Bk4k6+nWvnj9gn7v7RX/AGWbxD/7bUAb3xK+OvxJ0Hx9q3hn4d/AnXvH/wDZMcZv9WvdStdB0/8AfRpJH9jnmz9o/wCWnmYGY5Bitj4H/tFXPxA8Tax4K8ZeDL34Z/EPRbWHULvw/qWoW95FPbzySCOe0uI3/wBIjBjjEj+WPLkk8vrXf+PfiFoHwy8Hap4n8SatFoui6ZD597d3OR5eVwOcff4CJ13uRHy5FeR/BXwPr3jz4x6l8fPF+j3HhS61DQ/+Ea0LwvcBTc2mkC4Nx5+odhdySc+Qn+oTCOZJM7AD6Qa48v7yOPwrxWz+NUmv+Kfibd6Jo8+teGfANu1ldy6PFHfXur6rHALiSzs0jlyDBG4jKSDLz3GweX5D+Z7J9ndvLIklT58tz1r5c/4J33f/AAln7LfhfxPqcUL+IvEepaxq2sXkESRSX93JqFwr3EgjxniONM/9M0x9xKAIn/aW+OManV0/Za18eDP+P3zP+Elsf7Wazzv3/wBnY8z7R5f/AC6eZv3/ALvNew+F/jf4T8VfBO3+K9nqXleEJNLOuzXrYlltbdIy84dIjJiSPy3jkjTPzxyDrWF8avjVe+DdU0/wV4G0+PxZ8VdeR5dL0eZz9j0633+XJqGoSJzHaRv/ANtJJP3cfOdnzr+1R8Gbb4A/8Ewtf+H1pf3Gr2+iw2cRv7iMRSTXD6vbySP5YHyJ5kj7OTsTyxmTrQBvJ+3R8Th4F/4WQv7NviAfCZ/9N/t7+37b+0H0zzcfbP7P8vzP9X+8/wBZs2fP5nl/vK9o8efHiw8I+DfA/wASoEtb/wCG+sTWkF/qz/6I+nWt/wCWtnqBed48QJJJGkiFPMCXPmfJ5DpJ6V/wi2gP4bHhZ9HsP7Ae0/s5NJ+yJ9j+ybPL+z+X/q/L2fu/L6Y7Yr4Z+A+l2evf8EeL+01C1jvLceFfEVztkQPGkkVxfyxv/vpJGj/74TpQB+hsaiNcBNlSV5v+z34mv/GvwH+G3iDWZ/ter6v4b0y/vJimzzJ5LaOSR8f7716RQAUUUUAfPP7RX7TVn8E9S0Pwn4e0W68dfFDxHKg0jwZYXMcEk0BOJLmWTnyIEVJP3h7o+fkjkkjxfAH7UGvX3xT0f4efFT4Za18LfF+vxz3uiW66hBqmn6hFAm+UJeQcJOg8x3jI/wBXGnOZER8P9ofQfHXwj/aO0D4+eEvDMvj/AEaLRI/CPiPw1pds7arFZveG4+12SA4ncSFAY/b0kMkHjP7RXxu8Z/GPxx+z04+FXiTwH4Etfibovn6l4zto7DUbjVBJ+6jjtN5fyPIMp8zkO/yfIY8OAfR/xI+O/wATNH8dal4b+HfwH8QfEE6T5f2rV9Q1a00PT38yNJIvsU8+/wC14zIJP7jx471s/A79oqfx54k1jwX4z8G6j8M/iHotrDqF1oGoahb3sU9pO8gjuLO4jf8A0qMeWgkkCfu5JPL5Nd98RfHeh/DXwhqfinxHqkOiaNpavPeXkp2xoDx6HL5ARP8Ano/yYy4FeT/BXwDr/j74xX3x58V6RP4UvdQ0P/hG9C8MTgfbLXSBcm48+/Ofku5JMHyI/wDUJhHMj52AH0ZJdCPHyMfn2f8A168Zs/jU2veI/ibdaJotzrHhnwDCbK5m0dI7y81bVo4BcS2dpHHLnMEbpGY5BmSe42Dy/IfzPX47Z+0j53/PXy9/wTvu/wDhLP2W/C/ifU4oX8ReI9S1jVtYvIIkikv7uTULhXuJBHjPEcaZ/wCmaY+4lAEMn7S/xwjB1VP2XNf/AOEN/wCP37R/wktp/a72ed/mf2fjzPtHl/8ALp5m/f8Au69j8N/HDwr4n+Ctv8V7TUfK8IyaUdbmvOJ5LW2RN9x5iQF/3keyRHjj34dCPWsH41fGq98G6pp/grwNp8fiz4q68jy6Xo8zn7Hp1vv8uTUNQkTmO0jf/tpJJ+7j5zs+cf2rPgpafs8/8Ex9c+Hun6nPqkGjQWkR1G5i8uSeV9Xgkkfy+diF5JMfNwnlrmTrQBv/APDc/wATf+EB/wCFjt+zbr7fCWQPef20fENv/aDaYZf+Pz+z/L8z/V/vPv7Nnz+Z5f7yvavHnxys/CfhHwN8TIVs9Q+HGtS2cN/qsn+iNYWl+Y0s9Qd55I8QJJJGkkZTzAlz5mUEbpJ6X/wi2gP4bHhZ9HsP7Ae0/s5NJ+yJ9j+ybPL+z+X/AKvy9n7vy+mO2K+GfgPpdnr3/BHi/tNQtY7y3HhXxFc7ZEDxpJFcX8sb/wC+kkaP/vhOlAH6GxqFjwq7PapK83/Z78TX/jX4D/DbxBrM/wBr1fV/DemX95MU2eZPJbRySPj/AH3r0igAooooAKryTeX5mPnkCb/LqxWfdR+Y3l+VHcJJw6H+5QB8t6x+1v438TfEjxf4e+DvwV1D4oab4VvTpera9JrsGiW41BM+ZbxefH+/8vgEg9T02GN5PUP2cfj7pXx++Hv9u2mkXfh7U7G7m0zXNB1CIpcaVqEZQz28gIG/HmA78f74R96J5L/wS90qy0n9inwPcW9rb20l9LqVzcyRxxxvPIL6eLzJHH+sfy4403n+CNB0Apn7Omk2vh/9tz9rAafZW9vFJceGZ2S3iEY8ySxlklk4HJeRy7+7785oA+u/tH/TNvyr5/039oqTxF4E8YfEa08Lan4l8E6fqkmm6Fb+GIE1O/1pbe4NvPfwJHPseDz9+yPh/LtHnyRIiR9t8ffEmp+B/gH8Q/EGjTfZdW0jw9f6hY3PlJIUuI7eSSOTYfk++K539kHSLLRf2XfhFb2FtFp9qfCmmXTx26IiefLAkskmB/G7ySO/rv8AU0AeXa3+1P8AGf4d6Te+IvHn7M2q+HPBmmpJcapquieLLDV7u2iCf6z7LH5ZkG/YXfeNib36Ia9P+LPxu1nwrpfhiT4beBNW+LF/4njkutO/siWGPSjFiJ/MuL9z5dukkbuYzz5jjHeub+P3ja/+KF3rHwN8DQRat4h1TSZLfxTq1xGZbfwvpt0mxpLjy8eZdyx7/ItBgv8A6x9kcfz+weAfCdl8NvA/hnwpptzcXum6Hplvpdo98w8547eIRp5mMZf5P4E7UAeI+Df2oPG1j428O+G/jB8HtQ+FieJ7wWWi6t/bVnq2nzXPlySfZ7iWMx+RJJsRIEw7yOcY459I8dfEx/hn8S/BOlataWkHhnxdM+jWeqLJHC9hqwSSSCCUySfvEuY0kSPy0yklvs/efaE8vyXVMftofEHwrd6Jug+D3w+8Rwa5F4oiPz+IdXtN6RwWA6fZIy7+Zcc+ZJ+7i+4ZKu/8FDr6fw7+yv4g8X6ZDB/wkXh7UtJ1XSbyS2juHsryLU7fy5Y96ffAklX6SSJ/GaAPqiOMRxhe1PqKL/V1LQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeDWfwc17Wf2qNV+KPie40+/0TSdIh0jwbp1rLIxs/M+fULudHjIS5cgRJJARvgGySveaKAMHVdBsdd02607U7K31HTr6CS3ube9hEsUscgIkjeN87kccFOleVfsyfCfxX8E/hnN4O8Q6pa65a6PqVxbeGpxcSz3J0kSk2cd5I8afvY9+zEaeWkccYSvc6KAGp0p1FFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV4X+078G9e+MkfwsbQ59Phbwn490rxVerfSOnmWtp5u+OPYj5kPmcdBx1r3SigDhvil4Z8TeLPBep6b4Q8WDwP4jm8v7JrrabFqH2bEkZc/Z5PkkJjDx/8D9q+c/FHg/8AbI8e6LceH7vxV8KfBenaiBbXWveGxqY1SxtzIPMkt/NGwybN+OY+vyPGcOPsWigDzr4M/CPQ/gf8OdB8DeFluY9F0aJo4FuZi8jlpJJJJZDxl5JHkb+5/cCDAHGfDX4J614N/aM+N3xA1G7sH0jxt/Yn9mwW0sn2iL7JZvBL56FAnLv8mC+QOcV7xRQAV8zfGLSG8A/tRfCr4mpZWo07VoZ/AHiHUGjupJY0upBPpmxI/wB3GPt6eUZH/wCfyPr9+P6ZrD1vQbPxFp99YalZWt9YXlube4t7iASxzRvw8ciHh0IP6mgD5t+MX7O/jyT44ab8avgpqfhrRvHMumHQtd03xRbyf2fqlqMPG8ktvH5/nI8cHP8AGkcY3hEKSO+DP7OvjuT436n8ZvjNqPhvU/G0em/2Holh4WtHOmaTaffkkj89PPM8jvL7hJJPnIkCR/VS52/NULW437+Cf9ugD5q+FGnv8Qv2kPiv8TXtLcWWkw23gLw5fKl1bySRWkjz6pxIEjkQXj+R5if8+T9OTJ9NR79vz9axdE0O18N6ba6dptvBYaZawJbwW9onlxQRxgCOOOP7iIEGOPatqOPyxQA+iiigAooooAK8I+Ffwe1zwb+0d8bfiDf3Vi2jeOBobabb28j/AGiI2lm8EouMx7Bl3GzY78DtXu9FAHg3xm8L/HJPFVr4g+FHivwmbL7MtlceE/G2lyfY/M3yO96l3b/v/Mx5aCL/AFf3364rzrwz+z38XPi98VfCni74/eIvDb6H4Nmj1HQvCvgOS7isZtTRyY7y88/94Xj42IMjr/q/3iT/AF9RQBAI22IH/eHvXiX7G/we1z9nv9m/wh4A8S3Gn3ms6T9s8640t3kt38y8nnQJvRH+5IP4OoNe6UUAVvs4+1eafn7DP8NfMv7L/ha28CaH8RfgRq+maedK8Maref2bpclpPLbXfh3U5JLi2Mjz/JP873lu+OM25Q5++/1HWBdaHaXWqWmoS2lq2o2sUsEFyYt0kcchQyIkn8GXjj/79p6UAfG3g39nf9pr4A+D9T+Hnwo8U/D288CwyXR0C+8XwXY1fTYp8vsPkRm3keOSSRg7o+/PTYRFH7b8G/hZ4S/Yy/Z+j0KS9abR/DtjPquua9NZnfclEMlxcyRxjPEf7tE/eSeXHGnz+XXvK52/NWFrOiW3iCOOC+t7e7t45orhILiJHjE8ckckUmD/ABo8aOh9voQAeM/sa/D3WPBvwZg1jxRpMejeNPGeo3ni7xBbW5uIxFd30nmeX5U/zxukQhjePs8Z++fnPv8AbxeTHsqROlOoAKKKKACiiigCLy/3m+vD/wBmP4MeIPg3H8Uzrlxp8x8WePdT8VWS2TvJ5drc+V5cUm9ExIPL5xkc9a91ooA8y8Qfs9/DPxdr0+seIvhz4T8QazclPtGpapo1vc3EmxERN8jx5fARB7YFeP8Awo/Yp8NfD/8AaB+JXjS58HeCpND1SbSbjwpa22nR+bo8lpblLiSNPICW7vPskzF6Z619W0UAfLni3Sf2rdP8b+Im8I6z8KtT8IXF4JdNTxJb6lFcWtuYo8W/lwfI+H8zLl2Ll/4Bsjj739nn4Ft8DPBt5pl3rZ8T+INY1i88Qa7r/wBl+yf2jf3Eu8yeQHkSP5PKj/d8fus4+evZqKAOT8Y+GdP8ZeHNX8N6xbm+0TVbCewvrRXeM3EEibJI96fOMo5+5jvzXzv8CPBcXxb/AGTb74O/EG1hbU/D1rceA9btrKxePH2MBLO4g+1x8ubd7O7jlwVDyRuNn3K+rJI32/L+8/2JKxV8O2Eeq3N+tpbrfXVvHbTXGz9/PGhfy4zJ9/ahkkxn/no/qaAPjOT9nL9qyT4TH4OSeNvhqfABtP8AhHv+EmNpef262kf6v/j32fZ/M+z/ALvy/wDyL5n7+u/+O/gn/hU37KNn8F/ANnEb3xBDB4E0GO9s5Gjne7yl3cT/AGZPldLUXl3JPs2b43cg/wCrP1Yi7ErDk0GyutStdW+x27apbwSW0F46AyRwyNGZUR/vhXMcZ4P/ACzT0FAEHgnwtpvgvwjo3h3S7X7HpWkWken2dt5kkvkwRR7I498nzvhMcn0rpqht4vJj2VNQAUUUUAFFFFAHhX7Y3wY1r9oD9nHxb4B8NXVja61rBsxDPqsjx26eXeQTv5hRHP3Ijj5Opr0zxbpOo694d1G00jVzoWsT2s8dlqnkCf7BcPHiKfyHISTyziTy39MV1NFAHxsnhL9tXUtDstAvvGfwn0Td9nju/FGn2V5c6kgSRPMuI4ZY/s7yuAf3ZRE5Gzy+Nnu3wz+DGnfBX4TaV4D8CTmxstItHi0641TfeYuHJczzJvj37pJJJHjR4xzhPLzx6nRQB8WX/wAK/wBrL4reBb/wB408YfC3SNB1WwfSdW8R6NY315qskZi2SMIH8u3LS/cfGzZ5kjx4ISvrHwf4X0zwT4V0Xw1o9qbHSdKs4bCxt2leTy7eNNkab3+fhEHXnjvXRUUAfNH7W2mt4cvPhr8XLKytprr4da99p1G6mhu53g0O8jNnqjxwQf6x443jnz/ALc+6SbXxk8J/HGPxRZ+IPhP4r8JNZfZvsVx4T8b6ZJ9j8zfI73iXdv8Av/M/1cflf6v779cV7s8L+dvV8e1Z2h6HZ+HdIstM060ttOs7SCO3ht7OPy44Y0wEREA4QDigD5Z8M/s9/Fz4vfFXwp4u+P3iLw2+h+DZo9R0Lwr4Dku4rGbU0cmO8vPP/eF4+NiDI6/6v94k/UfGjT5fiv8AtGfCfwS9jb3+i+FLiTx5rUjpdo9tLGklvpGySP8Ad73uHuX8uT76Wb9so/0tWPY6Na2F5qs1pa2tvPqFyLi6kjhCGeTyki3yYHzv5cUaZJ+4iDsKANK1/wBSKmqOLd5ab/v96koAKKKKACiiigDwv9p34N698ZI/hY2hz6fC3hPx7pXiq9W+kdPMtbTzd8cexHzIfM46DjrXWfGLw9408SfDnW7LwB4htvC3jm4jUabrF1ZpcRwukm/ZIjo48uQDy87HMfmbwH2gV6RRQB8ceIvhX+1X8YrMeD/HHiT4ZeFPAuo+bbeIZvBEF3LqV3ZyRSJJbx/bI3jTzPM/1gw8Z+f58eW/vF1+z98OtQ8N+HPD+peC9A13RvDdpHZ6Tba1Yx6h9hgRETZG9wJH+4kfOefLTPSvT6KAPk74gfsKeCdc+Nvwo8SaJ4A8B6d4O8PnVz4i0n+xoE/tPz7ZI7T9ykHlzeXIHk/eY2fwV9M6Hodl4f0iz0zTrSDTrOzgjt4bWzj8uKGOPhERAOEA4/zxsUUAfM3xg0dvAX7UPwu+JqWlomlarDcfD/xBqDJdy3Ecd06z6Ztjj/dxj7fH5ZlP/P4mezx1Pil8DfiPo3xPn+JHwO1zQdK8S695EXizQ/GcMkumauLeCSO2n8yOP7RDJHkDZFsjkwj8bHEn0PrWhWviCzvdO1Gytb3T763a3uLe6jEsU0b5Ekbxn7689/75rbVdgoA+YPhf8CfiXr/xXtfiT8c/Eei6n4m8PxzweFNH8IQSR6bpKTwRxXM/mOiTzyybMeXIXSMbyP8AWII5Pg/pcnxA/aU+LXxNlt4TY6PBB4C8NXkaXUEk0dpI8+oh/MGyQfbHMHmJn/j0k6ffk+lpLYSPv/jrJ0PQbPw3pdlpul2sNhp1tBHBBa2sYjihjQYjSONPlRAB27cUAbUe/b8/Wn0yOPyxT6ACiiigAooooA8H+G3wZ13wP+0P8cviFe3VlJpHjY6KdMtred/tEf2Szkgl+0Ax4GXYbNhf8Kp/Grw5+0A3jjTdY+EfiDwWugNYGC/8O+M7W48oXAkLpdxz26eYXKHZ5ZdETyx98v8AJ9CUUAfLnwv+A3xI134oW/xJ+OXiHQtW8SaCLiPwno/g6CSPTdIWeCOK5uPMkQTzyybP9XIXjj+cjO9PL5j46/BH9oHx18dtJ8WeG5/hnqnhHwyyXPh3QfFkt/tgv/Lj8y/ljgjxJPG/mJGTI6RxkbESTL19lUUAeEfBqH9of/hLrj/hbD/DX/hG/sknk/8ACGfb/tn2jzE8vzPtHyeXs8zpznFe1raj7QZnbzH7f7FXKKAPmX9kfRZPhNH42+D1zbW9hF4N1u4n0G2toZz5mg30jXVlKZ5/kkfzPtlu+z+O256eY+I/hn9sC7v77SV8W/CeHSpr+4VPEH9l3/8AaFvbySP5Usdp/wAe5lgQpsjkdx+7TfJJy7/St1oNpf6lDqUtpatqNvFJBBdPEBKkchQyIj/fQF44ycf8809K3lzt+agDxf4c+BfDv7Kn7PulaK960Ph3wXoklxqOprDJ+88sPPeXBizIf3knmSeWN/8ArMJ0rG/ZB8A6r4S+Cser+JNJi0zxr411O78X+ILW3NxGILu9k8zyzHP+8ieOD7PGY+zxnr98+ya1oNpr6pBe21veQLPHcpHPEjoJopI5IpCD/HG8cboeo2D2I3U6UAR28Xkx7KmoooAKKKKACovL/eb6looA8H/Zr+CfiD4M/wDC0f7ZurG7Hirx/qfimy+wyu5S0uPL8tJS6D94PL5xx/t15X8dPgp+0J44+PWleK/Dlz8NdT8GeGfLm8N6F4ve/KwX2yPzL+eOCPY9wj+YkZLlI0+dESTL19mUUAeD/BiH9ob/AIS24HxZb4av4Z+zSeR/whv9pfbDd708vzPtHyeXs8z3z5dcAvhj9sXwey6bpHir4TeNLK3JEWv+KNOv9Pv7nf8AP+9t7QmFChOwbMjYiZ5L19b0UAfPf7Mf7OupfBWz17xB4p8RXHjH4o+Lp4LzxVrrOfLlkjR0jt7dDwkEQkOzCJ0/gTy44/WPGHhnT/Gnh3WvDWsWxvdF1WzmsL+2WV08+KRNkke9Pn5RyK6yoZI/46APBP2N9X1X/hSek+DvEKW0HirwHJJ4T1O1trWeCPNoFS3kjE4DvHJaPaT+YPv/AGgfc+4LHxS+DuueNP2ivgl4/wBOurFNE8CjXDqUdxI/2m4N3ZpBGIgI9hw8Z373TjpmvVm8O2K6hc36WVr/AGjdW8dvNcPGPNnij8zy43k++UQzyYz/AM9JP75roEXYlAHF+OfhL4N+JUlm3izwnofik2HmfZf7a02C88kSbC/l+YDsJ2R5/wBxPSvBfiB+wp4J1z42/CjxJongDwHp3g7w+dXPiLSf7GgT+0/PtkjtP3KQeXN5cgeT95jZ/BX1jRQB8u/tReE7Xxnovw6+B2l6Rp/9k+J9Wtm1XTWs7iG3tfDmmyR3F35TwDZb/Ollbp/18IOP9Yn07F/q6xodFto9WvNSitre31G6gjt57xIx5kiRmQxo7/x7DJJjn+N620XYlAD6KKKACvCP2yPgvrv7QX7Oni34f+GrjTrTWdZNmIp9SkeK3Hl3kE77yiO4+SLHTuK93ooA5nxWmuf8IzrB8Ktp8fiH7LMdN/tPzPsb3Xlt5Xn+X8/l+Z9/Z8+K+MvhR8Fv2uPhL/wkN/YXXwY1nxH4iu3vdZ8RaxJq0moX0hJ8rzGWNI0jiT93HHHGiIB9z75P3nRQBxPwt/4Tb/hC7D/hY39gf8Jj+8/tD/hF/P8A7Pz5r+V5Xn/vMeX5ec/x7687+Knwd1zxl+0X8EvH9hdWKaH4FXXDqUM8j/abg3dmkEQiAj2HDod+9049a96ooAK+aP2ttObw3efDj4uWVrbTXXw6177TqN1NFdzvBod5GbPVJEgg/wBY8cbxz5/gFufdH+l6geF/O3q+PagBY4vLHyV4b+zX8F9e+C4+KP8AbF3p92virx/qfimyFjK7lLS68vy0l3xj95+75xx/t17Bomh2nhrSLPTbC0trGxtIEt4LazTy4oY0HyIidgBWxQB86/E/wr+0daeONU1T4a+LvAer+H9QVFj0XxpplzAdH8uNARb3Fod8/nyeY7+bjy8R7K5v4V/s6/EfVPjNH8Wfjl4i0jV/FGjQPY+FtE8JPcJo+ixSReXPcjzxvkuJN7g+ZvGO7/uxB9XVXa3G/fwT/t0AfN3wn00/EP8AaW+LfxQlt4vsGkwW/gLw7fql1byTR2kjz6nvEg8uRPtr+R5kef8Aj0fGMb5PpaPft+frWLoeg2fhvS7LTdLtYbDTraCOCC1tYxHFDGgxGkcafKiADt24rajj8sUAPooooAK8L/ad+DevfGSP4WNoc+nwt4T8e6V4qvVvpHTzLW083fHHsR8yHzOOg4617pRQAV4L8VPg7rnjL9ov4JeP7C6sU0PwKuuHUoZ5H+03Bu7NIIhEBHsOHQ797px6171RQB5f8b9F+I194KMnwr1TQ9L8Yw3cDRv4gtZJbWaDzEM8BMYzHvC/f2P3A2ZEkfjWn/A741/F7x/4K1b42ax4Fj8PeDtXj8QWOheDLS8P2++jjdLeS4uJ5A8XkSGNxHHvST94JOiV9a0UANXO35q+aPjFpDeAf2ovhV8TUsrUadq0M/gDxDqDR3UksaXUgn0zYkf7uMfb08oyP/z+R9fvx/TNYet6DZ+ItPvrDUrK1vrC8tzb3FvcQCWOaN+HjkQ8OhB/U0AaNvvkt496fvP+mleJfsf/AAV1r9n79nfwl4C8Q3Njda1oxuxNcaZM8ls3nXk84Kb0Tokn9z9K92Vdgp1AHyDD8A/jT8B9U1ey+B3ibwbdeC9Y1O41S38M+ObO4iTw88h8yS3sDaceQ8kkv7shEjHlhMu8jv2n7Mf7O978D9L1vXfFviK48Z/EvxhJHeeJ9ckkIt55I94jggjwMQxpJIEGwEgH/Vpsjj+iqxNf0Cy8RaXdaZqFrbX+m3UbwT2d3D58U8b/AHw6HgigD5//AGR9Bl8SXHxI+LV5awh/iNrX2jS7qKCe3+0aFaRiz0yV7edcxvJGkk+cfOlwh6fIn0rbx+TBGlPTOz5qfQAUUUUAFeEfDD4K634N/aN+Nnj/AFS7sH0bxwuif2bDbyv9ohNpZvBKJ0KbOXf5MO/A7V7vRQAzyx5m7vXhf7NfwX174PJ8U21m40+5Pivx5qnimxWxleTy7W48vy45fMjT94PLOcZH+2a93ooA+Mfjn8Ef2hPHHx30fxX4dvPhrqXg7wz5c3hrQfF0l+yQX/lR79Qljgj2POj+YkZJ2Rp86JHITJXq/wAG4P2hv+EruP8AhbDfDT/hHPsjeT/whf2/7Z9o8xNnmfaPk8vZ5nTnOK93ooAq/Zf3/mP+8r5Z/Z103xB8JfB/xQ+Dvh+00my1jwXqF/ceE4dRhvWs30y/MlxpklxO/wDrE897iB/L6fZJByf3h+sKwLrQ7S61S01CW0tW1G1ilgguTFukjjkKGREk/gy8cf8A37T0oA+K/hb8GP2tfhS2vXdndfBjW/E+v3b32s+Jdbk1iS/v5M4jEkkaRoscaHy444440jQfIOXNfRn/AArXXPi58Br3wf8AGW30C51XWbK4s9VPhpZPscZMknlSW/2pC4kjj8p975xJHxXsq52/NTqAPhH/AIZz/aq/4VF/wpr/AITX4af8K++x/wDCP/8ACRfYrz+3f7Iz5ePI2fZ9/wBm/d7P/Im/97Xf/HfwT/wqb9lGz+C/gGziN74ghg8CaDHe2cjRzvd5S7uJ/syfK6WovLuSfZs3xu5B/wBWfq+sCTQbK61K11b7HbtqlvBJbQXjoDJHDI0ZlRH++Fcxxng/8s09BQBB4J8Lab4L8I6N4d0u1+x6VpFpHp9nbeZJL5MEUeyOPfJ874THJ9K6aobeLyY9lTUAFFFFAHjPxz0v4yapHodx8JNX8K2l5Z3rvqWm+MbaY213AY5ETZJbnzE2OQ+ABvIT94gR0k4f4cfA34p+JPi1oHxI+NGv+FLvVfDFne2eg6D4OtLqO1gluBGkl4888nmSSGPzYPLdHTYI3Hz5r6eooA+NPjx8Ff2gvHHx30rxV4ZuvhpqHg3w35dz4c0Dxc1/sgvjGm+/njgTY9wn7xIzvZI0w6IkmXr1P4NQ/tDHxXcf8LXb4af8I79kPkf8IR9v+2faPMTy/M+0fJ5ezzOnOcV7xRQBW+zj7R5rfOe2f4K+WP2ddN8QfCXwf8UPg74ftNJstY8F6hf3HhOHUYb1rN9MvzJcaZJcTv8A6xPPe4gfy+n2SQcn94frCsC60O0utUtNQltLVtRtYpYILkxbpI45ChkRJP4MvHH/AN+09KAPiv4W/Bj9rX4Utr13Z3XwY1vxPr9299rPiXW5NYkv7+TOIxJJGkaLHGh8uOOOONI0HyDlzX0Z/wAK11z4ufAa98H/ABlt9AudV1myuLPVT4aWT7HGTJJ5Ulv9qQuJI4/Kfe+cSR8V7KudvzU6gD4R/wCGc/2qv+FRf8Ka/wCE1+Gn/Cvvsf8Awj//AAkX2K8/t3+yM+XjyNn2ff8AZv3ez/yJv/e13/x38E/8Km/ZRs/gv4Bs4je+IIYPAmgx3tnI0c73eUu7if7MnyulqLy7kn2bN8buQf8AVn6vrAk0GyutStdW+x27apbwSW0F46AyRwyNGZUR/vhXMcZ4P/LNPQUAQeCfC2m+C/COjeHdLtfselaRaR6fZ23mSS+TBFHsjj3yfO+ExyfSumqG3i8mPZU1ABRRRQAVD5P7/fU1FAHxbpH7OXxt/Z58YeMbb4D6t8P5Ph94k1J9dj0TxjZTwtpV5JxcRW/2OMDyMJFsz9zYibODJJ6f+yt+znc/AXwfrcmv6pD4j+IXi7UpNb8Ua9bQR263N5Id5ijKIjiFPn2D1klcJHv8sfQdFAHJ+MPCtj428M6p4e1q2a90PVrGeyvrYSPH50cybHTenz/ceTpzz27fOfwa/wCFnal+yHe+BfC19oejfGTwWP8AhDWk1Gzu7fTbSS0eOOK4+eMvIZLB7e4jfYY3MkfybN8dfWUkf8dYf/CO2MOpXWoJZ26309tHbTXBjHmTxxmTykd/vFI/Pkx6eY/rQB8dfCv4N/ta/B3wjF4d0A/BEpJNJe32oXsutS32p3knMt5dzjmS4kIGXP0H3EFeg/tN/C/47/GH4X+E/DHhrWfBunSXMQPja3up7+3ttS+SPfZ28kIM6Wkj+eJPnjkKeWm/BkB+o44xHGF7U+gD5X+H2j/tV6HqnhvTtQsvgZp3g+ynt7a5s/D0erRSW9gCgkjt0P7tJBGMIPuA9eKuftdaSPiVaeBPg9FY217aeMdct59dt7qC6CDQbCSO7vJPPhH7hzIlnbguetyP99PpysBdDt4dWvtUigtodRvI4reW8jt0E7pGXMaO/V0TzJMDPG98YyaANqL/AFdS0xF2JT6ACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA//9k=" alt="" width="500" height="268" vspace="0" hspace="0" border="0" style="width:500px;height:268px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></strong></p><p>&nbsp;</p><p>&nbsp;</p><p>Note: P = Placebo (Number at Risk (flared)); A = Adalimumab (Number at Risk (flared)).</p><p>&nbsp;</p><p>Among the 68&nbsp;patients who flared in the group allocated to treatment withdrawal, 65 completed 12&nbsp;weeks of rescue therapy with adalimumab, out of which 37 (56.9%) had regained remission (ASDAS &lt;&nbsp;1.3) after 12&nbsp;weeks of restarting the open-label treatment.</p><p>&nbsp;</p><p>By Week&nbsp;68, patients receiving continuous adalimumab treatment showed statistically significant greater improvement of the signs and symptoms of active nr-axSpA as compared to patients allocated to treatment withdrawal during the double-blind period of the study (Table 15).</p><p>&nbsp;</p><p><strong>Table 1</strong><strong>5</strong></p><p><strong>Efficacy Response in Placebo-Controlled Period for Study nr-axSpA II</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Double-Blind</strong></p><p><strong>Response at Week 68</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>N=153</strong></p></td><td style="vertical-align:top"><p><strong>Adalimumab</strong></p><p><strong>N=152</strong></p></td></tr><tr><td style="vertical-align:top"><p>ASAS<sup>a,b</sup> 20</p></td><td style="vertical-align:top"><p>47.1%</p></td><td style="vertical-align:top"><p>70.4%***</p></td></tr><tr><td style="vertical-align:top"><p>ASAS<sup>a,b</sup> 40</p></td><td style="vertical-align:top"><p>45.8%</p></td><td style="vertical-align:top"><p>65.8%***</p></td></tr><tr><td style="vertical-align:top"><p>ASAS<sup>a</sup> Partial Remission</p></td><td style="vertical-align:top"><p>26.8%</p></td><td style="vertical-align:top"><p>42.1%**</p></td></tr><tr><td style="vertical-align:top"><p>ASDAS<sup>c</sup> Inactive Disease</p></td><td style="vertical-align:top"><p>33.3%</p></td><td style="vertical-align:top"><p>57.2%***</p></td></tr><tr><td style="vertical-align:top"><p>Partial Flare<sup>d</sup></p></td><td style="vertical-align:top"><p>64.1%</p></td><td style="vertical-align:top"><p>40.8%***</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a</sup> Assessment of SpondyloArthritis international Society</p><p><sup>b</sup> Baseline is defined as open label baseline when patients have active disease.</p><p><sup>c</sup> Ankylosing Spondylitis Disease Activity Score</p><p><sup>d</sup> Partial flare is defined as ASDAS &ge; 1.3 but &lt; 2.1 at 2 consecutive visits.</p><p>***, ** Statistically significant at p &lt;&nbsp;0.001 and &lt;&nbsp;0.01, respectively, for all comparisons between adalimumab and placebo.</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Psoriatic arthritis </em></p><p><em>&nbsp;</em></p><p>Adalimumab, 40&nbsp;mg every other week, was studied in patients with moderately to severely active psoriatic arthritis in two placebo-controlled studies, PsA studies I and II. PsA study I with 24&nbsp;week duration, treated 313&nbsp;adult patients who had an inadequate response to non-steroidal anti-inflammatory drug therapy and of these, approximately 50&nbsp;% were taking methotrexate. PsA study II with 12-week duration, treated 100&nbsp;patients who had an inadequate response to DMARD therapy. Upon completion of both studies, 383&nbsp;patients enrolled in an open-label extension study, in which 40&nbsp;mg adalimumab was administered every other week.</p><p>&nbsp;</p><p>There is insufficient evidence of the efficacy of adalimumab in patients with ankylosing spondylitis-like psoriatic arthropathy due to the small number of patients studied.</p><p>&nbsp;</p><p><strong>Table </strong><strong>16</strong></p><p><strong>ACR Response in Placebo-Controlled Psoriatic Arthritis Studies</strong></p><p><strong>(Percent of Patients)</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>PsA study I</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>PsA study II</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Response</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>N=162</strong></p></td><td style="vertical-align:top"><p><strong>Adalimumab</strong></p><p><strong>N=151</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>N=49</strong></p></td><td style="vertical-align:top"><p><strong>Adalimumab</strong></p><p><strong>N=51</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>ACR 20</p></td></tr><tr><td style="vertical-align:top"><p>Week 12</p></td><td style="vertical-align:top"><p>14%</p></td><td style="vertical-align:top"><p>58%***</p></td><td style="vertical-align:top"><p>16%</p></td><td style="vertical-align:top"><p>39%*</p></td></tr><tr><td style="vertical-align:top"><p>Week 24</p></td><td style="vertical-align:top"><p>15%</p></td><td style="vertical-align:top"><p>57%***</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>ACR 50</p></td></tr><tr><td style="vertical-align:top"><p>Week 12</p></td><td style="vertical-align:top"><p>4%</p></td><td style="vertical-align:top"><p>36%***</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>25%***</p></td></tr><tr><td style="vertical-align:top"><p>Week 24</p></td><td style="vertical-align:top"><p>6%</p></td><td style="vertical-align:top"><p>39%***</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>ACR 70</p></td></tr><tr><td style="vertical-align:top"><p>Week 12</p></td><td style="vertical-align:top"><p>1%</p></td><td style="vertical-align:top"><p>20%***</p></td><td style="vertical-align:top"><p>0%</p></td><td style="vertical-align:top"><p>14%*</p></td></tr><tr><td style="vertical-align:top"><p>Week 24</p></td><td style="vertical-align:top"><p>1%</p></td><td style="vertical-align:top"><p>23%***</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>*** p &lt; 0.001 for all comparisons between adalimumab and placebo</p><p>*&nbsp;&nbsp;&nbsp;&nbsp; p &lt; 0.05 for all comparisons between adalimumab and placebo</p><p>- Not applicable</p></td></tr></tbody></table><p>&nbsp;</p><p>ACR responses in PsA study I were similar with and without concomitant methotrexate therapy.</p><p>ACR responses were maintained in the open-label extension study for up to 136&nbsp;weeks.</p><p>&nbsp;</p><p>Radiographic changes were assessed in the psoriatic arthritis studies. Radiographs of hands, wrists, and feet were obtained at baseline and week 24 during the double-blind period when patients were on adalimumab or placebo and at week 48 when all patients were on open-label adalimumab. A modified Total Sharp Score (mTSS), which included distal interphalangeal joints (i.e. not identical to the TSS used for rheumatoid arthritis), was used.</p><p>&nbsp;</p><p>Adalimumab treatment reduced the rate of progression of peripheral joint damage compared with placebo treatment as measured by change from baseline in mTSS (mean &plusmn; SD) 0.8 &plusmn; 2.5 in the placebo group (at week 24) compared with 0.0 &plusmn; 1.9; (p&lt;0.001) in the adalimumab group (at week 48).</p><p>&nbsp;</p><p>In subjects treated with adalimumab with no radiographic progression from baseline to week 48 (n=102), 84% continued to show no radiographic progression through 144 weeks of treatment.</p><p>Adalimumab treated patients demonstrated statistically significant improvement in physical function as assessed by HAQ and Short Form Health Survey (SF 36) compared to placebo at week 24. Improved physical function continued during the open label extension up to week 136.</p><p>&nbsp;</p><p><em>Psoriasis</em></p><p><em>&nbsp;</em></p><p>The safety and efficacy of adalimumab were studied in adult patients with chronic plaque psoriasis (&ge;10% BSA involvement and Psoriasis Area and Severity Index (PASI) &ge;12 or &ge;10) who were candidates for systemic therapy or phototherapy in randomised, double-blind studies. 73% of patients enrolled in Psoriasis studies I and II had received prior systemic therapy or phototherapy. The safety and efficacy of adalimumab were also studied in adult patients with moderate to severe chronic plaque psoriasis with concomitant hand and/or foot psoriasis who were candidates for systemic therapy in a randomised double-blind study (Psoriasis study III).</p><p>&nbsp;</p><p>Psoriasis study I (REVEAL) evaluated 1,212&nbsp;patients within three treatment periods. In period A, patients received placebo or adalimumab at an initial dose of 80&nbsp;mg followed by 40&nbsp;mg every other week starting one week after the initial dose. After 16 weeks of therapy, patients who achieved at least a PASI 75 response (PASI score improvement of at least 75&nbsp;% relative to baseline), entered period B and received open-label 40&nbsp;mg adalimumab every other week. Patients who maintained &ge;PASI 75 response at week 33 and were originally randomised to active therapy in Period A, were re-randomised in period C to receive 40&nbsp;mg adalimumab every other week or placebo for an additional 19&nbsp;weeks. Across all treatment groups, the mean baseline PASI score was 18.9 and the baseline Physician&rsquo;s Global Assessment (PGA) score ranged from &ldquo;moderate&rdquo; (53&nbsp;% of subjects included) to &ldquo;severe&rdquo; (41&nbsp;%) to &ldquo;very severe&rdquo; (6&nbsp;%).</p><p>&nbsp;</p><p>Psoriasis study II (CHAMPION) compared the efficacy and safety of adalimumab <em>versus </em>methotrexate and placebo in 271&nbsp;patients. Patients received placebo, an initial dose of MTX 7.5&nbsp;mg and thereafter dose increases up to week 12, with a maximum dose of 25&nbsp;mg or an initial dose of 80&nbsp;mg adalimumab followed by 40&nbsp;mg every other week (starting one week after the initial dose) for 16&nbsp;weeks. There are no data available comparing adalimumab and MTX beyond 16&nbsp;weeks of therapy. Patients receiving MTX who achieved a &ge;PASI 50 response at week 8 and/or 12 did not receive further dose increases. Across all treatment groups, the mean baseline PASI score was 19.7 and the baseline PGA score ranged from &ldquo;mild&rdquo; (&lt;1%) to &ldquo;moderate&rdquo; (48%) to &ldquo;severe&rdquo; (46%) to &ldquo;very severe&rdquo; (6%).</p><p>&nbsp;</p><p>Patients participating in all Phase 2 and Phase 3 psoriasis studies were eligible to enrol into an open-label extension trial, where adalimumab was given for at least an additional 108&nbsp;weeks.</p><p>&nbsp;</p><p>In Psoriasis studies I and II, a primary endpoint was the proportion of patients who achieved a PASI 75 response from baseline at week 16 (see Tables 17 and18).</p><p>&nbsp;</p><p><strong>Table </strong><strong>17</strong></p><p><strong>Ps Study I (REVEAL) - Efficacy Results at 16 Weeks</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><p>&nbsp;</p></td><td><p><strong>Placebo</strong></p><p><strong>N=398</strong></p><p><strong>n (%)</strong></p></td><td><p><strong>Adalimumab 40 mg eow</strong></p><p><strong>N=814</strong></p><p><strong>n (%)</strong></p></td></tr><tr><td><p><strong>&ge;</strong><strong> PASI 75<sup>a</sup></strong></p></td><td><p>26 (6.5)</p></td><td><p>578 (70.9)<sup>b</sup></p></td></tr><tr><td><p><strong>PASI 100</strong></p></td><td><p>3 (0.8)</p></td><td><p>163 (20.0)<sup>b</sup></p></td></tr><tr><td><p><strong>PGA: Clear/minimal</strong></p></td><td><p>17 (4.3)</p></td><td><p>506 (62.2)<sup>b</sup></p></td></tr><tr><td colspan="3"><p><sup>a</sup> Percent of patients achieving PASI 75 response was calculated as centre-adjusted rate</p><p><sup>b</sup> p&lt;0.001, adalimumab vs. placebo</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Table 1</strong><strong>8</strong></p><p><strong>Ps Study II (CHAMPION) Efficacy Results at 16 Weeks</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>&nbsp;</strong></p><p><strong>N=53</strong></p><p><strong>n (%)</strong></p></td><td style="vertical-align:top"><p><strong>MTX</strong></p><p><strong>&nbsp;</strong></p><p><strong>N=110</strong></p><p><strong>n (%)</strong></p></td><td style="vertical-align:top"><p><strong>Adalimumab</strong><strong> </strong></p><p><strong>40 mg eow</strong></p><p><strong>N=108</strong></p><p><strong>n (%)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&ge;</strong><strong> PASI 75</strong></p></td><td style="vertical-align:top"><p>10 (18.9)</p></td><td style="vertical-align:top"><p>39 (35.5)</p></td><td style="vertical-align:top"><p>86 (79.6)<sup>a, b</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>PASI 100</strong></p></td><td style="vertical-align:top"><p>1 (1.9)</p></td><td style="vertical-align:top"><p>8 (7.3)</p></td><td style="vertical-align:top"><p>18 (16.7)<sup>c, d</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>PGA: Clear/minimal</strong></p></td><td style="vertical-align:top"><p>6 (11.3)</p></td><td style="vertical-align:top"><p>33 (30.0)</p></td><td style="vertical-align:top"><p>79 (73.1)<sup>a, b</sup></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><sup>a</sup> p&lt;0.001 adalimumab vs. placebo</p><p><sup>b</sup> p&lt;0.001 adalimumab vs. methotrexate</p><p><sup>c</sup> p&lt;0.01 adalimumab vs. placebo</p><p><sup>d</sup> p&lt;0.05 adalimumab vs. methotrexate</p></td></tr></tbody></table><p>&nbsp;</p><p>In Psoriasis study I, 28&nbsp;% of patients who were PASI 75 responders and were re-randomised to placebo at week 33 compared to 5&nbsp;% continuing on adalimumab, p&lt;0.001, experienced &ldquo;loss of adequate response&rdquo; (PASI score after week 33 and on or before week 52 that resulted in a &lt;PASI 50 response relative to baseline with a minimum of a 6-point increase in PASI score relative to week 33). Of the patients who lost adequate response after re-randomisation to placebo who then enrolled into the open-label extension trial, 38&nbsp;% (25/66) and 55&nbsp;% (36/66) regained PASI 75&nbsp;response after 12 and 24&nbsp;weeks of re-treatment, respectively.</p><p>&nbsp;</p><p>A total of 233 PASI 75 responders at week 16 and week 33 received continuous adalimumab therapy for 52 weeks in Psoriasis study I, and continued adalimumab in the open-label extension trial. PASI 75 and PGA of clear or minimal response rates in these patients were 74.7&nbsp;% and 59.0&nbsp;%, respectively, after an additional 108&nbsp;weeks of open-label therapy (total of 160&nbsp;weeks). In an analysis in which all patients who dropped out of the study for adverse events or lack of efficacy, or who dose-escalated, were considered non-responders, PASI 75 and PGA of clear or minimal response rates in these patients were 69.6&nbsp;% and 55.7&nbsp;%, respectively, after an additional 108&nbsp;weeks of open-label therapy (total of 160&nbsp;weeks).</p><p>&nbsp;</p><p>A total of 347 stable responders participated in a withdrawal and retreatment evaluation in an open-label extension study. During the withdrawal period, symptoms of psoriasis returned over time with a median time to relapse (decline to PGA &ldquo;moderate&rdquo; or worse) of approximately 5&nbsp;months. None of these patients experienced rebound during the withdrawal period. A total of 76.5% (218/285) of patients who entered the retreatment period had a response of PGA &ldquo;clear&rdquo; or &ldquo;minimal&rdquo; after 16 weeks of retreatment, irrespective of whether they relapsed during withdrawal (69.1&nbsp;%[123/178] and 88.8&nbsp;% [95/107] for patients who relapsed and who did not relapse during the withdrawal period, respectively). A similar safety profile was observed during retreatment as before withdrawal.</p><p>&nbsp;</p><p>Significant improvements at week 16 from baseline compared to placebo (studies I and II) and MTX (study II) were demonstrated in the DLQI (Dermatology Life Quality Index). In study I, improvements in the physical and mental component summary scores of the SF-36 were also significant compared to placebo.</p><p>&nbsp;</p><p>In an open-label extension study, for patients who dose escalated from 40&nbsp;mg every other week to 40&nbsp;mg weekly due to a PASI response below 50&nbsp;%, 26.4&nbsp;% (92/349) and 37.8&nbsp;% (132/349) of patients achieved PASI 75 response at week 12 and 24, respectively.</p><p>&nbsp;</p><p>Psoriasis study III (REACH) compared the efficacy and safety of adalimumab <em>versus </em>placebo in 72&nbsp;patients with moderate to severe chronic plaque psoriasis and hand and/or foot psoriasis. Patients received an initial dose of 80&nbsp;mg adalimumab followed by 40&nbsp;mg every other week (starting one week after the initial dose) or placebo for 16&nbsp;weeks. At week 16, a statistically significantly greater proportion of patients who received adalimumab achieved PGA of &#39;clear&#39; or &#39;almost clear&#39; for the hands and/or feet compared to patients who received placebo (30.6% <em>versus</em> 4.3%, respectively [p = 0.014]).</p><p>&nbsp;</p><p>Psoriasis study IV compared efficacy and safety of adalimumab <em>versus</em> placebo in 217&nbsp;adult patients with moderate to severe nail psoriasis. Patients received an initial dose of 80&nbsp;mg adalimumab followed by 40&nbsp;mg every other week (starting one week after the initial dose) or placebo for 26&nbsp;weeks followed by open-label adalimumab treatment for an additional 26&nbsp;weeks. Nail psoriasis assessments included the Modified Nail Psoriasis Severity Index (mNAPSI), the Physician&rsquo;s Global Assessment of Fingernail Psoriasis (PGA-F) and the Nail Psoriasis Severity Index (NAPSI) (see Table 19). Adalimumab demonstrated a treatment benefit in nail psoriasis patients with different extents of skin involvement (BSA&ge;10&nbsp;% (60&nbsp;% of patients) and BSA&lt;10&nbsp;% and &ge;5&nbsp;% (40&nbsp;% of patients)).</p><p>&nbsp;</p><p><strong>Table 19</strong></p><p><strong>Ps Study IV Efficacy Results at 16, 26 and 52 Weeks</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="2"><p><strong>Endpoint</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Week 16</strong></p><p><strong>Placebo-Controlled</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Week 26</strong></p><p><strong>Placebo-Controlled</strong></p></td><td style="vertical-align:top"><p><strong>Week 52</strong></p><p><strong>Open-label</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>N=108</strong></p></td><td style="vertical-align:top"><p><strong>Adalimumab</strong></p><p><strong>40 mg eow</strong></p><p><strong>N=109</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>N=108</strong></p></td><td style="vertical-align:top"><p><strong>Adalimumab</strong></p><p><strong>40 mg eow</strong></p><p><strong>N=109</strong></p></td><td style="vertical-align:top"><p><strong>Adalimumab</strong></p><p><strong>40 mg eow</strong></p><p><strong>N=80</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&ge; mNAPSI 75 (%)</strong></p></td><td style="vertical-align:top"><p>2.9</p></td><td style="vertical-align:top"><p>26.0<sup>a</sup></p></td><td style="vertical-align:top"><p>3.4</p></td><td style="vertical-align:top"><p>46.6<sup>a</sup></p></td><td style="vertical-align:top"><p>65.0</p></td></tr><tr><td style="vertical-align:top"><p><strong>PGA-F</strong><strong> </strong><strong>clear/minimal and</strong></p><p><strong>&ge;2</strong><strong>-grade improvement (%)</strong></p></td><td style="vertical-align:top"><p>2.9</p></td><td style="vertical-align:top"><p>29.7<sup>a</sup></p></td><td style="vertical-align:top"><p>6.9</p></td><td style="vertical-align:top"><p>48.9<sup>a</sup></p></td><td style="vertical-align:top"><p>61.3</p></td></tr><tr><td style="vertical-align:top"><p><strong>Percent Change in Total</strong></p><p><strong>Fingernail NAPSI (%)</strong></p></td><td style="vertical-align:top"><p>-7.8</p></td><td style="vertical-align:top"><p>-44.2<sup>a</sup></p></td><td style="vertical-align:top"><p>-11.5</p></td><td style="vertical-align:top"><p>-56.2<sup>a</sup></p></td><td style="vertical-align:top"><p>-72.2</p></td></tr></tbody></table><p><sup>a</sup> p&lt;0.001, adalimumab vs. placebo</p><p>&nbsp;</p><p>Adalimumab treated patients showed statistically significant improvements at week 26 compared with</p><p>placebo in the DLQI.</p><p>&nbsp;</p><p><em>Paediatric plaque psoriasis</em></p><p>&nbsp;</p><p>The efficacy of adalimumab was assessed in a randomised, double-blind, controlled study of 114&nbsp;paediatric patients from 4 years of age with severe chronic plaque psoriasis (as defined by a PGA &ge;4 or &gt;20% BSA involvement or &gt;10&nbsp;% BSA involvement with very thick lesions or PASI &ge;20 or &ge;10 with clinically relevant facial, genital, or hand/ foot involvement) who were inadequately controlled with topical therapy and heliotherapy or phototherapy.</p><p>&nbsp;</p><p>Patients received adalimumab 0.8&nbsp;mg/kg eow (up to 40&nbsp;mg), 0.4&nbsp;mg/kg eow (up to 20&nbsp;mg), or methotrexate 0.1 &ndash; 0.4&nbsp;mg/kg weekly (up to 25&nbsp;mg). At Week 16, more patients randomised to adalimumab 0.8&nbsp;mg/kg had positive efficacy responses (e.g., PASI 75) than those randomised to 0.4&nbsp;mg/kg eow or MTX.</p><p>&nbsp;</p><p><strong>Table 20</strong></p><p><strong>Paediatric Plaque Psoriasis Efficacy Results at 16 Weeks</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>MTX<sup>a</sup></p><p>N=37</p></td><td style="vertical-align:top"><p>Adalimumab 0.8&nbsp;mg/kg eow</p><p>N=38</p></td></tr><tr><td style="vertical-align:top"><p><strong>PASI 75<sup>b</sup></strong></p></td><td style="vertical-align:top"><p>12 (32.4%)</p></td><td style="vertical-align:top"><p>22 (57.9%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>PGA: Clear/minimal<sup>c</sup></strong></p></td><td style="vertical-align:top"><p>15 (40.5%)</p></td><td style="vertical-align:top"><p>23 (60.5%)</p></td></tr></tbody></table><p><sup>a</sup> MTX = methotrexate</p><p><sup>b</sup> P=0.027, adalimumab 0.8 mg/kg <em>versus</em> MTX</p><p><sup>c</sup> P=0.083, adalimumab 0.8 mg/kg <em>versus</em> MTX</p><p>&nbsp;</p><p>Patients who achieved PASI 75 and PGA clear or minimal were withdrawn from treatment for up to 36&nbsp;weeks and monitored for loss of disease control (i.e. a worsening of PGA by at least 2&nbsp;grades). Patients were then re-treated with adalimumab 0.8&nbsp;mg/kg eow for an additional 16 weeks and response rates observed during retreatment were similar to the previous double-blind period: PASI 75 response of 78.9&nbsp;% (15 of 19&nbsp;subjects) and PGA clear or minimal of 52.6&nbsp;% (10 of 19&nbsp;subjects).</p><p>&nbsp;</p><p>In the open label period of the study, PASI 75 and PGA clear or minimal responses were maintained for up to an additional 52&nbsp;weeks with no new safety findings.</p><p>&nbsp;</p><p><em>Hidradenitis suppurativa</em></p><p><em>&nbsp;</em></p><p>The safety and efficacy of adalimumab were assessed in randomised, double-blind, placebo-controlled studies and an open-label extension study in adult patients with moderate to severe hidradenitis suppurativa (HS) who were intolerant, had a contraindication or an inadequate response to at least a 3-month trial of systemic antibiotic therapy. The patients in HS-I and HS-II had Hurley Stage II or III disease with at least 3 abscesses or inflammatory nodules.</p><p>&nbsp;</p><p>Study HS-I (PIONEER I) evaluated 307&nbsp;patients with 2&nbsp;treatment periods. In Period A, patients received placebo or adalimumab at an initial dose of 160&nbsp;mg at week 0, 80&nbsp;mg at week 2, and 40&nbsp;mg every week starting at week 4 to week 11. Concomitant antibiotic use was not allowed during the study. After 12&nbsp;weeks of therapy, patients who had received adalimumab in Period A were re-randomised in Period B to 1 of 3&nbsp;treatment groups (adalimumab 40&nbsp;mg every week, adalimumab 40&nbsp;mg every other week, or placebo from week 12 to week 35). Patients who had been randomised to placebo in Period A were assigned to receive adalimumab 40&nbsp;mg every week in Period B.</p><p>&nbsp;</p><p>Study HS-II (PIONEER II) evaluated 326&nbsp;patients with 2 treatment periods. In Period A, patients received placebo or adalimumab at an initial dose of 160&nbsp;mg at week 0 and 80&nbsp;mg at week 2 and 40&nbsp;mg every week starting at week 4 to week 11. 19.3&nbsp;% of patients had continued baseline oral antibiotic therapy during the study. After 12 weeks of therapy, patients who had received adalimumab in Period A were re-randomised in Period B to 1 of 3 treatment groups (adalimumab 40&nbsp;mg every week, adalimumab 40&nbsp;mg every other week, or placebo from week 12 to week 35). Patients who had been randomised to placebo in Period A were assigned to receive placebo in Period B.</p><p>&nbsp;</p><p>Patients participating in studies HS-I and HS-II were eligible to enrol into an open-label extension study in which adalimumab 40&nbsp;mg was administered every week. Mean exposure in all adalimumab population was 762&nbsp;days. Throughout all 3&nbsp;studies patients used topical antiseptic wash daily.</p><p>&nbsp;</p><p><em><u>Clinical Response</u></em></p><p><em><u>&nbsp;</u></em></p><p>Reduction of inflammatory lesions and prevention of worsening of abscesses and draining fistulas was assessed using Hidradenitis Suppurativa Clinical Response (HiSCR; at least a 50&nbsp;% reduction in total abscess and inflammatory nodule count with no increase in abscess count and no increase in draining fistula count relative to Baseline). Reduction in HS-related skin pain was assessed using a Numeric Rating Scale in patients who entered the study with an initial baseline score of 3 or greater on a 11&nbsp;point scale.</p><p>&nbsp;</p><p>At week 12, a significantly higher proportion of patients treated with adalimumab <em>versus</em> placebo achieved HiSCR. At week 12, a significantly higher proportion of patients in study HS-II experienced a clinically relevant decrease in HS-related skin pain (see Table 21). Patients treated with adalimumab had significantly reduced risk of disease flare during the initial 12 weeks of treatment.</p><p>&nbsp;</p><p><strong>Table </strong><strong>21</strong></p><p><strong>Efficacy Results at 1</strong><strong>2 Weeks</strong><strong>, HS Studies I and II</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>HS study I</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>HS study II</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td><td style="vertical-align:top"><p><strong>Adalimumab </strong></p><p><strong>40 mg Weekly</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td><td style="vertical-align:top"><p><strong>Adalimumab </strong></p><p><strong>40 mg Weekly</strong></p></td></tr><tr><td><p><strong>Hidradenitis Suppurativa</strong></p><p><strong>Clinical Response (HiSCR)<sup>a</sup></strong></p></td><td><p>N=154</p><p>40 (26.0%)</p></td><td><p>N=153</p><p>64 (41.8%) *</p></td><td><p>N=163</p><p>45 (27.6%)</p></td><td><p>N=163</p><p>96 (58.9%) ***</p></td></tr><tr><td style="vertical-align:top"><p><strong>&ge; 30% Reduction in Skin Pain<sup>b</sup></strong></p></td><td style="vertical-align:top"><p>N=109</p><p>27 (24.8%)</p></td><td style="vertical-align:top"><p>N=122</p><p>34 (27.9%)</p></td><td style="vertical-align:top"><p>N=111</p><p>23 (20.7%)</p></td><td style="vertical-align:top"><p>N=105</p><p>48 (45.7%) ***</p></td></tr></tbody></table><p>* p&lt;0.05, ***p&lt;0.001, adalimumab <em>versus</em> placebo</p><p><sup>a</sup> Among all randomised patients</p><p><sup>b</sup> Among patients with baseline HS-related skin pain assessment &ge; 3, based on Numeric Rating Scale 0 &ndash; 10; 0 = no skin pain, 10 = skin pain as bad as you can imagine</p><p>&nbsp;</p><p>Treatment with adalimumab 40&nbsp;mg every week significantly reduced the risk of worsening of abscesses and draining fistulas. Approximately twice the proportion of patients in the placebo group in the first 12&nbsp;weeks of studies HS-I and HS-II, compared with those in the adalimumab group experienced worsening of abscesses (23.0&nbsp;% vs 11.4&nbsp;%, respectively) and draining fistulas (30.0&nbsp;% vs 13.9&nbsp;%, respectively).</p><p>&nbsp;</p><p>Greater improvements at week 12 from baseline compared to placebo were demonstrated in skin specific health-related quality of life, as measured by the Dermatology Life Quality Index (DLQI; studies HS-I and HS-II), patient global satisfaction with medication treatment as measured by the Treatment Satisfaction Questionnaire - medication (TSQM; studies HS-I and HS-II), and physical health as measured by the physical component summary score of the SF-36 (study HS-I).</p><p>&nbsp;</p><p>In patients with at least a partial response to adalimumab 40&nbsp;mg weekly at week 12, the HiSCR rate at week 36 was higher in patients who continued weekly adalimumab than in patients in whom dosing frequency was reduced to every other week, or in whom treatment was withdrawn (see Table 22).</p><p>&nbsp;</p><p><strong>Table 22</strong></p><p><strong>Proportion of Patients<sup>a</sup> Achieving HiSCR<sup>b</sup> at Weeks 24 and 36 After</strong></p><p><strong>Treatment Reassignment from Weekly Adalimumab at Week 12</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p><strong>Placebo</strong></p><p><strong>(treatment withdrawal)</strong></p><p><strong>N = 73</strong></p></td><td style="vertical-align:bottom"><p><strong>Adalimumab 40&nbsp;mg</strong></p><p><strong>every other week</strong></p><p><strong>N = 70</strong></p></td><td style="vertical-align:bottom"><p><strong>Adalimumab 40&nbsp;mg</strong></p><p><strong>weekly</strong></p><p><strong>N = 70</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Week 24</strong></p></td><td style="vertical-align:top"><p>24 (32.9%)</p></td><td style="vertical-align:top"><p>36 (51.4%)</p></td><td style="vertical-align:top"><p>40 (57.1%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Week 36</strong></p></td><td style="vertical-align:top"><p>22 (30.1%)</p></td><td style="vertical-align:top"><p>28 (40.0%)</p></td><td style="vertical-align:top"><p>39 (55.7%)</p></td></tr></tbody></table><p><sup>a</sup> Patients with at least a partial response to adalimumab 40&nbsp;mg weekly after 12&nbsp;weeks of treatment</p><p><sup>b</sup> Patients meeting protocol-specified criteria for loss of response or no improvement were required to discontinue from the studies and were counted as nonresponders</p><p>&nbsp;</p><p>Among patients who were at least partial responders at week 12, and who received continuous</p><p>weekly adalimumab therapy, the HiSCR rate at week 48 was 68.3% and at Week 96 was 65.1%. Longer term treatment with adalimumab 40&nbsp;mg weekly for 96&nbsp;weeks identified no new safety findings.</p><p>&nbsp;</p><p>Among patients whose adalimumab treatment was withdrawn at week 12 in studies HS-I and HS-II, the HiSCR rate 12&nbsp;weeks after re-introduction of adalimumab 40&nbsp;mg weekly returned to levels similar to that observed before withdrawal (56.0&nbsp; %).</p><p>&nbsp;</p><p><em>Adolescent hidradenitis suppurativa</em></p><p><em>&nbsp;</em></p><p>There are no clinical trials with adalimumab in adolescent patients with HS. Efficacy of adalimumab for the treatment of adolescent patients with HS is predicted based on the demonstrated efficacy and exposure-response relationship in adult HS patients and the likelihood that the disease course, pathophysiology, and drug effects are substantially similar to that of adults at the same exposure levels. Safety of the recommended adalimumab dose in the adolescent HS population is based on cross-indication safety profile of adalimumab in both adults and paediatric patients at similar or more frequent doses (see section 5.2).</p><p>&nbsp;</p><p><em>Crohn&rsquo;s disease</em></p><p><em>&nbsp;</em></p><p>The safety and efficacy of adalimumab were assessed in over 1,500&nbsp;patients with moderately to severely active Crohn&rsquo;s disease (Crohn&rsquo;s Disease Activity Index (CDAI) &ge;220 and &le;450) in randomised, double-blind, placebo-controlled studies. Concomitant stable doses of aminosalicylates, corticosteroids, and/or immunomodulatory agents were permitted and 80&nbsp;% of patients continued to receive at least one of these medications.</p><p>&nbsp;</p><p>Induction of clinical remission (defined as CDAI &lt;150) was evaluated in two studies, CD study I (CLASSIC I) and CD study II (GAIN). In CD study I, 299&nbsp;TNF-antagonist naive patients were randomised to one of four treatment groups; placebo at weeks 0 and 2, 160&nbsp;mg adalimumab at week 0 and 80&nbsp;mg at week 2, 80&nbsp;mg at week 0 and 40&nbsp;mg at week 2, and 40&nbsp;mg at week 0 and 20&nbsp;mg at week 2. In CD study II, 325 patients who had lost response or were intolerant to infliximab were randomised to receive either 160&nbsp;mg adalimumab at week 0 and 80&nbsp;mg at week 2 or placebo at weeks 0 and 2. The primary non-responders were excluded from the studies and therefore these patients were not further evaluated.</p><p>&nbsp;</p><p>Maintenance of clinical remission was evaluated in CD study III (CHARM). In CD study III, 854&nbsp;patients received open-label 80&nbsp;mg at week 0 and 40&nbsp;mg at week 2. At week 4 patients were randomised to 40 mg every other week, 40&nbsp;mg every week, or placebo with a total study duration of 56&nbsp;weeks. Patients in clinical response (decrease in CDAI &ge;70) at week 4 were stratified and analysed separately from those not in clinical response at week 4. Corticosteroid taper was permitted after week 8.</p><p>&nbsp;</p><p>CD study I and CD study II induction of remission and response rates are presented in Table 23.</p><p><strong>&nbsp;</strong></p><p><strong>Table </strong><strong>23</strong></p><p><strong>Induction of Clinical Remission and Response</strong></p><p><strong>(Percent of Patients)</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3"><p><strong>CD</strong><strong> </strong><strong>study I: Infliximab Naive Patients</strong></p></td><td colspan="2"><p><strong>CD study II: Infliximab Experienced Patients</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td><p><strong>Placebo</strong></p><p><strong>&nbsp;</strong></p><p><strong>N=74</strong></p></td><td><p><strong>Adalimumab</strong></p><p><strong>80/40</strong><strong>&nbsp;mg</strong></p><p><strong>N=75</strong></p></td><td><p><strong>Adalimumab</strong></p><p><strong>160/80</strong><strong>&nbsp;mg N=76</strong></p></td><td><p><strong>Placebo</strong></p><p><strong>&nbsp;</strong></p><p><strong>N=166</strong></p></td><td><p><strong>Adalimumab</strong></p><p><strong>160/80</strong><strong>&nbsp;mg</strong></p><p><strong>N=159</strong></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Week 4</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Clinical remission</strong></p></td><td><p>12%</p></td><td><p>24%</p></td><td><p>36%*</p></td><td><p>7%</p></td><td><p>21%*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Clinical response (CR-100)</strong></p></td><td><p>24%</p></td><td><p>37%</p></td><td><p>49%**</p></td><td><p>25%</p></td><td><p>38%**</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p>All p-values are pairwise comparisons of proportions for adalimumab <em>versus</em> placebo</p><p>* &nbsp;&nbsp;p &lt;0.001</p><p>** p &lt;0.01</p></td></tr></tbody></table><p>&nbsp;</p><p>Similar remission rates were observed for the 160/80&nbsp;mg and 80/40&nbsp;mg induction regimens by week 8 and adverse events were more frequently noted in the 160/80&nbsp;mg group.</p><p>&nbsp;</p><p>In CD study III, at week 4, 58&nbsp;% (499/854) of patients were in clinical response and were assessed in the primary analysis. Of those in clinical response at week 4, 48&nbsp;% had been previously exposed to other TNF-antagonists. Maintenance of remission and response rates are presented in Table 24. Clinical remission results remained relatively constant irrespective of previous TNF-antagonist exposure.</p><p>&nbsp;</p><p>Disease-related hospitalisations and surgeries were statistically significantly reduced with adalimumab compared with placebo at week 56.</p><p>&nbsp;</p><p><strong>Table </strong><strong>24</strong></p><p><strong>Maintenance of Clinical Remission and Response</strong></p><p><strong>(Percent of Patients)</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td><p><strong>Placebo</strong></p><p><strong>&nbsp;</strong></p></td><td><p><strong>40</strong><strong>&nbsp;mg </strong><strong>Adalimumab every other week</strong></p></td><td><p><strong>40</strong><strong>&nbsp;mg </strong><strong>Adalimumab every week</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Week 26 </strong></p></td><td><p><strong>N=170</strong></p></td><td><p><strong>N=172</strong></p></td><td><p><strong>N=157</strong></p></td></tr><tr><td style="vertical-align:top"><p>Clinical remission</p></td><td><p>17&nbsp;%</p></td><td><p>40&nbsp;%*</p></td><td><p>47&nbsp;%*</p></td></tr><tr><td style="vertical-align:top"><p>Clinical response (CR-100)</p></td><td><p>27&nbsp;%</p></td><td><p>52&nbsp;%*</p></td><td><p>52&nbsp;%*</p></td></tr><tr><td style="vertical-align:top"><p>Patients in steroid-free remission for &gt;=90 days<sup>a</sup></p></td><td><p>3&nbsp;% (2/66)</p></td><td><p>19% (11/58)**</p></td><td><p>15% (11/74)**</p></td></tr><tr><td style="vertical-align:top"><p><strong>Week </strong><strong>56</strong></p></td><td><p><strong>N=170</strong></p></td><td><p><strong>N=172</strong></p></td><td><p><strong>N=157</strong></p></td></tr><tr><td style="vertical-align:top"><p>Clinical remission</p></td><td><p>12&nbsp;%</p></td><td><p>36&nbsp;%*</p></td><td><p>41&nbsp;%*</p></td></tr><tr><td style="vertical-align:top"><p>Clinical response (CR-100)</p></td><td><p>17&nbsp;%</p></td><td><p>41&nbsp;%*</p></td><td><p>48&nbsp;%*</p></td></tr><tr><td style="vertical-align:top"><p>Patients in steroid-free remission for &gt;=90 days<sup>a</sup></p></td><td><p>5&nbsp;% (3/66)</p></td><td><p>29&nbsp;% (17/58)*</p></td><td><p>20&nbsp;% (15/74)**</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>* &nbsp;&nbsp;p &lt;0.001 for adalimumab <em>versus</em> placebo pairwise comparisons of proportions</p><p>** p &lt;0.02 for adalimumab <em>versus</em> placebo pairwise comparisons of proportions</p><p><sup>a</sup> &nbsp;&nbsp;Of those receiving corticosteroids at baseline</p></td></tr></tbody></table><p>&nbsp;</p><p>Among patients who were not in response at week 4, 43&nbsp;% of adalimumab maintenance patients responded by week 12 compared to 30&nbsp;% of placebo maintenance patients. These results suggest that some patients who have not responded by week 4 benefit from continued maintenance therapy through week 12. Therapy continued beyond 12&nbsp;weeks did not result in significantly more responses (see section 4.2).</p><p>&nbsp;</p><p>117/276&nbsp;patients from CD study I and 272/777&nbsp;patients from CD studies II and III were followed through at least 3&nbsp;years of open-label adalimumab therapy. 88 and 189&nbsp;patients, respectively, continued to be in clinical remission. Clinical response (CR-100) was maintained in 102 and 233&nbsp;patients, respectively.</p><p>&nbsp;</p><p><em><u>Quality of </u></em><em><u>l</u></em><em><u>ife </u></em></p><p><em><u>&nbsp;</u></em></p><p>In CD study I and CD study II, statistically significant improvement in the disease-specific inflammatory bowel disease questionnaire (IBDQ) total score was achieved at week 4 in patients randomised to adalimumab 80/40&nbsp;mg and 160/80&nbsp;mg compared to placebo and was seen at weeks 26 and 56 in CD study III as well among the adalimumab treatment groups compared to the placebo group.</p><p>&nbsp;</p><p><em>Paediatric Crohn&rsquo;s disease</em></p><p>&nbsp;</p><p>Adalimumab was assessed in a multicentre, randomised, double-blind clinical trial designed to evaluate the efficacy and safety of induction and maintenance treatment with doses dependent on body weight (&lt;40&nbsp;kg or &ge;40&nbsp;kg) in 192&nbsp;paediatric subjects between the ages of 6 and 17 (inclusive) years, with moderate to severe Crohn&acute;s disease (CD) defined as Paediatric Crohn&#39;s Disease Activity Index (PCDAI) score &gt;30. Subjects had to have failed conventional therapy (including a corticosteroid and/or an immunomodulator) for CD. Subjects may also have previously lost response or been intolerant to infliximab.</p><p>&nbsp;</p><p>All subjects received open-label induction therapy at a dose based on their Baseline body weight: 160&nbsp;mg at week 0 and 80&nbsp;mg at week 2 for subjects &ge;40&nbsp;kg, and 80&nbsp;mg and 40&nbsp;mg, respectively, for subjects &lt;40&nbsp;kg.</p><p>&nbsp;</p><p>At week 4, subjects were randomised 1:1 based on their body weight at the time to either the Low Dose or Standard Dose maintenance regimens as shown in Table 25.</p><p>&nbsp;</p><p><strong>Table 25</strong></p><p><strong>Maintenance regimen</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><p><strong>Patient Weight</strong></p></td><td><p><strong>Low dose</strong></p></td><td><p><strong>Standard dose</strong></p></td></tr><tr><td><p>&lt;40&nbsp;kg</p></td><td><p>10&nbsp;mg eow</p></td><td><p>20&nbsp;mg eow</p></td></tr><tr><td><p>&ge;40&nbsp;kg</p></td><td><p>20&nbsp;mg eow</p></td><td><p>40&nbsp;mg eow</p></td></tr></tbody></table><p>&nbsp;</p><p><em><u>Efficacy results</u></em></p><p>&nbsp;</p><p>The primary endpoint of the study was clinical remission at week 26, defined as PCDAI score &le;10.</p><p>&nbsp;</p><p>Clinical remission and clinical response (defined as reduction in PCDAI score of at least 15 points from Baseline) rates are presented in Table 26. Rates of discontinuation of corticosteroids or immunomodulators are presented in Table 27.</p><p>&nbsp;</p><p><strong>Table 26</strong></p><p><strong>Paediatric CD Study</strong></p><p><strong>PCDAI Clinical Remission and Response</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><p>&nbsp;</p></td><td><p><strong>Standard Dose</strong></p><p><strong>40/20&nbsp;mg eow</strong></p><p><strong>N=93</strong></p></td><td><p><strong>Low Dose</strong></p><p><strong>20/10&nbsp;mg eow</strong></p><p><strong>N=95</strong></p></td><td><p><strong>P value</strong>*</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Week 26</strong></p></td></tr><tr><td style="vertical-align:top"><p>Clinical remission</p></td><td><p>38.7&nbsp;%</p></td><td><p>28.4&nbsp;%</p></td><td><p>0.075</p></td></tr><tr><td style="vertical-align:top"><p>Clinical response</p></td><td><p>59.1&nbsp;%</p></td><td><p>48.4&nbsp;%</p></td><td><p>0.073</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Week 52</strong></p></td></tr><tr><td style="vertical-align:top"><p>Clinical remission</p></td><td><p>33.3&nbsp;%</p></td><td><p>23.2&nbsp;%</p></td><td><p>0.100</p></td></tr><tr><td style="vertical-align:top"><p>Clinical response</p></td><td><p>41.9&nbsp;%</p></td><td><p>28.4&nbsp;%</p></td><td><p>0.038</p></td></tr></tbody></table><p>* p value for Standard Dose <em>versus </em>Low Dose comparison</p><p><strong>&nbsp;</strong></p><p><strong>Table 27</strong></p><p><strong>Paediatric CD Study</strong></p><p><strong>Discontinuation of Corticosteroids or Immunomodulators and Fistula Remission</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><p>&nbsp;</p></td><td><p><strong>Standard Dose</strong></p><p><strong>40/20&nbsp;mg eow</strong></p></td><td><p><strong>Low Dose</strong></p><p><strong>20/10&nbsp;mg eow</strong></p></td><td><p><strong>P value<sup>1</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Discontinued corticosteroids</strong></p></td><td><p><strong>N=33</strong></p></td><td><p><strong>N=38</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Week 26</p></td><td><p>84.8&nbsp;%</p></td><td><p>65.8&nbsp;%</p></td><td><p>0.066</p></td></tr><tr><td style="vertical-align:top"><p>Week 52</p></td><td><p>69.7&nbsp;%</p></td><td><p>60.5&nbsp;%</p></td><td><p>0.420</p></td></tr><tr><td style="vertical-align:top"><p><strong>Discontinuation of Immunomodulators<sup>2</sup></strong></p></td><td><p><strong>N=60</strong></p></td><td><p><strong>N=57</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Week 52</p></td><td><p>30.0&nbsp;%</p></td><td><p>29.8&nbsp;%</p></td><td><p>0.983</p></td></tr><tr><td style="vertical-align:top"><p><strong>Fistula remission<sup>3</sup></strong></p></td><td><p><strong>N=15</strong></p></td><td><p><strong>N=21</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Week 26</p></td><td><p>46.7&nbsp;%</p></td><td><p>38.1&nbsp;%</p></td><td><p>0.608</p></td></tr><tr><td style="vertical-align:top"><p>Week 52</p></td><td><p>40.0&nbsp;%</p></td><td><p>23.8&nbsp;%</p></td><td><p>0.303</p></td></tr></tbody></table><p><sup>1</sup> p value for Standard Dose <em>versus </em>Low Dose comparison</p><p><sup>2</sup> Immunosuppressant therapy could only be discontinued at or after week 26 at the investigator&#39;s discretion if the subject met the clinical response criterion</p><p><sup>3</sup> Defined as a closure of all fistulas that were draining at Baseline for at least 2 consecutive post-Baseline visits</p><p>&nbsp;</p><p>Statistically significant increases (improvement) from Baseline to week 26 and 52 in Body Mass Index and height velocity were observed for both treatment groups.</p><p>&nbsp;</p><p>Statistically and clinically significant improvements from Baseline were also observed in both treatment groups for quality of life parameters (including IMPACT III).</p><p>&nbsp;</p><p>One hundred patients (n=100) from the Paediatric CD study continued in an open-label long-term extension study. After 5&nbsp;years of adalimumab therapy, 74.0&nbsp;% (37/50) of the 50&nbsp;patients remaining in the study continued to be in clinical remission, and 92.0&nbsp;% (46/50) of patients continued to be in clinical response per PCDAI.</p><p>&nbsp;</p><p><em>Ulcerative Colitis</em></p><p><em>&nbsp;</em></p><p>The safety and efficacy of multiple doses of adalimumab were assessed in adult patients with moderately to severely active ulcerative colitis (Mayo score 6 to 12 with endoscopy subscore of 2 to 3) in randomised, double-blind, placebo-controlled studies.</p><p>&nbsp;</p><p>In study UC-I, 390 TNF-antagonist na&iuml;ve patients were randomised to receive either placebo at weeks 0 and 2, 160&nbsp;mg adalimumab at week 0 followed by 80&nbsp;mg at week 2, or 80&nbsp;mg adalimumab at week 0 followed by 40&nbsp;mg at week 2. After week 2, patients in both adalimumab arms received 40&nbsp;mg eow. Clinical remission (defined as Mayo score &le;2 with no subscore &gt;1) was assessed at week 8.</p><p>&nbsp;</p><p>In study UC-II, 248&nbsp;patients received 160&nbsp;mg of adalimumab at week 0, 80&nbsp;mg at week 2 and 40&nbsp;mg eow thereafter, and 246&nbsp;patients received placebo. Clinical results were assessed for induction of remission at week 8 and for maintenance of remission at week 52.</p><p>&nbsp;</p><p>Patients induced with 160/80&nbsp;mg adalimumab achieved clinical remission <em>versus</em> placebo at week 8 in statistically significantly greater percentages in study UC-I (18&nbsp;% vs. 9&nbsp;% respectively, p=0.031) and study UC-II (17&nbsp;% vs. 9&nbsp;% respectively, p=0.019). In study UC-II, among those treated with adalimumab who were in remission at week 8, 21/41 (51&nbsp;%) were in remission at week 52.</p><p>&nbsp;</p><p>Results from the overall UC-II study population are shown in Table 28.</p><p>&nbsp;</p><p><strong>Table </strong><strong>28</strong></p><p><strong>Response, Remission and Mucosal Healing in Study UC-II</strong></p><p><strong>(Percent of Patients)</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Placeb</strong><strong>o</strong></p></td><td style="vertical-align:top"><p><strong>Adalimumab </strong></p><p><strong>40</strong><strong>&nbsp;mg</strong><strong> eow</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Week 52</strong></p></td><td style="vertical-align:top"><p><strong>N</strong><strong>=246</strong></p></td><td style="vertical-align:top"><p><strong>N</strong><strong>=248</strong></p></td></tr><tr><td style="vertical-align:top"><p>Clinical Response</p></td><td style="vertical-align:top"><p>18&nbsp;%</p></td><td style="vertical-align:top"><p>30&nbsp;%*</p></td></tr><tr><td style="vertical-align:top"><p>Clinical Remission</p></td><td style="vertical-align:top"><p>9&nbsp;%</p></td><td style="vertical-align:top"><p>17&nbsp;%*</p></td></tr><tr><td style="vertical-align:top"><p>Mucosal Healing</p></td><td style="vertical-align:top"><p>15&nbsp;%</p></td><td style="vertical-align:top"><p>25&nbsp;%*</p></td></tr><tr><td style="vertical-align:top"><p>Steroid-free remission for &ge; 90 days<sup>a</sup></p></td><td style="vertical-align:top"><p>6&nbsp;%</p><p>(N=140)</p></td><td style="vertical-align:top"><p>13&nbsp;%*</p><p>(N=150)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Week 8 and 52 </strong></p></td></tr><tr><td style="vertical-align:top"><p>Sustained Response</p></td><td style="vertical-align:top"><p>12&nbsp;%</p></td><td style="vertical-align:top"><p>24&nbsp;%**</p></td></tr><tr><td style="vertical-align:top"><p>Sustained Remission</p></td><td style="vertical-align:top"><p>4&nbsp;%</p></td><td style="vertical-align:top"><p>8&nbsp;%*</p></td></tr><tr><td style="vertical-align:top"><p>Sustained Mucosal Healing</p></td><td style="vertical-align:top"><p>11&nbsp;%</p></td><td style="vertical-align:top"><p>19&nbsp;%*</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Clinical remission is Mayo score &le;2 with no subscore &gt;1;</p><p>Clinical response is decrease from baseline in Mayo score &ge;3 points and &ge;30% plus a decrease in the rectal bleeding subscore [RBS] &ge;1 or an absolute RBS of 0 or 1;</p><p>*&nbsp;&nbsp; p&lt;0.05 for adalimumab vs. placebo pairwise comparison of proportions</p><p>** p&lt;0.001 for adalimumab vs. placebo pairwise comparison of proportions</p><p><sup>a</sup> &nbsp;&nbsp;&nbsp;Of those receiving corticosteroids at baseline</p></td></tr></tbody></table><p>&nbsp;</p><p>Of those patients who had a response at week 8, 47&nbsp;% were in response, 29&nbsp;% were in remission, 41&nbsp;% had mucosal healing, and 20&nbsp;% were in steroid-free remission for &ge;90&nbsp;days at week 52.</p><p>&nbsp;</p><p>Approximately 40% of patients in study UC-II had failed prior anti-TNF treatment with infliximab. The efficacy of adalimumab in those patients was reduced compared to that in anti-TNF na&iuml;ve patients. Among patients who had failed prior anti-TNF treatment, week 52 remission was achieved by 3&nbsp;% on placebo and 10&nbsp;% on adalimumab.</p><p>&nbsp;</p><p>Patients from studies UC-I and UC-II had the option to roll over into an open-label long-term extension study (UC III). Following 3&nbsp;years of adalimumab therapy, 75&nbsp;% (301/402) continued to be in clinical remission per partial Mayo score.</p><p>&nbsp;</p><p><em><u>Hospitalisation rates</u></em></p><p><em><u>&nbsp;</u></em></p><p>During 52&nbsp;weeks of studies UC-I and UC-II, lower rates of all-cause hospitalisations and UC-related hospitalisations were observed for the adalimumab-treated arm compared to the placebo arm. The number of all cause hospitalisations in the adalimumab treatment group was 0.18 per patient year <em>vs</em>. 0.26 per patient year in the placebo group and the corresponding figures for UC-related hospitalisations were 0.12 per patient year <em>vs. </em>0.22 per patient year.</p><p><em>&nbsp;</em></p><p><em><u>Quality of </u></em><em><u>l</u></em><em><u>ife</u></em></p><p><em><u>&nbsp;</u></em></p><p>In study UC-II, treatment with adalimumab resulted in improvements in the Inflammatory Bowel Disease Questionnaire (IBDQ) score.</p><p>&nbsp;</p><p><em>Uveitis</em></p><p>&nbsp;</p><p>The safety and efficacy of adalimumab were assessed in adult patients with non-infectious intermediate, posterior, and panuveitis, excluding patients with isolated anterior uveitis, in two randomised, double- masked, placebo-controlled studies (UV I and II). Patients received placebo or adalimumab at an initial dose of 80&nbsp;mg followed by 40&nbsp;mg every other week starting one week after the initial dose. Concomitant stable doses of one non-biologic immunosuppressant were permitted.</p><p>&nbsp;</p><p>Study UV I evaluated 217&nbsp;patients with active uveitis despite treatment with corticosteroids (oral prednisone at a dose of 10 to 60&nbsp;mg/day). All patients received a 2-week standardised dose of prednisone 60&nbsp;mg/day at study entry followed by a mandatory taper schedule, with complete corticosteroid discontinuation by week 15.</p><p>&nbsp;</p><p>Study UV II evaluated 226&nbsp;patients with inactive uveitis requiring chronic corticosteroid treatment (oral prednisone 10 to 35&nbsp;mg/day) at baseline to control their disease. Patients subsequently underwent a mandatory taper schedule, with complete corticosteroid discontinuation by week 19.</p><p>&nbsp;</p><p>The primary efficacy endpoint in both studies was &acute;time to treatment failure&acute;. Treatment failure was defined by a multi-component outcome based on inflammatory chorioretinal and/or inflammatory retinal vascular lesions, anterior chamber (AC) cell grade, vitreous haze (VH) grade and best corrected visual acuity (BCVA).</p><p>&nbsp;</p><p><em><u>Clinical Response</u></em></p><p>&nbsp;</p><p>Results from both studies demonstrated statistically significant reduction of the risk of treatment failure in patients treated with adalimumab <em>versus</em> patients receiving placebo (See Table 29). Both studies demonstrated an early and sustained effect of adalimumab on the treatment failure rate <em>versus </em>placebo (see Figure 2).</p><p>&nbsp;</p><p><strong>Table 29</strong></p><p><strong>Time to Treatment Failure in Studies UV I and UV II</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><p>Analysis Treatment</p></td><td><p>N</p></td><td><p>Failure N (%)</p></td><td><p>Median Time to Failure (months)</p></td><td><p>HR<sup>a</sup></p></td><td><p>CI 95% for HR</p></td><td><p><em>P</em> Value<sup>b</sup></p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>Time to Treatment Failure At or After Week 6 in study U</strong><strong>V I</strong></p><p>Primary analysis (ITT)</p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>107</p></td><td style="vertical-align:top"><p>84 (78.5)</p></td><td style="vertical-align:top"><p>3.0</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Adalimumab</p></td><td style="vertical-align:top"><p>110</p></td><td style="vertical-align:top"><p>60 (54.5)</p></td><td style="vertical-align:top"><p>5.6</p></td><td style="vertical-align:top"><p>0.50</p></td><td style="vertical-align:top"><p>0.36,0.70</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>Time to Treatment Failure At or After Week 2 in study UV II</strong></p><p>Primary analysis (ITT)</p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>111</p></td><td style="vertical-align:top"><p>61 (55.0)</p></td><td style="vertical-align:top"><p>8.3</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Adalimumab</p></td><td style="vertical-align:top"><p>115</p></td><td style="vertical-align:top"><p>45 (39.1)</p></td><td style="vertical-align:top"><p>NE<sup>c</sup></p></td><td style="vertical-align:top"><p>0.57</p></td><td style="vertical-align:top"><p>0.39,0.84</p></td><td style="vertical-align:top"><p>0.004</p></td></tr></tbody></table><p>Note: &nbsp;Treatment failure at or after week 6 (study UV I), or at or after week 2 (study UV II), was counted as event. Drop outs due to reasons other than treatment failure were censored at the time of dropping out.</p><p><sup>a </sup>HR of adalimumab vs placebo from proportional hazards regression with treatment as factor</p><p><sup>b </sup>2-sided <em>P </em>value from log rank test</p><p><sup>c </sup>NE = not estimable. Fewer than half of at-risk subjects had an event</p><p><strong>&nbsp;</strong></p><p><strong>Figure </strong><strong>2: Kaplan-Meier Curves Summarizing Time to Treatment Failure on or after Week 6 (Study UV I) or Week 2 (Study UV II)</strong></p><p><strong><img src="data:image/png;base64,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" alt="" width="450" height="211" vspace="0" hspace="0" border="0" style="width:450px;height:211px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></strong></p><p><strong><img src="data:image/png;base64,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" alt="" width="450" height="210" vspace="0" hspace="0" border="0" style="width:450px;height:210px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></strong></p><p>&nbsp;</p><p>Note: P# = Placebo (Number of Events/Number at Risk); A# = Adalimumab (Number of Events/Number at Risk).</p><p>&nbsp;</p><p>In study UV I statistically significant differences in favour of adalimumab <em>versus</em> placebo were observed for each component of treatment failure. In study UV II, statistically significant differences were observed for visual acuity only, but the other components were numerically in favour of adalimumab.</p><p>&nbsp;</p><p>Of the 417&nbsp;subjects included in the uncontrolled long-term extension of studies UV I and UV II, 46&nbsp;subjects were regarded ineligible (e.g. developed complications secondary to diabetic retinopathy, due to cataract surgery or vitrectomy) and were excluded from the primary analysis of efficacy. Of the 371 remaining patients, 276 evaluable patients reached 78&nbsp;weeks of open-label adalimumab treatment. Based on the observed data approach, 222 (80.4&nbsp;%) were in quiescence (no active inflammatory lesions, AC cell grade &le;&nbsp;0.5+, VH grade &le;&nbsp;0.5+) with a concomitant steroid dose &le;&nbsp;7.5&nbsp;mg per day, and 184 (66.7&nbsp;%) were in steroid-free quiescence. BCVA was either improved or maintained (&lt;&nbsp;5 letters deterioration) in 88.4&nbsp;% of the eyes at week&nbsp;78. Among the patients who discontinued the study prior to week&nbsp;78, 11% discontinued due to adverse events, and 5&nbsp;% due to insufficient response to adalimumab treatment.</p><p>&nbsp;</p><p><em><u>Quality of Life</u></em></p><p>&nbsp;</p><p>Patient reported outcomes regarding vision-related functioning were measured in both clinical studies, using the NEI VFQ-25. Adalimumab was numerically favoured for the majority of subscores with statistically significant mean differences for general vision, ocular pain, near vision, mental health, and total score in study UV I, and for general vision and mental health in study UV II. Vision related effects were not numerically in favour of adalimumab for colour vision in study UVI and for colour vision, peripheral vision and near vision in study UV II.</p><p><em>&nbsp;</em></p><p><em>Paediatric Uveitis</em></p><p>&nbsp;</p><p>The safety and efficacy of adalimumab was assessed in a randomized, double-masked, controlled study of 90&nbsp;paediatric patients from 2 to &lt;&nbsp;18&nbsp;years of age with active JIA-associated noninfectious anterior uveitis who were refractory to at least 12&nbsp;weeks of methotrexate treatment. Patients received either placebo or 20&nbsp;mg adalimumab (if &lt;&nbsp;30&nbsp;kg) or 40&nbsp;mg adalimumab (if &ge;&nbsp;30&nbsp;kg) every other week in combination with their baseline dose of methotrexate.</p><p>&nbsp;</p><p>The primary endpoint was &lsquo;time to treatment failure&rsquo;. The criteria determining treatment failure were worsening or sustained non-improvement in ocular inflammation, partial improvement with development of sustained ocular co-morbidities or worsening of ocular co-morbidities, non-permitted use of concomitant medications, and suspension of treatment for an extended period of time.</p><p>&nbsp;</p><p><em><u>Clinical Response</u></em></p><p>&nbsp;</p><p>Adalimumab significantly delayed the time to treatment failure, as compared to placebo (See Figure 3, P&nbsp;&lt;&nbsp;0.0001 from log rank test). The median time to treatment failure was 24.1&nbsp;weeks for subjects treated with placebo, whereas the median time to treatment failure was not estimable for subjects treated with adalimumab because less than one-half of these subjects experienced treatment failure. Adalimumab significantly decreased the risk of treatment failure by 75&nbsp;% relative to placebo, as shown by the hazard ratio (HR = 0.25 [95&nbsp;% CI: 0.12, 0.49]).</p><p><strong>Figure 3: Kaplan-Meier Curves Summarizing Time to Treatment Failure in the Paediatric Uveitis Study</strong></p><p><br /><img src="data:image/jpeg;base64,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" alt="" width="450" height="372" vspace="0" hspace="0" border="0" style="width:450px;height:372px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p><u>Immunogenicity</u></p><p><u>&nbsp;</u></p><p>Anti-adalimumab antibodies may develop during adalimumab treatment. Formation of anti-adalimumab antibodies is associated with increased clearance and reduced efficacy of adalimumab. There is no apparent correlation between the presence of anti-adalimumab antibodies and the occurrence of adverse events.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The European Medicines Agency has deferred the obligation to submit the results of the studies with the reference medicinal product containing adalimumab in one or more subsets of the paediatric population in ulcerative colitis, see section 4.2 for information on paediatric use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption and distribution</u></p><p><u>&nbsp;</u></p><p>After subcutaneous administration of a single 40&nbsp;mg dose, absorption and distribution of adalimumab was slow, with peak serum concentrations being reached about 5&nbsp;days after administration. The average absolute bioavailability of adalimumab estimated from three studies following a single 40&nbsp;mg subcutaneous dose was 64&nbsp;%. After single intravenous doses ranging from 0.25 to 10&nbsp;mg/kg, concentrations were dose proportional. After doses of 0.5&nbsp;mg/kg (~40&nbsp;mg), clearances ranged from 11 to 15&nbsp;ml/hour, the distribution volume (Vss) ranged from 5 to 6&nbsp;litres and the mean terminal phase half-life was approximately two weeks. Adalimumab concentrations in the synovial fluid from several rheumatoid arthritis patients ranged from 31-96&nbsp;% of those in serum.</p><p>&nbsp;</p><p>Following subcutaneous administration of 40&nbsp;mg of adalimumab every other week in adult rheumatoid arthritis (RA) patients the mean steady-state trough concentrations were approximately 5&nbsp;&mu;g/ml (without concomitant methotrexate) and 8 to 9&nbsp;&mu;g/ml (with concomitant methotrexate), respectively. The serum adalimumab trough levels at steady-state increased roughly proportionally with dose following 20, 40 and 80&nbsp;mg subcutaneous dosing every other week and every week.</p><p>&nbsp;</p><p>Following the administration of 24&nbsp;mg/m<sup>2</sup> (up to a maximum of 40&nbsp;mg) subcutaneously every other week to patients with polyarticular juvenile idiopathic arthritis (JIA) who were 4 to 17&nbsp;years the mean trough steady-state (values measured from week 20 to 48) serum adalimumab concentration was 5.6 &plusmn; 5.6&nbsp;&micro;g/ml (102&nbsp;% CV) for adalimumab without concomitant methotrexate and 10.9 &plusmn; 5.2&nbsp;&micro;g/ml (47.7&nbsp;% CV) with concomitant methotrexate.</p><p>&nbsp;</p><p>In patients with polyarticular JIA who were 2 to &lt;4&nbsp;years old or aged 4 and above weighing &lt;15&nbsp;kg dosed with adalimumab 24&nbsp;mg/m<sup>2</sup> , the mean trough steady-state serum adalimumab concentrations was 6.0 &plusmn; 6.1&nbsp;&micro;g/ml (101% CV) for adalimumab without concomitant methotrexate and 7.9 &plusmn; 5.6&nbsp;&micro;g/ml (71.2% CV) with concomitant methotrexate.</p><p>&nbsp;</p><p>Following the administration of 24&nbsp;mg/m<sup>2</sup> (up to a maximum of 40&nbsp;mg) subcutaneously every other week to patients with enthesitis-related arthritis who were 6 to 17&nbsp;years, the mean trough steady-state (values measured at week 24) serum adalimumab concentrations were 8.8 &plusmn; 6.6&nbsp;&mu;g/ml for adalimumab without concomitant methotrexate and 11.8 &plusmn; 4.3&nbsp;&mu;g/ml with concomitant methotrexate.</p><p>&nbsp;</p><p>Following subcutaneous administration of 40&nbsp;mg of adalimumab every other week in adult non-radiographic axial spondyloarthritis patients, the mean (&plusmn;SD) trough steady-state concentration at Week 68 was 8.0 &plusmn; 4.6&nbsp;&mu;g/ml.</p><p>&nbsp;</p><p>In adult patients with psoriasis, the mean steady-state trough concentration was 5&nbsp;&mu;g/ml during adalimumab 40&nbsp;mg every other week monotherapy treatment.</p><p>&nbsp;</p><p>Following the administration of 0.8&nbsp;mg/kg (up to a maximum of 40&nbsp;mg) subcutaneously every other week to paediatric patients with chronic plaque psoriasis, the mean &plusmn; SD steady-state adalimumab trough concentration was approximately 7.4 &plusmn; 5.8&nbsp;&mu;g/ml (79% CV).</p><p>&nbsp;</p><p>In adult patients with hidradenitis suppurativa, a dose of 160&nbsp;mg adalimumab on week 0 followed by 80&nbsp;mg on week 2 achieved serum adalimumab trough concentrations of approximately 7 to 8&nbsp;&mu;g/ml at week 2 and week 4. The mean steady-state trough concentration at week 12 through week 36 were approximately 8 to 10&nbsp;&mu;g/ml during adalimumab 40&nbsp;mg every week treatment.</p><p>&nbsp;</p><p>Adalimumab exposure in adolescent HS patients was predicted using population pharmacokinetic modelling and simulation based on cross-indication pharmacokinetics in other paediatric patients (paediatric psoriasis, juvenile idiopathic arthritis, paediatric Crohn&rsquo;s disease, and enthesitis-related arthritis). The recommended adolescent HS dosing schedule is 40&nbsp;mg every other week. Since exposure to adalimumab can be affected by body size, adolescents with higher body weight and inadequate response may benefit from receiving the recommended adult dose of 40&nbsp;mg every week.</p><p>&nbsp;</p><p>In patients with Crohn&rsquo;s disease, the loading dose of 80&nbsp;mg adalimumab on week 0 followed by 40&nbsp;mg adalimumab on week 2 achieves serum adalimumab trough concentrations of approximately 5.5&nbsp;&mu;g/ml during the induction period. A loading dose of 160&nbsp;mg adalimumab on week 0 followed by 80&nbsp;mg adalimumab on week 2 achieves serum adalimumab trough concentrations of approximately 12&nbsp;&mu;g/ml during the induction period. Mean steady-state trough levels of approximately 7&nbsp;&mu;g/ml were observed in Crohn&rsquo;s disease patients who received a maintenance dose of 40&nbsp;mg adalimumab every other week.</p><p>&nbsp;</p><p>In paediatric patients with moderate to severe CD, the open-label adalimumab induction dose was 160/80&nbsp;mg or 80/40&nbsp;mg at weeks 0 and 2, respectively, dependent on a body weight cut-off of 40&nbsp;kg. At week 4, patients were randomised 1:1 to either the Standard Dose (40/20&nbsp;mg eow) or Low Dose (20/10&nbsp;mg eow) maintenance treatment groups based on their body weight. The mean (&plusmn;SD) serum adalimumab trough concentrations achieved at week 4 were 15.7&plusmn;6.6&nbsp;&micro;g/ml for patients &ge;40&nbsp;kg (160/80&nbsp;mg) and 10.6&plusmn;6.1&nbsp;&micro;g/ml for patients &lt;40&nbsp;kg (80/40&nbsp;mg).</p><p>&nbsp;</p><p>For patients who stayed on their randomised therapy, the mean (&plusmn;SD) adalimumab trough concentrations at week 52 were 9.5&plusmn;5.6&nbsp;&mu;g/ml for the Standard Dose group and 3.5&plusmn;2.2&nbsp;&mu;g/ml for the Low Dose group. The mean trough concentrations were maintained in patients who continued to receive adalimumab treatment eow for 52 weeks. For patients who dose escalated from eow to weekly regimen, the mean (&plusmn;SD) serum concentrations of adalimumab at week 52 were 15.3&plusmn;11.4&nbsp;&mu;g/ml (40/20&nbsp;mg, weekly) and 6.7&plusmn;3.5&nbsp;&mu;g/ml (20/10&nbsp;mg, weekly).</p><p>&nbsp;</p><p>In patients with ulcerative colitis, a loading dose of 160&nbsp;mg adalimumab on week 0 followed by 80&nbsp;mg adalimumab on week 2 achieves serum adalimumab trough concentrations of approximately 12&nbsp;&mu;g/ml during the induction period. Mean steady-state trough levels of approximately 8&nbsp;&mu;g/ml were observed in ulcerative colitis patients who received a maintenance dose of 40&nbsp;mg adalimumab every other week.</p><p><u>&nbsp;</u></p><p>In adult patients with uveitis, a loading dose of 80&nbsp;mg adalimumab on week 0 followed by 40&nbsp;mg adalimumab every other week starting at week 1, resulted in mean steady-state concentrations of approximately 8 to 10&nbsp;&micro;g/mL.</p><p><u>&nbsp;</u></p><p>Adalimumab exposure in paediatric uveitis patients was predicted using population pharmacokinetic modelling and simulation based on cross-indication pharmacokinetics in other paediatric patients (paediatric psoriasis, juvenile idiopathic arthritis, paediatric Crohn&rsquo;s disease, and enthesitis-related arthritis). No clinical exposure data are available on the use of a loading dose in children &lt;&nbsp;6&nbsp;years. The predicted exposures indicate that in the absence of methotrexate, a loading dose may lead to an initial increase in systemic exposure.</p><p><u>&nbsp;</u></p><p>Population pharmacokinetic and pharmacokinetic/pharmacodynamic modelling and simulation predicted comparable adalimumab exposure and efficacy in patients treated with 80&nbsp;mg every other week when compared with 40&nbsp;mg every week (including adult patients with RA, HS, UC, CD or Ps, patients with adolescent HS, and paediatric patients &ge; 40&nbsp;kg with CD).</p><p><u>&nbsp;</u></p><p><u>Exposure-response relationship in paediatric population</u></p><p><u>&nbsp;</u></p><p>On the basis of clinical trial data in patients with JIA (pJIA and ERA), an exposure-response relationship was established between plasma concentrations and PedACR 50 response. The apparent adalimumab plasma concentration that produces half the maximum probability of PedACR 50 response (EC50) was 3 &mu;g/ml (95% CI: 1-6 &mu;g/ml).</p><p>&nbsp;</p><p>Exposure-response relationships between adalimumab concentration and efficacy in paediatric patients with severe chronic plaque psoriasis were established for PASI 75 and PGA clear or minimal, respectively. PASI 75 and PGA clear or minimal increased with increasing adalimumab concentrations, both with a similar apparent EC50 of approximately 4.5 &mu;g/mL (95% CI 0.4-47.6 and 1.9-10.5, respectively).</p><p><u>&nbsp;</u></p><p><u>Elimination</u></p><p><u>&nbsp;</u></p><p>Population pharmacokinetic analyses with data from over 1,300&nbsp;RA patients revealed a trend toward higher apparent clearance of adalimumab with increasing body weight. After adjustment for weight differences, gender and age appeared to have a minimal effect on adalimumab clearance. The serum levels of free adalimumab (not bound to anti-adalimumab antibodies, AAA) were observed to be lower in patients with measurable AAA.</p><p>&nbsp;</p><p><u>Hepatic or renal impairment</u></p><p><u>&nbsp;</u></p><p>Adalimumab has not been studied in patients with hepatic or renal impairment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on studies of single dose toxicity, repeated dose toxicity, and genotoxicity.</p><p>&nbsp;</p><p>An embryo-foetal developmental toxicity/perinatal developmental study has been performed in cynomolgus monkeys at 0, 30 and 100&nbsp;mg/kg (9-17&nbsp;monkeys/group) and has revealed no evidence of harm to the foetuses due to adalimumab. Neither carcinogenicity studies, nor a standard assessment of fertility and postnatal toxicity, were performed with adalimumab due to the lack of appropriate models for an antibody with limited cross-reactivity to rodent TNF and to the development of neutralising antibodies in rodents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>&nbsp;</em></p><p>Sodium citrate</p><p>Citric acid monohydrate</p><p>Histidine</p><p>Histidine hydrochloride monohydrate</p><p>Sorbitol</p><p>Polysorbate 20</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C &ndash; 8&deg;C). Do not freeze. Keep the pre-filled syringe or pre-filled pen in&nbsp; outer carton in order to protect from light.</p><p>&nbsp;</p><p>A single Hadlima pre-filled syringe or pre-filled pen may be stored at temperatures up to a maximum of 25&deg;C for a period of up to 28&nbsp;days. The syringe or pen must be protected from light, and discarded if not used within the 28-day period.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hadlima 40</u><u>&nbsp;</u><u>mg solution for injection in pre-filled syringe</u></p><p>&nbsp;</p><p>0.8&nbsp;ml solution for injection in single-use pre-filled syringe (type I glass) with a stainless steel needle, a rigid needle shield, a rubber plunger (bromobutyl), a plunger rod, a safe-shield body and a finger flange for patient use.</p><p>&nbsp;</p><p>Packs of:</p><p>&nbsp;&nbsp;&nbsp; 2 pre-filled syringes</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Hadlima 40</u><u>&nbsp;</u><u>mg solution for injection in pre-filled pen</u></p><p>&nbsp;</p><p>0.8&nbsp;ml solution for injection in single-use pre-filled pen for patient use containing a pre-filled syringe. The syringe inside the pen is made from type I glass with a stainless steel needle, a rigid needle shield, a rubber plunger (bromobutyl).</p><p>&nbsp;</p><p>Packs of:</p><p>&nbsp;&nbsp;&nbsp; 2 pre-filled pens</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Samsung Bioepis
76, Songdogyoyuk-ro,, 
Yeonsu-gu, Incheon, 
21987, 
Republic of Korea

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                08/2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>